Thiosemicarbazones Target Multiple Resistance Pathways in Cancer by Stacy, Alexandra Elizabeth
 
 
Thiosemicarbazones 
Target Multiple 
Resistance Pathways in 
Cancer 
 
Alexandra Stacy B.Sc. (Hons. I) 
Department of Pathology, Faculty of Medicine 
 
The University of Sydney 
 
 
 
A thesis submitted in fulfilment of the requirements for the degree of Doctor of 
Philosophy 13.10.2016
i 
 
Acknowledgements 
I would like to thank my supervisor, Prof Des Richardson, for his contributions to my 
PhD project. His support, both intellectual and financial, allowed me to achieve 
results that would otherwise have not been possible. 
 
My co-supervisor, Dr Patric Jansson, has been my greatest resource for ideas, 
trouble-shooting and encouragement. This thesis would not be where it is today 
without Pat’s optimism and input. 
 
To Dr Durai Palanimuthu, Prof Paul Bernhardt and Dr Danuta Kalinowski, I am 
grateful for their help in completing scientific experiments and in preparing the 
manuscripts of my chapters for publication. Their contributions were critical in getting 
the manuscripts accepted.  
 
To Dr Michael Carnell, Dr Alexander MacMillan and Dr Renee Whan of The 
Biomedical Imaging Facility, I am thankful for their microscopy expertise and input 
regarding experimental design. The knowledge and experience I gained from 
working in their facility was truly invaluable.  
 
To my family, I owe my deepest gratitude for their constant support over the duration 
of my studies. I never would have been able to complete this thesis without them.   
ii 
 
Declaration 
 
I certify that the intellectual content of this thesis is the product of my own work and 
that all the assistance received in preparing this thesis and sources have been 
acknowledged. This thesis has not been submitted for any degree or any other 
purposes. 
 
 
  
Alexandra Stacy 
  
iii 
 
Authorship Attributions 
 
Chapter 3 of this thesis is published as “Stacy AE, Palanimuthu D, Bernhardt PV, 
Kalinowski DS, Jansson PJ, Richardson DR. (2016). Structure-Activity Relationships 
of Di-2-Pyridylketone, 2-Benzoylpyridine and 2-Acetylpyridine Thiosemicarbazones 
for Overcoming Pgp-Mediated Drug Resistance J. Med. Chem. 59(18): 8601-20.” 
 
I designed the studies with P.J.J. and D.R.R., interpreted the data, performed 
experiments and wrote the manuscript. D.P. and P.V.B performed experiments and 
contributed to the manuscript preparation. P.J.J, D.S.K. and D.R.R contributed to the 
manuscript preparation. 
 
Chapter 4 of this thesis is published as “Stacy AE, Palanimuthu D, Bernhardt PV, 
Kalinowski DS, Jansson PJ, Richardson DR. (2016). Zinc(II)-thiosemicarbazone 
complexes are localised to the lysosomal compartment where they transmetallate 
with copper ions to induce cytotoxicity. J. Med. Chem. 59(10): 4965-84.” 
 
I designed the studies with P.J.J. and D.R.R., interpreted the data, performed 
experiments and wrote the manuscript. D.P. and P.V.B performed experiments and 
contributed to the manuscript preparation. P.J.J, D.S.K. and D.R.R contributed to the 
manuscript preparation. 
iv 
 
In addition to the statement above, where I am not the corresponding author of the 
published item, permission to include the published material has been granted by the 
corresponding author 
 
Alexandra Stacy   22.08.2016 
Student Name         Signature          Date 
 
As supervisor for the candidature upon which this thesis is based, I can confirm that 
the authorship attribution statement above is correct. 
 
Professor Des Richardson 
Supervisor Name    Signature        Date 
v 
 
Abstract 
Multidrug resistance (MDR) is a significant obstacle in the successful treatment of 
cancer. To date, no therapies that target MDR have reached the clinic. Our 
thiosemicarbazone compound, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone 
(Dp44mT), induces greater cytotoxicity in drug resistant cancer cells that express the 
drug efflux transporter, P-glycoprotein (Pgp), than in their non-drug resistant 
counterparts. 
  
Herein, the structure-activity relationships of selected thiosemicarbazones were 
explored and the novel mechanism underlying their ability to overcome MDR was 
examined. Only thiosemicarbazones with electron-withdrawing substituents at the 
imine carbon mediated Pgp-dependent potentiated cytotoxicity and caused Pgp-
dependent lysosomal membrane permeabilisation (LMP). This LMP relied on 
copper(II) chelation, reactive oxygen species generation and increased relative 
lipophilicity.  
 
We also synthesised fluorescent zinc(II) complexes of our potently anti-cancer 
thiosemicarbazones to assess their intracellular distribution. The Zn(II) complexes 
generally showed significantly greater cytotoxicity than the thiosemicarbazones 
alone. Confocal fluorescence imaging showed that the Zn(II) complex of our lead 
compound, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), 
was localised to lysosomes. Under lysosomal conditions, the Zn(II) complexes were 
shown to transmetallate with copper ions, leading to redox-active Cu(II) complexes 
that induced LMP and cytotoxicity.  
vi 
 
Furthermore, we investigated the anti-cancer efficacy of Dp44mT and DpC in Bcl-2 
over-expressing, melanoma cells. Herein, we demonstrated that DpC decreased Bcl-
2 expression, while Dp44mT did not. Furthermore, we showed that the mechanism 
by which DpC and Dp44mT exerted their cytotoxicity in melanoma cells did not 
involve copper ion binding or ROS generation. DpC, but not Dp44mT, induced 
autophagosome formation and increased the accumulation of acidic vesicles (e.g., 
autolysosomes), regardless of Bcl-2 expression.  
 
This thesis significantly expands current knowledge regarding novel strategies of 
overcoming MDR, which can be implemented in the design of innovative 
therapeutics. 
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Chapter 1 - Introduction 
 
1.1Aroylhyrdrazone and Thiosemicarbazones for 
Cancer Treatment 
For more than 25 years, our laboratory has developed ligands as anti-cancer agents 
(Baker et al., 1992; Becker et al., 2003; Darnell and Richardson, 1999; Richardson et 
al., 1995; Richardson and Milnes, 1997). Aroylhydrazones such as hydroxy-1-
naphthylaldehyde isonicotinoyl hydrazone (311) were investigated first, and are 
biologically effective iron ion chelators, forming tridentate ligands via their O-N-O 
system (Fig. 1.1) (Ponka et al., 1979).  
 
These agents possess favourable properties such as oral availability, high 
membrane permeability, and simple synthesis (Kalinowski and Richardson, 2005; 
Kalinowski et al., 2007; Richardson et al., 1995; Richardson, 1997). Investigations of 
the biological activity of 311 found that it inhibits ribonucleotide reductase (RR), 
resulting in growth inhibition and apoptosis of cancer cells(Green et al., 2001; 
Richardson, 1997). Additional molecular targets include cell cycle regulators cyclins 
D1, D2, and D3, cyclin-dependent kinase 2 and the cyclins A and B1; the expression 
of which is reduced by 311 and results in cell cycle arrest (Gao and Richardson, 
2001). 
 
In an attempt to increase the cytotoxicity of aroylhydrazones such as 311, analogues 
with additional lipophilic groups were synthesised (Richardson et al., 1995). These 
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ligands have similar yet more potent properties to 311, with di-2-pyridylketone 
isonicotinyl hydrazone (PKIH) (Fig. 1.1) emerging as the lead compound from the 
series. Aside from their selective anti-proliferative activity towards cancer cells, they 
also affect the cell cycle by increasing the expression of proteins involved in G1/S 
arrest (Becker et al., 2003). Furthermore, the redox activity of the complexes of PKIH 
and its analogues plays an important role in their cytotoxicity (Becker et al., 2003). 
 
Thiosemicarbazones were originally developed for the treatment of tuberculosis 
(Domagk et al., 1946; Donovick et al., 1950), however they have been found to have 
a broad range of therapeutic uses ranging from anti-viral to anti-cancer (Brockman et 
al., 1956; Brownlee and Hamre, 1951; Hamre et al., 1950; Klayman et al., 1979; 
Liberta and West, 1992; Shipman et al., 1986). Indeed, 2-formylpyridine 
thiosemicarbazone was the first agent of this class to demonstrate potent anti-cancer 
activity (Brockman et al., 1956). This property has since made thiosemicarbazones 
the focus of extensive research and development (Kalinowski and Richardson, 
2005). Similarly to aroylhydrazones, one of the mechanisms that mediates the anti-
cancer activity of thiosemicarbazones is the inhibition of RR through iron ion 
chelation (Cory et al., 1994; Finch et al., 2000; Green et al., 2001; Sartorelli et al., 
1971; Yu et al., 2011). Subsequent studies demonstrated that this was only one of a 
multitude of anti-cancer mechanisms mediated by thiosemicarbazones including the 
inhibition of oncogenic signalling pathways and the formation of redox-active 
transition metal complexes which are coordinated via the N-N-S system (Fig. 1.1, 
1.3) (Jansson et al., 2010a; Jansson et al., 2010b; Kovacevic et al., 2011; Kovacevic 
et al., 2013; Lovejoy et al., 2011; Lovejoy et al., 2012; Richardson et al., 2006; Yu et 
al., 2009b; Yuan et al., 2004).  
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One of the first thiosemicarbazones to enter clinical trials was 3-amino-2-
pyridinecarboxaldehyde thiosemicarbazone (3-AP), which has been in greater than 
20 multi-centre clinical trials (Fig. 1.1) (Knox et al., 2007; Merlot et al., 2013; Odenike 
et al., 2008; Traynor et al., 2010). However, 3-AP has suffered multiple problems, 
including low efficacy in some tumour types and serious side effects such as 
methaemoglobinaemia (Knox et al., 2007; Merlot et al., 2013; Traynor et al., 2010).  
 
 
Figure 1.1 Structures of 311, PKIH and 3-AP  
Whereas 311 has an O-N-O system, PKIH, an aroylhydrazone, chelates transition 
metals through its N-N-O system (blue highlights). 3-AP, a thiosemicarbazone, 
chelates transition metals through its N-N-S system (red highlights). 
 
 
1.2 Development of New Generation 
Thiosemicarbazones for Cancer Treatment 
The anti-cancer efficacy of aroylhydrazones, such as 311 and PKIH, and 
thiosemicarbazones, such as 3-AP, prompted the development of 
aroylhydrazone/thiosemicarbazone hybrids (Kalinowski and Richardson, 2005). 
Concerted structure-activity studies identified several series of ligands with marked 
and selective anti-tumour activity in vitro and/or in vivo (Kalinowski et al., 2007; 
PKIH 3-AP311
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Richardson et al., 2009; Yu et al., 2012). These series included the di-2-
pyridylketone thiosemicarbazone (DpT) series (Chen et al., 2012; Liu et al., 2012; 
Lovejoy et al., 2012; Richardson et al., 2006; Whitnall et al., 2006; Yuan et al., 2004), 
the 2-benzoylpyridine thiosemicarbazone (BpT) (Kalinowski et al., 2007) and 2-
acetylpyridine thiosemicarbazone (ApT) series of ligands (Richardson et al., 2009) 
that also showed marked and selective anti-tumour activity in vitro and/or in vivo 
(Fig. 1.2) (Kalinowski et al., 2007; Richardson et al., 2009; Yu et al., 2012).  
The DpT series was developed first, based on the high activity of PKIH and 3-AP 
(Becker et al., 2003; Knox et al., 2007; Merlot et al., 2013; Odenike et al., 2008; 
Traynor et al., 2010). The success of the DpT series led to the synthesis of the BpT 
series, which was developed in order to explore the role of aromatic substituents on 
the anti-proliferative effects of the DpT series (Fig. 1.2) (Kalinowski et al., 2007). The 
ApT series explored the effects of replacing the parent ketone of DpT series, di-2-
pyridylketone, with 2-acetylpyridine in order to create an agent similar to the clinically 
trialled 3-AP (Fig. 1.2) (Richardson et al., 2009).  
 
1.2.1 Efficacy of the DpT Series 
Of the DpT analogues, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone 
(Dp44mT) is the best characterised. Dp44mT acts in a polypharmacological manner, 
targeting primary tumour growth, metastasis and drug resistance (Jansson et al., 
2015a). 
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Figure 1.2 Hybrid aroylhydrazones-thiosemicarbazones of the DpT, BpT and 
ApT series  
Hybrid aroylhydrazone-thiosemicarbazones chelate transition metals through their N-
N-S systems. The DpT and BpT series differ to the ApT series in that the ApT series 
possesses only 1 aromatic ring on its imine carbon, as opposed to 2 like the DpT 
and BpT series (green highlights). The BpT and DpT series differ in the type of 
aromatic substituents on the imine carbon (orange highlights): DpT has a dipyridyl 
substituent; BpT possesses a phenyl ring and a pyridyl ring.  
 
 
Specifically, Dp44mT can target tumour growth by inducing G1/S cell cycle 
arrest (Dixon et al., 2013; Noulsri et al., 2009) and inhibiting oncogenic signalling 
pathways including transforming growth factor-β (TGF-β) (Kovacevic et al., 2013), c-
Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) (Yu 
and Richardson, 2011), Ras/extracellular regulated kinase (ERK) (Kovacevic et al., 
2013), protein kinase B (AKT)/phosphatidylinositol-3-kinase (PI3K) (Dixon et al., 
2013; Kovacevic et al., 2013), STAT3 (Lui et al., 2015), cellular-sarcoma kinase (c-
Src) (Liu et al., 2015) and Rho-associated Coiled-coil-containing protein Kinase 1 
(ROCK1)/phosphorylated Myosin Light Chain 2 (pMLC2) pathways (Sun et al., 
2013).  
 
DpT BpT ApT
N
H
N N
N
S
R
R
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Dp44mT can suppress metastasis through up-regulation of N-myc downstream-
regulated gene 1 (NDRG1), which inhibits primary tumour growth, angiogenesis and 
metastasis of cancer in vivo (Bae et al., 2013; Kovacevic and Richardson, 2006; 
Maruyama et al., 2006). The metastasis suppressor NDRG1 is up-regulated by 
Dp44mT via hypoxia-inducible factor-1α (HIF-1α)-dependent (Le and Richardson, 
2004) and -independent mechanisms (Lane et al., 2013), both related to iron 
depletion. The anti-tumour activity of Dp44mT is also mediated by the formation of 
complexes with iron and copper ions that exhibit pronounced redox activity (Jansson 
et al., 2010a; Jansson et al., 2010b; Lovejoy et al., 2011). Furthermore, Dp44mT is 
able to overcome multidrug resistance (MDR) in cancer, which will be discussed 
further in Section 1.6 (Jansson et al., 2015a; Seebacher et al., 2016a; Whitnall et al., 
2006). 
 
Significantly, Dp44mT demonstrated markedly more pronounced anti-proliferative 
activity in vitro than the clinically trialled 3-AP (Whitnall et al., 2006; Yuan et al., 
2004). Additionally, Dp44mT demonstrated greater tolerability with less side effects 
(Richardson et al., 2006; Whitnall et al., 2006), which has been independently 
validated by a number of research groups (Gaal et al., 2014; Ishiguro et al., 2014; 
Liu et al., 2012; Rao et al., 2009). Unfortunately, Dp44mT induced cardiac fibrosis at 
high non-optimal doses (Whitnall et al., 2006) and this led to the design and 
synthesis of a second generation of DpT analogues (Kovacevic et al., 2011; Lovejoy 
et al., 2012). These novel agents were derived from previous studies which showed 
that increasing lipophilicity via the replacement of the terminal H at N4 with an alkyl 
group, also increased anti-proliferative activity (Kalinowski and Richardson, 2005; 
Lovejoy and Richardson, 2002; Richardson et al., 2006; Yuan et al., 2004). Of these 
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ligands, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) was 
identified as the lead agent (Kovacevic et al., 2011; Lovejoy et al., 2012). DpC 
possessed many advantages over Dp44mT, such as: potent anti-tumour activity in 
vitro and in vivo against multiple tumour-types; greater tolerability when administered 
orally, as well as intravenously (Lovejoy et al., 2012; Yu et al., 2012); and an 
improved side-effect profile inducing less cardiotoxicity and methaemoglobin 
generation (Kovacevic et al., 2011; Lovejoy et al., 2012; Quach et al., 2012). 
Notably, due to its optimal properties, DpC has entered clinical trials towards the end 
of 2016 (ClinicalTrials.gov Identifier NCT02688101) for the treatment of advanced 
cancers (Jansson et al., 2015a).  
 
1.2.2 Efficacy of the BpT Series 
Another strategy that was taken in an attempt to overcome the cardiotoxicity induced 
by high, non-optimal doses of Dp44mT, led to the generation of the BpT series. In 
order to increase lipophilicity and redox cycling, the non-coordinating 2-pyridyl ring 
was removed and replaced with a less electron-withdrawing phenyl group (Fig. 1.2) 
(Kalinowski et al., 2007). Indeed, the anti-proliferative activity of the BpT series was 
found to be greater than that of the DpT series in vitro (Kalinowski et al., 2007; Yu et 
al., 2012).  
 
The redox activity of the BpT- complexes was demonstrated to be greater than the 
DpT- complexes, likely due to the lowered redox potentials due to the phenyl moiety 
found in the BpT but not DpT series (Fig. 1.2) (Kalinowski et al., 2007). The greater 
redox activity potentially accounts for the increased anti-proliferative activity of the 
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BpT series (Kalinowski et al., 2007). Furthermore, the lead analogue of the series, 2-
benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone (Bp44mT), was shown to be 
orally active against the growth of a human lung xenograft model (Yu et al., 2012). In 
this model Bp44mT also caused a marked decrease in cyclin D1 and 
p21CIP1/WAF1 expression in the tumours, which should prevent cell cycle 
progression and induce apoptosis (Yu et al., 2012). Compared to Dp44mT, Bp44mT 
had a better side-effect profile, as it did not induce weight loss or cardiac fibrosis (Yu 
et al., 2012). However, Bp44mT treatment was associated with mild reversible 
anaemia and hepatotoxicity (Yu et al., 2012).  
 
1.2.3 Efficacy of the ApT Series 
In order to examine the effects of substituents at the imine carbon and to create a 
thiosemicarbazone similar to the clinically trialled 3-AP (Knox et al., 2007; Odenike et 
al., 2008; Traynor et al., 2010), the ApT series of analogues was developed (Fig. 
1.2) (Richardson et al., 2009). The electron-withdrawing aromatic rings that are 
found in the DpT and BpT series were, in the ApT series, replaced with an 
inductively-donating methyl group (Fig.1.2) (Richardson et al., 2009). Four of the six 
ApT chelators showed potent anti-proliferative effects, comparable to the DpT and 
BpT series (Richardson et al., 2009).  
 
The chelation efficiency of the ApT series was also similar to the DpT and BpT series 
(Richardson et al., 2009). However, the ApT-Fe(III) complexes demonstrated lower 
Fe(ll/lll) redox potentials than the DpT or BpT series (Richardson et al., 2009), and 
the Cu(II) complex of 2-acetylpyridine-4,4-dimethyl-3-thiosemicarbazone (Ap44mT) 
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exhibited lower Cu(ll/l) redox potentials than the Cu(II) complex of Dp44mT (Jansson 
et al., 2010a). This was attributed to the inductively donating imine methyl group in 
close proximity to the metal centre (Jansson et al., 2010a; Richardson et al., 2009). 
Despite this, the [Fe(III)-ApT] complexes were still able to oxidise ascorbate at levels 
similar to the DpT series (Richardson et al., 2009); and although the Cu(II) complex 
of Ap44mT was less redox-active than the Cu(II) complex of Dp44mT in vitro, both 
complexes displayed similar redox activity in vivo (Jansson et al., 2010a). However, 
the anti-proliferative activity of the Cu(II) complex of Ap44mT was less than the 
Cu(II) complex of Dp44mT (Jansson et al., 2010a)  
 
 
1.3 Thiosemicarbazones, Transition Metals and 
Redox Cycling 
Thiosemicarbazones chelate transition metals, such as iron, copper and zinc, in a 
tridentate fashion via their N-N-S system (French and Blanz, 1966). They can form 
both 1:1 transition metal/ligand complexes, and 1:2 complexes (Jansson et al., 
2010b). In particular, α-N-heterocyclic can bind a vast range of transition metals (Fig. 
1.3). The formation of redox-active complexes with transition metals has been 
demonstrated to increase thiosemicarbazone cytotoxicity both in vitro (Antholine et 
al., 1976; Blanz et al., 1970; Crim and Petering, 1967; Jansson et al., 2010b; 
Kalinowski et al., 2007; Lovejoy et al., 2011; Richardson et al., 2006; Richardson et 
al., 2009; Saryan et al., 1979; Van Giessen et al., 1973) and in vivo (Petering et al., 
1967; Yu et al., 2012).  
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Figure 1.3 Structure of α-pyridyl thiosemicarbazones and their transition metal 
(M) complexes 
A α-pyridyl thiosemicarbazones can form 1:1 complexes with a range of transition 
metals (M) B α-pyridyl thiosemicarbazones can form 1:2 complexes with M. C M that 
α-pyridyl thiosemicarbazones can form complexes with. 
 
 
1.3.1 Transition Metals and Redox Cycling 
The transition metals are located in the d block of the periodic table and form stable 
ions that have incompletely filled d sub-shells (Petrucci et al., 2002). The presence of 
unpaired electrons in their d orbitals makes transition metals highly reactive and also 
means that they have multiple oxidation states (Petrucci et al., 2002). This unique 
electronic structure generally allows transition metals to participate in redox 
reactions, involving the loss (oxidation) or gain (reduction) of one or more electrons 
(Young and Woodside, 2001). This makes transition metals ideal co-factors in 
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enzymes that carry out fundamental biological functions. However, transition metals 
can cause damage to biomolecules, either through direct interaction or by mediating 
the formation of reactive oxygen species (ROS) through redox cycling (Gutteridge et 
al., 1979). Thus, transition metals are tightly regulated within the cell to prevent 
metal-induced toxicity (Stohs and Bagchi, 1995).  
 
Of the transition metals, there is ample evidence for the roles of both iron and copper 
in oxidative stress-induced disease (Stohs and Bagchi, 1995; Young and Woodside, 
2001). These elements play a key role in the formation of the hydroxyl radical (HO•) 
in vivo, via the Haber-Weiss reaction (Fig. 1.4) (Haber and Weiss, 1932). The 
reaction occurs in two parts, first involving the reduction of a transition metal by O2•–; 
followed by the oxidation of the transition metal with H2O2 to form the HO• radical 
and HO–, which is known as the Fenton Reaction (Fig. 1.4) (Haber and Weiss, 
1932). 
 
 
Figure 1.4 The Haber-Weiss Reaction. 
Fe3+ + O2•– Fe2+ + O2
Fenton reaction:
Fe2+ + H2O2 Fe3+ + HO- + HO•
Net reaction:
O2•– + H2O2 O2 + HO– + HO•
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1.3.2 Important Transition Metals Chelated by 
Thiosemicarbazones 
1.3.2.1. Iron  
Iron is a vital element for living organisms, as it is essential for the functioning of 
many proteins and enzymes that are involved in cell growth and division (Kovacevic 
et al., 2011; Lovejoy et al., 2012). Indeed, iron depletion results in cell cycle arrest 
(Kovacevic et al., 2011; Lovejoy et al., 2012). Intracellular iron may be present as 
part of the labile iron pool, bound to the iron storage protein, ferritin, or bound to 
enzymes where it acts as a cofactor (Jansson et al., 2015a; Lovejoy et al., 2012; 
Quach et al., 2012; Yu et al., 2012). However, it is the very feature which makes iron 
a powerful catalyst that also makes it potentially toxic to cells: the redox cycling of 
iron ions leads to the generation of the HO• via the Haber-Weiss reaction (Fig. 1.4, 
Section 1.3.1) (Gutteridge et al., 1979; Halliwell, 1978). Hence, iron is carefully 
regulated within cells in order to prevent the formation of harmful free radicals and 
the resultant oxidative stress (Richardson et al., 2009).  
 
In the context of human disease, iron-induced oxidative stress is evident in iron 
overload diseases such as β-thalassaemia and Friedreich’s ataxia (Blanz et al., 
1970; Crim and Petering, 1967). Furthermore, the ROS produced by iron redox 
cycling have been implicated in many disease states due to the damage they cause 
to DNA, lipids and proteins (Section 1.3.3) (Gutteridge, 1995; Imlay et al., 1988; 
Stadtman, 1990).  
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1.3.2.2 Copper  
Similarly to iron, copper is also essential to the function of most organisms, acting as 
a co-factor for a variety of enzymes that have roles as diverse as anti-oxidant 
defence e.g. superoxide dismutase; mitochondrial respiration e.g. cytochrome c 
oxidase; and nervous system function e.g. dopamine β-monooxygenase (Antholine 
et al., 1976; Gaggelli et al., 2006; Petering et al., 1967; Van Giessen et al., 1973). 
Once taken up by the cell, copper can be found bound to metallothionein proteins 
and bound to enzymes; or it is incorporated into ceruloplasmin which contains up to 
95% of the copper found in serum (Cowley et al., 2005; Kalinowski et al., 2007; 
Kowol et al., 2010; Richardson et al., 2006; Richardson et al., 2009; Saryan et al., 
1979; Yuan et al., 2004). Lysosomes also contain a large proportion of intracellular 
copper due to degradation of copper-containing metalloproteins by lysosomal 
cathepsins (Gupte and Mumper, 2009; Kurz et al., 2010; Terman and Kurz, 2013). 
Under standard physiological conditions, an upper limit of 1 x 10-18 M of free Cu(II) 
has been calculated (Jansson et al., 2010b; Lippard, 1999; Rae et al., 1999). 
Unbound copper ions virtually non-existent within the cell as it is too redox-active 
and acts as a catalyst in the generation of damaging ROS and free radicals (Gaggelli 
et al., 2006). Furthermore, copper out-competes other divalent metals to bind cellular 
ligands, thereby affecting the functioning of biomolecules directly (Gaal et al., 2014; 
Irving and Williams, 1953; Kalinowski et al., 2007).  
 
Even when bound to proteins or enzymes, copper is still able to directly catalyse the 
formation of ROS or exert pro-oxidant effects on biomolecules (Jansson et al., 
2010b; Lovejoy et al., 2011). Indeed, copper causes DNA and protein oxidation and 
lipid peroxidation (Antholine et al., 1976; Blanz et al., 1970; Crim and Petering, 1967; 
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Gutierrez et al., 2014; Gutteridge, 1984; Jansson et al., 2010a; Petering et al., 1967; 
Van Giessen et al., 1973). Unsurprisingly, copper has been linked to disease 
progression or severity where oxidative stress is involved in the pathogenesis, such 
as cancer, arteriosclerosis and Alzheimer’s disease (Cowley et al., 2005; Jansson et 
al., 2010a; Jansson et al., 2010b; Kalinowski et al., 2007; Kowol et al., 2010; 
Richardson et al., 2009; Saryan et al., 1979). Moreover, serum and tumour copper 
levels are significantly elevated in cancer patients (Goodman et al., 2004; Gupte and 
Mumper, 2009). The importance of copper homeostasis is also highlighted by the 
genetic disorders, Menkes disease and Wilson’s disease, that result in fatal copper 
deficiency or damaging copper build-up in the liver and brain, respectively (Jansson 
et al., 2015a; Sartorelli et al., 1970).  
 
1.3.2.3 Zinc  
Zinc is an essential trace element and is the second most abundant transition metal 
found in the human body after iron (Kovacevic et al., 2011; Outten and O'Halloran, 
2001; Vallee, 1988). Zinc can act as a co-factor in the formation of a structural motif 
in proteins, which is commonly referred to as a zinc finger (Lovejoy et al., 2011; 
Vallee, 1988). However, zinc is generally directly involved in catalysis and is found in 
the active site of enzymes such as human carbonic anhydrase II (Outten and 
O'Halloran, 2001; Richardson et al., 2009). In biological systems zinc always occurs 
as a divalent cation, Zn2+/Zn(II), with a fully occupied d shell (Cowley et al., 2005). 
Zn(II) is therefore not redox-active as neither the potential oxidised form, Zn3+, nor 
the reduced form, Zn+, can be formed under physiological conditions (Kowol et al., 
2010). As a structural element in nucleic acid-binding and gene regulatory proteins, 
Zn2+ therefore possess an advantage over redox-active transition metals such as 
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iron and copper ions, which promote free radical generation and DNA damage 
(Cowley et al., 2005). 
 
1.3.3 Redox Damage to Biomolecules Mediated by Iron and Copper 
Ions 
Iron and copper ions can mediate damage to biomolecules either by interacting with 
them directly or by mediating the formation of the free radical, HO•, via the Fenton 
Reaction (Fig. 1.4,1.5). The production of ROS is inevitable in aerobic life and their 
damaging interactions with DNA, lipids and proteins (Fig. 1.5) (Antholine et al., 1976; 
Blanz et al., 1970; Crim and Petering, 1967; Gutierrez et al., 2014; Gutteridge, 1995; 
Imlay et al., 1988; Jansson et al., 2010a; Petering et al., 1967; Stadtman, 1990; Van 
Giessen et al., 1973) have acknowledged roles in the aetiology and pathogenesis of 
many diseases (Blanz et al., 1970; Cowley et al., 2005; Crim and Petering, 1967; 
Gutteridge, 1984; Jansson et al., 2010a; Jansson et al., 2010b; Kalinowski et al., 
2007; Kowol et al., 2010; Richardson et al., 2009; Saryan et al., 1979).  
 
ROS act as oxidising agents, accepting electrons from biomolecules that result in the 
reduction of the ROS and oxidation of the biomolecules (Gaetke and Chow, 2003; 
Welch et al., 2002). Transition metal ions such as Fe(II/III) and Cu(I/II) bind with high 
affinity to DNA, meaning that the HO• radical can be produced in close proximity to 
DNA via the Fenton Reaction (Gutteridge, 1984; Kohen et al., 1986). Importantly, the 
HO• radical is known to react with all components of DNA (purines, pyrimidines and 
the deoxyribose backbone) and is responsible for the majority of ROS-mediated 
DNA damage that occurs (Domagk et al., 1946; Donovick et al., 1950; Liberta and 
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West, 1992). Oxidative damage to DNA can result from the formation of DNA-protein 
cross-links (Hamre et al., 1950), apurinic sites (Hamre et al., 1950) and DNA strand 
breaks (Shipman et al., 1986) all of which lead to mutations (Fig. 1.5) (Brownlee and 
Hamre, 1951). Additionally, the presence of iron and copper ions can greatly 
enhance the oxidative degradation of lipids (Blanz et al., 1970; Gutteridge et al., 
1979; Petering et al., 1967). Cell membranes are vulnerable to oxidation, known as 
lipid peroxidation, as the double bonds found in polyunsaturated fatty acids are a 
ready target for attack by HO• produced by the redox cycling of iron or copper ions 
(Gutteridge, 1995; Reichard and Ehrenberg, 1983; Sartorelli et al., 1970). It has been 
estimated that around 60 molecules of linoleic acid (the most common poly-
unsaturated fatty acid found in cell membranes) are consumed per oxidant that 
reacts with the lipid bilayer (Crim and Petering, 1967). The consequences of lipid 
peroxidation affect the functioning of the cell membrane by disrupting ion channels, 
membrane transport proteins or by causing the membrane to become permeable, 
leading to cell death (Fig. 1.5) (Van Giessen et al., 1973).  
 
Almost all amino acids are vulnerable to oxidation by HO• radicals, produced when 
H2O2 encounters iron or copper ions found in the binding sites of proteins (Saryan et 
al., 1979; Stadtman, 1990). Radicals can target and cause damage to both the 
backbone and the amino acid side chains of proteins (Knox et al., 2007; Stadtman, 
1990). This damage may result in inter- and intra-protein cross-links, protein 
fragmentation and conformational changes in structure (Fig. 1.5.) (Baker et al., 1992; 
Darnell and Richardson, 1999; Merlot et al., 2013; Richardson et al., 1995; 
Richardson and Milnes, 1997; Stadtman, 1990). Oxidative damage to proteins can 
therefore affect cell functioning due to the loss of enzymatic, transport and regulatory 
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protein function (Becker et al., 2003; Stadtman, 1990; Whitnall et al., 2006; Yuan et 
al., 2004).  
 
 
Figure 1.5 Examples of damage to biomolecules caused by the HO• radical.  
The redox cycling of copper and iron ions produces the highly reactive HO• radical 
via the Fenton reaction. The HO• radical induces oxidative damage to biomolecules 
including: DNA damage such as strand breaks and apurinic sites; protein damage 
such as cross-linking and fragmentation; and lipid peroxidation in membranes. 
 
 
1.4 Multidrug Resistance and Cancer 
When cancer patients fail to respond to surgical excision and/or radiotherapy or their 
cancer is too advanced, the next line of treatment is chemotherapy (Gillet and 
Gottesman, 2010; Gottesman, 2002). While some patients go into complete 
remission following treatment, others show only a transient response or fail to 
respond at all (Gillet and Gottesman, 2010; Gottesman, 2002). This resistance to 
chemotherapy is commonly conferred against a variety of both structurally and 
HO•
DNA damage 
e.g. strand breakage Lipid peroxidation
Protein damage e.g. cross-linking
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mechanistically unrelated drugs and is known as cancer multidrug resistance (MDR), 
which may be inherent or acquired (Gillet and Gottesman, 2010; Gottesman, 2002).  
 
The mechanisms behind this failure to respond can be divided into three categories: 
(1) pharmacokinetic resistance e.g. increased metabolism (Ekhart et al., 2009) or 
poor tumour penetration (Minchinton and Tannock, 2006); (2) intrinsic tumour cell 
resistance e.g. altered drug transport (Gottesman, 2002) or inhibition of apoptosis 
(Dunn et al., 1997; Kroemer, 1997); and (3) tumour microenvironment-related factors 
(Minchinton and Tannock, 2006; Tomida and Tsuruo, 1999) e.g. hypoxia or acidosis 
(Fig. 1.6) (Gerweck et al., 2006; Seebacher et al., 2016a). Although there are 
multiple mechanisms that tumour cells use to evade apoptosis, two of the best-
characterised mechanisms involve increased drug efflux by members of the 
adenosine triphosphate (ATP)-binding cassette (ABC) family (Fig. 1.6) (Gillet and 
Gottesman, 2010; Gottesman, 2002), and evasion of apoptosis by increased 
expression of B cell lymphoma 2 (Bcl-2) (Fig. 1.6) (Thomas et al., 2013; Youle and 
Strasser, 2008). An additional mechanism of MDR involves sequestration of 
cytotoxic chemotherapeutics inside lysosomes, which prevents them from reaching 
their intended intracellular targets and thus decreases their cytotoxicity (Fig. 1.6) 
(Appelqvist et al., 2013; Zhitomirsky and Assaraf, 2016).  
 
19 
 
 
Figure 1.6 Mechanisms of MDR 
The three mechanisms of MDR that will be the focus of this thesis are (1) Enhanced 
drug (yellow circle) efflux by ABC transporters; (2) Inhibition of intrinsic apoptosis by 
increased expression of Bcl-2 family members (orange oval); (3) Drug sequestration 
in lysosomes, preventing the drug from reaching its target e.g. DNA in the nucleus.  
 
 
 
1.4.1 Pgp, a Member of the ABC Family of Drug Efflux Transporters 
Members of the ABC family are transmembrane proteins that bind and hydrolyse 
ATP, the energy from which is then utilised to efflux substrates across cell 
membranes (Fletcher et al., 2010; Gillet and Gottesman, 2010; Gottesman and 
Pastan, 1993; Gottesman et al., 2002). The substrate specificity of the family 
members varies widely; they are responsible for the transport of biological substrates 
such as hormones, lipids, metabolic products, and also xenobiotics, including 
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chemotherapeutics (Fletcher et al., 2010; Gillet and Gottesman, 2010; Gottesman 
and Pastan, 1993; Gottesman et al., 2002). There are 48 known members of the 
ABC superfamily which are divided into seven subfamilies, designated A to G, on the 
basis of sequence and structural homology (Fletcher et al., 2010; Gillet and 
Gottesman, 2010; Gottesman and Pastan, 1993; Gottesman et al., 2002).  
 
The ABC transporters are highly conserved in evolution, generally consisting of two 
nucleotide (ATP) binding domains (NBDs) and two transmembrane domains (TMDs), 
although some exist as half transporters which must at least homo- or hetero-
dimerise to become functional transporters (Fletcher et al., 2010; Gillet and 
Gottesman, 2010; Gottesman and Pastan, 1993; Gottesman et al., 2002). The TMDs 
are usually found at the N-terminal and contain 6-12 α-helices that span the 
membrane and confer substrate specificity. The NBDs are located at the C-terminal 
in the cytoplasm and contain both the ATP-binding sequences, Walker A and B 
motifs, found in other ATPases; and the ABC signature or C motif, which is unique to 
the family (Fletcher et al., 2010; Gillet and Gottesman, 2010; Gottesman and Pastan, 
1993; Gottesman et al., 2002).  
 
When a substrate binds to the transporter, one of the NBDs is activated to hydrolyse 
ATP, which results in a major conformational change in the transporter, releasing the 
substrate on the other side of the membrane (Fletcher et al., 2010; Gillet and 
Gottesman, 2010; Gottesman and Pastan, 1993; Gottesman et al., 2002). The 
hydrolysis of a second molecule of ATP then returns the transporter to its native 
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conformation, ready to repeat the cycle (Fletcher et al., 2010; Gillet and Gottesman, 
2010; Gottesman and Pastan, 1993; Gottesman et al., 2002). 
 
The three ABC transporters that are most extensively studied in the context of MDR 
are P-glycoprotein (Pgp, also known as MDR1 or ABCB1), multidrug resistance 
associated protein 1 (MRP1, also known as ABCC1) and ATP-binding cassette, sub-
family G, isoform 2 protein (ABCG2, also known as breast cancer resistance protein, 
BCRP) (Cole et al., 1992; Doyle et al., 1998; Fletcher et al., 2010; Gillet and 
Gottesman, 2010; Gottesman and Pastan, 1993; Gottesman, 2002; Gottesman et 
al., 2002; Stacy et al., 2013). Of these three, Pgp has been the focus of concentrated 
research as its clinical relevance in the MDR phenotype is well established 
(Gottesman et al., 2002; Juliano and Ling, 1976). Thus, Pgp will be discussed in 
depth as a major focus of this thesis. 
 
Juliano and Ling (1976) first discovered Pgp almost 40 years ago in Chinese 
hamster ovary cells selected for colchicine resistance. However, Pgp was found to 
also confer resistance to a variety of mechanistically and structurally unrelated drugs 
(Juliano and Ling, 1976). The 170 kDa protein is encoded by the MDR1 gene located 
on chromosome 7q21 (Ganapathi et al., 1996), and is the most thoroughly 
characterised of the ABC transporters (Fletcher et al., 2010; Gillet and Gottesman, 
2010; Gottesman and Pastan, 1993; Gottesman et al., 2002). Pgp is expressed in a 
wide variety of cancers where it effluxes chemotherapeutics from the cell, thus 
decreasing their cytotoxicity and contributing to treatment failure (Fletcher et al., 
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2010; Gillet and Gottesman, 2010; Gottesman and Pastan, 1993; Gottesman et al., 
2002). Pgp has therefore been the focus of research aimed at overcoming MDR.  
 
1.4.1.1 Structure and Transport Models of Pgp 
Pgp is synthesised as a 140 kDa polypeptide precursor that is later N-glycosylated in 
the first extracellular linker region to become a 170 kDa transmembrane protein 
containing 1280 amino acids (Fig. 1.7) (Chen et al., 1986; Greer and Ivey, 2007; 
Gros et al., 1986; Juliano and Ling, 1976). To date, no high-resolution crystal 
structures of human Pgp have been generated, thus it is difficult to make concrete 
assertions regarding the structure of human Pgp. Current homology models are 
based on mouse and Caenorhabditis elegans Pgp proteins, which have 87% and 
46% sequence homology with human Pgp, respectively (Aller et al., 2009; Jin et al., 
2012; Li et al., 2014). The transporter consists of 2 halves with 6 N-terminal TMDs 
and 1 C-terminal NBD each, joined by a linker region (Fig. 1.7) (Li et al., 2014; 
Rosenberg et al., 2005). The N- and C-terminals as well as the NBDs are both 
intracellular (Fig. 1.7) (Kartner et al., 1985). The TMDs are predicted to form the 
substrate-binding sites and the central pore through which substrates are 
transported across the membrane (Li et al., 2014; Rosenberg et al., 2005). The 
presence of aromatic residues in the mammalian Pgp translocation pathway likely 
facilitates the recognition and transport of neutral/cationic molecules (Ferreira et al., 
2013; Li et al., 2014). It has been suggested that there are up to three binding sites 
within the central pore: two that are substrate-binding sites, and one that is a 
modulator-binding site (Ferreira et al., 2013; Shapiro and Ling, 1997; Sharom et al., 
2005).  
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Substrates of Pgp, being relatively hydrophobic (Section 1.4.1.4), partition into the 
lipid bilayer where they interact with the transporter’s substrate binding sites (Fig. 
1.7) (Aller et al., 2009; Higgins and Gottesman, 1992; Kessel, 1989; Pearce et al., 
1989; Sharom, 1997; Sharom, 2014). Although the exact mechanism of Pgp 
substrate binding and transport remains elusive, Pgp and other ABC transporters are 
thought to act by an alternating access model, whereby substrate binding to the 
inward-facing conformation of the transporter stimulates ATPase activity (Fig. 1.7) 
(Callaghan et al., 2006; Senior et al., 1995; Urbatsch et al., 1995). The hydrolysis of 
one molecule of ATP then generates the energy needed to cause a switch to an 
outward-facing conformation of the transporter, resulting in the release of the 
substrate into the extracellular space (Aller et al., 2009; Higgins and Gottesman, 
1992; Kessel, 1989; Pearce et al., 1989; Sharom, 1997; Sharom, 2014). Hydrolysis 
of another ATP molecule is then needed to ‘re-set’ the transporter so that it can bind 
substrates again (Aller et al., 2009; Higgins and Gottesman, 1992; Kessel, 1989; 
Pearce et al., 1989; Sharom, 1997; Sharom, 2014).  
 
1.4.1.2 Pgp in Normal Physiology 
Despite Pgp being thought of mainly as a drug resistance protein, like all ABC 
transporters, it also plays a role in normal physiology. The transporter is widely 
distributed throughout the body and its localisation suggests that its main 
physiological role is to protect the body from exposure to toxins (Gottesman et al., 
2002; Sharom, 2011).  
 
24 
 
 
Figure 1.7 Membrane topology and transport model of Pgp  
A Pgp consists of 2 halves with 6 N-terminal TMDs and 1 C-terminal NBD each, 
joined by a linker region. The N- and C-terminals as well as the NBDs are both 
intracellular. The 140 kDa polypeptide precursor that is N-glycosylated in the first 
extracellular linker region to become a 170 kDa transmembrane protein. B 
Substrates partition into the lipid bilayer where they interact with the transporter’s 
substrate binding sites. The hydrolysis of one molecule of ATP then generates the 
energy needed to cause a switch to an outward-facing conformation of the 
transporter, resulting in the release of the substrate into the extracellular space. 
Hydrolysis of another ATP molecule is then needed to ‘re-set’ the transporter so that 
it can bind substrates again. 
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Pgp has been found in the apical membrane of the large and small intestine, liver 
bile ductules and kidney proximal tubules, which all have excretory roles; as well as 
in the adrenal glands, the placenta and the apical membrane of endothelial cells 
lining the capillaries of the brain (Cordon-Cardo et al., 1990; Fojo et al., 1987; 
Thiebaut et al., 1987; Thiebaut et al., 1989; van der Valk et al., 1990).  
 
Pgp protects against xenobiotic exposure in three main ways: (1) Pgp is expressed 
in the apical membrane of enterocytes in the gastrointestinal mucosa, where it 
pumps substrates in the basal to apical membrane direction into the lumen of the 
gastrointestinal tract, thus limiting drug absorption and oral bioavailability (Thiebaut 
et al., 1987); (2) if a xenobiotic reaches the blood circulation, Pgp is constitutively 
expressed in the canalicular membrane of hepatocytes and the luminal membrane of 
proximal tubule cells in the kidney, promoting xenobiotics excretion into bile and 
urine, respectively (Cordon-Cardo et al., 1990; Sugawara et al., 1988; Thiebaut et 
al., 1987); (3) finally, Pgp expression in the brain, testis and foetal circulation, limits 
the penetration of xenobiotics to sensitive tissues (Cordon-Cardo et al., 1990; 
Sugawara et al., 1988). In this way, Pgp limits absorption, actively eliminates and 
limits the tissue distribution of xenobiotics. 
 
1.4.1.3 Pgp in Cancer and MDR  
Generally, intrinsic Pgp expression is found in solid tumours originating from areas 
where Pgp is endogenously expressed, specifically, the kidney, liver, colon, 
pancreas and adrenal glands (Fojo et al., 1987; Goldstein et al., 1989; Kakehi et al., 
1988; Kanamaru et al., 1989). Additionally, Pgp is found in leukaemia, non-Hodgkin's 
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lymphoma, neuroblastoma, sarcoma, and astrocytoma and non-small cell lung 
cancer (Bourhis et al., 1989a; Chan et al., 1997; Goldstein et al., 1989; Herweijer et 
al., 1990; Lai et al., 1989; Oka et al., 1997; Pirker et al., 1989; Pirker et al., 1991; 
Rothenberg et al., 1989; Sato et al., 1990a; Sato et al., 1990b). Pgp expression can 
also be selected for by exposure to chemotherapy, and has been found following 
treatment and relapse in breast cancer, ovarian cancer, lymphoma, leukaemia, 
neuroblastoma, pheochromocytoma, rhabdomyosarcoma and multiple myeloma 
(Bourhis et al., 1989b; Dalton et al., 1989; Gerlach et al., 1987; Izquierdo et al., 
1995; Ro et al., 1990; Schneider et al., 1989).  
 
While several of the ABC transporters have been associated with MDR in cancer, 
Pgp especially has been demonstrated to play a significant role in clinical drug 
resistance (Gillet and Gottesman, 2010; Gottesman, 2002; Gottesman et al., 2002; 
Sharom, 2011). Many lines of evidence highlight the importance of Pgp in MDR, 
including: (1) high levels of Pgp expression has been found in a wide variety of 
tumour types and cancer cell lines, and its expression is associated with MDR 
(Alvarez et al., 1995; Cordon-Cardo et al., 1990; Fojo et al., 1987; Szakacs et al., 
2004); (2) increased Pgp expression is associated with acquired drug resistance 
following chemotherapy in patients or exposure of cells to Pgp substrates (Abolhoda 
et al., 1999; Bell et al., 1985; Bourhis et al., 1989b; Dalton et al., 1989; Gerlach et al., 
1987; Goldstein et al., 1989; Ro et al., 1990; Schneider et al., 1989); (3) modulation 
of Pgp with inhibitors (Section 1.5.1) sensitises cells (de Bruin et al., 1999; Hyafil et 
al., 1993; Solary et al., 1991) and in some cases, patients (Advani et al., 1999; 
Greenberg et al., 2004; Sonneveld et al., 1996; Tidefelt et al., 2000), to anti-cancer 
agents that are Pgp substrates; (4) expression of Pgp in tumours is associated with 
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poor clinical outcomes such as treatment failure, decreased overall survival and an 
aggressive phenotype (Chan et al., 1991; Colone et al., 2008; Katoh et al., 2008; 
Miletti-Gonzalez et al., 2005; Oda et al., 2005; Ohtsuki et al., 2007; Weinstein et al., 
1991). 
 
Despite ample evidence for Pgp playing a significant role in MDR, attempts to target 
Pgp using inhibitors have been largely unsuccessful (Section 1.5.1). It has been 
suggested that this may be due to the high degree of functional redundancy within 
the ABC family (Holohan et al., 2013). Indeed, there is considerable substrate 
overlap between Pgp and MRP1 (Cole, 2014), which is also thought to play a role in 
MDR (Nooter et al., 1995; Triller et al., 2006; Zalcberg et al., 2000). It has also been 
estimated that as many as half of the 48 identified ABC transporters may be involved 
in drug resistance (Szakacs et al., 2004). 
 
1.4.1.4 Pgp Substrates 
Pgp can detect a wide variety of substrates, likely due to the presence of multiple 
binding sites that give it more flexibility than many other transport pumps (Table 1.1) 
(Aller et al., 2009). Pgp substrates range in size from small molecules like organic 
cations and amino acids, to large macromolecules such as polysaccharides and 
proteins (Gottesman and Pastan, 1993).  
 
In general Pgp substrates are hydrophobic, and a “rule of four” has been developed 
to predict whether a compound will be a Pgp substrate (Didziapetris et al., 2003; 
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Ford and Hait, 1990). Briefly, if a compound has at least 8 nitrogen and oxygen 
atoms, a molecular weight of over 400 and is an acid with a pKa of greater than 4, it 
is likely to be a Pgp substrate (Didziapetris et al., 2003). In addition to biological 
substrates such as steroid hormones, Pgp also transports a multitude of xenobiotics 
ranging from chemotherapeutics, HIV protease inhibitors, steroids, 
immunosuppressants, antibiotics, antihistamines, antiarrhythmics, etc (Table 1.1) 
(Fletcher et al., 2010; Gottesman et al., 2002; Kim, 2002).  
 
 
Table 1.1 Substrates of Pgp 
Class Compound
Chemotherapeutics Colchicine, Doxorubicin, 
Daunorubicin, Etoposide, Paclitaxel, 
Vinblastine, Vincristine, Imatinib, 
Topotecan, Methotrexate
HIV Protease Inhibitors Amprenavir, Indinavir, Nelfinavir, 
Saquinavir
Steroid hormones Aldosterone, Estradiol-17B-d-
glucuronide, Cortisol, 
Dexamethasone,
Methylprednisolone
Immunosuppressants and their 
analogues
Cyclosporine, Valspodar, Sirolimus, 
Tacrolimus
Antibiotics Tetracycline, Rifampicin, 
Doxycycline, Erythromycin
Anti-arrhythmics Digoxin, Diltiazem, Nifedipine
Antihistamines Cimetidine, Fexofenadine,
Terfenadine
Natural substrates Flavonoids, Curcuminoids, 
Colchicine, Actinomycin D
Fluorescent substrates Rhodamine 123, Hoechst 33342, 
LysoTracker, Calcein AM
29 
 
1.4.2 The Bcl-2 Family and Regulation of Apoptosis 
A hallmark of B cell follicular lymphoma was discovered to be chromosomal 
translocations in a previously unknown gene, BCL2 (Tsujimoto et al., 1985). This 
gene encodes the Bcl-2 protein, which due to the chromosomal translocations was 
greatly over-expressed (Bakhshi et al., 1985); and led to the discovery of the Bcl-2 
family. Bcl-2 is the founding member of the Bcl-2 family of proteins, which have 
shared sequence homology within conserved Bcl-2 homology (BH) domains (Cory 
and Adams, 2002; Danial, 2007). The Bcl-2 family proteins act as master regulators 
of the intrinsic pathway of apoptosis (Cory and Adams, 2002; Czabotar et al., 2014; 
Youle and Strasser, 2008).  
 
The family members are grouped into three classes: (1) multi-domain anti-apoptotic 
which includes Bcl-2 (Tsujimoto et al., 1985); B cell lymphoma extra-large (Bcl-XL) 
(Boise et al., 1993); Bcl-2-like protein 2 (Bcl-w) (Gibson et al., 1996); Bcl-2-like 
protein A1A (A1A) (Savitsky et al., 1995); myeloid cell leukaemia sequence 1 (Mcl1) 
(Kozopas et al., 1993); Bcl-2 like protein 10 (Bcl-B) (Kozopas et al., 1993) (Table 
1.2) (2) multi-domain pro-apoptotic which includes BCL-2-associated X protein (Bax) 
(Oltvai et al., 1993); Bcl-2 antagonist/killer (Bak) (Chittenden et al., 1995; Kiefer et 
al., 1995); Bcl-2-related ovarian killer protein (Bok) (Hsu et al., 1997) (Table 1.2); and 
(3) Bcl-2 homology 3 (BH3)-only proteins that exert pro-apoptotic effects, including 
Bcl-2 antagonist of cell death (Bad) (Yang et al., 1995); Bcl-2-interacting killer (Bik) 
(Boyd et al., 1995); Bcl-2-interacting mediator of cell death (Bim) (O'Connor et al., 
1998); BH3-interacting domain death agonist (Bid) (Wang et al., 1996); harakiri (Hrk) 
(Inohara et al., 1997); Bcl-2 modifying factor (BmF) (Puthalakath et al., 2001); Noxa 
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(Oda et al., 2000); p53 up-regulated modulator of apoptosis (Puma) (Nakano and 
Vousden, 2001) (Table 1.2).  
 
The BH3-only proteins can be further divided into activators (Bim and Bid), which 
interact directly with Bax and Bak to activate them (Certo et al., 2006; Kuwana et al., 
2005; Letai et al., 2002; Oh et al., 2006; Walensky et al., 2006); and sensitisers, 
which bind to anti-apoptotic family members and inhibit their function (Table 1.2) 
(Chen et al., 2005; Willis et al., 2005; Willis et al., 2007). 
 
The balance between BH3-only and pro-apoptotic family members, and anti-
apoptotic family members, regulates mitochondrial outer membrane 
permeabilisation, the critical “point of no return” in apoptosis (Cheng et al., 2001; 
Chipuk et al., 2006; Huang and Strasser, 2000). When BH3-only proteins are 
induced by cytotoxic stresses, they promote apoptosis by neutralising anti-apoptotic 
Bcl-2 family members and releasing activated Bax and Bak (Fig. 1.8) (Czabotar et 
al., 2014; Merino et al., 2009; Youle and Strasser, 2008).  
 
In the direct activation model, the binding of sensitisers to anti-apoptotic Bcl-2 family 
members results in the release of activator BH3-only proteins which can then directly 
activate Bax and Bak (Fig. 1.8) (Cory and Adams, 2002; Danial, 2007; Youle and 
Strasser, 2008). Sensitiser BH3-only proteins do not activate Bax and Bak directly, 
but lower the threshold for apoptosis by occupying anti-apoptotic members and 
releasing activators to trigger Bax and Bak oligomerisation (Fig. 1.8) (Cory and 
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Adams, 2002; Danial, 2007; Youle and Strasser, 2008). Alternatively, in the indirect 
activation model, binding of BH3 only proteins to anti-apoptotic family members 
triggers the release of activated Bax and Bak (Fig. 1.8) (Cory and Adams, 2002; 
Danial, 2007; Youle and Strasser, 2008).  
 
Activated Bax and Bak can homo-oligomerise and permeabilise the mitochondrial 
outer membrane (Fig. 1.8) (Czabotar et al., 2014; Wei et al., 2001; Youle and 
Strasser, 2008). Proteins from within the mitochondrial intermembrane space then 
diffuse into the cytosol (Fig. 1.8). The best studied of these proteins is cytochrome c 
(Kluck et al., 1997), which binds to apoptotic protease-activating factor-1 (APAF1) 
and assembles into the apoptosome (Riedl and Salvesen, 2007; Zou et al., 1997). 
The apoptosome then induces the activation of caspase 9 (Li et al., 1997; Riedl and 
Salvesen, 2007), which in turn activates the effector caspases that orchestrate the 
death of the cell.  
 
 
 
Table 1.2 The Bcl-2 family members 
Multi-domain 
anti-apoptotic
Multi-domain
pro-apoptotic
BH3-only
Activators                 Sensitisers
Bcl-2 Bax Bik Bad
Bcl-XL Bak Bim Puma
Bcl-w Bok Bid
A1A BmF
Mcl-1 Hrk
Bcl-B Noxa
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Figure 1.8 The Bcl-2 family members and the regulation of apoptosis 
 (A) In the direct activation model, the binding of sensitisers (red) to anti-apoptotic 
Bcl-2 family members (blue) results in the release of activator BH3-only proteins 
(green), which can then directly activate Bax and Bak (purple). (B) Alternatively, in 
the indirect activation model, binding of BH3 only proteins (green) to anti-apoptotic 
family members (blue) triggers the release of activated Bax and Bak (purple). In both 
cases, Bax and Bak can then homoligomerise and form a pore in the mitochondrial 
outer membrane, resulting in mitochondrial outer membrane permeabilisation. 
Proteins from inside the mitochondria, such as cytochrome c (yellow), can diffuse 
into the cytosol, triggering the intrinsic cascade of cell death effectors.  
 
 
 
1.4.2.1 Bcl-2 Structure and Interactions with Bcl-2 Family Members 
Bcl-2 has four BH domains that each consist of a helical bundle of hydrophobic helix-
turn-helices, surrounding a hydrophobic core helix (Petros et al., 2001). This 
hydrophobic fold is formed by the BH1, BH2 and BH3 domains and is the interface 
for interactions with the amphipathic alpha helix of BH3 domains belonging to pro-
apoptotic family members and BH3-only proteins (Lee et al., 2008; Liu et al., 2003; 
Petros et al., 2001; Sattler et al., 1997). These interactions mainly occur at the 
mitochondrial outer membrane, where Bcl-2 is anchored by a C-terminal 
hydrophobic transmembrane domain (Nguyen et al., 1993). However, Bcl-2 is also 
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found anchored to the endoplasmic reticulum and the nuclear envelope (Lithgow et 
al., 1994). Bcl-2 family can be post-translationally modified, predominantly via 
phosphorylation of Ser and Thr residues within the a1-a2 loop (Dai et al., 2013). For 
example, the phosphorylation of the Ser70 residue of Bcl-2 alters the conformation of 
the a1-a2 loop and increases its binding to Bak and Bim, making the cell resistant to 
chemotherapeutic agents (Dai et al., 2013).  
 
Bcl-2 exerts its anti-apoptotic function by binding to the pro-apoptotic family 
members Bax and Bak, which prevents them from causing mitochondrial outer 
membrane permeabilisation (Certo et al., 2006). Bcl-2 can also be bound by the 
amphipathic BH3 helix (Lee et al., 2008; Liu et al., 2003; Petros et al., 2001; Sattler 
et al., 1997) of the BH3-only proteins Bid, Bim, Bad, Puma, Bmf and to a lesser 
extent, Bik (Chen et al., 2005). In this case, the binding of the BH3-only domain 
proteins neutralise the anti-apoptotic activity of Bcl-2. Bcl-2 will also bind to the 
autophagy inducer, Beclin 1, which contains a region that resembles a BH3 domain 
(Chang et al., 2010; Liang et al., 1998). This happens only at the endoplasmic 
reticulum and appears to inhibit autophagy (Chang et al., 2010; Pattingre et al., 
2005). Phosphorylation of the a1-a2 loop prevents Bcl-2 from binding Beclin 1 and 
inhibiting autophagy (Wei et al., 2008).  
 
1.4.2.2 Bcl-2 in Cancer and MDR 
Dysregulated expression of the Bcl-2 family members has been demonstrated to be 
an underlying cause or contributor in many different types of cancer, as impaired 
apoptosis is a key aspect of tumour development (Thomas et al., 2013). Indeed, in 
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90% of B cell lymphoma the expression of Bcl-2 is greatly increased (Weiss et al., 
1987) due to the chromosomal translocation t(14, 18) that places Bcl-2 next to the 
enhancer of the immunoglobulin heavy chain promoter (Cleary et al., 1986). Aside 
from haematopoietic cancers (Bincoletto et al., 1999; Hermine et al., 1996; Tothova 
et al., 2002), other, diverse types of cancer where Bcl-2 over-expression has been 
found include glioma (Weller et al., 1995) melanoma (Grover and Wilson, 1996), 
breast (Joensuu et al., 1994), prostate (McDonnell et al., 1992), small cell lung 
cancer (Jiang et al., 1995), colorectal cancer (Sinicrope et al., 1995) and bladder 
cancer (Gazzaniga et al., 1996). In many of these cancers, Bcl-2 has been linked to 
severity of malignancy, poor clinical response and poor prognosis (Bincoletto et al., 
1999; Grover and Wilson, 1996; Hermine et al., 1996; Joensuu et al., 1994; 
McDonnell et al., 1992; Tothova et al., 2002).  
 
BH3-only proteins are essential transducers of stress signals generated in response 
to many chemotherapeutics. Over-expression of anti-apoptotic family members such 
as Bcl-2, which bind to BH3 only proteins and prevent them from activating Bak/Bax, 
allows cancer cells to ignore apoptotic signals generated in response to 
chemotherapeutics which contributes to MDR (Amundson et al., 2000; Dole et al., 
1994; Miyashita and Reed, 1993; Schmitt et al., 2000; Shibata et al., 1999; Strasser 
et al., 1993; Thomas et al., 1996; Vaux et al., 1988; Wang et al., 2013). In this 
manner, over-expression of Bcl-2 mediates resistance to a variety of structurally and 
mechanistically unrelated chemotherapeutics including dexamethasone (Skommer et 
al., 2006), doxorubicin (Skommer et al., 2006) 5-fluorouracil (Wu et al., 2015), 
etoposide (Wang et al., 2013), and cisplatin (Wang et al., 2013).  
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1.4.3 Lysosomes as More than ‘Suicide Bags’ 
Lysosomes are degradative organelles which digest macromolecules and  
organelles so that their components may be recycled (Appelqvist et al., 2013). These 
components are delivered to lysosomes as a result of either endocytosis or 
autophagy (Appelqvist et al., 2013). Lysosomes consist of a lipid/protein bilayer 
(Saftig et al., 2010) and an acidic lumen that contains the digestive enzymes, acid 
hydrolases (Lübke et al., 2009). Since their discovery in the 1950’s, our knowledge 
of the physiological roles of lysosomes has expanded beyond that of simple ‘suicide 
bags’- a term coined by Christian de Duve, who won the Nobel Prize in Physiology in 
Medicine for their discovery (Appelmans et al., 1955; De Duve et al., 1955; De Duve, 
1965). We now know that beyond their basic digestive role, lysosomes also play a 
role in processes such as plasma membrane repair (McNeil, 2002), exocytosis 
(Rodriguez et al., 1997), apoptosis (Turk et al., 2002) and regulation of metabolites 
such as cholesterol (Carstea et al., 1997).  
 
1.4.3.1 Formation and Properties of Lysosomes 
Lysosomes are formed through a dynamic process involving fusions of vesicles from 
the trans-Golgi network with endosomes (Huotari and Helenius, 2011; Saftig and 
Klumperman, 2009). The vesicles of the endolysosomal pathway are characterised 
as early endosomes that form via endocytosis (pH 6), which mature into late 
endosomes (pH 5) and finally lysosomes (pH < 5) (Dunn and Maxfield, 1992; Geuze 
et al., 1988; Stoorvogel et al., 1991).  
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The maturation process takes approximately 40 mins and involves exchange of 
membrane components, movement to the perinuclear area, formation of intraluminal 
vesicles, a decrease in luminal pH, acquisition of lysosomal components, and 
changes in morphology (Huotari and Helenius, 2011; Saftig and Klumperman, 2009). 
The maturation requires a series of exchanges with vesicles which contain acid 
hydrolases and membrane proteins like lysosomal membrane associated protein 1 
(LAMP1) and LAMP2, trafficked from the trans-Golgi network (Huotari and Helenius, 
2011; Saftig and Klumperman, 2009). Although it is difficult to distinguish between 
intermediates in the endolysosomal pathway, markers of early endosomes include 
early endosomal antigen 1 (EEA1) (Mu et al., 1995) and Rab5 (Rink et al., 2005), 
whereas endosomes have mannose-6-phosphate receptors; both of which are not 
found in lysosomes (Brown et al., 1986). Once lysosomes are formed, they are able 
to fuse with autophagosomes. In the autophagic pathway, a new double membrane 
called a phagophore is formed, which engulfs cytoplasmic contents and forms an 
autophagosome. The formation of the double membrane vesicle, the 
autophagosome, involves a complex interplay of proteins such as the class III 
phosphoinositide 3-kinase∙Beclin 1 complex, ATG5·ATG12, and microtubule-
associated protein 1 light chain 3 (LC3)-phosphatidylethanolamine conjugation 
system (Kondo et al., 2005). The fusion of autophagosomes with lysosomes results 
in the degradation of the cytoplasmic contents of the autophagosome (Kondo et al., 
2005).  
 
The purpose of this process is to recycle cellular components (Kondo et al., 2005). 
However, autophagy plays a more complex role in maintaining cellular homeostasis, 
as it can either protect the cell against stressors such as nutrient deprivation, or it 
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can promote apoptosis, depending on the stimulus received (Mukhopadhyay et al., 
2014). Furthermore, autophagy has also been linked to tumour progression, drug 
resistance (Tsuchihara et al., 2009) and metastasis (Kenific et al., 2010). 
 
Lysosomes have a pH of below 5, maintained by a membrane vacuolar H+-ATPase 
(V-ATPase), which pumps protons into the lysosome against the concentration 
gradient (Mellman et al., 1986; Ohkuma et al., 1982; Schneider, 1981). The low pH is 
optimal for the functioning of the acid hydrolases, as it loosens the structures of 
macromolecules, making them easier to digest (Coffey and De Duve, 1968; 
Schneider, 1981). More than 60 acid hydrolases have been found in lysosomes, 
including proteases (Bohley and Seglen, 1992), phosphatases (Pohlmann et al., 
1988), nucleases (Slor and Lev, 1971), sulphatases (Bond et al., 1997), lipases 
(Goldstein et al., 1975), and glycosidases (Appelmans et al., 1955). The cathepsin 
family of proteases has been widely studied (Bohley and Seglen, 1992). Within this 
family, the three subtypes are serine, cysteine and aspartic proteases, named 
according to which amino acid is found in their active site (Bohley and Seglen, 1992; 
Rossi et al., 2004; Turk et al., 2002). The hydrolases that are found in the highest 
concentrations are the cysteine proteases cathepsins B and L and the aspartic 
protease cathepsin D (Bohley and Seglen, 1992). The highly-glycosylated lysosomal 
membrane is thought to protect the lipid bilayer from degradation by acid hydrolases 
(Granger et al., 1990). More than 25 membrane proteins have been identified, of 
which 50% are LAMP 1 and LAMP2 (Saftig et al., 2010). LAMP1 and LAMP2 are 
important in maintaining lysosomal membrane integrity, and regulating lysosomal 
trafficking and fusion with autophagosomes (Saftig et al., 2010).  
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Lysosomes have relatively high concentrations of transition metals such as iron and 
copper ions, due to the degradation of proteins that contain transition metals in their 
active site (Gupte and Mumper, 2009; Kurz et al., 2006; Yu et al., 2003). Oxidative 
stressors can activate Fenton-type reactions, generating the HO˙ radical; the 
presence of high levels of iron and copper ions therefore make lysosomes sensitive 
to oxidative stress (Gupte and Mumper, 2009; Kurz et al., 2006; Terman and Kurz, 
2013; Yu et al., 2003). Additionally, the redox capacity of Cu(II) is promoted by the 
acidic pH and milieu of lysosomes (Gupte and Mumper, 2009; Kurz et al., 2010; 
Terman and Kurz, 2013) The HO˙ radical attacks the lipid bilayer of the lysosome 
causing lipid peroxidation that can ultimately result in permeabilisation of the 
lysosomal membrane (Gupte and Mumper, 2009; Kurz et al., 2006; Yu et al., 2003).  
 
1.4.3.2 Lysosomes in Cancer and MDR 
Lysosomes in cancer cells differ dramatically from those in normal cells in terms of 
their volume, cellular distribution and enzyme activity (Kallunki et al., 2013). These 
changes have been linked to increased tumourigenic potential, progression and 
metastasis (Kallunki et al., 2013; Yu et al., 2016). Lysosomes are not only linked to 
cancer as drivers of malignant transformation and progression; they are also 
involved in MDR due to drug sequestration (Appelqvist et al., 2013; Piao and 
Amaravadi, 2015; Zhitomirsky and Assaraf, 2016). 
 
Several cathepsins, namely cathepsins B, S, E and L, are negative prognostic 
indicators in cancer (Gocheva et al., 2006; Keliher et al., 2013; Kos and Lah, 1998; 
Small et al., 2013). Cathepsin B, for example, is associated with increased 
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progression, invasion and metastasis in in vitro, in vivo and clinical studies (Bengsch 
et al., 2014; Chen et al., 2011; Gocheva et al., 2006; Premzl et al., 2003; Withana et 
al., 2012). It is thought that the increased expression of lysosomal cathepsins in 
cancer may result in their increased excretion into the extracellular space, which in 
turn promotes invasion and metastasis due to their digestion of basement 
membranes (Gocheva et al., 2006; Recklies et al., 1982; Sloane et al., 1981). Other 
lysosomal changes that have been associated with cancer include increased LAMP-
1 expression on the surface of highly metastatic cells (Furuta et al., 2001); and 
alterations to the tumour microenvironment by V-ATPase, which promotes invasion 
(Fais et al., 2007) 
 
Lysosomes act as mediators of MDR primarily by sequestering chemotherapeutics 
(Fig. 1.9). Hydrophobic weak bases, such as sunitinib (Gotink et al., 2011), 
doxorubicin (Herlevsen et al., 2007), daunorubicin (Gong et al., 2006) and vincristine 
(Groth-Pedersen et al., 2007), are able to easily diffuse through both the plasma 
membrane of the cell and the lysosomal membrane (Zhitomirsky and Assaraf, 
2015a). Once inside lysosomes, these drugs become protonated due to the low pH 
and their ionised forms are ‘trapped’ inside lysosomes, unable to diffuse out (Fig. 
1.9) (Mahoney et al., 2003). The sequestered chemotherapeutics are unable to 
access their targets, so are rendered ineffective (Fig. 1.9) (Zhitomirsky and Assaraf, 
2015a). Indeed, increased lysosomal trapping of chemotherapeutics has been 
observed in MDR cell lines (Gong et al., 2003; Hurwitz et al., 1997; Schindler et al., 
1996). Interestingly, the pH of lysosomes in MDR cells has been shown to be more 
acidic than in lysosomes of drug-sensitive cells, which facilitates enhanced drug 
sequestration in MDR cell lines (Altan et al., 1998; Gong et al., 2003; Kramer et al., 
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1998). In addition to diffusion, there is also evidence of active transport of 
chemotherapeutics into the lysosome by ABC transporters such as Pgp, MRP1 and 
ABCA3 (Chapuy et al., 2008; Jansson et al., 2015b; Rajagopal and Simon, 2003b; 
Seebacher et al., 2016a; Yamagishi et al., 2013).  
 
 
Figure 1.9 Lysosomal drug sequestration 
Hydrophobic weak bases (red triangle) diffuse through the plasma membrane and 
the lysosomal membrane. ABC transporters in the lysosomal membrane can also 
actively transport drugs into lysosomes. Once inside lysosomes, the hydrophobic 
weak bases are protonated by the low pH of the lysosomal lumen. The hydrophobic 
weak bases are unable to diffuse back out of lysosomes and access their targets, 
such as DNA in the nucleus.   
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1.5 Targeting MDR 
Targeting MDR is clinically important as it is a major factor that contributes to 
treatment failure (Gillet and Gottesman, 2010). Resistance can develop by numerous 
mechanisms including increased drug efflux (Pgp), evasion of drug-induced 
apoptosis (Bcl-2), and activation of detoxifying systems (lysosomal drug 
sequestration) (Gillet and Gottesman, 2010). Specific targeting of each of these 
mechanisms in order to overcome MDR has been thoroughly investigated, with 
varying degrees of success.  
 
1.5.1 Targeting Pgp-Mediated MDR 
As Pgp mediates the resistance to many common anti-cancer drugs, the majority of 
efforts to target Pgp have focused on Pgp inhibitors (Gottesman et al., 2002). Initial 
trials using 1st generation inhibitors failed as the inhibitors used, such as verapamil 
and cyclosporine A, were only weak inhibitors of Pgp and toxic at high doses 
(Benson et al., 1985; Damiani et al., 1998; Lum et al., 1992; Miller et al., 1991). 
Novel 2nd generation inhibitors with greater Pgp specificity were then developed 
aiming to overcome these obstacles (Table 1.3). For example, valspodar (PSC-833) 
has 10- to 20-fold greater specificity for Pgp than cyclosporine A, although it also 
inhibits ABCG2 and MRP1 (Jachez et al., 1993; Keller et al., 1992). However, 
valspodar and other 2nd generation inhibitors also failed to demonstrate clinical 
efficacy in several clinical trials involving cancers such as acute myeloid leukaemia 
and ovarian cancer (Table 1.3) (Baer et al., 2002; Fracasso et al., 2001; van der Holt 
et al., 2005).  
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These issues led researchers to design 3rd generation inhibitors with increased 
specificity and potency towards Pgp (Table 1.3). Elacridar (Ela, GF120918) was the 
first of the 3rd generation inhibitors to be developed (Hyafil et al., 1993) and has 
shown minimal toxicity in phase I clinical trials (Elgie et al., 1999; Kuppens et al., 
2007). Although Ela inhibits Pgp potently, it also inhibits ABCG2 (de Bruin et al., 
1999; Maliepaard et al., 2001). Tariquidar (XR9051), another 3rd generation inhibitor, 
exhibited many favourable characteristics in pre-clinical studies (Dale et al., 1998; 
Martin et al., 1999). Being 10- to 30-fold more potent than valspodar, tariquidar was 
able to increase sensitivity of Pgp-expressing cells to Pgp substrates such as 
doxorubicin and paclitaxel at concentrations as low as 25 to 80 nM (Table 1.3) (Dale 
et al., 1998; Martin et al., 1999; Mistry et al., 2001). While tariquidar demonstrated 
the ability to increase the efficacy of doxorubicin or taxane chemotherapy, toxicity 
was a serious issue and resulted in the abandonment of phase III clinical trials (Fox 
and Bates, 2007; Pusztai et al., 2005). However, the National Cancer Institute is still 
conducting further phase I/II trials of tariquidar, with results pending (Fox and Bates, 
2007). Although pre-clinical data was promising, other 3rd generation inhibitors such 
as zosuquidar (LY335979) and ONT-093 failed to produce significant results in 
clinical trials (Cripe et al., 2006; Kuppens et al., 2005; Rubin et al., 2002; Sandler et 
al., 2004). Despite the apparent lack of clinical efficacy to date, research into the 
area of Pgp inhibitors remains ongoing and it is hoped that by selecting for specific 
clinical scenarios, these agents may yet demonstrate clinical efficacy.  
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Table 1.3 Inhibitors of Pgp 
 
1.5.2 Targeting Bcl-2-Mediated MDR 
Impaired apoptosis is a key aspect of tumour development and also contributes to 
MDR (Thomas et al., 2013). Indeed, Bcl-2 mediates resistance to structurally and 
mechanistically unrelated chemotherapeutics (Skommer et al., 2006; Wang et al., 
2013; Wu et al., 2015). Targeting Bcl-2 is an important approach in overcoming 
MDR, and has taken three main directions: (1) antisense oligonucleotides and 
antibody targeting; (2) BH3-only peptidomimetics; and (3) small molecule inhibitors 
(Lessene et al., 2008; Thomas et al., 2013). The two approaches that have been 
explored and are pertinent to Bcl-2 are antisense antisense oligonucleotides and 
antibodies, and small molecule inhibitors (Table 1.4).  
 
Antisense oligonucleotides function by binding to target mRNA and forming a DNA 
heteroduplex which is susceptible to degradation by RNAse H (Olie and 
Name Alias Specificity Generation
Valspodar PSC-833 Pgp 2nd
Biricodar VX-710 Pgp, ABCG2,
MRP1
2nd
Tariquidar XR-9576 Pgp and ABCG2 3rd
Zosuquidar LY335979 Pgp, ABCG2,
MRP1
3rd
Laniquidar R101933 Pgp 3rd
Elacridar GF120918 Pgp and ABCG2 3rd
ONT-93 Pgp 3rd
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Zangemeister-Wittke, 2001). This reduces the levels of the target mRNA and thus 
the expression of the target protein (Olie and Zangemeister-Wittke, 2001). 
Oblimersen (G-3139), an 18-mer oligonucleotide complimentary to the BCL2 gene, 
was one of the first antisense oligonucleotides trialled (Olie and Zangemeister-
Wittke, 2001). Oblimersen did not obtain Food and Drug Administration approval as 
it failed to show survival advantage in melanoma, multiple myeloma and chronic 
myelocitic leukaemia (O'Brien et al., 2009). However, in a Phase II combination 
study with dacarbazine, oblimersen demonstrated improved survival and 
progression-free survival in melanoma patients (Bedikian et al., 2006).  
 
Unfortunately, the clinical use of antisense oligonucleotides will always be limited 
due to their susceptibility to DNAse-mediated degradation and non-specific targeting 
(Dai et al., 2005). Similarly, although antibodies have been produced that inhibit Bcl-
2 expression and one has been show to increase cytotoxicity in response to 
chemotherapies in cancer; their instability in vivo limits its practical use as a therapy 
(Piche et al., 1998).  
 
A more promising approach has been the development of small molecule Bcl-2 
inhibitors, which are defined as organic molecules with molecular weights less than 
750 Da (Thomas et al., 2013). The principle mechanism of small molecule inhibitors 
is to mimic the action of BH3-only proteins by binding to the hydrophobic fold in Bcl-2 
and other anti-apoptotic Bcl-2 family members (Lessene et al., 2008; Thomas et al., 
2013). In doing so, the small molecule inhibitors antagonise the anti-apoptotic activity 
of Bcl-2 by preventing its heterodimerisation with the pro-apoptotic family members, 
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Bax and Bak (Thomas et al., 2013). Gossypol (BL-193) is a natural polyphenol (Wu, 
1989) that binds to the hydrophobic fold of Bcl-2 and Bcl-XL and was the first small 
molecule inhibitor investigated (Table 1.4) (Kitada et al., 2003). The demonstrated 
anti-proliferative effects of Gossypol in cancer cells (Gilbert et al., 1995; Le Blanc et 
al., 2002; Wu et al., 1989) has led to it entering clinical trials (Stein et al., 1992; Van 
Poznak et al., 2001), however toxicity issues (Stein et al., 1992) spurned the further 
development of second and third generation derivatives such as TW37 (Table 1.4) 
(Mohammad et al., 2007; Verhaegen et al., 2006; Wang et al., 2006) and 
Apogossypolone (ApoG2) (Becattini et al., 2004; Hu et al., 2009; Sun et al., 2009), 
respectively. Both TW37 and ApoG2 have the advantage of inhibiting not only Bcl-2 
and Bcl-XL, but also Mcl-1 (Mohammad et al., 2007; Verhaegen et al., 2006; Wang et 
al., 2006). To date, TW37 and ApoG2 have been shown to induce apoptosis in 
cancer (Hu et al., 2009; Mohammad et al., 2007; Sun et al., 2009; Verhaegen et al., 
2006; Wang et al., 2006).  
 
Abbott Laboratories has also developed a series of small molecule inhibitors (MW 
less than 750 Da), starting with ABT-737 (Table 1.4) (Oltersdorf et al., 2005). ABT-
737 binds to Bcl-2, Bcl-XL and Bcl-W by mimicking the BH3 domain of Bad. The 
primary target of ABT-737 is Bcl-2-Bim dimers, which it disrupts more effectively than 
Bcl-XL-Bim and Bcl-W-Bim dimers (Merino et al., 2012; van Delft et al., 2006). Bim 
released by the binding of ABT-737 to Bcl-2 can directly activate Bax and Bak, 
leading to apoptosis (Merino et al., 2012; van Delft et al., 2006). The orally-available 
derivative of ABT-737, ABT-263 (Navitoclax), has demonstrated efficacy as both a 
single agent an in combination studies in clinical trials (Table 1.4) (Tse et al., 2008). 
However, the ability of ABT-263 to bind Bcl-XL, has resulted in dose-limiting toxicity 
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issues, as Bcl-XL controls platelet lifespan (Mason et al., 2007; Zhang et al., 2007). A 
more recently developed analogue, ABT-199 that is selective for Bcl-2, seems to 
have overcome this issue (Souers et al., 2013). More recently, Bcl-2 inhibitors have 
been developed that also bind to Mcl-1, such as Obatoclax (Konopleva et al., 2008), 
HA14-1 (Manero et al., 2006), Sabutoclax (Dash et al., 2011) and BI-97D6 (Table 
1.4) (Wei et al., 2011).  
 
 
Table 1.4 Bcl-2 inhibitors 
 
 
Name Alias Specificity Class/Generation
Oblimersen G-3139 Antisense oligonucleotide
Gossypol BL-193 Bcl-2, Bcl-XL Small molecule inhibitor
TW37 Bcl-2, Bcl-XL, Mcl-1 Small molecule inhibitor/ 2nd
generation Gossypol derivative
ApoG2 Bcl-2, Bcl-XL, Mcl-1 Small molecule inhibitor/ 3rd
generation Gossypol derivative
ABT-737 Navitoclax Bcl-2, Bcl-XL, Bcl-W Small molecule inhibitor
ABT-263 Bcl-2, Bcl-XL, Bcl-W Small molecule inhibitor, 2nd
generation
ABT-199 Bcl-2>>>>
AT-101 Bcl-2, Bcl-XL, Mcl-1 Small molecule inhibitor
Obatoclax GX015-070 Bcl-2, Bcl-XL, Bcl-W,
Mcl-1
Small molecule inhibitor
HA14-1 Bcl-2, Bcl-XL
Sabutoclax BI-97C1 Bcl-2, Bcl-XL, Mcl-1
Bfl-1
Small molecule inhibitor/ 3rd
generation Gossypol derivative
BI-97D6 Bcl-2, Bcl-XL, Mcl-1
Bfl-1
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1.5.3 Targeting Lysosomes in MDR 
Overcoming lysosomal drug sequestration has been an important objective for 
successful treatment of MDR cancer. Several approaches have been taken to 
overcome lysosomal drug sequestration including altering the structure of drugs to 
decrease their pKa (Duvvuri et al., 2005), increasing lysosomal pH using V-ATPase 
inhibitors and inducing apoptosis using lysosomotropic agents (Zhitomirsky and 
Assaraf, 2016).  
 
Modifying the structures of existing drugs to improve efficacy against specific targets 
has long been a validated method of drug discovery. Doxorubicin and daunorubicin 
are examples of weakly basic chemotherapeutics, which are sequestered in 
lysosomes as the low pH inside the lysosome favours their protonation (Duvvuri et 
al., 2005; Egorin et al., 1980). Once protonated they become trapped, unable to 
diffuse back through the lipid bilayer to reach their nuclear target (Duvvuri et al., 
2005; Rutherford and Willingham, 1993). It has been shown that altering the 
structure of daunorubicin to decrease its pKa and thus decrease its lysosomal 
sequestration, significantly increases the efficacy of daunorubicin against MDR 
cancer cells (Duvvuri et al., 2005). Interestingly, it has also been demonstrated that 
the presence of Pgp in the lysosomal membrane can also enhance lysosomal 
sequestration of doxorubicin and other anti-cancer agents (Seebacher et al., 2016a; 
Seebacher et al., 2015; Yamagishi et al., 2013). 
 
Increasing lysosomal pH can decrease sequestration of hydrophobic weak bases. 
There are several well-known inhibitors of V-ATPase which are generally of microbial 
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origin, such as baflomycin A1, and concanamycin A (Fais et al., 2007). Such 
inhibitors have been shown to increase sensitivity to doxorubicin, daunorubicin and 
epirubicin as the alkalisation of the lysosome results in their release from the 
lysosome and redistribution to the cytosol and nucleus (Altan et al., 1998; Ouar et 
al., 2003; Schindler et al., 1996; Zhitomirsky and Assaraf, 2015b). However, these 
agents generally have multiple other targets and effects within the cell, which makes 
them somewhat unsuitable for this purpose (Zhitomirsky and Assaraf, 2015a) 
 
Lysosomotropic agents such as chloroquine have been shown to reduce lysosomal 
drug sequestration and increase MDR cancer cell sensitivity to chemotherapeutics 
(Yamagishi et al., 2013). Disrupting the lysosomal membrane can cause apoptosis 
or necrosis, as the acidic and degradative contents of the lysosomal lumen spill out 
into the cytosol of the cell (Erdal et al., 2005; Repnik et al., 2014). Unfortunately, 
lysosomotropic agents can also trigger lysosomal biogenesis, which ultimately only 
serves to increase drug sequestration (Zhitomirsky and Assaraf, 2015a). However, it 
has been shown that Dp44mT can selectively and potently target the lysosomes in 
MDR cells and induce cell death by rupturing the lysosomal membrane (Section 1.6) 
(Jansson et al., 2015b). Additional methods of inducing cell death using 
lysosomotropic mechanisms include loading lysosomes with photosensitisers which 
when activated cause cell death by disrupting the stability of the lysosomal 
membrane (Adar et al., 2012; Nowak-Sliwinska et al., 2015). 
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1.6 Selective activity of Dp44mT against MDR  
Dp44mT possesses a number of characteristics that enable it to target lysosomes. 
For many weakly basic drugs, including chemotherapeutics, lysosomal sequestration 
decreases their efficacy by preventing them from reaching their intended targets 
(Gong et al., 2003; Hurwitz et al., 1997; Schindler et al., 1996). Similarly, Dp44mT 
sequestered in lysosomes as it is polyprotic and is protonated at the lower pH of 
lysosomal lumens (Lovejoy et al., 2011). However, as part of the mechanism of 
action of Dp44mT, it forms redox-active Fe(III) and Cu(II) complexes (Jansson et al., 
2010a; Jansson et al., 2010b; Kalinowski et al., 2007; Lovejoy et al., 2011; 
Richardson et al., 2006; Richardson et al., 2009; Yuan et al., 2004).  
 
The redox activity of these complexes of Dp44mT produces HO˙ radicals that 
damage lysosomal membranes through lipid peroxidation (Gutierrez et al., 2014; 
Jansson et al., 2010b; Lovejoy et al., 2011). The permeabilisation of lysosomal 
membranes by the redox-active Dp44mT complexes results in apoptosis due to the 
release of degradative lysosomal cathepsins into the cytosol (Gutierrez et al., 2014; 
Jansson et al., 2015a; Lovejoy et al., 2011; Repnik et al., 2014; Roberg et al., 1999; 
Turk et al., 2002; Turk and Turk, 2009).  
 
Interestingly, Dp44mT and its Cu(II) complex are potently more cytotoxic in drug 
resistant cells expressing Pgp, relative to their non-Pgp expressing counterparts 
(Jansson et al., 2015b; Whitnall et al., 2006). Pgp, expressed in lysosomal 
membranes, actively transports Dp44mT into lysosomes, where it is protonated by 
50 
 
the acidic environment and trapped (Jansson et al., 2015b; Lovejoy et al., 2011). In 
this manner, Dp44mT is able to “hijack” mechanisms that the cell normally uses to 
evade cell death, namely: ABC transporter drug efflux and lysosomal drug 
sequestration. Furthermore, Dp44mT targets the pro-survival autophagy pathway 
(Gutierrez et al., 2014), which also regulates tumour progression, drug resistance 
(Tsuchihara et al., 2009) and metastasis (Kenific et al., 2010). Although Dp44mT 
induces the autophagic-initiation pathway, Dp44mT also induced permeabilisation of 
the lysosomal membrane (Gutierrez et al., 2014). This led to cell death by a 
combination of preventing the cancer cells from completing the autophagic process 
and leaking of degradative lysosomal enzymes into the cytosol (Gutierrez et al., 
2014). 
 
The ability of Dp44mT to selectively target MDR cells and overcome MDR is an 
exciting therapeutic prospect. While key components of the mechanism by which 
Dp44mT selectively targets MDR are established (Jansson et al., 2015b), it has also 
been demonstrated that Dp44mT is an inappropriate drug candidate due to 
undesirable side effects in vivo such as methaemoglobinaemia (Quach et al., 2012) 
and cardiotoxicity (Whitnall et al., 2006). It would therefore be of interest to establish 
whether other thiosemicarbazones are capable of similarly targeting MDR cells, as 
Dp44mT does (Jansson et al., 2015b; Whitnall et al., 2006). Furthermore, many 
other mechanisms of drug resistance exist in addition to ABC transporter drug efflux 
and lysosomal drug sequestration, such as evasion of apoptosis mediated by Bcl-2 
family members. 
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1.7 Aims of the Thesis 
1. Assess the structure-activity relationships and mechanisms that enable 
thiosemicarbazones and their Cu(II) complexes to overcome Pgp mediate MDR 
2. Examine the effects of zinc binding on thiosemicarbazone cytotoxicity and 
intracellular localisation. Elucidate mechanisms of action where relevant. 
3. Explore the efficacy of thiosemicarbazones (Dp44mT and DpC) against Bcl-2-
mediated MDR in melanoma. Examine mechanisms of action where applicable. 
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Chapter 2 - Materials and Methods 
 
2.1 Reagents 
General Reagents Source 
2',7'-dichlorodihydrofluorescein (H2DCF-DA) Sigma-Aldrich (St. Louis, MO, 
USA) 
3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) 
Sigma-Aldrich (St. Louis, MO, 
USA) 
Ammonium tetrathiomolybdate (TM) Sigma-Aldrich (St. Louis, MO, 
USA) 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich (St. Louis, MO, 
USA) 
Elacridar (Ela) Sigma-Aldrich (St. Louis, MO, 
USA) 
N-acetylcysteine (NAC) Sigma-Aldrich (St. Louis, MO, 
USA) 
Phosphate buffered saline (PBS) Sigma-Aldrich (St. Louis, MO, 
USA) 
 
 
Cell Culture Reagents Source 
DMEM Gibco® (Life Technologies Australia Pty Ltd, 
Mulgrave, VIC, Australia) 
Foetal bovine serum Sigma-Aldrich (St. Louis, MO, USA) 
Fungizone Gibco® (Life Technologies Australia Pty Ltd, 
Mulgrave, VIC, Australia) 
Non-essential amino acids Gibco® (Life Technologies Australia Pty Ltd, 
Mulgrave, VIC, Australia) 
Penicillin, streptomycin, L-
glutamine 
Gibco® (Life Technologies Australia Pty Ltd, 
Mulgrave, VIC, Australia) 
Vinblastine Sigma-Aldrich (St. Louis, MO, USA) 
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Synthetic Reagents Source 
2-benzoylpyridine Sigma-Aldrich (St. Louis, MO, USA) 
2-methyl-3-thiosemicarbazide Sigma-Aldrich (St. Louis, MO, USA) 
3-AP Synthesised as previously reported (Liu et al., 1992) 
4,4-dimethyl-3-
thiosemicarbazide Alfa Aesar (Ward Hill, MA, USA) 
Ap44mT Synthesised as previously reported (Richardson et al., 2009) 
Dp44mT Synthesised as previously reported (Richardson et al., 2006)} 
DpC Synthesised as previously reported (Lovejoy et al., 2012) 
Bp44mT Synthesised as previously reported (Kalinowski et al., 2007) 
CuCl2.2H2O Sigma-Aldrich (St. Louis, MO, USA) 
Cu(ClO4)2.6H2O Sigma-Aldrich (St. Louis, MO, USA) 
Di-2-pyridyl ketone Sigma-Aldrich (St. Louis, MO, USA) 
Diethyl ether Sigma-Aldrich (St. Louis, MO, USA) 
Ethanol Sigma-Aldrich (St. Louis, MO, USA) 
Triethylamine Sigma-Aldrich (St. Louis, MO, USA) 
ZnCl2 Sigma-Aldrich (St. Louis, MO, USA) 
ZnClO4 Sigma-Aldrich (St. Louis, MO, USA) 
 
 
 
Fluorescent Reagents Source 
Acridine Orange (AO) Sigma-Aldrich (St. Louis, MO, USA) 
Deep Red, DRAQ5™ ThermoFisher Scientific Australia Pty 
Ltd (Scoresby, VIC, Australia) 
FITC conjugated secondary antibody Life Technologies Australia Pty Ltd 
(Mulgrave, VIC, Australia) 
LysoTracker® Deep Red ThermoFisher Scientific Australia Pty 
Ltd (Scoresby, VIC, Australia) 
MitoTracker® Deep Red ThermoFisher Scientific Australia Pty 
Ltd (Scoresby, VIC, Australia) 
ProLong® Gold Antifade Mountant with 
DAPI 
ThermoFisher Scientific Australia Pty 
Ltd (Scoresby, VIC, Australia) 
TexasRed conjugated secondary antibody Cell Signaling (Danvers, MA, USA) 
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Antibodies Source 
β actin Sigma-Aldrich (St. Louis, MO, USA) 
Bcl-2 Cell Signaling Technology 
LC3 Sigma-Aldrich (St. Louis, MO, USA) 
 
 
2.2 Synthesis of Novel Thiosemicarbazones and 
Complexes 
2.2.1 Bp2mT 
To a solution of 2-methyl-3-thiosemicarbazide (1.05 g, 10 mmol) in ethanol (25 mL), 
2-benzoylpyridine (1.83 g, 10 mmol) and glacial acetic acid (10 drops) were added 
and refluxed for 1 h. The precipitated thiosemicarbazide was filtered and discarded. 
The ligand, Bp2mT, was isolated as light brown crystals from the slow evaporation of 
mother liquor. Yield: 60%. 1H NMR (DMSO-d6) δ ppm 8.53, 8.77 (1H, d, CH, E/Z 
isomers), 8.18 (1H, d, CH), 7.91, 8.00 (1H, t, CH), 7.71 (2H, bs, NH2), 7.41-7.53 (5H, 
m, Ph), 7.27 (1H, m, CH), 2.99, 3.02 (3H, s, CH3,). 13C NMR (DMSO-d6) δ ppm 
181.5, 181.4, 162.6, 161.9, 155.4, 154.4, 150.3, 149.1, 137.7, 137.1, 136.7, 135.4, 
131.2, 129.8, 129.3, 129.0, 128.8, 128.7, 125.3, 124.9, 124.8, 123.8, 41.6, 41.3. ESI-
MS in MeOH: found mass: 293.00, Calcd. mass for C14H14N4SNa: 293.08 [M+Na+]+. 
Anal. Calcd. for C14H14N4S (%): C, 62.20; H, 5.22; N, 20.72; S, 11.80. Found (%): C, 
62.02; H, 5.22; N, 20.74; S, 11.78. 
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2.2.2 Cu(II) Complexes Synthesis 
The 1:2 Cu(II) complexes with Bp44mT, DpC and 3-AP were prepared using a 
reported procedure with slight modifications, as described below (Jansson et al., 
2010a). To a hot solution of Bp44mT, 3-AP or DpC·HCl (0.5 mmol) in ethanol (5 mL), 
triethylamine (56 mg, 0.55 mmol for 3-AP or Bp44mT; 112 mg, 1.1 mmol for 
DpC·HCl) followed by Cu(ClO4)2.6H2O (93 mg, 0.25 mmol) were added and refluxed 
for 60 min. After cooling to room temperature, the solution was poured into diethyl 
ether (20 mL). The precipitate formed was collected by vacuum filtration, washed 
with copious amounts of diethyl ether and dried in vacuo.  
 
2.2.2.1 [Cu(Bp44mT)(Bp44mT-H)](ClO4) 
Dark brown solid. 90 mg, yield: 57%. The single crystals suitable for X-ray diffraction 
were obtained from the slow diffusion of diethyl ether into a methanol solution. Mass 
data (ESI+, CH3CN): m/z: Calcd. for CuC30H31N8S2: 630.15 [M−ClO4]+; found: 
630.13. Anal. Calcd. (%) for CuC30H31N8S2ClO4·(H2O)4(C2H5OH): C 45.28, H 5.34, N 
13.20, S 7.55. Found: C 45.47, H 5.22, N 12.94, S 7.44. IR, cm-1: 3510 (br, O-H), 
1550 (m, C=N), 1393 (s), 1320 (s), 1253 (s), 1091 (vs, ClO4), 913 (m), 789 (s, C−S), 
700 (s), 624 (s) (br, broad; vs, very strong; s, strong; m, medium; w, weak). 
UV−visible in DMSO [λmax, nm (ε, M−1 cm−1 )]: 425 (18 500), 351 (19 500), 310 
(27 700). 
 
2.2.2.2 [Cu(3-AP)(3-AP-H)](ClO4) 
Brown solid. Yield: 75%. Mass data (ESI+, CH3CN): m/z: Calcd. for CuC14H16N10S2, 
452.05 [M−ClO4]+; found: 551.97 (100%). Anal. Calcd. (%) for 
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CuC14H17N10S2ClO4·(H2O)1(C2H5OH)0.5: C 30.35, H 3.74, N 23.60, S 10.81. Found: 
C 30.11, H 3.56, N 23.24, S 11.27. IR, cm-1: 3428 (m, N-H), 3358 (m, NH), 3176, 
2151 (w), 1632 (m), 1597 (m, C=N), 1469 (s), 1442 (s), 1323 (m), 1250 (m), 1097 
(vs, ClO4), 900 (m), 848 (m), 801 (m, C−S), 704 (w), 626 (vs). UV−visible in DMSO 
[λmax, nm (ε, M−1 cm−1)]: 444 (25 200), 458(sh) (24 200), 385 (20 800), 295 (45 500). 
 
2.2.2.3 [Cu(DpC)(DpC-H)]ClO4 
Dark brown solid. Yield: 41%. Mass data (ESI+, CH3CN): m/z: Calcd. for 
CuC38H45N10S2, 768.27 [M+H+]+; found: 768.22 (100%). Anal. Calcd. (%) for 
CuC38H45N10S2ClO4·(H2O)2(C2H5OH)1: C 50.52, H 5.83, N 14.73, S 6.74. Found: C 
50.45, H 5.67, N 14.63, S 6.19. IR, cm-1: 3428 (br, O-H), 2929 (m), 2855 (m), 1486 
(s, C=N), 1305 (s), 1247 (m), 1088 (vs, ClO4), 929 (w), 792 (m, C−S), 742 (m), 623 
(s). UV−visible in DMSO [λmax, nm (ε, M−1 cm−1 )]: 430 (25 700), 384 (18 000) (sh), 
314 (26 400). 
Caution: Perchlorate salts are potentially explosive and should only be handled in 
small quantities, never be heated in the solid state or scraped from sintered glass 
frits. 
 
2.2.2.4 [Cu(Bp44mT-H)Cl] 
The 1:1 Cu(II) complex, [Cu(Bp44mT-H)Cl] was synthesised following a literature 
procedure, as described (West et al., 1995). Bp44mT (142 mg, 0.5 mmol) and 
CuCl2.2H2O (86 mg, 0.5 mmol) was added to ethanol (7 mL) and refluxed for 30 min 
to provide a dark brown solid. This was filtered off, washed with ethanol followed by 
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diethyl ether and dried in vacuo to afford 160 mg of the desired product. The single 
crystals were obtained by slow diffusion of diethyl ether into a methanol solution. 
Yield: 95%. Mass data (ESI+, CH3CN): m/z: Calcd. for: CuC15H15N4SClNa, 403.99 
[M+Na+]+; Found: 403.83 (80%); Calcd. for Cu2C30H32N8S2Cl, 729.07 [2M−Cl+2H+]+; 
Found: 728.96 (100%). Anal. Calcd. (%) for: CuC15H15N4SCl: C 47.12, H 3.95, N 
14.65, S 8.38. Found: C 47.31, H 3.95, N 14.60, S 8.23. IR, cm-1: 2919 (w), 1592 
(m), 1548 (m), 1515 (s, C=N), 1393 (vs), 1299 (vs), 1245 (vs), 1128 (s), 970 (m), 791 
(s, C−S), 726 (m), 655 (s). UV−visible in DMSO [λmax, nm (ε, M−1 cm−1 )]: 430 (18 
400), 310 (16 300). 
 
 2.2.3 Zinc Complexes Synthesis 
2.2.3.1 General procedure  
Complexes [Zn(Dp44mT)Cl2], [Zn(Ap44mT)Cl2] and [Zn(DpC)Cl2] were synthesised 
as described below. One mole equivalent of ZnCl2 was added to hot ethanolic (30 
mL) solution of either Dp44mT or Ap44mT or DpC·HCl and refluxed for 30 min. 
Precipitate formed was collected by filtration under hot condition and washed with 
ethanol, diethylether and dried in vacuo. Complexes [Zn(Dp44mT)2], [Zn(Ap44mT)2] 
and [Zn(DpC)2](ClO4)2 were prepared by a general procedure where either Dp44mT 
or Ap44mT or DpC·HCl (1 mmol) in ethanol (25 mL) was reacted with ZnClO4 (0.186 
g, 0.5 mmol) in the presence of triethyl amine (0.51 g, 5 mmol) under reflux for 30 
min. After cooling to room temperature, precipitate was filtered off, washed with 
ethanol followed by copious amounts of diethylether and dried in vacuo. 
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2.2.3.2 [Zn(Dp44mT)Cl2]  
Dp44mT (0.4 g, 1.40 mmol) and ZnCl2 (0.195 g, 1.43 mmol) were used as substrates 
for the preparation of [Zn(Dp44mT)Cl2]. Product was isolated as a bright yellow solid 
(0.52 g). Yield: 88%. 1H NMR (500 MHz, CDCl3): δ 3.32 (6H, bs, N(CH3)2), δ 7.53-
7.57 (2H, m, CHpy), δ 7.74 (2H, bs, CHpy), δ 7.97-8.03 (2H, m, CHpy), δ 8.64 (1H, d, 
CHpy), δ 8.83 (1H, d, CHpy), δ 14.83 (1H, bs, NH). 13C NMR (125 MHz, d6-DMSO): δ 
49.07 (N(CH3)2), δ 124.71 (py), δ 125.22 (py), δ 125.60 (py), δ 127.43 (py), δ 139.30 
(py), δ 139.98 (py), δ 141.27 (py), δ 148.35 (py), δ 148.60 (py), δ 150.00 (C=N), δ 
180.46 (C=S). ESI-MS (+ve mode in MeOH) found mass: 347.92 (67%), 632.86 
(100%). Calc. mass for C14H14N5SZn ([M−2Cl-−H+]+: 348.02, C28H29N10S2Zn ([M−2Cl-
+L+H+]+: 633.13. Anal. Calc. for C14H15N5SCl2Zn·H2O (%): C 38.25, H 3.90, N 15.93, 
S 7.29. Found (%): C 38.22, H 3.81, N 15.75, S 7.26. IR Data/ cm-1: 3495 (w, NH), 
2981 (w, CH), 2883 (w, CH), 2827 (w, CH), 1598 (m), 1547 (vs, C=N), 1439 (m), 
1420 (m), 1388 (m), 1317 (s), 1235 (m, thioamide), 1138 (m), 1055 (m), 1006 (m), 
904 (m), 802 (m, C=S), 751 (m), 650 (s), 630 (s). UV-Vis in DMSO: [λmax (nm) (ε/ M-1 
cm-1)]: 309 (10600), 420 (14600). 
 
2.2.3.3 [Zn(Ap44mT)Cl2] 
Zn(Ap44mT)Cl2 was prepared using general procedure except that Ap44mT (0.50 g, 
2.25 mmol) and ZnCl2 (0.31 g, 2.27 mmol) were used. Yellow solid (0.7 mg). Yield: 
88%. 1H NMR (500 MHz, d6-DMSO): δ 2.53 (3H, s, CH3), δ 3.32 (6H, s, N(CH3)2 ), δ 
7.49-7.67 (1H, broad doulet, CHpy), δ 7.99 (1H, bs, CHpy), δ 8.14 (1H, bs, CHpy), δ 
8.67 (1H, bs, CHpy). ESI-MS in MeOH: found mass: 284.99 (95%), 506.79 (100%). 
Calc. mass for C10H13SN4Zn ([M−2Cl-−H+]+): 285.02, C20H26S2N8Zn ([M−2Cl-
+L+H+]+): 507.11. Anal. Calc. for C10H14N4SCl2Zn (%): C 33.50, H 3.94, N 15.62, S 
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8.94. Found (%): C 33.46, H 4.03, N 15.26, S 8.98. IR Data/ cm-1: 3262 (w, NH), 
2976 (w, CH), 1626 (m), 1563 (vs, C=N), 1473 (m), 1440 (m), 1388 (m), 1352 (m), 
1307 (s), 1222 (s, thioamide), 1110 (m), 1017 (m), 898 (m), 814 (s, C=S), 777 (vs), 
747 (m), 733 (m), 640 (m). UV-Vis in DMSO: [λmax (nm) (ε/ M-1 cm-1)]: 307 (11300), 
404 (18400). 
 
2.2.3.4 [Zn(DpC)Cl2]  
 Zn(DpC)Cl2 was prepared using general procedure where DpC·HCl (0.350 g, 0.90 
mmol) and ZnCl2 (0.122 g, 0.90 mmol) were used. Yellow solid (0.36 g). Yield: 82%. 
1H NMR (500 MHz, d6-DMSO): δ 1.17-1.81 (11H, m, cyclohexyl), δ 3.13 (3H, bs, 
NCH3), δ 7.59 (1H, t, 3JH,H = 8.5 Hz, py), δ 7.65 (1H, t, 3JH,H = 7.0 Hz, py), δ 7.80 
(2H, bs, py), δ 8.04 (1H, t, 3JH,H = 9.5 Hz, py), δ 8.11 (1H, t, 3JH,H = 9.0 Hz, py), δ 
8.67 (1H, s, py), δ 8.86 (1H, dd, 3JH,H = 5.5 Hz, py). 13C NMR (125 MHz, d6-DMSO): 
δ 18.83 (CH2, cyclohexyl), δ 25.35 (CH2, cyclohexyl), δ 25.82 (CH2, cyclohexyl), δ 
29.73 (NCH, cyclohexyl), δ 56.31 (NCH3), δ 124.41 (py), δ 124.47 (py), δ 125.28 
(py), δ 127.42 (py), δ 138.81 (py), δ 139.39 (py), δ 148.33 (py), δ 148.69 (C=N). ESI-
MS in MeOH: found mass: 416.05, 768.98. Calc. mass for C19H22SN5Zn [M−2Cl-
−H+]+: 416.09, C38H45S2N10Zn [M−2Cl-+L+H+]+: 769.26. Anal. Calc. for 
C19H23N5SCl2Zn (%): C 46.59, H 4.73, N 14.30, S 6.55. Found (%): C 46.46, H 4.78, 
N 13.96, S 6.51. IR Data/ cm-1: 3071 (w, CH), 2944 (w, CH), 2862 (CH), 1597 (m), 
1514 (vs, C=N), 1473 (m), 1445 (m), 1403 (m), 1326 (m), 1296 (s), 1230 (s, 
thioamide), 1190 (m), 1151 (m), 1002 (s), (m), 808 (vs, C=S), 776 (m), 749 (s), 639 
(s), 614 (m). UV-Vis in DMSO: [λmax (nm) (ε/ M-1 cm-1)]: 310 (11500), 423 (11500). 
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2.2.3.5 [Zn(Dp44mT)2] 
Orange yellow solid (0.28 g). Yield: 88%. 1H NMR (500 MHz, CDCl3): δ 3.21 (6H, s, 
N(CH3)2), δ 7.05 (1H, ddd, CHpy), δ 7.33 (1H, ddd, CHpy), δ 7.31-7.35 (1H, m, CHpy), 
δ 7.49-7.54 (1H, td, CHpy), δ 7.82-7.87 (1H, td, CHpy), 7.94 (1H, d, CHpy), 8.14 (1H, 
dd, 3JH,H = 6.0 Hz, CHpy), 8.77 (1H, dd, 3JH,H = 4.0 Hz, CHpy). 13C NMR (125 MHz, 
CDCl3): δ 122.95 (py), δ 123.10 (py), 123.44 (py), 127.89 (py), δ 135.37 (py), δ 
137.80 (py), δ 142.41 (py), δ 147.17 (C=N), δ 149.16 (py), 150.15 (py), 153.80 (py), 
δ 183.07 (C-S). ESI-MS in MeCN: found mass: 632.86 (100%). Calc. mass for 
C28H29N10S2Zn ([M+H+]+: 633.13. Anal. Calc. for C28H28N10S2Zn (%): C 53.04, H 4.45, 
N 22.09, S 10.11. Found (%): C 52.84, H 4.38, N 20.76, S 9.63. IR Data/ cm-1: 3077 
(w, NH), 2936 (w, CH), 1559 (m, C=N), 1473 (m), 1317 (m), 1238 (m, thioamide), 
1006 (m), 975 (m), 906 (m), 803 (m, C=S), 622 (s). UV-Vis in DMSO: [λmax (nm) (ε/ 
M-1 cm-1)]: 309 (21900), 418 (26800).  
 
2.2.3.6 [Zn(Ap44mT)2] 
Yellow solid (0.21 g). Yield: 84%. Single crystals suitable for X-ray diffraction were 
grown in a NMR tube. 1H NMR (500 MHz, CDCl3): δ 2.59 (3H, s, CH3C=N), δ 3.32 
(6H, s, N(CH3)2), δ 7.01 (1H, dd, CHpy), δ 7.46 (1H, d, 3JH,H = 5 Hz, CHpy), δ 7.61-
7.64 (1H, m, CHpy), δ 7.90 (1H, d, 3JH,H = 5.0 Hz, CHpy). 13C NMR (125 MHz, CDCl3): 
δ 13.65 (CH3C=N), δ 39.70 (N(CH3)2), δ 120.41 (py), δ 123.18 (py), δ 138.14 (py), 
143.33 (py), δ 146.80 (C=N), δ 151.06 (py), δ 178.9 (C-S). ESI-MS in MeCN: found 
mass: 285.00 (100%), 506.87 (85%), 792.93 (80%). Calc. mass for C10H13SN4Zn 
[M−L]+: 285.02, C20H27N8S2Zn [M+H+]+: 507.11, C30H39S3N12Zn2 [2M+L]+: 793.11. 
Anal. Calc. for C20H26N8S2Zn·0.5H2O (%): C 46.46, H 5.26, N 21.67, S 12.41. Found 
(%): C 46.59, H 5.04, N 21.64, S 12.47. IR Data/ cm-1: 1561 (m, C=N), 1479 (w), 
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1310 (m), 1226 (m, thioamide), 1018 (m), 902 (m), 813 (m, C-S), 788 (m), 623 (s). 
UV-Vis in DMSO: [λmax (nm) (ε/ M-1 cm-1)]: 309 (22300), 404 (30600).  
 
2.2.3.7 [Zn(DpC)2]·(ClO4)2 
[Zn(DpC)2](ClO4)2 was prepared using general procedure without addition of triethyl 
amine. Yellow solid (0.29 g). Yield: 59%. 1H NMR (500 MHz, d6-DMSO): δ 1.13-1.76 
(11H, m, cyclohexyl), δ 3.12 (3H, s, NCH3), δ 7.60 (1H, t, 3JH,H = 6.5 Hz, CHpy), δ 
7.67 (1H, t, 3JH,H = 6.0 Hz, CHpy), δ 7.82 (2H, bs, CHpy), δ 8.04 (1H, t, CHpy), δ 8.13 
(1H, bs, CHpy), δ 8.66 (1H, bs, CHpy), δ 8.86 (1H, d, CHpy), δ 8.88 (1H, d, 3JH,H = 5.0 
Hz, CHpy). 13C NMR (125 MHz, d6-DMSO): δ 19.01 (CH2, cyclohexyl), δ 25.27 (CH2, 
cyclohexyl), δ 25.77 (CH2, cyclohexyl), δ 29.63 (NCH, cyclohexyl), δ 56.50 (NCH3), δ 
125.07 (CHpy), δ 125.60 (py), δ 125.82 (py), δ 126.09 (py), δ 127.65 (py), δ 128.08 
(py), δ 139.50 (py), δ 140.76 (py), δ 147.60 (py), δ 148.42 (py), 149.33 (C=N), δ 
180.16 (C=S). ESI-MS in MeCN: found mass: 768.98 (100%). Calc. mass for 
C32H42S3N12Zn ([M−2ClO4+CH3CN−H+]+): 769.22. Anal. Calc. for 
C38H46N10S2O8Cl2Zn (%): C 46.99, H 4.77, N 14.42, S 6.60. Found (%): C 46.74, H 
4.74, N 14.36, S 6.21. IR Data/ cm-1: 2931 (w), 2856 (w), 1501 (m, C=N), 1477 (m), 
1301 (m), 1238 (m, thioamide), 1090 (vs, ClO4), 1006 (m), 927 (m), 807 (s, C=S), 
704 (m), 623 (s). UV-Vis in DMSO: [λmax (nm) (ε/ M-1 cm-1)]: 315 (22700), 423 
(31500).  
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2.3 X-ray Crystallography 
Data were collected at 190 K on an Oxford Diffraction Gemini CCD diffractometer 
(Abingdon, United Kingdom) with Cu-Kα radiation (1.54184 Å). Data reduction and 
empirical absorption corrections (multiscan) were carried out using Oxford Diffraction 
CrysAlisPro software. The structure was solved by direct methods with SHELX-86 
and refined by full matrix least-squares on F2 with SHELXL-97 (Farrugia, 1999; 
Sheldrick, 2008). All non-hydrogen atoms were refined anisotropically except O-
atoms attached to Cl5, Cl6, Cl7 and Cl8 (disordered perchlorates). Hydrogen atoms 
were included at their calculated positions using a riding model. The N-H protons 
were first identified from difference maps, but then constrained. Molecular structure 
diagrams were produced with ORTEP3 (Farrugia, 1997). Crystal data in CIF format 
have been deposited with the Cambridge Crystallographic Data Centre (CCDC 
1062686 & 1062687). 
 
2.4 Binding Studies 
 Zn-ligand binding studies were carried out in Mops buffer (pH=7.3, 50 mM, NaCl, 
100 mM, DMSO, 10% (v/v)) and in DMSO alone. To the ligand (50 µM) solution, 
increasing concentration of ZnCl2 was added gradually and incubated. After 3 min, 
absorption spectra were measured, subsequently their binding ratio was calculated 
by plotting λmax that appeared between 380-450 nm against Zn/ligand molar ratio. 
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2.5 Cell Culture 
The KB31 (-Pgp) and the vinblastine-resistant variant KBV1 (+Pgp) cell lines were 
grown in DMEM. SW480 cells were grown in RPMI. M14 Bcl-2 and PC cells were 
grown in RPMI with G418 (800 μM). All cells were grown under standard growth 
conditions. All media were supplemented with foetal bovine serum (10%), penicillin 
(100 U/mL), streptomycin (100 mg/mL), L-glutamine (2 mM), non-essential amino 
acids, sodium pyruvate (1 mM) and fungizone (0.25 μg/mL). KBV1 (+Pgp) cells were 
grown constantly in the presence of vinblastine (1 μg/mL) to ensure high Pgp 
expression (Jansson et al., 2015a; Yamagishi et al., 2013).  
 
2.6 Determination of Pgp-ATPase Activity 
Whether or not the thiosemicarbazones and their Fe(III) and Cu(II) complexes are 
Pgp substrates was assessed using the Pgp Glo™ Assay System (Promega 
Corporation, Madison, WI, USA). The assay was performed according to the 
manufacturer’s instructions as described previously, using thiosemicarbazones and 
their Fe(III) or Cu(II) complexes (50 μM). Briefly, Pgp-enriched membranes (0.5 
mg/mL) and Mg(II)-ATP (5 mM) were incubated for 40 min/37 °C with the test 
agents, and ATP levels were detected as a luciferase-generated luminescent signal. 
As relevant negative controls, the well characterised Pgp inhibitor, vanadate, was 
utilised (Urbatsch et al., 1994). As a positive control, verapamil-stimulated Pgp-
ATPase activity was measured in the presence of the Pgp control substrate, 
verapamil (200 µM) (Ogihara et al., 2006).  
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2.7 Cellular Proliferation Assay 
Proliferation was examined using the MTT assay. Briefly, cells were seeded in 96 
well plates and allowed to adhere overnight. The seeding densities used were of 5 x 
103 cells/well for KBV1 cells, 2 x 103 cells/well for KB31 cells, 10 x 103 cells/well for 
SW480 cells and 1 x 104 for M14 Bcl-2 and PC cells. The thiosemicarbazones and 
Zn-thiosemicarbazone complexes were added to the plates and incubated for 24 
h/37°C. In studies involving the use of the Pgp inhibitor, Ela, thiosemicarbazones 
were added to the plates in the presence of absence of Ela (0.1 μM) and incubated 
for 24 h/37°C. For assays conducted with TM, TM was added to cells 3 h before the 
addition of Zn complexes, followed by a 24 h incubation with the Zn complexes. As 
shown previously, MTT colour formation was directly proportional to the number of 
viable cells (Richardson et al., 1995), validating its use in these studies. Results 
were processed and analysed according to standard procedures (Kalinowski et al., 
2007; Lovejoy et al., 2012; Richardson et al., 2006; Richardson et al., 2009; Whitnall 
et al., 2006; Yuan et al., 2004). For assays conducted with N-acetyl cysteine (NAC), 
NAC (10 mM) was added to the cells 3 h prior to the thiosemicarbazones. 
 
2.8 Redox Activity Assessment 
2.8.1 In Vivo 
In order to assess ROS generation by the thiosemicarbazones and their Fe(III) and 
Cu(II) complexes, H2DCF-DA oxidation was assessed in vitro using standard 
experimental procedures and conditions (Jansson et al., 2010a; Lovejoy et al., 
2011). Briefly, KBV1 cells were seeded to give approximately 50% confluence the 
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next day. H2DCF-DA (30 mM) and Ela (0.1 µM) were then added and the cells were 
incubated at 37°C/30 min. The H2DCF-DA was then removed, before the 
thiosemicarbazones (10 mM) and Ela were added and the cells were again incubated 
at 37°C/30 min. The treatments were subsequently removed and the cells were 
harvested with PBS/EDTA and centrifuged (1000 rpm/5 min) prior to being re-
suspended in cold PBS prior to conducting flow cytometry using a FACS Canto 
(Becton Dickinson, USA). In these studies, 10,000 events/sample were recorded and 
the data analysis conducted using FloJo software version 7.5.5. (Tree Star, Inc; 
Ashland, OR, USA). 
 
2.8.2 In Vitro 
Studies were conducted as described with H2DCF (5 μmol/L)(Lovejoy et al., 2011; 
Myhre et al., 2003). As a positive control, Zn(II), Cu(II) at 5 μmol/L was reduced 
using cysteine (100 μmol/L) in either Hanks Buffered Saline Solution (HBSS, pH = 
7.4) or 150 mmol/L acetate buffer (pH = 5.0). Hydrogen peroxide (100 μmol/L) was 
then added to initiate hydroxyl radical generation. Dp44mT, [Zn(Dp44mT)2], 
Ap44mT, [Zn(Ap44mT)2] DpC and [Zn(DpC)2] (5 μmol/L) were added to examine 
hydroxyl radical production, in the presence or absence of Cu(II) (5 μmol/L) or TM 
(250 μmol/L).  
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2.9 Microscopy 
2.9.1 Lysosomal Membrane Permeabilisation Assays 
Lysosomal membrane permeabilisation (LMP) was assessed using a Zeiss Axio 
Observer:Z camera and AxioVision Rel. 4.7 Software (Zeiss, Oberkochen, Germany) 
1 fluorescence microscope equipped with GFP and TexasRed filters. Images were 
captured using an AxioCam camera and AxioVision Rel. 4.7 Software (Zeiss). Data 
analysis was performed using ImageJ v 1.48 software. For acridine orange (AO) 
studies (Yu et al., 2009a), cells were seeded to give 50% confluence and left to 
adhere overnight. Cells were then incubated with AO (2.5 μg/mL) for 12 min/37°C, 
washed 3 times with PBS and then incubated for 30 min/37°C with the 
thiosemicarbazones (10 or 30 μM), either alone, or pre-coordinated with Fe(III) or 
Cu(II) (10 μM), +/- Ela (0.1 μM), +/- NAC (5 mM) or +/-TM (10 μM). Further studies 
were also conducted where cells were incubated for 1 h/37°C with the 
thiosemicarbazones (10 μM), or the Zn complexes (10 μM), +/-TM (250 μM). The 
cells were then washed 3 times and imaged. Alternatively, cells were incubated with 
thiosemicarbazones for 24 h prior to incubation with AO, as previously described. 
 
LMP was also assessed via immunofluorescence using the lysosomal markers, 
lysosomal-associated membrane protein 2 (LAMP2) and Cathepsin D (Yu et al., 
2009a). KBV1 cells were seeded onto coverslips at a density of 3 x 104 cells/ml and 
left to adhere overnight/37oC. Cells were then treated with Dp44mT or Ap44mT (25 
mM), +/- Ela (0.1 µM), +/-NAC (5 mM), +/- TM (25 mM) for 24 h/37oC. Treatment was 
followed by methanol fixation for 15 min and digitonin permeabilisation (100 µM/10 
min) at room temperature. After blocking with 1% bovine serum albumin for 30 min at 
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room temperature, immunocytochemistry was performed with LAMP2 (Cell 
Signaling, Danvers, MA, USA) and cathepsin D (Cell Signaling), using TexasRed 
and FITC conjugated secondary antibodies. Coverslips were mounted on slides 
using ProLong® Gold Antifade Mountant with DAPI (ThermoFisher Scientific).  
 
2.9.2 Intracellular Localisation of (Zn[DpC]) 
Intracellular localisation of [Zn(DpC)] was examined using the fluorescent probes 
LysoTracker® Deep Red, MitoTracker® Deep Red and DRAQ5™. Images were 
acquired using a Zeiss LSM 780 confocal microscope with a 100 x oil-immersion 
objective. Data analysis was performed using ImageJ v 1.48 software and the 
associated JACoP plugin. To examine nuclear localisation, DRAQ5™ was added to 
cells at concentrations recommended by the manufacturer. Cells were incubated 
with DRAQ5™ for 10 min/37°C, followed by another 10 min/37°C incubation with 
[Zn(DpC)]. Cells were then washed 3 x with PBS prior to imaging in Live Cell 
Imaging Solution. Excitation wavelengths were set at 405 and 633 nm, and emission 
detected between 410-510 nm and 685-695 nm.  
 
Mitochondrial localisation was assessed using MitoTracker® Deep Red. Cells were 
treated with 50 nM of Mitotracker® Deep Red for 10 min/37°C, before 100 mM of 
[Zn(DpC)] was added and cells were incubated for 10 min/ 37°C. Cells were then 
washed 3 x with PBS prior to imaging in Live Cell Imaging Solution. Excitation 
wavelengths were set at 405 and 633 nm, and emission detected between 410-510 
nm and 685-695 nm. Lysosomal localisation was assessed using LysoTracker® 
Deep Red. Cells were treated with 50 nM of LysoTracker® Deep Red for 10 min/ 
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37°C, before 100 mM of [Zn(DpC)] was added and cells were incubated for 10 min/ 
37°C. Cells were then washed 3 x with PBS prior to imaging in Live Cell Imaging 
Solution. Excitation was set at 405 nm (LysoTracker® Deep Red exhibits a small 
excitation peak at ~400 nm) and emission detected between 410-510 nm and 685-
695 nm.  
 
2.10 Western Blotting 
Protein extraction and Western blotting were performed using standard methods 
(Gao and Richardson, 2001). Immunodetection of proteins was carried out using 
antibodies against Bcl-2 (catalogue number 2872; Cell Signalling Technology), LC3 
(catalogue number MBPM036; Abacus-ALS, Meadowbrook, QLD, Australia) and b-
actin (catalogue number A1978; Sigma Aldrich). Secondary antibodies included 
horseradish peroxidase-conjugated anti-rabbit (catalogue number A6154; Sigma 
Aldrich) and anti-mouse (catalogue number A4416; Sigma Aldrich). The membrane 
was developed using enhanced chemiluminescence and imaged using a ChemiDoc 
(Bio-Rad) imager. Densitometric analysis was performed using Image Lab Software 
(Bio-Rad), normalised to b-actin. 
 
2.11 Silencing using RNA Interference 
Cells were seeded into plates and allowed to adhere overnight. Cells were 
transfected with ONTARGET plus siRNA oligos (Dharmacon, Lafayette, CO) for 8 
h/37°C in serum-free OPTIMEM (Sigma Aldrich) media using Lipofectamine 2000 
(Invitrogen), according to the manufacturer’s instructions. The cells were then 
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incubated in MEM media supplemented with FCS for 96 h/37°C, prior to further 
experiments. The siRNAs purchased from Dharmacon were: ONTARGET plus non-
targeting pool (negative control siRNA, catalogue number D-001810-01) and SMART 
pool ONTARGET plus Bcl-2 siRNA (catalogue number L-003307-00-005).  
 
2.12 Statistical Analysis 
All statistical analysis using two-way ANOVA or Student’s t-test were performed 
using GraphPad Prism (v6.0, GraphPad Software, Inc, La Jolla, CA, USA). 
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Chapter 3 - Structure-Activity Relationships of 
Di-2-Pyridylketone, 2-Benzoylpyridine and 2-
Acetylpyridine Thiosemicarbazones for 
Overcoming Pgp-Mediated Drug Resistance 
(Taken from Stacy et al (2016) J. Med. Chem.) 
 
3.1 Introduction 
Cancer remains a major cause of mortality and morbidity worldwide and new anti-
cancer agents are essential to develop (Jansson et al., 2015a). One class of 
compounds that has been extensively investigated is the thiosemicarbazone group 
that exert their effects through their ability to effectively sequester transition metals 
(Yu et al., 2009b). Of these, 3-AP (Fig. 3.1A), has entered greater than 20 multi-
centre clinical trials, but has suffered multiple problems, including low efficacy in 
some tumour-types and significant side effects, including methaemoglobinemia 
(Knox et al., 2007; Merlot et al., 2013; Traynor et al., 2010). 
 
Over the last 20 years, our laboratory has focused on the development of ligands for 
clinical use, with a particular emphasis on agents for cancer treatment (Baker et al., 
1992; Becker et al., 2003; Darnell and Richardson, 1999; Richardson et al., 1995; 
Richardson and Milnes, 1997). Through concerted structure-activity relationship 
studies, novel ligands of the DpT series that show potent and selective anti-tumour 
activity and anti-metastatic activity both in vitro and in vivo were developed (Chen et 
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al., 2012; Liu et al., 2012; Lovejoy et al., 2012; Richardson et al., 2006; Whitnall et 
al., 2006; Yuan et al., 2004). Of these DpT analogues, Dp44mT (Fig. 3.1B), is the 
most well characterised and has been shown to target the lysosome to induce 
lysosomal membrane permeabilisation (LMP) (Gutierrez et al., 2014; Jansson et al., 
2015b; Lovejoy et al., 2011).  
 
Significantly, Dp44mT demonstrated markedly more pronounced anti-proliferative 
activity than 3-AP and greater tolerability with less side effects (Whitnall et al., 2006; 
Yuan et al., 2004). However, Dp44mT induced cardiac fibrosis at high non-optimal 
doses (Whitnall et al., 2006) and this undesirable property led to the design and 
synthesis of a second generation of DpT analogues (Kovacevic et al., 2011; Lovejoy 
et al., 2012). These new agents were designed based upon a key structure−activity 
relationship derived from our previous studies in which the replacement of the 
terminal H at N4 with an alkyl group increased anti-proliferative activity (Lovejoy and 
Richardson, 2002; Richardson et al., 2006; Yuan et al., 2004). Of these ligands, DpC 
(Fig. 3.1C) was identified as the lead agent (Kovacevic et al., 2011; Lovejoy et al., 
2012). Both Dp44mT and DpC demonstrate selectivity towards cancer cells over 
normal cells both in vitro and in vivo (Kalinowski et al., 2007; Lovejoy et al., 2012; 
Stefani et al., 2011; Stefani et al., 2013; Whitnall et al., 2006). However, the 
advantages of DpC over Dp44mT include: (1) that DpC demonstrates greater anti-
tumour activity than Dp44mT in vivo against pancreatic tumour xenografts, showing 
substantially enhanced efficacy than the gold standard agent for this disease, 
gemcitabine (Kovacevic et al., 2011); (2) DpC demonstrates pronounced anti-tumour 
activity and tolerability when administered orally, as well as intravenously, while 
Dp44mT is toxic when given via the oral route (Lovejoy et al., 2012; Yu et al., 2012); 
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(3) DpC demonstrates potent anti-tumour activity in vitro and in vivo against multiple 
belligerent tumour-types without inducing cardiotoxicity (Kovacevic et al., 2011; 
Lovejoy et al., 2012); and (4) unlike Dp44mT, DpC is markedly and significantly less 
active at inducing methaemoglobin generation (Quach et al., 2012). Moreover, due 
to its optimal properties, DpC has entered clinical trials in early 2016 for the 
treatment of advanced and resistant cancers (NCT02688101) which highlights its 
selectivity and tolerability (Jansson et al., 2015a). 
 
Concurrently with the DpT series of ligands, the synthesis and characterisation of 
several other series of thiosemicarbazones were also initiated in our laboratories 
(Jansson et al., 2015a). These included the BpT (e.g., Bp44mT; Fig. 3.1D) and ApT 
(e.g. Ap44mT; Fig. 3.1E) series of ligands that also showed marked and selective 
anti-tumour activity in vitro and/or in vivo (Kalinowski et al., 2007; Richardson et al., 
2009; Yu et al., 2012). As a relevant control, 2-benzoylpyridine 2-
methylthiosemicarbazone (Bp2mT), a BpT analogue that cannot chelate metals, was 
also synthesised where a methyl group substituted at N2 prevents electron 
delocalisation and the binding of metal ions (Fig. 3.1F). 
 
Integral to the mechanism of action of these ligands, it was demonstrated that they 
form redox-active Fe(III) and Cu(II) complexes (Jansson et al., 2010a; Jansson et al., 
2010b; Kalinowski et al., 2007; Lovejoy et al., 2011; Richardson et al., 2006; 
Richardson et al., 2009; Yuan et al., 2004). Moreover, two of these agents, namely 
Dp44mT and DpC are substrates of the drug transporter, Pgp, and are effluxed out 
of cells, but also are transported into lysosomes by utilising Pgp on the lysosomal 
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membrane (Jansson et al., 2015b; Seebacher et al., 2016b; Seebacher et al., 
2016c). Notably, as a part of endocytosis in Pgp expressing cells, the Pgp-containing 
plasma membrane buds inward to form an early endosome. Upon endocytosis there 
is inversion of the topology of Pgp in the endosomal membrane that leads to the 
transport of Pgp substrates, including Dp44mT and DpC, into the lysosomal interior 
(Jansson et al., 2015b; Seebacher et al., 2016b; Seebacher et al., 2016c; Yamagishi 
et al., 2013). During this process, the catalytic active site and ATP-binding domain of 
Pgp are still exposed to the cytosol and enable Pgp to “pump” substrates from the 
cytosol into lysosomes (Yamagishi et al., 2013). Within the lysosomes, these agents 
become trapped due to protonation of the compounds at the acidic pH of the 
organelle, bind copper and redox cycle to generate reactive oxygen species that 
induce LMP, and apoptotic cell death (Gutierrez et al., 2016; Jansson et al., 2015b; 
Lovejoy et al., 2011). Clearly, the ability of Dp44mT to “hijack” Pgp and markedly 
overcome resistance to standard chemotherapies is an important advantage, as 
MDR is a major impediment to the successful treatment of cancer (Jansson et al., 
2015a; Leonard et al., 2003). 
 
The ATP-binding cassette transporters, such as Pgp, are one of the most commonly 
encountered MDR mechanisms, and are responsible for the cellular efflux of a broad 
variety of cytotoxic drugs and one of the most clinically significant drug transport 
mechanisms (Higgins, 2007; Leonard et al., 2003). In fact, Pgp has been linked to 
poorer clinical outcomes in solid tumours and haematological malignancies (Higgins, 
2007; Leonard et al., 2003). Past efforts aimed at targeting Pgp have largely focused 
on direct inhibitors, although clinical trials have yet to provide convincing proof of 
their efficacy (Coley, 2010; Szakacs et al., 2006). Hence, alternative strategies at 
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overcoming resistance, such as that offered by Dp44mT (Jansson et al., 2015b; 
Whitnall et al., 2006), are critical to develop. 
 
Considering the marked activity of Dp44mT in overcoming drug resistance, the 
current study investigated the structural requirements of thiosemicarbazones 
necessary to target drug resistant cancer cells using the aforementioned mechanism 
of hijacking lysosomal Pgp to potentiate lysosomal targeting (Jansson et al., 2015b). 
To assess this, four structurally-related thiosemicarbazones belonging to the DpT, 
BpT, and ApT series were examined, namely: Dp44mT (Fig. 3.1B), DpC (Fig. 3.1C), 
Bp44mT (Fig. 3.1D) and Ap44mT (Fig. 3.1E). This choice of agents was based on 
their marked and selective anti-cancer efficacy (Kalinowski et al., 2007; Lovejoy et 
al., 2012; Richardson et al., 2009; Yu et al., 2012; Yuan et al., 2004). The activity of 
these compounds was compared to the clinically trialled thiosemicarbazone, 3-AP 
(Knox et al., 2007; Traynor et al., 2010) (Fig. 3.1A) and the negative control BpT 
analogue, Bp2mT (Fig. 3.1F).  
 
Herein, we identify crucial structural-activity relationships that enable 
thiosemicarbazones of these classes to overcome MDR which includes: (1) the 
presence an electron-withdrawing substituent at the imine carbon (that results in an 
appropriate redox potential of its Cu complex to oxidise biological substrates and 
induce ROS generation); (2) sufficient relative lipophilicity to enable facile membrane 
transport and to act as an effective Pgp substrate; and (3) the ability of the ligand to 
bind Cu(II) and generate ROS that is essential for inducing LMP that kills drug 
resistant tumour cells. 
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Figure 3.1. Line drawings of the ligands (A-F); mechanism of action of 
thiosemicarbazones in Pgp-mediated drug resistance (G); and line drawings of 
new copper complexes examined in this investigation (H-K).  
Structure of (A) 3-AP, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; (B) 
Dp44mT, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone; (C) DpC, di-2-
pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone; (D) Bp44mT, 2-
benzoylpyridine 4,4-dimethyl-3-thiosemicarbazone; (E) Ap44mT, 2-acetylpyridine 
4,4-dimethyl-3-thiosemicarbazone; and (F) Bp2mT, 2-benzoylpyridine 2-methyl-3-
thiosemicarbazone. Structure of new thiosemicarbazones Cu complexes (G) 
[Cu(Bp44mT)(Bp44mT-H)]ClO4; (H) [Cu(DpC)(DpC-H)]ClO4; (I) [Cu(3-AP)(3-AP-
H)]ClO4; and (J) [Cu(Bp44mT-H)Cl]. 
 
 
3.3 Results and Discussion 
3.3.1 Synthesis and Characterisation of Novel Thiosemicarbazones 
The tridentate thiosemicarbazone ligands, Dp44mT, DpC, Bp44mT and Ap44mT 
(Fig. 3.1B-E), were synthesised and characterised, as previously described 
(Kalinowski et al., 2007; Lovejoy et al., 2012; Richardson et al., 2006; Richardson et 
al., 2009). The compound, Bp2mT (Fig. 3.1F), was synthesised in an analogous 
manner by refluxing equimolar amounts of 2-benzoylpyridine and 2-methyl-3-
(A) (B) (C) (D) (E) (F)
(G) (H) (I) (J)
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thiosemicarbazide in ethanol with glacial acetic acid as a catalyst. 1H and 13C NMR 
spectral analysis revealed the presence of both E and Z isomers of Bp2mT in 50:50 
ratio in d6-DMSO (Fig. 3.2, 3.3). Furthermore, our group has already demonstrated 
that the same class of 2-benzoylpyridine thiosemicarbazones exist as 
interconvertible E/Z isomers in solution (Stariat et al., 2010).  
 
The 1:1 and 1:2 Cu(II)/ligand complexes with selected ligands were also synthesised 
(Figs. 3.1G-J). Significantly, the thiosemicarbazone Cu(II) complexes were important 
to characterise as it is well known that the Dp44mT-Cu(II) complex is markedly 
active and crucial in terms of inducing LMP and overcoming drug resistance 
(Jansson et al., 2015b; Lovejoy et al., 2011). The 1:2 Cu(II)/ligand complexes of 
Bp44mT (Fig. 3.1G), DpC (Fig. 3.1H) and 3-AP (Fig. 3.1I) were obtained by refluxing 
2 equivalents of the respective thiosemicarbazone with one equivalent of 
Cu(ClO4)2.6H2O in ethanol in the presences of the base, triethylamine, for 1 h. On 
the other hand, the 1:1 Cu(II)/ligand complex, [Cu(Bp44mT-H)Cl] (Fig. 3.1J), was 
prepared by refluxing an ethanolic solution of equimolar amounts of Bp44mT and 
CuCl2. All complexes were characterised by ESI-MS, UV−visible and IR 
spectroscopy and their purity was confirmed by elemental analysis. 
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Fig. 3.2 1H NMR spectrum of Bp2mT.  
1H NMR spectral analysis revealed the presence of both E and Z isomers of 
Bp2mT in 50:50 ratio in d6-DMSO. 
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Fig. 3.3 13C NMR spectrum of Bp2mT.  
13C NMR spectral analysis revealed the presence of both E and Z isomers of 
Bp2mT in 50:50 ratio in d6-DMSO. 
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3.3.2 Novel Crystal Structures 
Single crystals of the Cu(II) complexes of Bp44mT (both 1:1 and 1:2 Cu/ligand) 
suitable for X-ray diffraction were obtained by slow vapour diffusion of diethyl ether 
into methanol solutions of each compound. The molecular structures of 
[Cu(Bp44mT)(Bp44mT-H)]ClO4 and [Cu(Bp44mT-H)Cl] are shown in Figures 3.3A 
and B, respectively, and their crystal data are presented in Table 3.1. The structure 
of [Cu(Bp44mT)(Bp44mT-H)]ClO4 comprised four complex cations in the asymmetric 
unit, each with essentially the same coordination geometry (Fig. 3.4A). 
 
The Cu ion was coordinated to two ligands in an asymmetric manner to give a 
distorted square pyramidal geometry, where the deprotonated ligand acted as a 
tridentate chelator (N-N-S), while the neutral ligand acted as a bidentate (N-S) 
chelator (Fig. 3.4A). The bidentate coordinated ligand is found in its Z-isomeric form 
which is incapable of binding as a tridentate ligand. The positions of the phenyl and 
pyridyl rings are reversed by comparison with the tridentate deprotonated ligand, 
which is in its E-isomeric form. The fact that both isomers are observed here within 
the same complex illustrates that conversion between the two is facile in solution and 
that they equilibrate, as shown by NMR.  
 
The presence of the proton on the thiosemicarbazone group most likely stabilises the 
ligand in the Z-isomeric form (through the intra-molecular H-bond to the pyridine ring; 
Fig. 3.4A). This prevents the ligand from isomerising to the E-form, where the three 
donor atoms are on the same side of the ligand. The intra-molecular hydrogen 
bonding between the NH and the N of the pyridine ring in the neutral Z-isomeric 
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Bp44mT ligand was preserved (Fig. 3.4A) In fact, the conformation of the neutral 
ligand in [Cu(Bp44mT)(Bp44mT-H)]ClO4 is almost the same as found in the free 
ligand (Jayakumar et al., 2011), except that the phenyl ring is rotated out of the plane 
of the ligand by the presence of the Cu atom. Two of the four independent 
perchlorate anions were well defined, but the other two were disordered over several 
sites and refined with partial occupancies. The coordination geometry of the 
[Cu(Bp44mT)(Bp44mT-H)]ClO4 complex was quite different from the geometries of 
other analogous 1:2 Cu(II)/ligand complexes, namely [Cu(Ap44mT-H)2] and 
[Cu(Dp44mT-H)2], that were reported earlier by our group as tridentate ligands both 
in their deprotonated form (Bernhardt et al., 2009; Jansson et al., 2010b). The 
structure of the 1:1 complex, [Cu(Bp44mT-H)Cl], was more conventional and 
crystallised in a centrosymmetric dimeric five-coordinate configuration, where the S 
atom of an adjacent complex coordinated weakly in the axial site (Cu…S1’ > 2.9 Å). 
A view of the dimer seen in the solid state is shown in Figure 3.3B. 
 
There are other Cu(II) complexes of Bp44mT that have been characterised, including 
a bis-acetato-bridged dimer [(Bp44mT-H)Cu(µ-OAc)2Cu(Bp44mT-H)] and a bis-azido 
bridged dimer [(Bp44mT-H)Cu(µ-N3)2Cu(Bp44mT-H)] (Jayakumar et al., 2014; 
Kunnath et al., 2012). There are also examples of related 2-benzoylpyridine 
thiosemicarbazones coordinating to Cu(II) in either their deprotonated (monoanionic) 
or protonated (neutral) forms (Dobritzsch et al., 2005; Joseph et al., 2004; Lobana et 
al., 2012; Sreekanth and Kurup, 2003; West et al., 1995; Yang et al., 2013a). 
However, the structure of [Cu(Bp44mT)(Bp44mT-H)]+ reported herein is a hybrid of 
both forms within the same complex. Significantly, no similar examples are known in 
the literature where the acid and base forms of a benzoylpyridine thiosemicarbazone 
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are coordinated to the same metal ion. The closest analogue is the Cu(II) complex of 
acetylpyridine thiosemicarbazone, where one of the two ligands is deprotonated, but 
in that case, both ligands bind in a tridentate manner to give a six-coordinate 
complex (Souza et al., 1996). 
The C-S bond length of the thiosemicarbazone is a reliable indicator of the state of 
deprotonation. Deprotonation of the NH-C=S moiety leads to the N=C-S- form being 
the dominant contributor to the structure and the C-S bond is invariably longer than 
1.73 Å. By contrast, when the neutral ligand is bound, the C=S bond retained double 
bond character (C-S < 1.7 Å). This was also seen here in the structure of 
[Cu(Bp44mT)(Bp44mT-H)]ClO4 (Fig. 3.4A) and [Cu(Bp44mT-H)Cl] (Fig. 3.4B). 
 
As observed previously, Cu(II) complexes of the tridentate thiosemicarbazones 
preferred to form 1:1 complexes due to the Jahn-Teller effect operative on the d9 
electronic ground state, which weakens the two axial coordinate bonds perpendicular 
to the more strongly bound thiosemicarbazone (Jansson et al., 2010b). This is 
essentially the case with [Cu(Bp44mT)(Bp44mT-H)]ClO4, where the bidentate 
coordinated ligand was the one that occupies the axial coordination site, and the 
axial Cu-N bonds of all four molecules in the asymmetric unit are long (Fig. 3.4A). 
The Cu-N and Cu-S bond lengths in [Cu(Bp44mT-H)Cl] and the tridentate 
(deprotonated) ligand in [Cu(Bp44mT)(Bp44mT-H)]ClO4 were not significantly 
different. As expected, the central Cu-N imine bond was the shortest in the 
meridionally coordinated ligand. 
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Herein, the in situ generated 1:1 Cu(II)/ligand complexes were used in all biological 
studies. This was done as comprehensive EPR studies with the 1:2 Cu(II)/ligand 
complexes, namely [Cu(Dp44mT-H)2] and [Cu(Ap44mT-H)2], clearly demonstrated 
that these complexes partially dissociate to form the corresponding 1:1 Cu(II)/ligand 
complexes as the dominant species in solution (Jansson et al., 2010b). Moreover, 
the 1:1 complexes were found to be the active species that mediated tumour cell 
cytotoxicity (Jansson et al., 2010b; Lovejoy et al., 2012). The in situ 1:1 Cu(II)/ligand 
complexes were prepared by the addition of equimolar amounts of the ligand and 
CuCl2 in DMSO to give a final 10 mM solution of the complex. A rapid change in 
colour of the solution was observed upon mixing the ligand and CuCl2, indicating the 
formation of the resultant complex. Notably, all in situ complexes in this study were 
checked against our pre-synthesised metal-ligand complexes using UV-Vis 
spectrophotometry to ensure complexation (Jansson et al., 2010b). 
 
 
Figure 3.4. ORTEP views (30% probability ellipsoids) of the Cu(II) complexes  
(A) [Cu(Bp44mT)(Bp44mT-H)]+; and (B) [Cu(Bp44mT-H)Cl]. 
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 [Cu(Bp44mT)(Bp44mT-H)]ClO4 [Cu(Bp44mT-H)Cl] 
Formula  
Formula weight  
Crystal system  
Space group  
Colour 
a (Å) 
C30H31ClCuN8O4S2 
730.74 
Triclinic 
P`1 
Dark-brown 
9.2567(1) 
C15H15ClCuN4S 
382.36 
Monoclinic 
P21/c 
Dark-brown 
9.6179(4) 
b (Å) 
c (Å) 
α (deg) 
β (deg) 
γ (deg) 
V (Å3) 
T (K) 
Z 
R1 (obsd data) 
wR2 
GOF 
CCDC 
14.1387(1) 
51.6543(4) 
90.287(1) 
94.629(1) 
91.203(1) 
6736.71(1) 
190(2)  
8 
0.0734 
0.2188 
1.040 
1062686 
8.2794(5) 
20.0050(9) 
 
 90.344(4) 
 
1592.98(14)  
190(2)  
4 
0.0406 
0.1037 
1.076 
1062687 
Table 3.1 Crystal Data 
 
 
3.3.3 Structural Analysis of Novel Thiosemicarbazones 
The thiosemicarbazones assessed in this investigation were chosen based upon 
previous studies demonstrating their potent and selective in vitro and in vivo 
activities (Kalinowski et al., 2007; Kovacevic et al., 2011; Lovejoy et al., 2012; 
Richardson et al., 2009; Whitnall et al., 2006; Yu et al., 2012; Yuan et al., 2004). 
Particular attention was paid to choosing structurally diverse thiosemicarbazones in 
order to develop an understanding of which pharmacophores confer the novel ability 
to overcome MDR, demonstrated previously for Dp44mT (Jansson et al., 2015b). 
Hence, the ligands, Bp44mT, DpC, Ap44mT and 3-AP (Fig. 3.5), were selected and 
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possess the following common features, including that all ligands are α-N-
heterocyclic thiosemicarbazones that bind transition metals through their pyridyl 
nitrogen, imine nitrogen and thiocarbonyl sulfur atoms (Bernhardt et al., 2009; 
Jansson et al., 2010b; Kalinowski et al., 2007; Lovejoy et al., 2012; Richardson et al., 
2009). Moreover, each of these selected thiosemicarbazones possess the same 
ionisable sites (Gutierrez et al., 2014) as Dp44mT that allow the ligand to be neutral 
at physiological pH (pH 7.4), but become charged at lysosomal pH (pH ~ 5-5.5), 
resulting in lysosomal trapping of the ligand and Cu(II) complex formation that 
enables LMP (Lovejoy et al., 2011). 
 
However, each analogue contains substitutional variations at the: (1) imine carbon 
and (2) terminal N4 atom that will lead to differences in lipophilicity, inductive effects 
etc., that will alter biological activity. For example, Bp44mT differs from Dp44mT only 
in that it possesses a phenyl ring relative to the pyridyl ring at the imine position of 
Dp44mT (Fig. 3.5; see blue highlight). On the other hand, DpC also contains the di-
2-pyridyl moiety present in Dp44mT (Fig. 3.5; see blue highlight), but possesses a 
methyl and a cyclohexyl ring at the N4 position instead of the dimethyl moiety found 
in Dp44mT (Fig. 3.5; see green highlight). The ligand, Ap44mT, contains a methyl 
group at the imine carbon instead of the pyridyl or phenyl moiety (Fig. 3.5; see blue 
highlight) and possesses a dimethyl substitution at the terminal N4 atom similar to 
that of Dp44mT and Bp44mT (Fig. 3.5; see green highlight).  
 
The well-characterised thiosemicarbazone, 3-AP, that has entered clinical trials 
(Knox et al., 2007; Traynor et al., 2010), was used as a reference compound for 
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comparison to the other thiosemicarbazones. In contrast to Dp44mT, Bp44mT, DpC 
and Ap44mT, 3-AP is unsubstituted at the imine carbon (Fig. 3.5; see blue highlight) 
and at the terminal N4 atom (Fig. 3.5; see green highlight). Additionally, 3-AP 
contains an amine substituent at the 3-position of the coordinating pyridyl ring (Fig. 
3.5; see orange highlight). As a negative control, we also included Bp2mT in our 
studies, as this compound has a methyl substituent at the N2 position of the 
thiosemicarbazone backbone (Fig. 3.5; see purple highlight). This prevents electron 
delocalisation and like its close structural analogue, Dp2mT, this prevents metal 
binding and leads to a compound devoid of activity (Chen et al., 2012; Yuan et al., 
2004). Notably, Bp2mT, contains the 2-benzoylpyridine moiety of Bp44mT (Fig. 3.5; 
see blue highlight), but is unsubstituted at the terminal N4 atom (Fig. 3.5; see green 
highlight). 
 
3.3.4 Differential Thiosemicarbazone Cytotoxicity in Pgp-
Expressing Cells 
The ability of Dp44mT to mediate potentiated cytotoxicity in drug resistant cancer 
cells is inherently related to the fact that it is a Pgp substrate (Jansson et al., 2015b). 
Others have also demonstrated that structurally different thiosemicarbazones are 
selectively cytotoxic towards Pgp-expressing MDR cells, although the precise 
molecular mechanism involved was not clearly established (Hall et al., 2009; Hall et 
al., 2011). Therefore, we first investigated whether any of the other 
thiosemicarbazones in this study also mediated Pgp-potentiated cytotoxicity similar 
to that observed with Dp44mT (Jansson et al., 2015b). 
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Figure 3.5. Structural analysis of the thiosemicarbazones examined herein. 
 Structures of the thiosemicarbazones included in the study highlighting the 
substitutional variations around the imine carbon (blue highlight) and terminal N4 
atom (green highlight); as well as the amine substituent at the 3-position of the 
coordinating pyridyl ring of 3-AP (orange highlight) and methyl substituent at the N2 
position of the thiosemicarbazone backbone of Bp2mT (purple highlight). 
 
 
To initially assess this, cellular proliferation studies were performed using a well 
characterised pair of cell lines, namely KBV1 (+Pgp) cells which hyper-express Pgp, 
and KB31 (-Pgp) cells which express only extremely low levels of this protein 
(Jansson et al., 2015b; Seebacher et al., 2015; Yamagishi et al., 2013). These 
experiments were performed in the presence or absence of the well characterised 
Pgp inhibitor, Elacridar (Ela) (Hyafil et al., 1993; Jansson et al., 2015b; Kemper et 
al., 2004; Yamagishi et al., 2013), to study the effect of Pgp on the anti-proliferative 
activity of the thiosemicarbazones. Significantly, Ela was implemented as the Pgp 
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inhibitor of choice, as it gave similar results to Pgp siRNA-treated cells (Jansson et 
al., 2015b) and is markedly easier to use.  
 
Our previous studies have implemented a range of Pgp expressing cell-types to 
demonstrate the effect of Dp44mT in terms of its ability to hijack Pgp and overcome 
drug resistance (Jansson et al., 2015b). We have specifically chosen the KBV1 and 
KB31 cell lines for this investigation, as: (1) the effect of Dp44mT was typical of that 
found in multiple other Pgp containing cell-types (Jansson et al., 2015b); and (2) due 
to the intensive nature of the studies and the range of thiosemicarbazones utilised, it 
was experimentally practical to use this pair of well characterised cells (Jansson et 
al., 2015b; Seebacher et al., 2015; Yamagishi et al., 2013). Finally, these cell-types 
do not express other common ABC transporters (e.g., MRP1 and ABCG2), and 
compensatory mechanisms do not lead to resistance to thiosemicarbazones in KB31 
cells (Jansson et al., 2015b). 
 
Using KB31 (-Pgp) cells, no significant (p > 0.05) difference in cytotoxicity was 
observed between cells incubated with the thiosemicarbazones, Dp44mT, Bp44mT, 
DpC, or Ap44mT alone, or these thiosemicarbazones in combination with the Pgp 
inhibitor, Ela (0.1 µM) after a 24 h/37ºC incubation (Fig. 3.6). Clearly, this is due to 
the lack of Pgp in these cells, which provides an appropriate negative control and 
demonstrates that Ela has no intrinsic biological activity in the absence of Pgp, as 
shown previously (Jansson et al., 2015b; Yamagishi et al., 2013). Bp44mT displayed 
the most potent anti-proliferative activity of all the thiosemicarbazones in KB31 (-
Pgp) cells, with this agent possessing a significantly (p < 0.001) lower IC50 value than 
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Dp44mT, DpC and Ap44mT (Fig. 3.6). In contrast, Bp2mT (the negative control 
agent) and 3-AP demonstrated very poor anti-proliferative activity with IC50 values > 
800 mM (Fig. 3.6). 
 
In accordance with our previously published results (Jansson et al., 2015b), Dp44mT 
was 13-fold more cytotoxic towards drug resistant KBV1 (+Pgp) cells than in KB31 (-
Pgp) cells (Fig. 3.6). Importantly, in contrast to KB31 (-Pgp) cells, Pgp inhibition with 
Ela significantly (p < 0.001) decreased the cytotoxicity of Dp44mT in KBV1 (+Pgp) 
cells (Fig. 3.6). This confirmed that the potentiated cytotoxicity of Dp44mT in KBV1 
cells was Pgp-dependent. Bp44mT was 13.2-fold more cytotoxic in KBV1 (+Pgp) 
than KB31 (-Pgp) cells, making it the most cytotoxic of the thiosemicarbazones 
tested in these cells. Similarly, DpC was 8.1-fold more cytotoxic in KBV1 (+Pgp) cells 
than in KB31 (-Pgp) cells (Fig. 3.6). As observed with Dp44mT, Pgp inhibition with 
Ela resulted in a marked and significant (p < 0.001) decrease in the cytotoxicity of 
Bp44mT and DpC in KBV1 cells (Fig. 3.6).  
 
Although Ap44mT was 2.1-fold more cytotoxic in KBV1 (+Pgp) cells compared to 
KB31 (-Pgp) cells, contrary to the other thiosemicarbazones, Ela had no significant 
(p > 0.05) effect on the cytotoxicity of Ap44mT in KBV1 cells (Fig. 3.6). Similarly to 
the results using KB31 cells, no appreciable cytotoxicity was observed with either 
Bp2mT or 3-AP in KBV1 cells, despite both thiosemicarbazones being examined at 
concentrations up to 800 mM (Fig. 3.6). 
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The decrease in cytotoxicity (i.e., increased IC50 values) of Dp44mT, Bp44mT and 
DpC observed in KB31 (-Pgp) cells relative to KBV1 (+Pgp) cells suggested that Pgp 
could potentiate the cytotoxicity of these agents. This was confirmed using the Pgp 
inhibitor, Ela, which reversed the potentiated cytotoxicity in KBV1 (+Pgp) cells (Fig. 
3.6). However, Pgp inhibition using Ela had no significant (p > 0.05) effect on the 
cytotoxicity of Ap44mT (Fig. 3.6). Hence, this observation suggested that in contrast 
to Dp44mT, Bp44mT and DpC, that Pgp was not involved in potentiating the 
cytotoxicity of Ap44mT. On the other hand, Bp2mT and 3-AP were not cytotoxic to 
KBV1 or KB31 cells even at concentrations as high as 800 mM (Fig. 3.6). This is due 
to the fact that Bp2mT is a negative control, which cannot bind metals that is 
necessary for these agents to generate ROS and induce cytotoxicity (Chen et al., 
2012; Yuan et al., 2004). On the other hand, 3-AP is a thiosemicarbazone that lacks 
marked anti-proliferative activity (Gutierrez et al., 2014), which could have 
contributed to its failure in multiple clinical trials (Knox et al., 2007; Merlot et al., 
2013; Traynor et al., 2010). The pronounced differences in the observed cytotoxicity 
of this group of thiosemicarbazones and their differential ability to target Pgp-
expressing cells, demonstrated that further assessment of their structure-activity 
relationships was warranted. 
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Figure 3.6 MTT assay demonstrates the potentiated cytotoxicity of Dp44mT, 
Bp44mT and DpC in KBV1 cells  
Dp44mT, Bp44mT and DpC exert potentiated cytotoxicity to Pgp-expressing KBV1 
cells that can be reversed in the presence the Pgp-inhibitor, Ela. In contrast, the 
cytotoxicity of the thiosemicarbazones was not significantly (p > 0.05) affected by Ela 
in KB31 cells (-Pgp). KB31 (-Pgp) or KBV1 (+Pgp) were incubated with Dp44mT, 
Bp44mT, DpC, or Ap44mT alone, or these thiosemicarbazones in combination with 
the Pgp inhibitor, Ela (0.1 µM) for 24 h/37°C. The MTT assay was then used to 
examine proliferation. Results are mean ± SD (3 experiments). *** p < 0.001 versus 
the respective ligand or complex, as shown. 
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3.3.5 A Range of Thiosemicarbazones and their Fe(III) and Cu(II) 
Complexes Increase Pgp-ATPase Activity Suggesting they are Pgp 
Substrates 
Our laboratories have demonstrated that the potentiated cytotoxicity of Dp44mT in 
MDR cells such as the KBV1 (+Pgp) cell-type is due to Dp44mT acting as a Pgp 
substrate (Jansson et al., 2015b). Herein, Pgp expression was demonstrated to be a 
prerequisite for the increased cytotoxicity of Dp44mT, Bp44mT and DpC, but did not 
markedly affect the cytotoxicity of Ap44mT, especially after incubation with the Pgp 
inhibitor, Ela (Fig. 3.6). Therefore, the Pgp-ATPase assay was used to assess if the 
differential cytotoxicity of the thiosemicarbazones towards Pgp-expressing cells 
could be explained by their ability to act as Pgp substrates.  
 
The ability of the thiosemicarbazones and their Fe(III) and Cu(II) complexes to act as 
Pgp substrates and increase ATPase activity of Pgp was measured using purified 
membrane preparations containing high levels of Pgp (Jansson et al., 2015b; 
Urbatsch et al., 1994). This was vital to assess in order to judge the potential of Pgp 
to transport thiosemicarbazones across the lysosomal membrane into the lysosome 
to induce LMP (Jansson et al., 2015b). A compound is considered to be a Pgp 
substrate if its ATPase activity is above the control activity (> 1), while a Pgp inhibitor 
decreases Pgp-ATPase activity below the control level (< 1) (Urbatsch et al., 1994). 
In these experiments, Pgp-enriched membranes (0.5 mg/mL) and Mg(II)-ATP (5 mM) 
were incubated for 40 min/37°C with thiosemicarbazones and their Fe(III) or Cu(II) 
complexes (50 μM), and ATP levels were then measured. The well-characterised 
Pgp substrate, Verapamil (200 μM) (Ogihara et al., 2006), was used as a positive 
control, while sodium orthovanadate (“Vanadate”; 100 μM) was used as a well 
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characterised inhibitor of Pgp-activity (Urbatsch et al., 1994). In the current study, the 
positive control substrate, Verapamil, significantly (p < 0.001) increased Pgp-ATPase 
activity by 5-fold, while the inhibitor, Vanadate, significantly (p < 0.001) decreased 
Pgp-ATPase activity by 11.9-fold relative to the control level (Fig. 3.7). In addition, 
neither Cu(II) nor Fe(III) alone (i.e., controls for Cu(II) and Fe(III) thiosemicarbazone 
complexes) had any significant (p > 0.05) effect on Pgp-ATPase activity. 
 
All thiosemicarbazones significantly (p < 0.001) stimulated Pgp-ATPase activity, 
indicating that all were Pgp substrates (Fig. 3.7). The three most effective 
thiosemicarbazones that increased Pgp-ATPase activity were (in descending order): 
Bp44mT, DpC and Dp44mT, which increased it to 7.9-, 7.4- and 6.6-fold greater than 
the control, respectively. Both Ap44mT and Bp2mT were less effective and resulted 
in 5.1- and 5.2-fold increases in Pgp-ATPase activity, respectively (Fig. 3.7). In 
contrast, 3-AP, a previously reported Pgp substrate (Rappa et al., 1997), resulted in 
the lowest increase in Pgp activity in this series of thiosemicarbazones (i.e., 4.6-fold 
versus the control; Fig. 3.7).  
 
As observed with the free ligands, all of the Cu(II) thiosemicarbazone complexes 
were also Pgp substrates (Fig. 3.7). Specifically, [Cu(Dp44mT)] was the best Pgp 
substrate and mediated a 9.9-fold increase in basal Pgp activity relative to the 
control, which was significantly (p < 0.001) greater than Dp44mT alone. Of note, 
[Cu(Bp44mT)] resulted in a 7.6-fold increase in Pgp-ATPase activity relative to the 
control, which was comparable to Bp44mT alone (Fig. 3.7). Both [Cu(DpC)] and 
[Cu(Ap44mT)] induced a 8.6 and 9.1-fold increase in Pgp activity versus the control, 
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respectively, which were significantly (p < 0.001) greater than the respective 
thiosemicarbazones alone. Upon addition of Cu(II) to Bp2mT, there was no 
significant (p > 0.05) alteration in Pgp-ATPase activity relative to Bp2mT alone (Fig. 
3.7), which is consistent with the fact that this compound does not bind metal ions 
(Chen et al., 2012; Yuan et al., 2004). In contrast, [Cu(3-AP)] significantly (p < 0.001) 
increased Pgp-ATPase activity relative to the 3-AP ligand, with 3-AP and [Cu(3-AP)] 
increasing Pgp-ATPase activity 4.6- and 5.9-fold relative to the control, respectively 
(Fig. 3.7). 
 
Similarly to the Cu(II) complexes, all of the Fe(III) complexes also acted as Pgp 
substrates and mediated significantly (p < 0.001) increased Pgp-ATPase activity 
relative to the control (Fig. 3.7). Notably, [Fe(Dp44mT)2] acted as the best substrate 
of all of the substrates examined, resulting in a 11.7-fold increase in basal Pgp-
ATPase activity relative to the control. In fact, this stimulation of Pgp-ATPase activity 
by [Fe(Dp44mT)2] was significantly (p < 0.001) higher than Dp44mT alone, or the 
[Cu(Dp44mT)] complex (Fig. 3.7). The fold change in Pgp-ATPase activity mediated 
by [Fe(Bp44mT)2], [Fe(DpC)2], or [Fe(Ap44mT)2] were similar, resulting in a 9.8-, 
10.1- and 10.0-fold change in Pgp activity versus the control, respectively. On the 
other hand, there was no significant (p > 0.05) difference in Pgp-ATPase stimulation 
induced by Bp2mT in the presence of Fe(III) compared to Bp2mT alone, again due 
to the fact that this agent is a negative control that cannot bind metal ions (Chen et 
al., 2012; Yuan et al., 2004). The [Fe(3-AP)2] complex mediated a significant (p < 
0.001) increase in Pgp-ATPase activity in comparison to the control, resulting in a 
9.0-fold increase in Pgp activity (Fig. 3.7). The Pgp-ATPase activity of the [Fe(3-
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AP)2] complex was significantly (p < 0.001) greater than either 3-AP alone or [Cu(3-
AP)]. 
 
Overall, the fold-change in Pgp-ATPase activity mediated by the thiosemicarbazones 
and their complexes generally resulted in the following trend: thiosemicarbazone 
ligand < Cu(II) complex < Fe(III) complex. The only thiosemicarbazones to deviate 
from this trend were: (1) [Cu(Bp44mT)] did not have significantly (p > 0.05) greater 
Pgp-ATPase activity than the ligand; (2) [Fe(Ap44mT)2], which did not mediate 
significantly (p > 0.05) greater Pgp-ATPase activity than [Cu(Ap44mT)]; and (3) 
Bp2mT, which did not have significantly (p > 0.05) different Pgp-ATPase activity in 
the presence of Cu(II) or Fe(III) as it is unable to bind metal ions. These results in 
Figure 3.7 demonstrate that the differences in cytotoxicity observed in Pgp-
expressing KBV1 cells (Fig. 3.6) is not entirely dependent on their ability to act as 
Pgp substrates. 
 
Notably, Pgp substrates are known to be lipophilic in nature (Kimura et al., 2004; 
Schmid et al., 1999; Seelig and Landwojtowicz, 2000) and this property may explain 
the differences in the Pgp-ATPase activity mediated by the thiosemicarbazones and 
their complexes observed herein (Fig. 3.7). For example, upon comparison of the 
ligands, those with higher lipophilicity, including Bp44mT (calculated log P: 2.88) 
(Broto et al., 1984; Ghose and Crippen, 1987; Viswanadhan et al., 1987) and DpC 
(calculated log P: 4.00) (Broto et al., 1984; Ghose and Crippen, 1987; Viswanadhan 
et al., 1987), mediated the greatest increase in Pgp-ATPase activity observed (Fig. 
3.7). In contrast, those ligands that were relatively less hydrophobic, such as 
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Ap44mT (calculated log P: 1.18) (Broto et al., 1984; Ghose and Crippen, 1987; 
Viswanadhan et al., 1987) and 3-AP (calculated log P: -0.08) (Broto et al., 1984; 
Ghose and Crippen, 1987; Viswanadhan et al., 1987) were poorer Pgp substrates. 
Moreover, the markedly increased Pgp-ATPase activity observed with the Cu(II) and 
Fe(III) complexes relative to the ligand may also be attributed to their lipophilic 
nature (Richardson et al., 2006). Thus, the overall differences in the ligand/complex 
lipophilicity may play a role in both their ability to initially enter the cell which is well 
known for related ligands and thiosemicarbazones of this class (Richardson et al., 
1995; Stefani et al., 2011), and also for their subsequent avidity for transport by Pgp 
across membranes, like other substrates (Kimura et al., 2004; Schmid et al., 1999; 
Seelig and Landwojtowicz, 2000). 
 
3.3.6 Differential Effects of the Thiosemicarbazones and their Fe(III) 
or Cu(II) Complexes on Lysosomal Integrity 
The potentiated cytotoxicity of Dp44mT in Pgp-expressing cells was previously 
reported to be due to the Pgp-mediated sequestration of Dp44mT into lysosomes 
(Jansson et al., 2015b). In fact, once transported into this organelle via lysosomal 
membrane Pgp, Dp44mT can bind endogenous Cu(II) to generate ROS and cause 
LMP (Jansson et al., 2015b). The lysosome is an active site of Cu(II) recycling in the 
cell via the process of autophagy (Gupte and Mumper, 2009; Kurz et al., 2010; 
Terman and Kurz, 2013), and hence, it is an important target for this class of ligands 
(Gutierrez et al., 2014; Jansson et al., 2015b; Lovejoy et al., 2011).  
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Figure 3.7 Pgp-ATPase assay demonstrates the thiosemicarbazones and their 
Fe(III) and Cu(II) complexes are all Pgp substrates.  
Pgp-enriched membranes (0.5 mg/mL) and Mg(II)-ATP (5 mM) were incubated for 
40 min/37°C with thiosemicarbazones and their Fe(III) or Cu(II) complexes (50 μM), 
and ATP levels were detected as a luciferase-generated luminescent signal. The 
well-characterised Pgp substrate, Verapamil (200 μM) was used as a positive 
control, while sodium orthovanadate (“Vanadate”; 100 μM) was used as a well 
characterised inhibitor of Pgp-activity. Results are mean ± SD (3 experiments). *** p 
< 0.001 relative to the indicated incubation condition in Fig. 3.7. 
 
 
As all of the thiosemicarbazones in this study and their Fe(III) and Cu(II) complexes 
were observed to act as Pgp substrates (Fig. 3.7), yet only some resulted in 
potentiated cytotoxicity in Pgp over-expressing KBV1 cells (Fig. 3.6), we investigated 
whether lysosomal sequestration and the resultant LMP is affected by 
thiosemicarbazone structure and/or coordination with Cu(II) or Fe(III) (Fig. 3.8). By 
using the classical lysosomal marker, acridine orange (AO) (Lovejoy et al., 2011; 
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Pierzynska-Mach et al., 2014), lysosomal integrity was assessed in KB31 (-Pgp) and 
KBV1 (+Pgp) cells by fluorescence microscopy (Fig. 3.8A, C) and quantified (Fig. 
3.8B, D) as AO intensity/cell. Notably, AO, is well known to accumulate in intact 
lysosomes to result in red punctate fluorescence, but it exhibits an increase in green 
fluorescence upon redistribution to the cytosol or nucleus after LMP (Gutierrez et al., 
2014; Lovejoy et al., 2011; Nicolini et al., 1979; Nilsson et al., 1997).  
 
After a 30 min/37oC incubation with KB31 (-Pgp) cells, the classical punctuate 
pattern of orange/red AO-stained lysosomes was observed following incubation with 
all thiosemicarbazones, in the presence and absence of Cu(II), suggesting that 
lysosomal damage had not occurred (Fig. 3.8A). This result was corroborated by the 
quantification of AO intensity/cell, with no significant (p > 0.05) decrease being 
observed under any of the treatment conditions, compared to vehicle-treated control 
cells (Fig. 3.8B). 
 
Examining KBV1 (+Pgp) cells, incubation with the thiosemicarbazones alone after 30 
min/37oC also did not significantly (p > 0.05) affect lysosomal membrane integrity 
compared to the respective control (Fig. 3.8Ci, Di). However, following incubation 
with [Cu(Dp44mT)], [Cu(Bp44mT)] or [Cu(DpC)], the red AO stain dissipated, 
suggesting that lysosomal membrane integrity was compromised (Fig. 3.8Cii). 
Indeed, quantification confirmed that the red AO staining significantly (p < 0.001) 
decreased for [Cu(Dp44mT)], [Cu(Bp44mT)], or [Cu(DpC)] relative to the control 
(Fig. 3.8Dii). In contrast, following incubation with [Cu(Ap44mT)], Cu and Bp2mT, or 
[Cu(3-AP)], no significant (p > 0.05) decrease in red AO staining was observed 
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relative to the control (Fig. 3.8Cii, Dii), which suggested that LMP did not occur. As 
observed for the thiosemicarbazone ligands alone, none of the Fe(III) complexes 
affected lysosomal membrane integrity after a 30 min incubation (Fig. 3.8Ciii, Diii).  
 
The decrease in red AO intensity mediated by [Cu(Dp44mT)], [Cu(Bp44mT)] and 
[Cu(DpC)] was Pgp-dependent, as lysosomal damage was only observed in KBV1 
(+Pgp) cells (Fig. 3.8C, D), but not KB31 (-Pgp) cells (Fig. 3.8A, B). These results, 
like the MTT data (Fig. 3.6), highlighted the importance of Pgp in the anti-proliferative 
activity of these thiosemicarbazones. At the shorter time point utilised in this AO 
study (30 min versus 24 h used in MTT assays in Figure 3.6), only [Cu(Dp44mT)], 
[Cu(Bp44mT)] and [Cu(DpC)] mediated a decrease in red AO intensity, suggesting 
that Cu(II) is involved in mediating Pgp-dependent LMP. In fact, it is notable that 
previous studies have demonstrated that the Cu(II) complex of Dp44mT is more 
cytotoxic than its Fe(III) complex. 
 
3.3.7 Ability of the Thiosemicarbazones and their Fe(III) or Cu(II) 
complexes Complexes to Generate ROS  
The generation of ROS by the highly redox-active [Cu(Dp44mT)] complex has been 
shown to induce LMP (Lovejoy et al., 2011). To assess the role of redox stress in the 
results obtained for KBV1 (+Pgp) cells in Figures 3.8C and D, we next assessed the 
ability of all thiosemicarbazones alone and their Cu(II) and Fe(III) complexes to 
mediate ROS generation in order to determine if their redox activity could explain 
their efficacy at inducing LMP.  
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Figure 3.8 Only the Cu(II) complexes of Dp44mT, Bp44mT, or DpC induce 
lysosomal membrane permeabilisation (LMP) as shown by acridine orange 
(AO) staining in KBV1 (+Pgp) cells, but not KB31 (-Pgp) cells.  
(A, B) Incubation of KB31 (-Pgp) cells with either: (i) thiosemicarbazones; (ii) 
thiosemicarbazones (i.e., treatment) and Cu(II); or (iii) thiosemicarbazones and 
Fe(III) (10 μM, 30 min/37°C) does not significantly (p > 0.05) affect LMP relative to 
the control, as measured by the AO intensity/cell (% of control). (C, D) Incubation of 
KBV1 (+Pgp) cells with either: (i) thiosemicarbazones; (ii) thiosemicarbazones and 
Cu(II); or (iii) thiosemicarbazones and Fe(III) (10 μM, 30 min/37°C). Only Dp44mT, 
Bp44mT or DpC in the presence of Cu(II) mediate significant (p < 0.001) LMP 
relative to the control. Results in (A, C) are typical images from 3 experiments. 
Quantification in (B, D) are mean ± SD (3 experiments) *** p < 0.001 versus the 
control. Scale bar: 10 μm. 
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In these studies, the ability of the agents to mediate cellular ROS generation in KBV1 
(+Pgp) cells was evaluated via the oxidation of the non-fluorescent, redox-sensitive 
probe, 2',7'-dichlorodihydrofluorescein (H2DCF), to the highly fluorescent product, 
2',7'-dichlorofluorescein (DCF; Fig. 3.9) (Jansson et al., 2010a; Lovejoy et al., 2011; 
Yuan et al., 2004).DCF is a well-characterised redox probe and is commonly used 
for the measurement of ROS generation (Jansson et al., 2010b; Lovejoy et al., 2011; 
Myhre et al., 2003). 
 
After a 30 min/37˚C incubation of KBV1 (+Pgp) cells with the positive control, H2O2 
(50 µM), there was a significant (p < 0.001) 12.6-fold increase in DCF fluorescence 
compared to the control cells. Conversely, the CuCl2 and FeCl3 controls did not 
significantly (p > 0.05) affect DCF fluorescence relative to the controls (Fig. 3.9). All 
of the thiosemicarbazone ligands alone did not significantly (p > 0.05) increase DCF 
fluorescence compared to the control (Fig. 3.9). Therefore, under this short 
incubation protocol (30 min), significant levels of ROS were not generated by the 
thiosemicarbazones alone. Examining the effect of adding Cu(II) with the 
thiosemicarbazones, it was notable that neither [Cu(3-AP)] or Bp2mT in the 
presence of Cu(II) led to any significant (p > 0.05) alteration in DCF fluorescence 
relative to the control or the thiosemicarbazone alone (Fig. 3.9). However, 
[Cu(Dp44mT)], [Cu(Bp44mT), [Cu(DpC)] and [Cu(Ap44mT)] significantly (p < 0.001) 
increased intracellular DCF fluorescence relative to the control or their respective 
thiosemicarbazones alone (Fig. 3.9). Interestingly, [Cu(Dp44mT)] mediated the 
greatest fold change in intracellular DCF fluorescence, resulting in a 4.0-fold 
increase in DCF fluorescence relative to Dp44mT alone. Similarly, [Cu(Ap44mT)], 
[Cu(DpC)] and [Cu(Bp44mT)], increased intracellular DCF fluorescence by 2.6-, 3.0- 
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and 3.1-fold, respectively, in comparison to their corresponding thiosemicarbazones 
alone (Fig. 3.9). Of note, [Cu(Ap44mT)] mediated significantly (p < 0.001-0.01) 
decreased levels of DCF fluorescence relative to [Cu(Dp44mT)], [Cu(Bp44mT) or 
[Cu(DpC)] (Fig. 3.9).  
 
All of the thiosemicarbazones in the presence of Fe(III) generated comparable levels 
of DCF fluorescence when compared to the control or their respective 
thiosemicarbazones alone (Fig. 3.9). In summary, only [Cu(Dp44mT)], [Cu(Bp44mT) 
and [Cu(DpC)] demonstrated the greatest ability to induce ROS formation (Fig. 3.9) 
and to cause LMP as judged by using AO (Fig. 3.8 C, D). However, while 
[Cu(Ap44mT)] also significantly (p < 0.001) increased ROS (Fig. 3.9), it did not lead 
to LMP (Fig. 3.8C, D). This disparity may be related to the incubation time used, as 
[Cu(Ap44mT)] is a significantly (p < 0.001) less potent oxidant than [Cu(Dp44mT)], 
[Cu(Bp44mT), or [Cu(DpC)] (Fig. 3.9), which could be responsible for its lack of 
effect on LMP after a 30 min incubation (Fig. 3.8C, D). 
 
3.3.8 Lysosomal Membrane Permeabilisation Mediated by Dp44mT, 
Bp44mT and DpC is Dependent on Pgp, as Shown Using the Pgp 
Inhibitor, Ela 
The LMP observed upon incubation with [Cu(Dp44mT)], [Cu(Bp44mT)], or 
[Cu(DpC)], occurred only in KBV1 (+Pgp) cells (Figs. 3.8C, D), but not in KB31 (-
Pgp) cells (Figs. 3.8A, B).  
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Figure 3.9. The Cu(II) complexes of Dp44mT, Bp44mT and DpC demonstrate 
marked intracellular redox activity in KBV1 (+Pgp) cells, while the Ap44mT 
Cu(II) complex demonstrates lower efficacy.  
The redox activities of the thiosemicarbazones (10 μM, 30 min/37°C) were assessed 
in KBV1 (+Pgp) cells incubated with H2DCF-DA (30 μM, 30 min/37°C) with the 
fluorescence being measured by flow cytometry. The [Cu(Dp44mT)], [Cu(Bp44mT)], 
[Cu(DpC)] and [Cu(Ap44mT)] complexes are significantly (p < 0.001) more redox-
active than the thiosemicarbazones (ligands) alone, or the Fe(III) complexes. Note: 
H2O2 (50 µM) was included as a positive control. Additional controls include CuCl2 
and FeCl3 that were used in the preparation of the thiosemicarbazone Fe(III) and 
Cu(II) complexes. Results are mean ± SD (3 experiments). *** p < 0.001 versus the 
respective ligand or complex, as shown. 
 
 
Thus, the importance of Pgp in mediating LMP was assessed using KBV1 (+Pgp) 
cells by implementing the Pgp inhibitor, Ela, and assessing its effects on the activity 
of the Cu(II) complexes on AO staining (Fig. 3.10A). We also examined the effect of 
thiosemicarbazone structure on LMP by comparing [Cu(Dp44mT)], [Cu(Bp44mT)] 
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and [Cu(DpC)], that induced LMP, to [Cu(Ap44mT)] which did not, using KBV1 
(+Pgp) cells (Fig. 3.10A). 
 
In these studies, incubation of KBV1 (+Pgp) cells for 30 min/37oC with 
[Cu(Dp44mT)], [Cu(Bp44mT)], or [Cu(DpC)] resulted in a significant (p < 0.001) 
decrease in AO intensity relative to the control (Fig. 3.10Aiii), consistent with LMP, 
as demonstrated in Figures 3.8C, D. In contrast, [Cu(Ap44mT)] did not significantly 
(p > 0.05) affect AO intensity compared to the control KBV1 (+Pgp) cells (Fig. 
3.10Ai,iii). Interestingly, co-incubation with the Pgp inhibitor, Ela, prevented the 
decrease in AO intensity mediated by [Cu(Dp44mT)], [Cu(Bp44mT)] and [Cu(DpC)] 
(Fig. 3.10Aii). Indeed, the red intensity of AO staining was significantly (p < 0.001) 
greater for [Cu(Dp44mT)], [Cu(Bp44mT) and [Cu(DpC)] upon Ela co-incubation 
compared to these Cu(II) complexes alone (Fig. 3.10Aii,iii). This observation 
suggested that the LMP mediated by [Cu(Dp44mT)], [Cu(Bp44mT)] or [Cu(DpC)] 
was Pgp-dependent and could explain the potentiated cytotoxicity of these 
thiosemicarbazones in Pgp-expressing cells (Fig. 3.6). As [Cu(Ap44mT)] incubation 
alone did not result in LMP, it is unsurprising that co-incubation with Ela also did not 
significantly (p > 0.05) affect lysosomal integrity (Fig. 3.10Ai,ii,iii). 
 
To further examine the involvement of Pgp in thiosemicarbazone-mediated LMP, 
lysosomal stability was additionally examined via the intracellular distribution of the 
soluble lysosomal enzyme, Cathepsin D, and its co-localisation with lysosomal-
associated membrane protein 2 (LAMP2; Fig. 3.10B), in the presence or absence of 
the Pgp inhibitor, Ela (Hyafil et al., 1993; Kemper et al., 2004; Yamagishi et al., 
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2013). When lysosomal membrane integrity is compromised, intra-lysosomal 
Cathepsin D staining will decrease due to the release of this soluble enzyme out of 
the lysosome into the cytosol (Jansson et al., 2015b). In contrast, LAMP2 staining 
will be less affected, as LAMP2 is an integral part of the damaged lysosomal 
membrane (Eskelinen, 2006; Kagedal et al., 2001; Roberg et al., 1999) (Fig. 3.10B).  
 
In this study, Dp44mT and Ap44mT, were assessed since the studies above (Figs. 
3.8C, D) indicate that their respective Cu(II) complexes do, and do not, induce LMP, 
respectively. The uncoordinated thiosemicarbazone ligands were used in these 
studies to determine the role of LMP in the cytotoxicity observed during the 
proliferation assay, which was performed over a 24 h incubation (Fig. 3.6). Hence, 
these conditions implementing a 24 h incubation period were utilised, as 30 min 
incubations with these ligands alone did not have any significant (p > 0.05) effect on 
LMP (Fig. 3.8A, B). Notably, during the longer 24 h incubation period, the activity of 
the ligand is assessed in terms of its ability to enter KBV1 (+Pgp) cells, bind 
endogenous Cu(II) to form the redox-active complex, and then induce LMP after 
transport into the lysosome via Pgp. 
 
In these experiments, using KBV1 (+Pgp) cells either under control conditions or 
cells treated with Ela alone, both Cathepsin D (green; Fig. 3.10Bi) and LAMP2 (red; 
Fig. 3.10Bii) led to particulate staining typical of lysosomes (Jansson et al., 2015b). 
Moreover, due to their same lysosomal localisation, this staining was co-localised 
upon the electronic merge, leading to yellow, punctate fluorescence consistent with 
intact lysosomes (Fig. 3.10Biii), as observed in previous studies (Jansson et al., 
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2015b). After a 24 h incubation with Dp44mT, the fluorescence of Cathepsin D co-
localised with LAMP2 was significantly (p < 0.001) decreased relative to control 
KBV1 cells (Fig. 3.10Bi,iii,iv). In contrast, LAMP2 fluorescence was not significantly 
(p < 0.05) affected, as LAMP2 is an integral protein of lysosomal membranes, and 
unlike Cathepsin D, does not dissipate from lysosomes after LMP (Fig. 3.10Bii) 
(Eskelinen, 2006; Kagedal et al., 2001; Roberg et al., 1999). In contrast, in cells 
incubated with Dp44mT in the presence of Ela, the intensity of Cathepsin D and 
LAMP2 remained unchanged relative to the control (Fig. 3.10Bi,ii). Hence, in the 
presence of Dp44mT and Ela, there was markedly and significantly (p < 0.001) 
greater co-localisation of Cathepsin D and LAMP2 relative to cells incubated with 
Dp44mT alone (Fig. 3.10Biii). This led to a yellow punctate pattern consistent with 
undamaged lysosomes that retained Cathepsin D. In contrast to Dp44mT, no 
significant (p > 0.05) alteration in the co-localisation of Cathepsin D and LAMP2 was 
observed after incubation of KBV1 (+Pgp) cells with Ap44mT or Ap44mT + Ela when 
compared to the control (Fig. 3.10B). 
 
Collectively, the results in Figure 3.10B using the Pgp inhibitor, Ela, demonstrated 
that thiosemicarbazone-induced LMP was dependent on Pgp activity. Furthermore, 
we showed that LMP was Pgp-dependent for [Cu(Dp44mT)], [Cu(Bp44mT)] and 
[Cu(DpC)] (Fig. 3.10A), as well as Dp44mT alone (Fig. 3.10B). In contrast, both 
[Cu(Ap44mT)] (Fig. 3.10A) and Ap44mT (Fig. 3.10B) had no significant (p > 0.05) 
effect on lysosomal membrane stability. Importantly, the use of both the shorter (30 
min) time points for the AO studies (Fig. 3.10A) and longer time points (24 h) used 
for the Cathepsin D/LAMP2 studies (Fig. 3.10B) demonstrate the more potent effect 
of Dp44mT on LMP relative to Ap44mT.  
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Clearly, over 24 h there is greater opportunity for the ligand to bind endogenous 
Cu(II) to form redox-active complexes that can then induce LMP. Finally, it should be 
noted that both DpC and Bp44mT acted in an analogous manner to Dp44mT, 
resulting in LMP that was inhibited using Ela (Fig.3.11, 3.12). 
 
3.3.9 Lysosomal Membrane Permeabilisation Mediated by Dp44mT, 
Bp44mT and DpC is Dependent on Cu(II) 
As [Cu(Dp44mT)], [Cu(Bp44mT)] and [Cu(DpC)] mediated LMP (Figs. 3.8, 3.10A) in 
KBV1 (+ Pgp) cells, we investigated whether Cu(II) coordination was required to 
induce LMP or not. These experiments were performed using the non-cytotoxic 
Cu(II) chelator, tetrathiomolybdate (TM; Fig. 3.13) that has been shown to prevent 
LMP mediated by the Cu(II) complexes of Dp44mT and bis(thiosemicarbazones) by 
sequestering Cu(II) (Lovejoy et al., 2011; Stefani et al., 2015).  
 
Using the lysosomal stain, AO (Lovejoy et al., 2011; Stefani et al., 2015), we showed 
that the LMP mediated by [Cu(Dp44mT)], [Cu(Bp44mT) and [Cu(DpC)] over a 30 
min incubation was significantly (p < 0.001) abrogated in the presence of the Cu 
chelator, TM, relative to when the Cu(II) complex was added alone (Fig. 3.13Ai,ii,iii). 
Of note, TM itself did not significantly (p > 0.05) affect lysosomal membrane integrity 
as demonstrated by the presence of intact AO-stained lysosomes (Fig. 3.13Ai,ii,iii), 
which is consistent with the low cytotoxicity of this Cu chelator (Lovejoy et al., 2011; 
Stefani et al., 2015). Therefore, these results reveal that Cu(II) chelation by Dp44mT, 
Bp44mT and DpC was essential in order for LMP to occur. In contrast, 
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[Cu(Ap44mT)] did not mediate LMP, and thus, co-incubation with TM had no effect 
on lysosomal integrity (Fig. 3.13Ai,ii,iii). 
 
To further examine the role of Cu(II) chelation and LMP in the cytotoxic effects of the 
thiosemicarbazones, conditions analogous to that used during the MTT assay (24 
h/37oC) were again utilised (Fig. 3.13B). Control KBV1 (+Pgp) cells stained for the 
lysosomal enzyme, Cathepsin D (green), and lysosomal membrane protein, LAMP2 
(red), demonstrated co-localisation upon the merge to form a yellow, punctuate 
pattern indicative of intact lysosomes (Fig. 3.13Bi, ii, iii). Incubation of cells with TM 
alone had significant effect on the co-localisation of Cathepsin D and LAMP2. As 
shown in Figure 3.10B, KBV1 (+Pgp) cells were incubated for 24 h/37oC with the 
structurally different thiosemicarbazones, Dp44mT and Ap44mT, which 
demonstrated either marked LMP or no LMP, respectively. After incubation with 
Dp44mT, the intensity of Cathepsin D fluorescence co-localised with LAMP2 was 
significantly (p < 0.001) reduced relative to control cells, indicating the release of 
soluble Cathepsin D from this organelle upon LMP (Fig. 3.13Biii). 
 
However, in cells incubated with Dp44mT in the presence of the Cu chelator, TM, 
Cathepsin D and LAMP2 were co-localised, generating a yellow punctate pattern 
consistent with undamaged lysosomes (Fig. 3.13Bi,ii,iii). In fact, the level of 
Cathepsin D and LAMP2 co-localisation upon Dp44mT and TM co-incubation was 
comparable to control cells (Fig. 3.13Biv).  
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Figure 3.10. The Cu(II) complexes of Dp44mT, Bp44mT and DpC, but not 
Ap44mT, can induce LMP in Pgp-expressing KBV1 cells.  
(A) Incubation of KBV1 (+Pgp) cells with [Cu(Dp44mT)], [Cu(Bp44mT)] or 
[Cu(DpC)] (10 μM, 30 min/37°C), but not [Cu(Ap44mT)] (10 μM, 30 
min/37°C), results in a significant (iii; p < 0.001) increase in LMP, measured 
with AO as the AO intensity/cell (% control). The LMP was markedly reversed 
following treatment with the Pgp inhibitor, Ela (0.1 μM) (ii). (B) The lysosomal 
markers, Cathepsin D (i, green) and LAMP2 (ii, red), co-localise (yellow, iii) 
upon the electronic merge. Only incubation with Dp44mT, but not Ap44mT 
(25 µM, 24 h/37oC) in KBV1 cells (+Pgp) leads to: (i) a significant (p < 0.001) 
loss of lysosomal Cathepsin D; (ii) no marked alteration of LAMP2-stained 
lysosomes; and (iii) a decrease in yellow fluorescence upon the merge. 
Incubation of Dp44mT with Ela (0.1 µM) prevents Cathepsin D redistribution 
from LAMP2-stained lysosomes. Quantification of Cathepsin D intensity in the 
fluorescence images is shown in iv. The images in (A and B) are typical from 
3 experiments. The quantification in (Aiii, Biv) are mean ± SD (3 
experiments). ***, p < 0.001 versus untreated condition. Scale bar: 10 μm. 
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Figure 3.11. DpC-induced lysosomal membrane permeabilisation (LMP) in 
KBV1 cells (+Pgp) is inhibited by: the Pgp transport inhibitor Elacridar (Ela), 
copper-chelation using tetrathiomolybdate (TM) and the anti-oxidant, N-acetyl-
L-cysteine (NAC). 
The lysosomal markers, Cathepsin D (i, green) and LAMP2 (ii, red), co-localise 
(yellow, iii) upon the electronic merge. Only incubation of DpC (25 µM, 24 h/37oC) 
with KBV1 cells (+Pgp) leads to: (i) a significant (p < 0.001) loss of lysosomal 
Cathepsin D; (ii) no marked alteration of LAMP2-stained lysosomes; and (iii) a 
decrease in yellow fluorescence upon the merge. Incubation of DpC with either the 
Pgp inhibitor Elacridar (Ela; 0.1 µM), the copper chelator tetrathiomolybdate (TM; 10 
µM), or the anti-oxidant and cellular GSH precursor, N-acetyl-L-cysteine (NAC; 5 
mM), prevents Cathepsin D redistribution from LAMP2-stained lysosomes. 
Quantification of Cathepsin D intensity in the fluorescence images is shown in iv. 
The images are typical from 3 experiments. The quantitation in iv is mean ± SD (3 
experiments). ***, p < 0.001 versus untreated condition. Scale bar: 10 μm. 
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Figure 3.12. Bp44mT-induced lysosomal membrane permeabilisation (LMP) in 
KBV1 cells (+Pgp) is inhibited by: the Pgp transport inhibitor Elacridar (Ela), 
copper-chelation using tetrathiomolybdate (TM) and the anti-oxidant, N-acetyl-
L-cysteine (NAC). 
The lysosomal markers, Cathepsin D (i, green) and LAMP2 (ii, red), co-localise 
(yellow, iii) upon the electronic merge. Only incubation of Bp44mT (25 µM, 24 
h/37oC) with KBV1 cells (+Pgp) leads to: (i) a significant (p < 0.001) loss of 
lysosomal Cathepsin D; (ii) no marked alteration of LAMP2-stained lysosomes; and 
(iii) a decrease in yellow fluorescence upon the merge. Incubation of Bp44mT with 
either the Pgp inhibitor Elacridar (Ela; 0.1 µM), the copper chelator 
tetrathiomolybdate (TM; 10 µM), or the anti-oxidant and cellular GSH precursor, N-
acetyl-L-cysteine (NAC; 5 mM), prevents Cathepsin D redistribution from LAMP2-
stained lysosomes. Quantification of Cathepsin D intensity in the fluorescence 
images is shown in iv. The images are typical from 3 experiments. The quantitation 
in iv is mean ± SD (3 experiments). ***, p < 0.001 versus untreated condition. Scale 
bar: 10 μm. 
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In contrast to Dp44mT (Fig. 3.13Biv), no significant (p > 0.05) alteration in the co-
localisation of Cathepsin D and LAMP2 was observed using KBV1 cells upon 
incubation with Ap44mT in the presence or absence of TM in comparison to control 
cells (Fig. 3.13B), suggesting that LMP did not occur. In contrast to Dp44mT (Fig. 
3.13Biv), no significant (p > 0.05) alteration in the co-localisation of Cathepsin D and 
LAMP2 was observed using KBV1 cells upon incubation with Ap44mT in the 
presence or absence of TM in comparison to control cells (Fig. 3.13B), suggesting 
that LMP did not occur. 
 
It is notable that Ap44mT implemented at a 10-fold lower concentration than that 
used herein was observed to induce LMP in the presence of Cu(II) in previous 
studies using human SK-N-MC neuroepithelioma cells (Al-Eisawi et al., 2016). This 
result suggests that the KBV1 cells used herein were much more resistant to 
Ap44mT-mediated LMP relative to SK-N-MC cells and indicate that differences in 
their ability to handle oxidative stress and their overall sensitivity to 
thiosemicarbazones may contribute to this effect (Al-Eisawi et al., 2016; Jansson et 
al., 2015a). The important point is that the propensity to induce LMP was far more 
marked with Dp44mT relative to Ap44mT. 
 
The results in Figure 3.13 illustrated that Cu(II) chelation by Dp44mT, Bp44mT and 
DpC was necessary for LMP in Pgp-expressing KBV1 cells. This was true for 
[Cu(Dp44mT)], [Cu(Bp44mT) and [Cu(DpC)], as well as Dp44mT alone. Indeed, the 
Dp44mT ligand was able to mediate Cu(II)-dependent LMP after a 24 h incubation 
(Fig. 3.13B) relative to after 30 min when it could not (Fig. 3.8A, B). 
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This difference likely occurred as Dp44mT must enter the cell, bind endogenous 
Cu(II) and then form sufficient redox active complex within the lysosome in order to 
induce LMP. Regardless of the presence of Cu(II) or the incubation period used (i.e., 
30 min; Figs. 3.8C, D, 3.10A, 3.13A) or 24 h (Figs. 3.10B, 3.13B), Ap44mT was 
unable to induce appreciable LMP, suggesting that structural differences in the 
ligands played an important role in the ability of thiosemicarbazones to mediate 
Cu(II)-dependent LMP in Pgp-expressing cells. Significantly, DpC and Bp44mT 
behaved in a similar manner to Dp44mT, resulting in LMP that was inhibited using 
TM (Figs. 3.11, 3.12). 
 
3.3.10 Lysosomal Membrane Permeabilisation Mediated by 
Dp44mT, Bp44mT, or DpC is Dependent on Redox Stress 
The generation of ROS, due to redox cycling of metal complexes, is known to 
damage the membrane lipid bilayer, such as the lysosomal membrane (Ollinger and 
Brunk, 1995; Valko et al., 2007). Notably, [Cu(Dp44mT)], [Cu(Bp44mT) and 
[Cu(DpC)] mediated H2DCF oxidation in cells within 30 min, while [Cu(Ap44mT)] 
showed less activity (Fig. 3.9). Therefore, the role of cellular ROS generated by 
these [Cu(II)(thiosemicarbazones)] to result in LMP was assessed. These studies 
were performed using the anti-oxidant and cellular GSH precursor, N-acetyl-L-
cysteine (NAC), which enhances the production of GSH by cells and prevents LMP 
mediated by the Cu(II) complexes of Dp44mT and bis(thiosemicarbazones) (Lovejoy 
et al., 2011; Stefani et al., 2015). While [Cu(Dp44mT)], [Cu(Bp44mT)] and [Cu(DpC)] 
resulted in a significant (p < 0.001) decrease in red fluorescence associated with 
AO-stained lysosomes relative to the control, co-treatment with NAC prevented 
[Cu(II)(thiosemicarbazone)]-mediated lysosomal damage (Fig. 3.14A). 
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Figure 3.13. Cu(II) chelation by the non-toxic Cu(II) chelator, 
tetrathiomolybdate (TM), prevents: (A) LMP by Dp44mT; and (B) the release of 
Cathepsin D from LAMP2-stained lysosomes.  
Treatment of KBV1 (+Pgp) cells with [Cu(Dp44mT)], [Cu(Bp44mT)] or [Cu(DpC)] (10 
μM, 30 min/37°C), but not [Cu(Ap44mT)], mediates a significant (iii; p < 0.001) 
increase in LMP relative to control cells, measured with AO. The LMP was reversed 
following treatment with the Cu(II) chelator, TM (10 μM) (ii). (B) The lysosomal 
markers, Cathepsin D (i, green) and LAMP2 (ii, red), co-localise (yellow, iii) upon the 
electronic merge. Only incubation with Dp44mT, but not Ap44mT (25 µM, 24 h/37oC) 
in KBV1 cells (+Pgp) leads to: (i) a significant (p < 0.001) loss of lysosomal 
Cathepsin D; (ii) no marked alteration of LAMP2-stained lysosomes; resulting in (iii) 
decreased yellow fluorescence upon the merge relative to the control. Incubation of 
Dp44mT with TM (25 µM) prevents Cathepsin D redistribution from LAMP2-stained 
lysosomes. Quantification of Cathepsin D intensity in the fluorescence images is 
shown in iv. Images in (A) and (B) are typical of 3 experiments. The quantification in 
(Aiii, Biv) are mean ± SD (3 experiments). ***, p < 0.001 versus untreated condition. 
Scale bar: 10 μm. 
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In fact, incubation with NAC resulted in a significant (p < 0.001) increase in red 
fluorescence associated with intact AO-stained lysosomes relative to these 
[Cu(II)(thiosemicarbazones)] alone (Fig. 3.14A). On the other hand, as demonstrated 
in Figures 3.10A, 11A, [Cu(Ap44mT)] did not result in significant (p > 0.05) LMP, and 
thus, co-incubation with NAC had no significant (p > 0.05) effect on lysosomal 
integrity and was comparable to the control (Fig. 3.14A).  
 
As in Figures 3.10B and 3.14B, lysosomal stability was further studied by observing 
the intracellular distribution of the soluble lysosomal enzyme, Cathepsin D, and its 
association with lysosomal LAMP2 (Jansson et al., 2015b), after incubating Pgp-
expressing KBV1 cells with Dp44mT or Ap44mT for 24 h/37oC (Fig. 3.14B). The 
strong co-localisation of Cathepsin D with LAMP2, was observed as a punctate, 
yellow fluorescence in control cells and was significantly (p < 0.001) decreased upon 
incubation with Dp44mT (Fig. 3.14Biii,iv). However, in cells incubated with Dp44mT 
in the presence of NAC, the Cathepsin D fluorescence intensity co-localised with 
LAMP2 was significantly (p < 0.001) increased compared to Dp44mT alone. This 
observation suggested that NAC was able to alleviate Dp44mT-mediated oxidative 
stress and protect lysosomes from LMP (Fig. 3.14B). In contrast to Dp44mT, no 
significant (p > 0.05) alteration in the co-localisation of Cathepsin D and LAMP2 was 
observed after incubation of KBV1 (+Pgp) cells with Ap44mT in the presence or 
absence of NAC (Fig. 3.14B).  
 
This finding is consistent with our previous results (Fig. 3.9), which suggested that 
the Cu(II) complex of Ap44mT generated significantly lower levels of ROS than 
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Dp44mT, which may be insufficient to damage the lysosomal membrane and result 
in LMP. Notably, both DpC and Bp44mT behaved similarly to Dp44mT, resulting in 
LMP that was inhibited using NAC (Figs. 3.11, 3.12). 
 
The results in Figure 3.14 suggest that, in addition to acting as Pgp substrates and 
Cu(II) chelators (Figs. 3.6-11), the redox cycling of the [Cu(II)(thiosemicarbazones)] 
and the resultant formation of ROS was vital in their mechanism of action.  
 
 
3.4 Conclusions 
As described previously, all ligands included in this study were α-N-heterocyclic 
thiosemicarbazones with each analogue containing substitutional variations at the: 
(1) imine carbon and (2) terminal N4 atom. Critically, the identity of the substituent at 
the imine position proved to be pivotal in determining the ability of the 
thiosemicarbazone to form Cu(II) complexes that mediated sufficient ROS formation 
and subsequent LMP in Pgp-expressing cells. Only those analogues derived from di-
2-pyridylketone or 2-benzoylpyridine, namely, Dp44mT (Fig. 3.1B), DpC (Fig. 3.1C), 
or Bp44mT (Fig. 3.1D), contain the inductively electron-withdrawing 2-pyridyl or 
phenyl moieties (relative to hydrogen) at the imine position which result in marked 
LMP (Fig. 3.15A) and the death of Pgp-expressing cells (Fig. 3.6). In contrast, 
Ap44mT (Fig. 3.1E) has the inductively electron-donating methyl substituent (relative 
to hydrogen) positioned at the imine carbon, while a hydrogen is located at the imine 
116 
 
carbon of 3-AP (Fig. 3.1A), and these substitutions resulted in no LMP (Fig. 3.15B) 
and led to no enhanced death in Pgp-expressing cells (Fig. 3.6). 
 
Significantly, the Cu(II) complexes of Dp44mT, Bp44mT and DpC were observed to 
have potent, Pgp-dependent anti-proliferative activity (Fig. 3.6) and mediate LMP in 
Pgp-over-expressing KBV1 cells (Figs. 3.8C, D). All assessed ligands and their 
Cu(II) or Fe(III) complexes were found to act as Pgp substrates (Fig. 3.7) and this 
suggested that their ability to be transported into the lysosome by Pgp was not the 
only factor that was significant in terms of their ability to mediate LMP (Figs. 3.8, 
3.10) or cytotoxicity (Fig. 3.6) in KBV1 cells. 
 
One such additional factor is lipophilicity, which is well known to be involved in the 
efficacy of these and closely related ligands to transverse membranes and enter 
cells to chelate metal ions (Richardson et al., 1995; Stefani et al., 2011). Moreover, 
while all the thiosemicarbazones were Pgp substrates, generally the more lipophilic 
compounds induced greater Pgp-ATPase activity (i.e., ligands < Cu(II) complexes < 
Fe(III) complexes; Fig. 3.7), and this is in accordance with the fact that Pgp prefers 
lipophilic substrates for transport (Kimura et al., 2004; Schmid et al., 1999; Seelig 
and Landwojtowicz, 2000). Hence, the lower lipophilicity of the ligand, Ap44mT, may 
have potentially contributed to its reduced entry into the cell, its slightly lower activity 
as a Pgp substrate (relative to Dp44mT, Bp44mT and DpC; Fig. 3.7), and its 
decreased ability to induce LMP to overcome resistance.  
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Figure 3.14. The anti-oxidant and glutathione precursor, NAC, prevents the 
LMP in KBV1 (+Pgp) cells induced by Dp44mT, Bp44mT or DpC or their Cu(II) 
complexes 
 (A) Incubation of KBV1 (+Pgp) cells with [Cu(Dp44mT)], [Cu(Bp44mT)] or [Cu(DpC)] 
(10 μM, 30 min/37°C), but not [Cu(Ap44mT)], mediates a significant (iii; p < 0.001) 
increase in LMP, measured with AO as the AO intensity/cell (% of control). The LMP 
was reversed following incubation with the anti-oxidant, NAC (5 mM) (ii). (B) The 
lysosomal markers Cathepsin D (i, green) and LAMP2 (ii, red) co-localise (yellow, iii) 
upon merging. Only incubation with Dp44mT, but not Ap44mT (25 µM, 24 h/37o C) in 
KBV1 cells (+Pgp) leads to: (i) a significant (p < 0.001) loss of lysosomal Cathepsin 
D relative to the control; (ii) no marked effect on LAMP2-stained lysosomes; and (iii) 
decreased yellow fluorescence upon the electronic merge. Incubation of Dp44mT 
with NAC (5 mM) prevents Cathepsin D redistribution from LAMP2-stained 
lysosomes. Quantification of Cathepsin D intensity in the fluorescence images is 
shown in iv. Images in (A) and (B) are typical of 3 experiments. The quantification in 
(Aiii, Biv) are mean ± SD (3 experiments). ***, p < 0.001 versus untreated condition. 
Scale bar: 10 μm. 
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Another crucial factor that was identified in this study was the influence of inductive 
effects of substituents close to the metal-ligating site (Fig. 3.15). Our previous 
investigations have also demonstrated the ability of the inductive effects of 
substituents at the imine position of thiosemicarbazones to influence the 
electrochemistry of their resultant metal complexes (Jansson et al., 2010b; 
Kalinowski et al., 2007; Richardson et al., 2009). This is undoubtedly due to the 
close proximity of the imine position to the metal centre (Jansson et al., 2010b; 
Kalinowski et al., 2007; Richardson et al., 2009). The inclusion of inductively 
electron-withdrawing groups at the imine position results in Fe(III) or Cu(II) 
complexes with higher redox potentials (e.g., metal complexes of Dp44mT, DpC or 
Bp44mT) relative to the resultant Fe(III) or Cu(II) complexes derived from ligands 
containing inductively electron-donating substituents at the imine position (e.g., metal 
complexes of Ap44mT) (Jansson et al., 2010b; Kalinowski et al., 2007; Richardson 
et al., 2009). This consequently influences the redox behaviour of their metal 
complexes. 
 
Our laboratories have also previously demonstrated the increased ability of 
[Cu(Dp44mT)] to mediate the formation of ROS relative to [Cu(Ap44mT)] both in 
cells and cell-free systems (Jansson et al., 2010b). Moreover, the [Cu(Dp44mT)] 
complex mediated increased levels of cellular oxidative stress relative to 
[Cu(Ap44mT)], as demonstrated by the greater decrease in the GSH/GSSG ratio 
mediated by [Cu(Dp44mT)] (Jansson et al., 2010b). This effect was consistent with 
the higher redox potentials of the [Cu(Dp44mT)] complex relative to [Cu(Ap44mT)] 
(Jansson et al., 2010b). The current study demonstrated the ability of [Cu(Dp44mT)], 
[Cu(Bp44mT)] and [Cu(DpC)], to catalyse the marked oxidation of H2DCF to DCF in 
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cells (Fig. 3.9) and this suggested their ability to generate significant quantities of 
cytotoxic ROS that can lead to LMP (Figs. 3.8, 3.10-12), and induce cell death.  
 
While [Cu(Ap44mT)] also mediated the oxidation of H2DCF, it was significantly less 
redox-active than [Cu(Dp44mT)], [Cu(Bp44mT)], or [Cu(DpC)], suggesting that the 
lack of LMP in response to [Cu(II)(Ap44mT)] (Figs. 3.8C, D) may be related to the 
less potent redox activity of the complex. These results are in agreement with 
previous studies, suggesting that the inductively electron-withdrawing substituents 
located at the imine position of Dp44mT, Bp44mT and DpC result in the formation of 
Cu(II) complexes with redox potentials that lie in an optimal window that allow for a 
redox cycling mechanism to become established (Bernhardt et al., 2009; Jansson et 
al., 2010b; Lovejoy et al., 2012). This property results in Cu(II) complexes that can 
catalyse the production of ROS (Fig. 3.9) and the subsequent induction of LMP 
(Figs. 3.8, 3.9-11). In comparison, the inductively electron-donating effects of the 
imine methyl group of Ap44mT resulted in a Cu(II) complex with a lower redox 
potential (Jansson et al., 2010b) that lies outside of this optimal window, preventing 
sufficient generation of ROS (Fig. 3.9) to mediate LMP (Figs. 3.8, 3.10-12). This 
redox behaviour, in combination with the lower lipophilicity of Ap44mT, may play an 
important role in the inability of Ap44mT to mediate LMP relative to Dp44mT, 
Bp44mT, or DpC, leading to: (1) decreased passage of Ap44mT through the cell 
membrane; (2) decreased transport of Ap44mT by Pgp into the lysosome; and (3) 
decreased ROS generation by the Cu(II) complex of Ap44mT in the lysosome (Fig. 
3.15B). 
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It is of interest to note the difference between the Cu(II) and Fe(III) complexes of 
these thiosemicarbazones in terms of the failure to induce LMP (Fig. 3.8C,D). This 
occurred despite the fact that the Fe(III) complexes are Pgp substrates (Fig. 3.7) and 
that at least some of these compounds are redox active and cytotoxic. The 
difference in their ability to induce LMP is probably related to the efficacy of ROS 
generation that we demonstrate is far more pronounced for the Cu(II) complexes 
than the respective (Fe(III) complexes (Fig. 3.9). Hence, the appropriate redox 
potentials of the Cu(II) complexes of these ligands, relative to the Fe(III) complexes, 
leads to marked ROS generation that is crucial for inducing LMP. In fact, our 
laboratory has previously demonstrated that much longer incubations of cells with 
Fe(III) complexes than Cu(II) complexes are required before LMP is observed, 
namely 5 min for [Cu(Dp44mT)] relative to 24 h for [Fe(Dp44mT)2]. Importantly, the 
current studies assessed only short incubations (30 min) of the Fe(III) and Cu(II) 
complexes, and thus, only the Cu(II) complexes with greatest ROS generating 
activity (namely those of Dp44mT, Bp44mT and DpC) demonstrated LMP (Figs. 
3.8C,D, 3.9). 
 
In summary, in order to induce LMP in Pgp-expressing cells and overcome drug 
resistance, our studies demonstrate that this general group of thiosemicarbazones 
must possess five characteristics, namely: (1) inductively electron-withdrawing 
substituents at the imine carbon; (2) high relative lipophilicity; (3) Pgp substrate 
activity; (4) Cu(II) chelation efficacy; and (5) the induction of ROS generation (Fig. 
3.15). Based on these studies further “fine tuning” of thiosemicarbazone structural 
features could lead to more active agents to overcome multi-drug resistance via the 
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exploitation of lysosomal Pgp to induce LMP and the death of resistant tumour cells 
that are a major problem for cancer treatment. 
 
 
Figure 3.15. Schematic of the differences in structural features of 
thiosemicarbazones that either have a marked effect in terms of inducing LMP 
(e.g., as observed for Dp44mT, Bp44mT and DpC; 11A), or not (i.e., Ap44mT, 3-
AP; 11B).  
Key properties of thiosemicarbazones that enable LMP which is crucial for 
overcoming Pgp-mediated resistance in tumour cells include: (1) electron-
withdrawing inductive effects at the imine carbon; (2) lipophilicity; (3) being a Pgp 
substrate; (4) Cu(II) chelation; and (5) the generation of ROS. (A) For Dp44mT, 
Bp44mT and DpC, the presence of two aromatic substituents at the imine carbon 
leads to an electron-withdrawing inductive effect. This results in higher redox 
potentials which are within an “optimal window” for oxidising biological substrates 
and generating ROS. The increased lipophilicity enhances transport through 
biological membranes and transport via Pgp into the lysosome. (B) In contrast, for 3-
AP or Ap44mT, the presence an aromatic substituent and either a H-atom or an 
inductively electron-donating methyl, respectively, results in lower redox potentials 
that are less avid in terms of oxidising biological substrates and generating ROS. At 
the same time, the decreased relative lipophilicity of 3-AP or Ap44mT relative to 
Dp44mT, Bp44mT and DpC, results in decreased membrane permeability and lower 
activity as a Pgp substrate, and thus, decreased ability to induce LMP and overcome 
resistance. In contrast to all the agents above, Bp2mT, possessed a methyl group at 
N2 (Fig. 3.1F), preventing its ability to form Cu(II) complexes that inhibits ROS 
generation essential for LMP.  
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Chapter 4 - Zinc(II)-Thiosemicarbazone 
Complexes Are Localised to the Lysosomal 
Compartment Where They Transmetallate with 
Copper Ions to Induce Cytotoxicity 
(Taken from Stacy et al (2016) J. Med. Chem.) 
 
 
4.1 Introduction 
Since their origin as potential anti-tuberculosis agents (Domagk et al., 1946; 
Donovick et al., 1950), thiosemicarbazones and their metal complexes have been 
found to have a broad range of therapeutic uses (Hamre et al., 1950; Klayman et al., 
1979; Liberta and West, 1992). The demonstrated anti-viral activity (Brownlee and 
Hamre, 1951; Hamre et al., 1950; Shipman et al., 1986) of thiosemicarbazones led 
researchers to investigate their possible use as anti-cancer agents (Brockman et al., 
1956). Indeed, 2-formylpyridine thiosemicarbazone was the first of this class to 
demonstrate potent anti-cancer activity (Brockman et al., 1956). This property has 
since led this class of compounds to become the focus of extensive research and 
development. 
 
The anti-cancer efficacy of thiosemicarbazones was initially described to be due to 
their action as inhibitors of ribonucleotide reductase (Reichard and Ehrenberg, 1983; 
Sartorelli et al., 1970), which catalyses the rate-limiting step of DNA synthesis. 
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Subsequent studies demonstrated that effect represented only a fraction of their 
activity with the formation of redox-active metal complexes that generate ROS being 
of considerable significance to their mechanism of action (Richardson et al., 2006; 
Yu et al., 2009b; Yuan et al., 2004) Furthermore, early research demonstrated that 
N-heterocyclic thiosemicarbazones that utilise the N-N-S donor system (French and 
Blanz, 1966) in the formation of complexes with transition metals have increased 
cytotoxicity both in vitro (Antholine et al., 1976; Baker et al., 1992; Blanz et al., 1970; 
Crim and Petering, 1967; Saryan et al., 1979) and in vivo (Petering et al., 1967). One 
such thiosemicarbazone that was developed for cancer treatment was 3-AP, which 
has entered greater than 20 multi-centre clinical trials (Knox et al., 2007; Merlot et 
al., 2013; Odenike et al., 2008; Traynor et al., 2010). However, 3-AP has suffered 
multiple problems, including low efficacy in some tumour-types and serious side 
effects, including methaemoglobinaemia (Knox et al., 2007; Merlot et al., 2013; 
Odenike et al., 2008; Traynor et al., 2010). 
 
Over the last 20 years, our laboratory has developed ligands as anti-cancer agents 
(Baker et al., 1992; Becker et al., 2003; Darnell and Richardson, 1999; Richardson et 
al., 1995; Richardson and Milnes, 1997). Through extensive structure-activity 
relationship studies, the DpT series was designed by including the di-2-pyridylketone 
moiety into a structural backbone derived from previous aroylhydrazones (Becker et 
al., 2003; Bernhardt et al., 2003; Richardson et al., 2006; Yuan et al., 2004). The 
DpT analogues showed potent anti-tumour activity and anti-metastatic activity both in 
vitro and in vivo (Chen et al., 2012; Liu et al., 2012; Lovejoy et al., 2012; Richardson 
et al., 2006; Whitnall et al., 2006; Yuan et al., 2004). The best characterised member 
of the DpT analogues, Dp44mT (Fig. 3.1A), has been demonstrated to target the 
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lysosome via “hijacking” of the multidrug resistance pump, Pgp (Gutierrez et al., 
2014; Jansson et al., 2015b; Lovejoy et al., 2011; Seebacher et al., 2016a). Once 
inside the lysosome, Dp44mT redox cycles with copper ions to produce ROS that 
induce LMP and apoptosis (Gutierrez et al., 2014; Jansson et al., 2015b; Lovejoy et 
al., 2011).  
 
Importantly, the anti-proliferative effects of Dp44mT are significantly greater than 3-
AP and demonstrate improved tolerability (Whitnall et al., 2006). However, the 
cardiac fibrosis induced by high, non-optimal doses of Dp44mT (Whitnall et al., 
2006) led to the design and synthesis of novel thiosemicarbazones, including the 
second generation of DpT analogues and the ApT series, such as Ap44mT (Fig. 
4.1A), that also showed marked and selective anti-tumour activity in vitro and in vivo 
(Kowol et al., 2007a; Kowol et al., 2007b; Lovejoy et al., 2012; Richardson et al., 
2009). 
 
The second generation of DpT analogues, in which the terminal H at N4 was 
replaced with an alkyl group, showed particular promise (Kovacevic et al., 2011; 
Lovejoy and Richardson, 2002). Of these ligands, DpC (Fig. 4.1A) was identified as 
the lead agent (Kovacevic et al., 2011; Lovejoy et al., 2012) and possessed many 
advantages over Dp44mT, including: (1) greater anti-tumour activity than Dp44mT in 
vivo against tumour xenografts (Kovacevic et al., 2011; Lovejoy et al., 2012); (2) 
markedly improved tolerability when administered orally, as well as intravenously 
compared to Dp44mT that is toxic when given orally (Lovejoy et al., 2012; Yu et al., 
2012); (3) unlike Dp44mT, DpC does not induce oxidation of oxyhaemoglobin to 
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methaemoglobin in erythrocytes (Quach et al., 2012); (4) DpC demonstrates a 
markedly greater plasma half-life in the rat, namely 10.7 h versus 1.7 h for Dp44mT 
(Sestak et al., 2015); (5) the anti-tumour efficacy of DpC exceeds that of gemcitabine 
(the “gold standard” chemotherapy for pancreatic cancer) in vivo against pancreatic 
xenografts (Kovacevic et al., 2011) and (6) DpC does not induce cardiac fibrosis in 
nude mice even when given at markedly higher doses than Dp44mT (Kovacevic et 
al., 2011; Lovejoy et al., 2012). Significantly, due to these favourable properties, DpC 
was commercialised and has entered clinical trials in 2016 (ClinicalTrials.gov 
Identifier NCT02688101) for the treatment of advanced and resistant cancers 
(Jansson et al., 2015a). 
 
As with other thiosemicarbazones (Antholine et al., 1976; Blanz et al., 1970; Cowley 
et al., 2005; Crim and Petering, 1967; Kowol et al., 2010; Petering et al., 1967; 
Saryan et al., 1979; Van Giessen et al., 1973), it was observed that the DpT and ApT 
series form Zn(II) and Cu(II) complexes, of which the Cu(II) complexes potently 
mediate cancer cell death (Jansson et al., 2010a; Lovejoy et al., 2011; Richardson et 
al., 2006; Richardson et al., 2009; Yuan et al., 2004). Indeed, some 
thiosemicarbazone complexes of transition metals, such as Cu(II) and zinc (Zn(II)) 
complexes, generally exhibit greater anti-neoplastic activities both in vitro and in vivo 
than the thiosemicarbazones alone (Antholine et al., 1976; Blanz et al., 1970; 
Cowley et al., 2005; Crim and Petering, 1967; Jansson et al., 2010a; Kalinowski et 
al., 2007; Kowol et al., 2010; Lovejoy et al., 2011; Petering et al., 1967; Richardson 
et al., 2006; Richardson et al., 2009; Saryan et al., 1979; Van Giessen et al., 1973; 
Yuan et al., 2004). While the mechanism of action of such thiosemicarbazones have 
been examined previously (Jansson et al., 2015b; Kovacevic et al., 2011; Lovejoy et 
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al., 2011; Richardson et al., 2009; Sartorelli et al., 1970), relatively little has been 
done to unequivocally determine their subcellular distribution (Cowley et al., 2005; 
Kowol et al., 2010). Recent reports have demonstrated that the Zn(II) complexes of 
some mono and bis(thiosemicarbazones) possess intrinsic fluorescence, presenting 
an opportunity to examine their intracellular distribution that enables further insight 
into their mechanism of action (Cowley et al., 2005; Dayal et al., 2011; Kowol et al., 
2010; Lim et al., 2010; Pascu et al., 2007; Pascu et al., 2008). For example, [Zn(3-
AP)Cl2] has been shown to localise to the nucleoli of colon adenocarcinoma SW480 
cells (Kowol et al., 2010). 
 
Herein, in order to examine the subcellular distribution of our potent 
thiosemicarbazones, we synthesised and characterised their Zn(II) complexes based 
on their previously demonstrated marked and selective anti-cancer activity 
(Kalinowski et al., 2007; Lovejoy et al., 2012; Richardson et al., 2009; Yuan et al., 
2004). Dp44mT and DpC were included as our lead compounds, and Ap44mT was 
added as a structurally different thiosemicarbazone to enable elucidation of 
information on structure-activity relationships. Their anti-proliferative effects were 
examined in several tumour cell-types, and importantly the Zn(II) complexes showed 
significantly greater cytotoxicity than their thiosemicarbazone ligands alone. For the 
first time, the subcellular localisation of the [Zn(DpC)2](ClO4)2 complex was directly 
examined and demonstrated a predominantly lysosomal pattern of distribution. 
Importantly, we also show that [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and 
[Zn(DpC)2](ClO4)2 transmetallates with lysosomal copper ions to form redox-active 
Cu(II) complexes that mediate LMP and cytotoxicity. 
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4.3 Results and Discussion 
4.3.1 Synthesis and Characterisation of Novel Zn(II)-
Thiosemicarbazone Complexes 
A series of Zn(II) complexes were prepared from Dp44mT, Ap44mT and DpC•HCl at 
1:1 (Fig. 4.1B) and 1:2 (Fig. 4.1C) (Zn(II)/ligand) molar ratios. The 1:1 Zn(II) 
complexes were synthesised via the reaction of equimolar amounts of the 
thiosemicarbazone and ZnCl2 in ethanol, while the 1:2 Zn(II) complexes were 
obtained by reacting 2 equivalents of the corresponding thiosemicarbazone with 1 
equivalent of Zn(ClO4)2•6H2O in ethanol in the presence of triethylamine. All 
complexes were characterised by 1H and 13C NMR, IR, UV and mass spectrometry 
and their purity was assessed by elemental analysis and determined to be >95%.  
 
As expected, Dp44mT and Ap44mT formed neutral 1:2 (Zn(II)/ligand) complexes 
with Zn(ClO4)2•6H2O upon deprotonation of the NH-C=S moiety in the presence of 
the base, triethylamine (Fig. 4.1C). In contrast, even in the presence of excess base, 
DpC•HCl formed a cationic 1:2 (Zn(II)/ligand) complex with perchlorate counter ions 
(Fig. 4.1C), which is evident from the observation of strong vibrational stretching at 
1090 cm-1. 
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Figure 4.1. Line drawings of the thiosemicarbazones and their 1:1 and 1:2 
Zn(II) complexes relevant to this investigation. 
 (A) From left to right: Dp44mT, Ap44mT, DpC·HCl (B) [Zn(Dp44mT)Cl2], 
[Zn(Ap44mT)Cl2], [Zn(DpC)Cl2] (C) [Zn(Dp44mT-H2], [Zn(Dp44mT-H2], 
[Zn(DpC)2(ClO4)2] 
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4.3.2 X-ray Crystallography 
Four of the Zn(II) complexes were structurally characterised by single crystal X-ray 
analysis as the structure of these compounds provides important information that 
can be utilised to understand their biological activity (Jansson et al., 2010a; Lovejoy 
et al., 2012; Richardson et al., 2006; Richardson et al., 2009). Their thermal ellipsoid 
plots and the summary of crystallographic data are given in Figure 4.2 and Table 4.2, 
respectively.  
 
The 1:1 Zn(II)-thiosemicarbazone complex, [Zn(DpC)Cl2] (Fig. 4.2A) crystallised in 
ethanol, exhibits a five-coordinate geometry comprising a tridentate coordinated 
neutral thiosemicarbazone and two chlorido ligands. The geometry was 
approximately square pyramidal using the structural parameter τ defined by Addison 
et al (Addison et al., 1984), (τ = (α-β)/60 where α and β are the two largest 
coordinate angles; for square pyramidal, τ = 0; for trigonal bipyramidal, τ = 1), and in 
this case, τ = 0.16. The axially coordinated chlorido ligand (Cl2) was significantly 
more strongly bound (Zn-Cl2 2.246(1) Å) than the equatorial Zn-Cl1 bond (2.287(1) 
Å; Fig. 4.2A). The Zn-N bond to the pyridyl ring (2.169(4) Å) was stronger than to the 
imine N-atom (2.201(4) Å) (Table 4.1).  
 
This lengthening of the Zn-N bond was due to the trans influence of the Zn-Cl1 bond. 
There are several structurally similar dichloride Zn(II) complexes, and in all cases, 
the pyridyl thiosemicarbazone was coordinated in its neutral (thioamide) form 
(Kasuga et al., 2003; Kovala-Demertzi et al., 2006; Kowol et al., 2010; Shao et al., 
2014). In [Zn(DpC)Cl2], there is an intramolecular H-bond between the thioamide 
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proton attached to N3 and the non-coordinated pyridyl ring (Fig. 4.2A). Given the fact 
that N3 was protonated, the C=S bond is formally a double bond (1.684(5) Å) and 
the adjacent C-N(H) bond (C12-N3 1.365(6) Å) was consistent with a thioamide 
tautomer. The cyclohexyl ring exhibited rotational disorder about the N4-C bond with 
the two contributors being approximately equal (53%: 47%). The major contributor is 
shown in Figure 4.2A. 
 
The crystallisation of the analogous Zn(II) complex of Ap44mT in DMSO resulted in 
the 5-coordinate complex [Zn(Ap44mT-H)(Cl)(DMSO)] (Fig. 4.2B), where the 
thiosemicarbazone is deprotonated at N3 and only a single chlorido ligand was 
present. The structure comprises two complexed molecules in the asymmetric unit, 
both on general positions (Fig. 4.2B). The coordination sphere of each Zn(II) ion was 
completed by an axially O–bound DMSO (Fig. 4.2B). Notably, [Zn(Ap44mT-
H)(Cl)(DMSO)] adopts a geometry that was more distorted away from square 
pyramidal (τ=0.36) than [Zn(DpC)Cl2] (cf. Fig. 4.2A to 4.2B). The equatorial Zn-Cl 
bond (2.2790(5) Å) was similar to the equatorial Zn-Cl bond in [Zn(DpC)Cl2]. A 
notable feature was that the Zn1-N2a bond to the imine N-atom (2.100(2) Å) was 
much shorter than the bond to the pyridyl N-donor (2.148(2) Å). In fact, both Zn-N 
bonds in [Zn(Ap44mT-H)(Cl)(DMSO)] (Fig. 4.2B) were significantly shorter than 
those observed for [Zn(DpC)Cl2] (Fig. 4.2A) due to the augmented ionic contribution 
to the coordination bonds involving the anionic thiosemicarbazone (Table 4.1). 
Deprotonation also affected the internal ligand bond lengths. Relative to the neutral 
DpC ligand in [Zn(DpC)Cl2] (Fig. 4.2A), the C8a-S1a bond in the anionic (Ap44mT-
H)- lengthened to 1.738(2) Å, while the adjacent C8-N3 bond contracted (1.327(3) 
Å), which was indicative of the imine-thiolate form of the ligand (Fig. 4.2B). 
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The structure of the 1:2 complex [Zn(Ap44mT-H)2]•2CHCl3 revealed a distorted 
octahedral geometry (Fig. 4.2C). The two thiosemicarbazone ligands coordinate in 
their deprotonated form via the NNS donor atoms in a meridional fashion (Fig. 4.2C). 
The Zn(II) ion occupied a crystallographic two-fold axis of symmetry (Fig. 4.2C). 
Similar 1:2 Zn(II)-thiosemicarbazone complexes have been previously reported, and 
in most cases, both ligands are deprotonated at the thioamide N-atom (N3 in this 
structure) (Bermejo et al., 2007; Bernhardt et al., 2009; Castiñeiras et al., 2002; 
Kovala-Demertzi et al., 2006; Li Ming et al., 2008; Li et al., 2010; Stanojkovic et al., 
2010; Yang et al., 2013b). However, in some cases, the ligands are neutral, 
rendering the complex dicationic (Cheng et al., 2010; Kasuga et al., 2003). 
Deprotonation of the ligands in [Zn(Ap44mT-H)2]•2CHCl3 (Fig. 4.2C) leads to the 
same imine-thiolate form of the ligands observed in [Zn(Ap44mT-H)(Cl)(DMSO)] 
(Fig. 4.2B) on the basis of their C-S and C=N bond lengths (Table 4.1). The Zn-N 
and Zn-S coordinate bonds increase relative to [Zn(Ap44mT-H)(Cl)(DMSO)], 
principally due to the increase in coordination number (Table 4.1). As observed in 
the structure of [Zn(Ap44mT-H)(Cl)(DMSO)] (Fig. 4.2B), the Zn-N2 (imine) bond was 
much shorter than the Zn-N1 (pyridine) bond (Fig. 4.2C) (Table 4.1). 
 
As crystals of the 1:2 (Zn(II)/ligand) zinc complex of Dp44mT could not be obtained 
with the use of Zn(ClO4)2•6H2O in different solvents, an attempt to synthesise the 
same complex was conducted using ZnSO4.6H2O as the precursor salt. Crystals of 
[Zn(Dp44mT)2](HSO4)2 were obtained from an ethanol solution and the structure is 
shown in Figure 4.2D. The complex cation comprised two zwitterionic ligands of 
Dp44mT that are deprotonated at N3, but protonated at N5 (the non-coordinated 
pyridine) (Fig. 4.2D). Two hydrogen sulphate anions (each disordered) balance the 
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charge. The protons on N5A and N5B were clearly seen in difference maps and the 
C-N3 and C-S1 bond lengths were consistent with the imine-thiolate form of the 
ligand, as found in [Zn(Ap44mT-H)2].2CHCl3 and [Zn(Ap44mT-H)(Cl)(DMSO)] (Table 
4.1).  
 
Collectively, these physical studies demonstrate that both 1:1 and 1:2 Zn(II)-
thiosemicarbazone complexes can form. Although we know the chemical nature of 
the zinc complexes at solid state, their actual chemical species in water at pH: 7.4 is 
not known, but they are biologically-relevant and should be considered in terms of 
assessing their intracellular distribution (see below). 
 
 Zn-N1 Zn-N2 Zn-S1 C-S1 N3-C 
[Zn(Ap44mT-H)2] 2.205(3) 2.132(3) 2.4607(8) 1.736(3) 1.325(4) 
[Zn(Ap44mT-H)Cl(DMSO)] 2.148(2) 2.100(2) 2.4106(6) 1.738(2) 1.327(3) 
[Zn(Dp44mT)2](HSO4)2 2.205(3) 2.150(3) 2.449(1) 1.727(4) 1.361(5) 
[Zn(DpC)Cl2] 2.169(4) 2.201(4) 2.457(2) 1.684(5) 1.365(6) 
 
Table 4.1 Selected bond lengths. 
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Figure 4.2. ORTEP views of the Zn(II) complexes.  
(A) [Zn(DpC)Cl2]. (B) [Zn(Ap44mT-H)(Cl)(DMSO)]. (C) [Zn(Ap44mT-H)2]. (D) 
[Zn(Dp44mT-H)(Dp44mT)](HSO4). Solvents and counter ions, if any, were 
omitted for clarity. 
 
 
 
 
4.3.3 UV–Vis and Fluorescence Spectral Studies of the Zn(II) 
complexes 
In terms of determining the intracellular localisation of the Zn(II)-thiosemicarbazone 
complexes by the technique of fluorescence-based cellular imaging (Cowley et al., 
2005; Dayal et al., 2011; Kowol et al., 2010; Lim et al., 2010; Pascu et al., 2007; 
Pascu et al., 2008), it was important to determine their quantum yields in order to 
utilise appropriate complexes for these investigations.  
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Table 4.2. Crystal data. 
 
 
Absorption spectra of [Zn(Dp44mT)Cl2], [Zn(Ap44mT)Cl2], [Zn(DpC)Cl2], 
[Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 were recorded in DMSO 
and showed an absorption band observed between 404-425 nm (see Table 4.3 for 
λmax), which was characteristic of charge transfer transitions from sulphur to Zn(II) 
(Fig. 4.3A) (Türkkan et al., 2015). 
 [Zn(Ap44mT)(Cl
) (DMSO)] 
[Zn(DpC)Cl2] [Zn(Ap44mT-H)2] 
·2CHCl3 
[Zn(Dp44mT)(
HSO4)2] 
Formula 
weight  
M.W 
Crystal 
system  
Space group  
Colour 
Wavelength 
(Å) 
a (Å) 
b (Å) 
c (Å) 
α (deg) 
β (deg) 
γ (deg) 
V (Å3) 
T (K) 
Z 
R1 (obsd data) 
wR2 
GOF 
C12H19ClN4OS2Z
n 
400.25 
Monoclinic 
C2/c 
Yellow 
1.54180  
35.4880(9) 
7.8212(2)  
26.1152(6)  
 
108.757(3) 
 
6863.5(3)  
190(2)  
16 
0.0315 
0.0799 
1.040 
C19H23Cl2N5SZn 
489.75 
Monoclinic 
P21/c 
Yellow 
0.71073 
9.2036(3) 
8.4487(3) 
27.3261(14)  
 
95.267(4) 
 
2115.86(15) 
190(2)  
4 
0.0543 
0.1075 
1.027 
C22H28Cl6N8S2Zn 
746.71 
Monoclinic 
C2/c  
Yellow 
0.71073 
12.473(1)  
13.502(2)  
19.810(2) 
 
90.668(9) 
 
3335.9(6)  
190(2)  
4 
0.0428 
0.1100 
1.019 
C28H32N10O8S4
Zn 
830.25 
Triclinic 
P`1 
Yellow 
0.71073 
9.2029(5) 
14.1732(8) 
15.7067(10) 
116.794(6) 
101.212(5) 
91.723(5) 
1777.54(18) 
190(2)  
2 
0.0560 
0.1533 
1.022 
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Table 4.3 Photophysical properties of Zn(II) complexes. 
aEmission spectra were recorded with 420-nm excitation and 10 nm slit width in 
DMSO. 
bThe quantum yield was estimated using [Zn(3-AP)Cl2] (Φ = 21 × 10-3) as a 
reference. 
 
 
Fluorescence spectra of these zinc complexes (Fig. 4.3B) were measured in DMSO 
following excitation at 420 nm and the quantum yields were estimated (Table 4.3) 
using [Zn(3-AP)Cl2] as a standard (Kowol et al., 2010). It was observed that all 1:1 
(Zn(II)/ligand) complexes exhibited higher quantum yields than the corresponding 1:2 
(Zn(II)/ligand) complexes (Table 4.3), with a maximum of 1.34 × 10-3 for 
[Zn(Ap44mT)Cl2]. This value is close to the quantum yield exhibited by the well-
known Zn(II) bis(thiosemicarbazone) complex, [Zn(ATSM)], in DMSO (1.25 × 10-3), 
which has been used previously for cell imaging studies examining its distribution in 
cancer cells (Brockman et al., 1956). In addition, all complexes showed fluorescence 
in the green region of visible spectrum, which is amenable to fluorescence-based 
cellular imaging (Table 4.3). 
Complexes Absorbance λmax 
(nm) 
(ε × 10-4 M-1cm-1) 
Emissiona 
λmax (nm) 
Quantum yieldb 
Φ × 10-3 
[Zn(Dp44mT-H)2] 309 (2.2), 418 (2.7) 481 0.19 
[Zn(Ap44mT-H)2] 309 (2.2), 403 (3.1) 482 0.16 
[Zn(DpC)2](ClO4)2 315 (2.3), 423 (3.2) 532 0.36 
[Zn(Dp44mT)Cl2] 309 (1.1), 420 (1.5) 479 0.60 
[Zn(Ap44mT)Cl2] 307 (1.1), 404 (1.8) 512 1.34 
[Zn(DpC)Cl2] 310 (1.2), 423 (1.7) 533 0.54 
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Figure 4.3 Absorption and fluorescence spectra of Zn(II) complexes 
 (A) Absorption spectra of [Zn(Dp44mT)Cl2], [Zn(Ap44mT)Cl2], [Zn(DpC)Cl2], 
[Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 recorded in DMSO (10 
µM). (B) Fluorescence spectra of [Zn(Dp44mT)Cl2], [Zn(Ap44mT)Cl2], [Zn(DpC)Cl2], 
[Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 measured in DMSO (10 
µM) after excitation at 420 nm. 
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4.3.4 Zn(II)- Ligand Binding Studies 
Since we performed all biological studies in aqueous media containing DMSO, the 
binding behaviour of ligands with Zn(II) in DMSO alone and in MOPS buffer (pH: 7.4) 
containing DMSO (10% v/v) was examined using UV-visible spectroscopy. Notably, 
10% (v/v) DMSO was necessary due to the limited aqueous solubility of the ligands 
and resultant complexes over the duration of the experiment. 
 
The thiosemicarbazone, Dp44mT (Fig. 4.4A), displayed an intense peak in the UV 
region with a maximum at 340 nm in DMSO. However, the addition of Zn(II) induced 
a new peak in the visible region with a λmax at 422 nm with a clear isosbestic point at 
372 nm. Upon incremental addition of Zn(II) (0–1.6 equiv.), the intensity of a new 
peak at 422 nm increased linearly with a simultaneous decrease in absorption at 340 
nm, but saturated at approximately 1 equivalent with respect to Dp44mT (Fig. 4.4A). 
The presence of only 1 distinct isosbestic point confirmed the complete conversion of 
the ligand into a single Zn(II) complex. Further stoichiometric binding analysis as 
determined by plotting absorption maximum at 422 nm (A422) versus 
[Zn(II)]/[Dp44mT], confirmed the 1:1 binding ratio of Zn(II)/ligand (Fig. 4.4B).  
 
The binding studies of Dp44mT with Zn(II) were also examined in water containing 
10% DMSO and the results are shown in Figures 4.4C and 4.4D. The ligand 
Dp44mT exhibited a strong absorption band at 325 nm that decreased with a 
concomitant increase in the intensity of a new peak at 398 nm upon gradual addition 
of Zn(II) until a 0.5 equivalent with respect to Dp44mT was reached (Fig. 4.4C). 
However, further addition of Zn(II) did not increase the absorption at 398 nm. 
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Appearance of a single isosbestic point at 354 nm confirmed the formation of a 
single species (Fig. 4.4C). Stoichiometric analysis further revealed that Dp44mT 
formed 1:2 (Zn(II)/ligand) complexes with zinc (Fig. 4.4D).  
 
Similarly, Ap44mT and DpC ligands showed 1:1 binding behaviour with Zn(II) in 
DMSO, with isosbestic points at 360 and 372 nm, respectively (Fig. 4.5A, 4.6A). The 
1:1 binding ratio of ligand/Zn(II) in DMSO was also confirmed for Ap44mT (Fig. 4.5B) 
and DpC (Fig. 4.6B) via binding stoichiometric analysis. The absorption maximum 
was plotted against [Zn(II)]/[ligand] at 404 (A404) for Ap44mT (Fig. 4.5B) and 424 
(A424) for DpC (Fig. 4.6B). Binding studies were also performed in water containing 
10% DMSO for Ap44mT (Fig. 4.5C) and DpC (Fig. 4.6C). Similarly to Dp44mT, both 
ligands prefer to form 2:1 complexes (L/Zn(II)) rather of 1:1 complexes with Zn in an 
aqueous solution containing 10% DMSO. Strong absorption bands were found at 
308 nm for Ap44mT (Fig. 4.5C) and 338 nm for DpC (Fig. 4.6C) which were 
decreased with a concomitant increase in the intensity of a new peaks at 376 and 
444 nm, respectively, upon gradual addition of Zn(II) till 0.5 equiv. w.r. to ligand (Fig. 
4.5C, 4.6C). Appearance of isosbestic points at 356 nm for Ap44mT (Fig. 4.5C) and 
354 nm for DpC (Fig. 4.6C) confirmed the formation of single species. Further 
Stoichiometric analysis demonstrated that Ap44mT (Fig. 4.5D) and DpC (Fig. 4.6D) 
form 2:1 complexes with Zn(II) in water containing 10% DMSO. Similar results were 
also obtained when the concentration of DMSO in water was decreased to 0.5%, 
which was the maximum utilised in biological studies (Richardson et al., 2009).  
 
139 
 
Collectively, these binding studies demonstrate that the ligands, Dp44mT, Ap44mT 
and DpC, preferred to form 1:1 complexes with Zn(II) in DMSO alone, whereas they 
preferred to form 1:2 (Zn(II)/ligand) complexes in an aqueous solution containing 
DMSO. Notably, it is possible that the formation of the 1:2 (Zn(II)/ligand) complexes 
was inhibited in DMSO as this solvent can also act as a coordinating ligand. In fact, 
this was observed in the case of [Zn(Ap44mT)Cl2] in the solid state, where one of the 
chlorides was found to be replaced by DMSO to form the [Zn(Ap44mT-
H)(Cl)(DMSO)] complex when crystallised in DMSO. These ligands could form 1:2 
(Zn(II)/ligand) complexes with zinc in aqueous milieu and are the possible active 
species in cells. 
 
4.3.5 Cytotoxicity of Novel Zn(II)-thiosemicarbazone Complexes 
Examined in Different Tumour Cell-Types  
The ligands, Dp44mT, Ap44mT and DpC, have been shown to be potent cytotoxic 
agents in a variety of cancer cells and in vivo models (Jansson et al., 2010a; 
Jansson et al., 2015b; Kovacevic et al., 2011; Lovejoy et al., 2011; Lovejoy et al., 
2012; Whitnall et al., 2006; Yuan et al., 2004). Moreover, we have shown that the 
cytotoxicity of Dp44mT and DpC is potentiated when cells express high levels of the 
drug transporter, Pgp (Jansson et al., 2015a; Jansson et al., 2015b; Seebacher et 
al., 2016a; Whitnall et al., 2006). This is due to the ability of Pgp to transport the 
ligands into the lysosome to induce lysosomal rupture and cell death (Jansson et al., 
2015a; Jansson et al., 2015b; Seebacher et al., 2016a; Whitnall et al., 2006). Hence, 
this imparts these agents with the highly beneficial property of being able to 
effectively overcome Pgp-mediated drug resistance, which is a major problem in the 
clinics (Jansson et al., 2015a).  
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Figure 4.4. Zn(II)-Dp44mT Binding Studies.  
(A) Dp44mT (blue line) displayed an intense peak in the UV region with a maximum 
at 340 nm in DMSO (50 µM). Addition of Zn(II) induced a new peak in the visible 
region with a λmax at 422 nm with a clear isosbestic point at 372 nm, which saturated 
at nearly 1 equivalent with respect to Dp44mT (red line). (B) Binding stoichiometric 
analysis as determined by plotting the absorption maximum at 422 (A422) versus 
Zn2+/Dp44mT confirmed the 1:1 binding ratio of Zn(II)/Ligand. (C) Dp44mT (blue line, 
50 µM) exhibited a strong absorption band at 325 nm that decreased with a 
concomitant increase in the intensity of a new peak at 398 nm upon gradual addition 
of Zn(II) until 0.5 equivalents with respect to Dp44mT (red line) in MOPS buffer (pH: 
7.4) containing 10% DMSO. Appearance of an isosbestic point at 354 nm confirmed 
the formation of single species. (D) Stoichiometric analysis further revealed that the 
ligand, Dp44mT, formed 1:2 (Zn(II)/ligand) complexes with zinc in MOPS buffer (pH: 
7.4) containing 10% DMSO. 
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Figure 4.5. Zn(II)-Ap44mT Binding Studies 
(A) Ap44mT (blue line) displayed an intense peak in the UV region with a maximum 
at 308 nm in DMSO. Addition of Zn(II) induced a new peak in the visible region with 
a λmax at 404 nm with a clear isosbestic point at 360 nm, which saturated at nearly 1 
equivalent with respect to Ap44mT (red line) (B) Binding stoichiometric analysis as 
determined by plotting absorption maximum at 404 (A422) versus [Zn(II)]/[Ap44mT] 
confirmed 1:1 binding ratio of ligand/Zn(II) (C) Ap44mT (blue line) exhibited a strong 
absorption band at 308 nm that was decreased with a concomitant increase in the 
intensity of a new peak at 376 nm upon gradual addition of Zn(II) until 0.5 equiv. w.r. 
to Ap44mT (red line) in water containing 10% DMSO. Appearance of an isosbestic 
point at 356 nm confirmed the formation of single species. (D) Stoichiometric 
analysis further revealed that the ligand Ap44mT form 2:1 complexes with Zn(II) in 
water containing 10% DMSO. 
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Figure 4.6 Zn(II)-DpC Binding Studies  
(A) DpC (blue line) displayed an intense peak in the UV region with a maximum at 
338 nm in DMSO. Addition of Zn(II) induced a new peak in the visible region with a 
λmax at 424 nm with a clear isosbestic point at 372 nm, which saturated at nearly 1 
equivalent with respect to DpC (red line) (B) Binding stoichiometric analysis as 
determined by plotting absorption maximum at 424 (A422) versus [Zn(II)]/[DpC] 
confirmed 1:1 binding ratio of ligand/Zn(II) (C) DpC (blue line) exhibited a strong 
absorption band at 338 nm that was decreased with a concomitant increase in the 
intensity of a new peak at 444 nm upon gradual addition of Zn(II) until 0.5 equiv. w.r. 
to DpC (red line) in water containing 10% DMSO. Appearance of an isosbestic point 
at 354 nm confirmed the formation of single species. (D) Stoichiometric analysis 
further revealed that the ligand DpC form 2:1 complexes with Zn(II) in water 
containing 10% DMSO. 
 
 
(A) (B)
(C) (D)
143 
 
Moreover, we have established that Cu(II) complexes of the DpT and ApT series are 
more cytotoxic than the ligand alone (Jansson et al., 2010a). Interestingly, research 
from other laboratories has demonstrated that Zn(II)-thiosemicarbazone complexes 
are often more potently cytotoxic than the thiosemicarbazone ligands alone (Atassi 
et al., 1979; Kovala-Demertzi et al., 2006; Kowol et al., 2010; Petering et al., 1967). 
Therefore, studies examined the cytotoxicity of Dp44mT, Ap44mT and DpC relative 
to their respective 1:1 and 1:2 (Zn(II)/ligand) zinc complexes in a pair of cell-types 
used to assess Pgp-mediated drug resistance, namely, cervical carcinoma cell lines 
KBV1 (+Pgp; high Pgp expression) compared to KB31 (-Pgp; negligible Pgp 
expression) (Jansson et al., 2015b; Seebacher et al., 2016a; Seebacher et al., 2015; 
Yamagishi et al., 2013) (Fig. 4.7). This would provide data on the effectiveness of the 
Zn(II) complexes of thiosemicarbazones on overcoming Pgp-mediated resistance 
(Jansson et al., 2015b; Seebacher et al., 2016a) . We have also included the SW480 
colon (low Pgp expression) adenocarcinoma cell-type (Miklos et al., 2015; 
Montazami et al., 2015), which was of interest as it has been used previously to 
demonstrate that 3-AP entered the nucleus (Kowol et al., 2010). Several cell-types 
were included as it has been reported that the subcellular distribution of Zn(II)-
thiosemicarbazones can vary depending on the tumour cell-type examined (Cowley 
et al., 2005; Pascu et al., 2008), which could result in differences in cytotoxicity. 
 
(i) Cytotoxicity of Dp44mT and its Zn(II) Complexes: Similar trends in the IC50 
values of the 1:1 and 1:2 (Zn(II)/ligand) zinc complexes of Dp44mT, compared to 
Dp44mT alone, were found across the three cell-types (Fig. 4.7). Notably, 
[Zn(Dp44mT)Cl2] was 2.5-, 6.2- and 4.9-fold more cytotoxic (p < 0.01) than Dp44mT 
in KBV1 (+Pgp), KB31 (-Pgp) and SW480 (low Pgp) cells, respectively (Fig. 4.7). 
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Using KB31 cells, [Zn(Dp44mT-H)2] was also significantly (p < 0.001) more cytotoxic 
relative to Dp44mT (Fig. 4.7). However, in both KBV1 and SW480 cells, 
[Zn(Dp44mT-H)2] was less cytotoxic than Dp44mT, with IC50 values that were 3.7- 
and 5.2-fold (p < 0.001) higher than that of Dp44mT (Fig. 4.7). In all three cell-types, 
[Zn(Dp44mT-H)2] was significantly (p < 0.001) less cytotoxic than [Zn(Dp44mT)Cl2] 
(Fig. 4.7). The general trend for the IC50 values of Dp44mT and its Zn(II) complexes 
were therefore: [Zn(Dp44mT)Cl2] < Dp44mT < [Zn(Dp44mT-H)2]. This indicates that 
zinc complexes have different cytotoxic properties than the ligand alone. 
 
(ii) Cytotoxicity of Ap44mT and its Zn(II) Complexes: The IC50 values of the 1:1 
and 1:2 (Zn(II)/ligand) zinc complexes of Ap44mT, compared to the Ap44mT alone, 
followed a consistent trend across the KBV1, KB31 and SW480 cell-types (Fig. 4.7). 
In all cells examined, [Zn(Ap44mT)Cl2] was significantly (p < 0.001) more cytotoxic 
than Ap44mT. The IC50 values of [Zn(Ap44mT)Cl2] were 13.3-, 12.5- and 14.4-fold 
lower (p < 0.001) than Ap44mT in KBV1, KB31 and SW480 cells, respectively (Fig. 
4.7). Similarly, the IC50 values of [Zn(Ap44mT-H)2] in KBV1, KB31 and SW480 cells 
were 5.5-, 11.0- and 16.5-fold (p < 0.001) more cytotoxic than Ap44mT, respectively 
(Fig. 4.7). Notably, there was no significant (p > 0.05) difference between the 
cytotoxicity of [Zn(Ap44mT)Cl2] and [Zn(Ap44mT-H)2] (Fig. 4.7). The trend for the 
IC50 values of Ap44mT and its Zn(II) complexes was [Zn(Ap44mT)Cl2] = 
[Zn(Ap44mT-H)2] < Ap44mT (Fig. 4.7).  
 
(iii) Cytotoxicity of DpC and its Zn(II) Complexes: The trends in the IC50 values of 
DpC and its 1:1 and 1:2 (Zn(II)/ligand) zinc complexes were not entirely consistent 
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across the three cell-types (Fig. 4.7). Using KBV1 (+Pgp) cells, [Zn(DpC)Cl2] was 
less cytotoxic than DpC with an IC50 value 8.3-fold higher (p < 0.001) than DpC (Fig. 
4.7). However, assessing KB31 (-Pgp) and SW480 (low Pgp) cells, the IC50 values of 
[Zn(DpC)Cl2] were 1.2- and 2.6-fold lower (p < 0.05) than DpC, making [Zn(DpC)Cl2] 
more cytotoxic (Fig. 4.7). In KBV1 (+Pgp) cells, there was no significant (p > 0.05) 
difference between [Zn(DpC)2](ClO4)2 and DpC. In contrast, in the KB31 and SW480 
cell-types, [Zn(DpC)2](ClO4)2 was 1.6- and 5.4-fold (p < 0.01) more cytotoxic than 
DpC, respectively (Fig. 4.7). In all cell-types examined in this study, 
[Zn(DpC)2](ClO4)2 was significantly (p < 0.001-0.01) more cytotoxic than 
[Zn(DpC)Cl2], with IC50 values 7.3-, 1.3- and 2.36-fold less in KBV1, KB31 and 
SW480 cells, respectively (Fig. 4.7). The general trend in IC50 values for DpC and its 
Zn(II) complexes in KB31 and SW480 cells was [Zn(DpC)2](ClO4)2 < [Zn(DpC)Cl2] < 
DpC. However in KBV1 cells, the trend in IC50 values was [Zn(DpC)2](ClO4)2 = DpC 
< [Zn(DpC)Cl2] (Fig. 4.7). 
 
Interestingly, the cytotoxicity of Dp44mT, DpC and their 1:1 and 1:2 (Zn(II)/ligand) 
zinc complexes were greatest in KBV1 (+Pgp) cells compared to the KB31 (-Pgp) 
and SW480 (low Pgp) cell-types (Fig. 4.7). Indeed, the IC50 values of the Zn(II) 
complexes of Dp44mT and DpC in the KB31 and SW480 cell-types were between 
3.5- to 25-fold higher relative to those observed in KBV1 cells (Fig. 4.7). These 
observations are in good agreement with the fact that Dp44mT, DpC and their Cu(II) 
complexes exhibit potentiated cytotoxicity in Pgp-expressing cells (Jansson et al., 
2015b; Seebacher et al., 2016a; Whitnall et al., 2006), and from the current studies, 
it appears that the Zn(II) complexes may also be more cytotoxic in Pgp-expressing 
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cells (KBV1) than in low-Pgp expressing cells (KB31 and SW480) (Fig. 4.7). This 
would be clearly important for the treatment of Pgp-resistant tumours.  
 
In contrast to the Zn(II) complexes of Dp44mT and DpC, the cytotoxicity of the Zn(II) 
complexes of Ap44mT did not appear to be as greatly affected by Pgp expression 
(Fig. 4.7). Notably, the IC50 values of the 1:1 and 1:2 (Zn(II)/ligand) zinc complexes 
of Ap44mT were similar across all 3 cell-types, suggesting that their cytotoxicity was 
not dependent on Pgp expression (Fig. 4.7). This interesting structure-activity 
relationship reveals the replacement of the non-coordinating pyridine ring with a 
methyl substituent leads to the loss of Pgp-potentiated cytotoxicity. Thus, the di-2-
pyridyl moiety is an important pharmacophore that mediates the ability of these 
thiosemicarbazones to overcome Pgp-dependent resistance.  
 
In summary, with the exception of [Zn(Dp44mT-H)2] in KBV1 and SW480 cells, and 
[Zn(DpC)Cl2] in KBV1 cells, Zn(II) complexation resulted in more potent cytotoxic 
effects relative to the free ligand alone (Fig. 4.7). Notably, the Zn(II) complexes of 
Dp44mT and DpC appeared to exhibit potentiated cytotoxicity against Pgp-
expressing KBV1 cells, a property essential for overcoming Pgp-mediated drug 
resistance in tumours.  
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Figure 4.7. MTT assay of Dp44mT, Ap44mT and DpC and their respective 1:1 
and 1:2 (Zn(II)/ligand) zinc complexes in KBV1, KB31 and SW480 cells. 
The cytotoxicity of the ligands and their respective 1:1 and 1:2 (Zn(II)/ligand) zinc 
complexes using KBV1, KB31 and SW480 cells after a 24 h/37°C incubation. 
Results are mean ± SD (3 experiments). * p < 0.05, ** p < 0.01, *** p < 0.001 versus 
the respective ligand or complex, as shown.  
 
 
4.3.6 The Intracellular Localisation of [Zn(DpC)2](Cl2O4) is Not 
Nuclear 
Previous studies have highlighted the potential application of Zn(II) mono- and 
bis(thiosemicarbazones) for intracellular imaging (Cowley et al., 2005; Dayal et al., 
2011; Kowol et al., 2010; Lim et al., 2010; Pascu et al., 2007; Pascu et al., 2008). 
Understanding the intracellular localisation of agents can provide valuable 
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information regarding their potential mechanism(s) of action. There are significant 
advantages of using Zn(II) complexes over Cu(II) complexes, namely: (1) that they 
are relatively less toxic than Cu(II) complexes (Palanimuthu et al., 2013); and (2) 
they possess intrinsic fluorescence due to intra-ligand excitation, whereas Cu(II) is d9 
and paramagnetic (Pascu et al., 2010) and quenches the fluorescence of adjacent 
fluorophores (Pascu et al., 2007). 
 
Examples of using Zn(II) complexes as imaging tools for assessing intracellular 
localisation include the well-known anti-cancer thiosemicarbazone, 3-AP, which was 
shown to be localised to the nucleolus of SW480 cells (Kowol et al., 2010). However, 
other Zn(II)bis(thiosemicarbazones) have been reported to be localised to a range of 
subcellular organelles, including lysosomes and mitochondria (Cowley et al., 2005; 
Dayal et al., 2011; Pascu et al., 2008). Furthermore, the localisation of 
Zn(II)bis(thiosemicarbazone) complexes may be cell-type-dependent, as [Zn(ATSM)] 
has been shown to localise to the nucleus of PC-3 (prostate cancer) cells, while its 
lysosomal localisation was observed in IRGOV (ovarian cancer) cells (Cowley et al., 
2005).  
 
Considering that the subcellular distribution of other Zn(II)bis(thiosemicarbazones) 
has been shown to vary depending on the cell-type used, we sought to establish 
directly the intracellular localisation of the Zn(II) complexes of Dp44mT, Ap44mT and 
DpC in KBV1, KB31 and SW480 cells. The 1:2 (Zn(II)/ligand) complexes were 
utilised as binding studies suggested that these are the major species formed in 
aqueous solutions (Fig. 4.4, 4.5, 4.6). Both [Zn(Dp44mT-H)2] and [Zn(Ap44mT-H)2] 
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exhibited negligible intracellular fluorescence, an issue which has been encountered 
by others examining the subcellular distribution of different 
Zn(II)bis(thiosemicarbazones) complexes (Cowley et al., 2005; Pascu et al., 2008). 
Therefore, we focused our efforts on examining the intracellular distribution of the 
Zn(II) complex of our lead compound, DpC, which will enter clinical trials in 2016 
(ClinicalTrials.gov Identifier NCT02688101) (Jansson et al., 2015a).  
 
As some Zn(II)bis(thiosemicarbazones) (Cowley et al., 2005; Dayal et al., 2011; 
Kowol et al., 2010) have demonstrated nuclear localisation, their presence in the 
nucleus was assessed first, using the far red nuclear stain (Nuc), DRAQ5™ (Figs. 
4.8, 4.9, 4.10). After a 10 min/37°C incubation with KBV1 (+Pgp) cells, 
[Zn(DpC)2](ClO4)2 (50 µM) exhibited a punctate pattern of green fluorescence at 405 
nm (Fig. 4.8Ai). The Nuc stain assessed at 690 nm produced structurally well-
defined staining of the nucleus, with the nuclear membrane and nucleoli clearly 
delineated (Figs. 4.8Aii). Following co-incubation with [Zn(DpC)2](ClO4)2 and Nuc, 
the green fluorescence of [Zn(DpC)2](ClO4)2 did not overlap (Pearson’s correlation 
coefficient R = -0.01) with the red fluorescence of the Nuc stain (Figs. 4.8Aiii; see 
expanded view), as illustrated in the cytofluorogram (Fig. 4.8B). In KB31 (-Pgp) and 
SW480 cells a punctate pattern of green fluorescence was also observed following 
incubation with [Zn(DpC)2](ClO4)2 (Fig. 4.9Ai, 4.10Ai). Similarly to KBV1 cells (+Pgp; 
Fig. 4.8Aiii), a total lack of overlap between [Zn(DpC)2](ClO4)2 and the Nuc stain was 
also observed in KB31 (-Pgp) and SW480 cells (Fig. 4.9iii, 4.10iii), which had 
Pearson’s correlation coefficients of R = -0.08 and R = -0.01, respectively (Fig. 4.9B, 
4.10B). From these results, it was apparent that unlike the Zn(II) complex of 3-AP 
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(Kowol et al., 2010), [Zn(DpC)2](ClO4)2 was not localised to the nucleus/nucleoli of 
the cell.  
 
4.3.7 The Intracellular Localisation of [Zn(DpC)2](Cl2O4) is Not 
Mitochondrial 
We next assessed whether [Zn(DpC)2](ClO4)2 showed any co-localisation with the 
mitochondrion using MitoTracker® Deep Red (Mito; Fig 4.11, 4.12, 4.13), as some 
Zn(II)bis(thiosemicarbazones) display partial localisation to mitochondria (Pascu et 
al., 2008). Of relevance, our laboratory has demonstrated that Dp44mT can induce 
the release of holo-cytochrome c (h-cytc) from the mitochondrial intermembrane 
space into the cytosol (Yuan et al., 2004), a key step in mitochondrial-dependent 
apoptosis, suggesting some effect on the mitochondrion (Yang et al., 1997). The 
punctate pattern of green [Zn(DpC)2](ClO4)2 fluorescence at 405 nm was again 
observed in KBV1, KB31 and SW480 cells (Fig. 4.11Ai, 4.12Ai, 4.13Ai), while a 
typical, perinuclear punctate staining pattern was observed for Mito at 690 nm (Fig. 
4.11Aii, 4.12Aii, 4.13Aii). When the cells were incubated with both [Zn(DpC)2](ClO4)2 
and Mito, no co-localisation was apparent in any of the cell-types tested (Fig. 
4.11Aiii, 4.12Aiii, 4.13Aiii). Pearson’s correlation coefficients of R = 0.11, 0.08 and 
0.06 were obtained using KBV1, KB31 and SW480 cells, respectively, and support 
the lack of observable co-localisation (Fig. 4.11B, 4.12B, 4.13B). Hence, it can be 
concluded that [Zn(DpC)2](ClO4)2 does not localise in mitochondria. 
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Figure 4.8 The intracellular localisation of [Zn(DpC)2](Cl2O4) is not nuclear in 
the KBV1 cell line  
(A) (i) In the KBV1 cell line, incubation with [Zn(DpC)2](Cl2O4) (50 μM, 10 min/37°C) 
resulted in a punctate pattern of green (405 nm) fluorescence (ii) Incubation with the 
far red nuclear stain (690 nm, Nuc), DRAQ5™, generated well-defined staining of 
the nucleus, with the nuclear membrane and nucleoli clearly delineated (iii) Co-
incubation of KBV1 cells with [Zn(DpC)2](Cl2O4) and Nuc revealed no overlap 
between [Zn(DpC)2](Cl2O4) and Nuc (iv) The lack of co-localisation between 
[Zn(DpC)2](Cl2O4) and Nuc was confirmed by the Pearson’s correlation coefficient of 
R = -0.01. The images are typical from 3 experiments. Scale bar: 10 μm. 
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Figure 4.9 The intracellular localisation of [Zn(DpC)2](Cl2O4) is not nuclear in 
the KB31 cell line  
(A) (i) In the KB31 cell line, incubation with [Zn(DpC)2](Cl2O4) (50 μM, 10 min/37°C) 
resulted in a punctate pattern of green (405 nm) fluorescence (ii) Incubation with the 
far red nuclear stain (690 nm, Nuc), DRAQ5™, generated well-defined staining of 
the nucleus, with the nuclear membrane and nucleoli clearly delineated (iii) Co-
incubation of KB31 cells with [Zn(DpC)2](Cl2O4) and Nuc revealed no overlap 
between [Zn(DpC)2](Cl2O4) and Nuc (iv) The lack of co-localisation between 
[Zn(DpC)2](Cl2O4) and Nuc was confirmed by the Pearson’s correlation coefficient of 
R = -0.08. The images are typical from 3 experiments. Scale bar: 10 μm. 
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Figure 4.10 The intracellular localisation of [Zn(DpC)2](Cl2O4) is not nuclear in 
the SW480 cell line  
(A) (i) In the SW480 cell line, incubation with [Zn(DpC)2](Cl2O4) (50 μM, 10 
min/37°C) resulted in a punctate pattern of green (405 nm) fluorescence (ii) 
Incubation with the far red nuclear stain (690 nm, Nuc), DRAQ5™, generated well-
defined staining of the nucleus, with the nuclear membrane and nucleoli clearly 
delineated (iii) Co-incubation of SW480 cells with [Zn(DpC)2](Cl2O4) and Nuc 
revealed no overlap between [Zn(DpC)2](Cl2O4) and Nuc (iv) The lack of co-
localisation between [Zn(DpC)2](Cl2O4) and Nuc was confirmed by the Pearson’s 
correlation coefficient of R = -0.01. The images are typical from 3 experiments. Scale 
bar: 10 μm.  
154 
 
 
Figure 4.11 The intracellular localisation of [Zn(DpC)2](Cl2O4) is not 
mitochondrial in the KBV1 cell line 
(A) (i) In the KBV1 cell line, incubation with [Zn(DpC)2](Cl2O4) (50 μM, 10 min/37°C) 
resulted in a punctate pattern of green (405 nm) fluorescence (ii) Incubation with 
MitoTracker® Deep Red (690 nm, Mito) generated a typical spindle-like pattern (iii) 
Co-incubation of KBV1 cells with [Zn(DpC)2](Cl2O4) and Mito revealed no overlap 
between [Zn(DpC)2](Cl2O4) and Mito (iv) The lack of co-localisation between 
[Zn(DpC)2](Cl2O4) and Mito was confirmed by the Pearson’s correlation coefficient of 
R = 0.11. The images are typical from 3 experiments. Scale bar: 10 μm. 
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Figure 4.12 The intracellular localisation of [Zn(DpC)2](Cl2O4) is not 
mitochondrial in the KB31 cell line 
(A) (i) In the KB31 cell line, incubation with [Zn(DpC)2](Cl2O4) (50 μM, 10 min/37°C) 
resulted in a punctate pattern of green (405 nm) fluorescence (ii) Incubation with 
MitoTracker® Deep Red (690 nm, Mito) generated a typical spindle-like pattern (iii) 
Co-incubation of KB31 cells with [Zn(DpC)2](Cl2O4) and Mito revealed no overlap 
between [Zn(DpC)2](Cl2O4) and Mito (iv) The lack of co-localisation between 
[Zn(DpC)2](Cl2O4) and Mito was confirmed by the Pearson’s correlation coefficient of 
R = 0.08. The images are typical from 3 experiments. Scale bar: 10 μm. 
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Figure 4.13 The intracellular localisation of [Zn(DpC)2](Cl2O4) is not 
mitochondrial in the SW480 cell line 
(A) (i) In the SW480 cell line, incubation with [Zn(DpC)2](Cl2O4) (50 μM, 10 
min/37°C) resulted in a punctate pattern of green (405 nm) fluorescence (ii) 
Incubation with MitoTracker® Deep Red (690 nm, Mito) generated a typical spindle-
like pattern (iii) Co-incubation of SW480 cells with [Zn(DpC)2](Cl2O4) and Mito 
revealed no overlap between [Zn(DpC)2](Cl2O4) and Mito (iv) The lack of co-
localisation between [Zn(DpC)2](Cl2O4) and Mito was confirmed by the Pearson’s 
correlation coefficient of R = 0.06. The images are typical from 3 experiments. Scale 
bar: 10 μm.  
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4.3.8 The Intracellular Localisation of [Zn(DpC)2](Cl2O4) is 
Lysosomal 
Our previous results have indirectly suggested that the lead thiosemicarbazones, 
Dp44mT and DpC, are sequestered within lysosomes (Gutierrez et al., 2014; 
Jansson et al., 2015b; Lovejoy et al., 2011). Additionally, lysosomal distribution of 
the Zn(II)bis(thiosemicarbazone) complex [Zn(ATSM)] has been reported by others 
(Cowley et al., 2005). In all cell-types examined, incubation with [Zn(DpC)2](ClO4)2 
produced a punctate pattern of green fluorescence at 405 nm (Fig. 4.14Ai, 4.15Ai, 
4.16Ai). In addition, incubation with LysoTracker™ Deep Red (Lyso) resulted in a 
similar punctate pattern of red fluorescence at 690 nm (Fig. 4.14Aii, 4.15Aii, 4.16Aii). 
Interestingly, incubation with both [Zn(DpC)2](ClO4)2 (green) and Lyso (red) resulted 
in a punctate pattern of yellow fluorescence when the respective channels were 
merged, suggesting that [Zn(DpC)2](ClO4)2 and Lyso were co-localised (Fig. 4.14Aiii, 
4.15Aiii, 4.16Aiii). The Pearson’s correlation coefficients of R = 0.84, 0.86 and 0.84 
obtained for KBV1, KB31 and SW480 cells, respectively, also demonstrated that 
[Zn(DpC)2](ClO4)2 was co-localised to the lysosome (Fig. 4.14B, 4.15B, 4.16B).  
 
Previously it has been reported that Dp44mT (Jansson et al., 2015b; Lovejoy et al., 
2011; Seebacher et al., 2016a) and DpC (Seebacher et al., 2015) appear to be 
sequestered in lysosomes, where they redox cycle after complexation with copper 
ions to induce LMP. For the first time, these results provide direct evidence that the 
1:2 (Zn(II)/ligand) zinc complex of our lead compound, DpC, is sequestered in 
lysosomes. Other reports have shown that the localisation of some 
bis(thiosemicarbazones) can differ between cell-types (Cowley et al., 2005; Pascu et 
al., 2008). Nonetheless, the localisation of [Zn(DpC)2](ClO4)2 did not vary with 
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respect to the cells used, despite apparent cell-type dependent differences in 
cytotoxicity (Fig. 4.7). In addition, we found that [Zn(DpC)2](ClO4)2 entered and 
localised in the lysosome of both Pgp-expressing KBV1 cells and non-Pgp 
expressing KB31 and SW480 cells. These results demonstrated the ability of 
[Zn(DpC)2](ClO4)2 to localise to the lysosome, independent of Pgp expression. 
 
Collectively, these results in Figures 4.14-16 demonstrate that [Zn(DpC)2](ClO4)2 
clearly localises to the lysosomal compartment, but not the nucleus, or the 
mitochondrion in 3 cell lines and supports our previous studies using DpC that 
indirectly suggested its localisation in the lysosome (Seebacher et al., 2015).  
 
4.3.9 Effects of [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and 
[Zn(DpC)2](ClO4)2 on Lysosomal Integrity and the Induction of 
Lysosomal Membrane Permeabilisation  
Our previous results have suggested that the Cu(II) complexes of Dp44mT and DpC 
can be sequestered in lysosomes, where they generate ROS and cause LMP 
(Jansson et al., 2015b; Lovejoy et al., 2011). As [Zn(DpC)2](ClO4)2 is localised to 
lysosomes, we next assessed the effects of all 1:2 complexes, [Zn(Dp44mT-H)2], 
[Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 on lysosomal integrity, compared to the 
ligands, Dp44mT, Ap44mT and DpC (Fig. 4.17). The 1:2 (Zn(II)/ligand) zinc 
complexes were again used as binding studies suggest that the ligands prefer to 
form 1:2 (Zn(II)/ligand) complexes with zinc under aqueous conditions (Figs. 4.4, 4.5, 
4.6).  
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Figure 4.14 The intracellular localisation of [Zn(DpC)2](Cl2O4) is lysosomal in 
the KBV1 cell line  
(A) (i) In the KBV1 cell line, incubation with [Zn(DpC)2](Cl2O4) (50 μM, 10 min/37°C) 
resulted in a green (405 nm), punctate pattern (ii) Incubation with LysoTracker® 
Deep Red (Lyso) resulted in a typical, punctate pattern of red (690 nm) fluorescence 
(iii) Co-incubation of the KBV1 cell line with both [Zn(DpC)2](Cl2O4) (green) and Lyso 
(red) resulted in a yellow, punctate pattern of fluorescence on merge (iv) The co-
localisation of [Zn(DpC)2](Cl2O4) and Lyso was confirmed by the strong Pearson’s 
correlation coefficient of R = 0.84. The images are typical from 3 experiments. Scale 
bar: 10 μm.  
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Figure 4.15 The intracellular localisation of [Zn(DpC)2](Cl2O4) is lysosomal in 
the KB31 cell line 
(A) (i) In the KB31 cell line, incubation with [Zn(DpC)2](Cl2O4) (50 μM, 10 min/37°C) 
resulted in a green (405 nm), punctate pattern (ii) Incubation with LysoTracker® 
Deep Red (Lyso) resulted in a typical, punctate pattern of red (690 nm) fluorescence 
(iii) Co-incubation of the KB31 cell line with both [Zn(DpC)2](Cl2O4) (green) and Lyso 
(red) resulted in a yellow, punctate pattern of fluorescence on merge (iv) The co-
localisation of [Zn(DpC)2](Cl2O4) and Lyso was confirmed by the strong Pearson’s 
correlation coefficient of R = 0.86. The images are typical from 3 experiments. Scale 
bar: 10 μm.  
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Figure 4.16 The intracellular localisation of [Zn(DpC)2](Cl2O4) is lysosomal in 
the SW480 cell line 
(A) (i) In the SW480 cell line, incubation with [Zn(DpC)2](Cl2O4) (50 μM, 10 
min/37°C) resulted in a green (405 nm), punctate pattern (ii) Incubation with 
LysoTracker® Deep Red (Lyso) resulted in a typical, punctate pattern of red (690 
nm) fluorescence (iii) Co-incubation of the SW480 cell line with both 
[Zn(DpC)2](Cl2O4) (green) and Lyso (red) resulted in a yellow, punctate pattern of 
fluorescence on merge (iv) The co-localisation of [Zn(DpC)2](Cl2O4) and Lyso was 
confirmed by the strong Pearson’s correlation coefficient of R = 0.84. The images 
are typical from 3 experiments. Scale bar: 10 μm. 
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In these studies, lysosomal integrity was assessed by fluorescence microscopy 
using the classical lysosomal marker, AO (Gutierrez et al., 2014; Jansson et al., 
2010a; Lovejoy et al., 2011; Nicolini et al., 1979; Pierzynska-Mach et al., 2014), in 
KBV1, KB31 and SW480 cells (Fig. 4.17). Notably, AO, is well known to accumulate 
in intact lysosomes to result in red punctate fluorescence, but exhibits an increase in 
green fluorescence upon redistribution to the cytosol or nucleus after LMP (Gutierrez 
et al., 2014; Lovejoy et al., 2011; Nicolini et al., 1979; Nilsson et al., 1997; 
Pierzynska-Mach et al., 2014). 
 
In KBV1 (+Pgp), KB31 (-Pgp) and SW480 cells, the classical punctuate pattern of 
orange/red AO-stained lysosomes (Gutierrez et al., 2014; Jansson et al., 2015b; 
Lovejoy et al., 2011; Nicolini et al., 1979; Pierzynska-Mach et al., 2014) was 
observed following 1 h/37oC incubation with Dp44mT, Ap44mT and DpC (Fig. 4.17). 
However, using this very brief incubation with the ligand, the cells did not show a 
decrease in orange/red AO staining compared to the controls, indicating that 
lysosomal membrane integrity was intact and LMP had not occurred (Fig. 4.17). This 
has been shown previously for Dp44mT, where incubations of up to 24 h were 
required to demonstrate lysosomal permeabilisation (Lovejoy et al., 2011) and 
indicates a marked kinetic delay. In contrast, following incubation with [Zn(Dp44mT-
H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2, the red AO stain dissipated in all cell-
types, suggesting that lysosomal membrane integrity was compromised and LMP 
had occurred (Fig. 4.17). Clearly, relative to the ligand alone, the Zn(II) complex 
appears more facile in terms of inducing lysosomal rupture.  
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This may be explained by the increased lipophilicity of the Zn(II) complexes 
(Richardson et al., 2006), which facilitates their passage across the cellular and 
lysosomal membranes, relative to the ligands alone, leading to enhanced uptake, 
cytotoxicity (Fig. 4.7) and ability to induce LMP (Fig. 4.17).At the shorter time point 
utilised in this AO study (1 h) versus the longer incubation period used in MTT 
assays (24 h) in Fig. 4.7, only [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and 
[Zn(DpC)2](ClO4)2 mediated a decrease in orange/red AO intensity (Fig. 4.17). 
Indeed, these Zn(II) complexes were generally more cytotoxic than their respective 
ligands (Fig. 4.7). Hence, these results suggested that the increased cytotoxicity of 
the Zn(II) complexes may be due to their ability to decrease the integrity of lysosomal 
membranes (Fig. 4.17). 
 
 
4.3.10 [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 Can 
Transmetallate with Copper Ions to Generate Redox-Active Cu(II) 
Complexes 
The redox activity of the Cu(II) complexes of Dp44mT, Ap44mT and DpC has been 
demonstrated to be highly important for their mechanism of action as anti-tumour 
agents (Jansson et al., 2010a; Lovejoy et al., 2011). In agreement with the Irving-
Williams series (Irving and Williams, 1953), Dp44mT has a preference for binding 
Cu(II) over Zn(II) (Gaal et al., 2014). Furthermore, it has been demonstrated that 
Zn(II)bis(thiosemicarbazone) complexes can transmetallate with copper ions (Pascu 
et al., 2007).  
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Figure 4.17 [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4) induce 
LMP 
In KBV1, KB31 and SW480 cells, [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2], and 
[Zn(DpC)2](ClO4)2 appear to cause LMP, as demonstrated by the loss of the typical, 
red, punctate pattern of AO staining seen in control cells. The images are typical 
from 3 experiments. Scale bar: 10 μm. 
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Considering that the 1:2 (Zn(II)/ligand) zinc complex of Dp44mT is not redox-active 
(Berg and Shi, 1996; Bernhardt et al., 2009), yet the Zn(II) complexes exhibit 
enhanced cytotoxicity (Fig. 4.7) and lysosomal damage (Fig. 4.17) relative to the 
ligands alone, we next investigated whether the cytotoxicity of the Zn(II) complexes 
could be due to transmetallation involving exchange of Zn(II) for Cu(II). 
 
4.3.10 [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 Can 
Transmetallate with Copper Ions to Generate Redox-Active Cu(II) 
Complexes 
The redox activity of the Cu(II) complexes of Dp44mT, Ap44mT and DpC has been 
demonstrated to be highly important for their mechanism of action as anti-tumour 
agents (Jansson et al., 2010a; Lovejoy et al., 2011). In agreement with the Irving-
Williams series (Irving and Williams, 1953), Dp44mT has a preference for binding 
Cu(II) over Zn(II) (Gaal et al., 2014). Furthermore, it has been demonstrated that 
Zn(II)bis(thiosemicarbazone) complexes can transmetallate with copper ions (Pascu 
et al., 2007). Considering that the 1:2 (Zn(II)/ligand) zinc complex of Dp44mT is not 
redox-active (Berg and Shi, 1996; Bernhardt et al., 2009), yet the Zn(II) complexes 
exhibit enhanced cytotoxicity (Fig. 4.7) and lysosomal damage (Fig. 4.17) relative to 
the ligands alone, we next investigated whether the cytotoxicity of the Zn(II) 
complexes could be due to transmetallation involving exchange of Zn(II) for Cu(II). In 
these studies, the ability of the agents to mediate ROS generation was evaluated via 
the oxidation of the non-fluorescent, redox-sensitive probe, H2DCF, to the highly 
fluorescent product, DCF (Jansson et al., 2010a; Lovejoy et al., 2011; Yuan et al., 
2004). Notably, DCF is a well-characterised redox probe that is commonly used for 
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the measurement of ROS generation (Jansson et al., 2010a; Lovejoy et al., 2011; 
Myhre et al., 2003) .  
 
The oxidation of H2DCF to DCF was assessed in a cell-free system at both cytosolic 
pH 7.4 and lysosomal pH 5, as in previous studies (Fig. 4.18) (Jansson et al., 2010a; 
Lovejoy et al., 2011). At both cytosolic or lysosomal pH, CuCl2, Zn(ClO4)2 or the well 
characterised copper ion chelator, TM (Lovejoy et al., 2011; Stefani et al., 2015), did 
not generate DCF fluorescence, indicating that they were not redox-active (Fig. 
4.18). Similarly, Dp44mT alone did not result in an increase in DCF fluorescence and 
was not redox-active, which was in agreement with previous results (Fig. 4.18) 
(Lovejoy et al., 2011). As expected (Bernhardt et al., 2009), [Zn(Dp44mT-H)2] did not 
cause a significant (p > 0.05) increase in DCF fluorescence compared to the controls 
(Fig. 4.18).  
 
However, in accordance with previously published results (Lovejoy et al., 2011), 
[Cu(Dp44mT)] was highly redox-active resulting in a significant (p < 0.001) increase 
in DCF fluorescence relative to Dp44mT or [Zn(Dp44mT-H)2] (Fig. 4.18). 
Interestingly, the addition of Cu(II) to [Zn(Dp44mT-H)2] also resulted in significantly 
(p < 0.001) greater DCF fluorescence relative to Dp44mT or [Zn(Dp44mT-H)2] (Fig. 
4.18). This redox activity was abrogated by the addition of the Cu(II) chelator, TM, to 
[Zn(Dp44mT-H)2]+Cu(II), which caused a significant (p < 0.001) decrease in DCF 
fluorescence compared to [Cu(Dp44mT)] or [Zn(Dp44mT-H)2] + Cu(II) (Fig. 4.18).  
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These data suggest that although [Zn(Dp44mT-H)2] itself was not redox-active, in the 
presence of copper ions, transmetallation can occur, resulting in a redox-active 
[Cu(Dp44mT)] complex that can mediate the oxidation of H2DCF to DCF (Fig. 4.18). 
Similarly, [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4) followed the same trend as 
[Zn(Dp44mT-H)2], where the Zn(II) complexes did not generate DCF fluorescence, 
but in the presence of Cu(II), exhibited a significant (p < 0.001) increase in DCF 
fluorescence relative to the Zn(II) complexes alone (Fig. 4.18). The increased DCF 
fluorescence of [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4) in the presence of Cu(II) 
could also be negated upon addition of the copper ion chelator, TM (Fig. 4.18).  
 
These data again suggested that transmetallation may occur at both cytosolic or 
lysosomal pH, whereby [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4) exchange Zn(II) for 
Cu(II) and form redox-active Cu(II) complexes that can mediate the oxidation of 
H2DCF (Fig. 4.18)These results may explain the effect of [Zn(Dp44mT-H)2], 
[Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 on lysosomal membrane integrity (Fig. 
4.17), as it has been previously demonstrated that Dp44mT and DpC can form 
redox-active Cu(II) complexes which are sequestered in lysosomes (Jansson et al., 
2010a; Lovejoy et al., 2011; Seebacher et al., 2016a). The redox activity of these 
Cu(II) complexes results in the formation of ROS, which induce LMP and lead to cell 
death (Jansson et al., 2010a; Lovejoy et al., 2011; Seebacher et al., 2016a). This is 
a key mechanism by which these agents exert their cytotoxic effects, and could 
account for the cytotoxicity and LMP observed in the presence of the Zn(II) 
complexes (Fig. 4.7,4.17). The ability of the Zn(II) complexes to undergo 
transmetallation with copper ions and mediate the oxidation of H2DCF at lysosomal 
pH 5 (Fig. 4.18) is important, as [Zn(DpC)2](ClO4)2 is localised to lysosomes. This 
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finding suggests that transmetallation with copper ions and subsequent redox cycling 
could explain the LMP observed in Figure 4.17. 
 
4.3.11 Lysosomal Membrane Permeabilisation Mediated by 
[Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 is 
Dependent on Copper Ions  
Previous results have demonstrated that the redox activity of [Cu(Dp44mT)] and 
[Cu(DpC)] mediates LMP (Jansson et al., 2015a; Lovejoy et al., 2011; Seebacher et 
al., 2016a). The transmetallation of [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and 
[Zn(DpC)2](ClO4)2 with copper ions to generate redox-active Cu(II) complexes at 
both cytosolic (pH 7.4) and lysosomal pH (pH 5; Fig. 4.18), may explain their ability 
to mediate LMP (Fig. 4.17). Furthermore, it is unlikely that LMP occurs due to 
transmetallation of Zn(II) with Fe(III), as we previously demonstrated that the Fe(III)-
Dp44mT complex does not induce LMP (Lovejoy et al., 2011). To investigate 
whether copper ion transmetallation was required to induce LMP by [Zn(Dp44mT-
H)2], [Zn(Ap44mT-H)2 ] and [Zn(DpC)2](ClO4)2, we examined lysosomal rupture in the 
presence and absence of the non-cytotoxic Cu(II) chelator, TM. TM has been shown 
to prevent LMP-mediated by the Cu(II) complexes of Dp44mT and 
bis(thiosemicarbazones) by sequestering copper ions (Lovejoy et al., 2011; Stefani 
et al., 2015).  
 
Using the lysosomal integrity stain, AO (Gutierrez et al., 2014; Lovejoy et al., 2011; 
Nicolini et al., 1979; Pierzynska-Mach et al., 2014; Stefani et al., 2015), we assessed 
lysosomal membrane integrity in the KBV1, KB31 and SW480 cell-types. 
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Figure 4.18. The redox activity of [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and 
[Zn(DpC)2](ClO4)2 is dependent on transmetallation with copper ions.  
At cytosolic pH (pH 7.4) and cytosolic pH (pH 5.0), Dp44mT, Ap44mT and DpC and 
their respective 1:2 (Zn(II)/ligand) zinc complexes show minimal redox activity. 
However, the Cu(II) complexes and the Zn(II) complexes + Cu(II) show significantly 
(p < 0.001) greater redox activity than their respective thiosemicarbazones or Zn(II) 
complex counterparts alone. The addition of the Cu(II) chelator, TM, to the Zn(II) 
complexes + Cu(II) reaction mixture, resulted in significantly (p < 0.001) decreased 
redox activity comparable to Zn(II) complexes + copper ions. Results are mean ± SD 
(3 experiments). *** p < 0.001. 
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 [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 mediated apparent 
lysosomal membrane disruption, shown by the absence of the red, punctate pattern 
of AO staining, over a 1 h/37oC incubation (Fig. 4.19). However, the LMP mediated 
by [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 was abrogated in the 
presence of the copper ion chelator, TM in all cell-types, as the punctate pattern of 
red AO staining was comparable to control cells (Fig. 4.19). Of note, TM itself did not 
significantly (p > 0.05) affect lysosomal membrane integrity (data not shown), which 
is consistent with the low cytotoxicity of this copper ion chelator.(Lovejoy et al., 2011; 
Stefani et al., 2015)  
 
These results revealed that copper ions are involved in the induction of LMP 
observed following treatment with [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and 
[Zn(DpC)2](ClO4)2 (Fig. 4.19). This is likely due to transmetallation with copper ions 
within the lysosomes (where [Zn(DpC)2](ClO4)2 is sequestered; Fig. 4.14, 4.15, 4.16), 
which are known to have relatively high concentrations of copper ions, derived from 
autophagy of copper-containing proteins (Gupte and Mumper, 2009; Kurz et al., 
2010; Terman and Kurz, 2013). In fact, we have demonstrated that it is possible for 
[Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 to form redox-active 
Cu(II) complexes under lysosomal conditions (Fig. 4.18).  
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Figure 4.19. LMP mediated by [Zn(Dp44mT-H2)], [Zn(Ap44mT-H)2] and 
[Zn(DpC)2](ClO4)2 is dependent on copper ions.  
Incubation of KBV1, KB31 and SW480 cells with [Zn(Dp44mT-H2)], [Zn(Ap44mT-H)2] 
and [Zn(DpC)2](ClO4)2 results in the loss of red, punctate staining that is indicative of 
intact lysosomes in control cells. However, co-incubation with [Zn(Dp44mT-H2)], 
[Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 and the copper ion chelator, TM, prevents 
the loss of lysosomal membrane integrity observed with the Zn(II) complexes alone 
as the cells contain comparable amounts of red, AO-stained lysosomes as the 
control cells. The images are typical from 3 experiments. Scale bar: 10 μm. 
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4.3.12 Involvement of Copper Ions in the Cytotoxicity of 
[Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2  
Previous studies have shown that the binding of copper ions by TM can markedly 
inhibit the cytotoxicity of Cu(II)-Dp44mT and other Cu(II)-thiosemicarbazone 
complexes (Lovejoy et al., 2011; Stefani et al., 2015). As the Zn(II) complexes were 
demonstrated to transmetallate to form redox-active Cu(II) complexes (Fig. 4.18), 
MTT assays were conducted in order to assess the effect of copper ions on the 
cytotoxicity of the Zn(II) complexes (Lovejoy et al., 2011; Stefani et al., 2015).  
 
These MTT assays were carried out in the presence or absence of the non-toxic 
copper ion chelator, TM (Lovejoy et al., 2012; Stefani et al., 2015), in the KBV1, 
KB31 and SW480 cell-types. In the KBV1 cells, the addition of TM to [Zn(Dp44mT-
H)2] caused a significant (p < 0.01), 2.1-fold increase in the IC50 relative to 
[Zn(Dp44mT-H)2] (Fig. 4.20). TM also significantly (p < 0.05) decreased the 
cytotoxicity of [Zn(Ap44mT-H)2] by 3.8-fold (Fig. 4.20). Similarly, the addition of TM 
to [Zn(DpC)2](ClO4)2, significantly (p < 0.001) increased the IC50 of [Zn(DpC)2](ClO4)2 
by 44-fold (Fig. 4.20).  
 
The results in the KB31 and SW480 cell-types followed a similar trend as in the 
KBV1 cell-type. In the KB31 cells, TM caused a significant (p < 0.001), 2.5-fold 
increase in the IC50 of [Zn(Dp44mT-H)2] (Fig. 4.20). However, in the SW480 cells, 
the IC50 of [Zn(Dp44mT-H)2] was not significantly (p > 0.05) affected by the addition 
of TM (Fig. 4.20).  
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The IC50 values of [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 in both KB31 and SW480 
cells were significantly (p < 0.001-0.01) increased by TM between 3.4- to 6.8-fold 
(Fig. 4.20). These results demonstrated that the cytotoxicity of the Zn(II) complexes 
involved transmetallation with copper ions, as the copper ion chelator TM decreased 
the cytotoxicity of the Zn(II) complexes. This cytotoxicity was a result of lysosomal 
membrane disruption (Figs. 4.17, 4.19), caused by transmetallation and formation of 
ROS-generating Cu(II) complexes within lysosomes (Fig. 4.18). Indeed, it has been 
demonstrated previously that the Cu(II) complexes of Dp44mT and DpC (Jansson et 
al., 2015b; Lovejoy et al., 2011; Seebacher et al., 2016a) cause LMP via redox 
cycling within lysosomes. 
 
4.4 Conclusions 
For over a decade, the in vitro and in vivo anti-cancer activity of a range of 
thiosemicarbazone ligands derived from ApT, DpT and BpT series has been 
explored (Gutierrez et al., 2014; Jansson et al., 2010a; Jansson et al., 2015a; 
Jansson et al., 2015b; Kalinowski et al., 2007; Kovacevic et al., 2011; Lovejoy and 
Richardson, 2002; Lovejoy et al., 2012; Richardson et al., 2006; Richardson et al., 
2009). In spite of potent activity as Fe(III) and Cu(II) chelators, their intracellular 
localisation has been poorly understood. However, it appeared from indirect 
evidence that Dp44mT and DpC could be sequestered in lysosomes, where they 
could form redox-active Cu(II) complexes to induce LMP (Gutierrez et al., 2014; 
Jansson et al., 2010a; Jansson et al., 2015b; Lovejoy et al., 2011). 
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Figure 4.20 Copper ion chelation decreases the cytotoxicity of Zn(Dp44mT-
H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2.  
In the KBV1, KB31 and SW480 cell-types, 24 h/37°C incubation of cells with 
[Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 in the presence of the 
copper ion chelator, TM, resulted in significantly higher (p < 0.01) IC50 values relative 
to [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 alone. Results are 
mean ± SD (3 experiments). *p < 0.05; ** p < 0.01; *** p < 0.001. 
 
 
Precise determination of the subcellular distribution of the ligands, Dp44mT, Ap44mT 
and DpC, were limited by the lack of inherent fluorescence exhibited by the 
thiosemicarbazones. In order to circumvent this limitation, we have designed and 
synthesised a series of Zn(II)-thiosemicarbazone complexes of our lead compounds, 
Dp44mT and DpC. Further, we have also prepared Zn(II)-thiosemicarbazone 
complexes of Ap44mT, which was added as a structurally different 
thiosemicarbazone to enable elucidation of structure-activity relationships.  
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Previous studies have highlighted the application of Zn(II) mono- and 
bis(thiosemicarbazones) for intracellular imaging by utilising the intrinsic 
fluorescence of Zn(II) (Cowley et al., 2005; Dayal et al., 2011; Lim et al., 2010; 
Pascu et al., 2007; Pascu et al., 2008). We sought to take advantage of this useful 
property to examine the localisation of our Zn(II) complexes in different cancer cell-
types, which could provide information regarding mechanism(s) of action. 
 
Our studies demonstrated the ability of Dp44mT, Ap44mT and DpC to form both 1:1 
and 1:2 (Zn(II)/ligand) zinc complexes with distorted square pyramidal or octahedral 
geometry, respectively (Fig. 4.2). Interestingly, Zn(II)/ligand binding studies 
demonstrated the preference for the formation of 1:1 and 1:2 (Zn(II)/ligand) zinc 
complexes in DMSO and in aqueous solution (MOPS; pH: 7.4), respectively (Fig. 
4.4, 4.5, 4.6). Moreover, our fluorescence studies of the Zn(II) complexes in DMSO 
characterised their energy emission profile, which were utilised further for 
fluorescence-based cellular imaging experiments (Fig. 4.3).  
 
Proliferation assays evaluating the cytotoxicity of the 1:1 and 1:2 (Zn(II)/ligand) zinc 
complexes demonstrated that, in general, the majority of Zn(II) complexes were 
more cytotoxic than their corresponding free ligands in KBV1, KB31 and SW480 
cells (Fig. 4.7). Furthermore, the 1:1 and 1:2 (Zn(II)/ligand) complexes of Dp44mT 
and DpC were more cytotoxic in Pgp-expressing KBV1 cells relative to KB31 and 
SW480 cells that have low levels of Pgp expression (Jansson et al., 2015b; Miklos et 
al., 2015; Montazami et al., 2015; Seebacher et al., 2016a; Seebacher et al., 2015; 
Yamagishi et al., 2013) (Fig. 4.7). On the other hand, the cytotoxicity of the 1:1 and 
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1:2 (Zn(II)/ligand) complexes of Ap44mT were similar between all three cell-types, 
suggesting that Pgp expression did not affect its activity (Fig. 4.7). In terms of 
structure-activity relationships, the replacement of the non-coordinating pyridine ring 
of Dp44mT and DpC with the methyl substituent present in Ap44mT leads to the loss 
of Pgp-potentiated cytotoxicity and highlights the importance of the di-2-pyridyl 
pharmacophore in overcoming Pgp-dependent resistance. Previous reports have 
demonstrated that Dp44mT and DpC exhibit potentiated cytotoxicity in Pgp-
expressing cells (Jansson et al., 2015b; Seebacher et al., 2016a; Whitnall et al., 
2006) and the current data support these results (Fig. 4.7). 
 
Previous imaging studies involving Zn(II) thiosemicarbazone complexes 
demonstrated that the distribution of Zn(II)bis(thiosemicarbazones) varies depending 
on the cancer cell-type used (Cowley et al., 2005; Pascu et al., 2008). We therefore 
used three cell-types (i.e., KBV1, KB31 and SW480) to assess the localisation of our 
Zn(II) complexes. We assessed co-localisation with the nucleus (Fig. 4.8, 4.9, 4.10), 
mitochondria (Fig. 4.11, 4.12, 4.13) and lysosomes (Fig. 4.14, 4.15, 4.16), as similar 
Zn(II) thiosemicarbazone complexes have been reported to localise to these 
organelles (Cowley et al., 2005; Dayal et al., 2011; Kowol et al., 2010; Pascu et al., 
2008; Pascu et al., 2010). Our cell-based experiments utilised the 1:2 (Zn(II)/ligand) 
zinc complexes as binding studies demonstrated that this was the major species to 
form in aqueous solution (Fig. 4.4, 4.5, 4.6). In particular, we examined 
[Zn(DpC)2](ClO4)2, which exhibited good intracellular fluorescence and was also of 
special interest as DpC will enter clinical trials in 2016 (ClinicalTrials.gov Identifier 
NCT02688101) (Jansson et al., 2015a). The results of our co-localisation studies 
revealed that [Zn(DpC)2](ClO4)2 was localised to lysosomes in all three cell-types 
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(Fig. 4.14, 4.15, 4.16), rather than the nucleus (Fig. 4.8, 4.9, 4.10), or mitochondrion 
(4.11, 4.12, 4.13). 
Further mechanistic studies illustrated the role of intracellular copper ions on the 
cytotoxicity of the Zn(II) complexes. While the Zn(II) complexes were not redox-
active, as Zn(II) is unable to redox cycle (Berg and Shi, 1996), the addition of Cu(II) 
to the Zn(II) complexes caused a significant increase in DCF fluorescence (Fig. 
4.18). This increase in DCF fluorescence could be abrogated by the addition of the 
non-toxic copper ion chelator, TM, which suggested that the Zn(II) complexes could 
transmetallate with copper ions and form redox-active Cu(II) complexes (Fig. 4.18). 
Furthermore, TM could also reverse the LMP (Fig. 4.19) and cytotoxicity (Fig. 4.20) 
induced by the Zn(II) complexes. These studies with TM suggested that 
transmetallation with copper ions was integral to the anti-cancer activity observed 
with the Zn(II) complexes. 
 
Collectively, the results presented herein demonstrated that the mechanism of action 
of our Zn(II) complexes involved: (1) sequestration within lysosomes; (2) 
transmetallation with the intra-lysosomal copper ions (Gupte and Mumper, 2009; 
Kurz et al., 2010; Terman and Kurz, 2013) which produced redox-active complexes; 
and (3) induction of LMP-mediated cytotoxicity by ROS (Fig. 21).  
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Figure 4.21. Schematic illustrating the mechanism of action of Zn(II)-
thiosemicarbazone complexes.  
The mechanism of the Zn(II) complexes involves uptake into the cell followed by 
sequestration within lysosomes. The Zn(II) complexes transmetallate with copper 
ions present in the lysosomes to form redox-active complexes. The redox cycling of 
these newly formed Cu(II) complexes generates ROS, which causes LMP-mediated 
cytotoxicity. 
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Chapter 5 - DpC, but not Dp44mT, Overcomes 
Bcl-2-Mediated Multidrug Resistance in 
Melanoma 
 
 
5.1 Introduction 
The Bcl-2 family of proteins act as master regulators of the intrinsic pathway of 
apoptosis (Cory and Adams, 2002; Czabotar et al., 2014; Youle and Strasser, 2008). 
The family consists of three classes of proteins: (1) Bcl-2 homology 3 (BH3)-only 
proteins (“Initiators”) that exert pro-apoptotic effects; (2) multi-domain anti-apoptotic 
(“Guardians”), which include Bcl-2 (Tsujimoto et al., 1985); and (3) multi-domain pro-
apoptotic (“Effectors”), which includes Bcl-2-associated X protein (Bax) (Oltvai et al., 
1993). An interplay between the pro-apoptotic and anti-apoptotic Bcl-2 family members 
regulates the release of cytochrome c from the mitochondria, and subsequent activation 
of the effector caspases that induce apoptosis (Cory and Adams, 2002; Czabotar et al., 
2014; Danial, 2007). In addition to their role in regulating apoptosis, Bcl-2 family 
members have been found to regulate autophagy (Chang et al., 2010; Kihara et al., 
2001; Pattingre et al., 2005). A key protein involved in autophagy initiation, Beclin 1, is 
in fact a novel BH3-only protein that is inhibited by Bcl-2 (Chang et al., 2010; Kihara et 
al., 2001; Pattingre et al., 2005). 
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Dysregulated expression of the Bcl-2 family members is an underlying cause or 
contributor in many different types of cancer, as impairment of apoptosis is fundamental 
to carcinogenesis (Thomas et al., 2013). Over-expression of Bcl-2 occurs in a diverse 
range of cancers (Bincoletto et al., 1999; Gazzaniga et al., 1996; Hermine et al., 1996; 
Jiang et al., 1995; Joensuu et al., 1994; McDonnell et al., 1992; Sinicrope et al., 1995; 
Tothova et al., 2002; Weiss et al., 1987; Weller et al., 1995); including metastatic 
melanoma (Grover and Wilson, 1996), which is resistant to all standard chemotherapies 
(Soengas and Lowe, 2003). In many of these cancers, including melanoma, Bcl-2 has 
been linked to severity of malignancy, poor clinical response and poor prognosis 
(Bincoletto et al., 1999; Grover and Wilson, 1996; Hermine et al., 1996; Joensuu et al., 
1994; McDonnell et al., 1992; Tothova et al., 2002). Indeed, the Bcl-2 antisense 
oligonucleotide, oblimersen, was clinically trialled in advanced melanoma (Bedikian et 
al., 2006; Bedikian et al., 2014). 
 
Bcl-2 exerts its anti-apoptotic function by binding to the pro-apoptotic family members, 
Bax and Bak, which prevents them from causing mitochondrial outer membrane 
permeabilisation (Certo et al., 2006). Over-expression of Bcl-2 allows cancer cells to 
“ignore” apoptotic signals generated in response to chemotherapeutics, in the form of 
increased levels and activation of pro-apoptotic Bcl-2 family members (Amundson et al., 
2000; Dole et al., 1994; Miyashita and Reed, 1993; Schmitt et al., 2000; Shibata et al., 
1999; Strasser et al., 1993; Thomas et al., 1996; Vaux et al., 1988; Wang et al., 2013). 
Bcl-2 over-expression has consequently been found to contribute to MDR (Amundson et 
al., 2000; Dole et al., 1994; Miyashita and Reed, 1993; Schmitt et al., 2000; Shibata et 
  181 
al., 1999; Strasser et al., 1993; Thomas et al., 1996; Vaux et al., 1988; Wang et al., 
2013), making it an important drug target (Thomas et al., 2013). Indeed, inhibiting Bcl-2 
sensitises cells to standard chemotherapies in MDR cancers, such as melanoma 
(Nemati et al., 2014; Raisova et al., 2001; Watanabe et al., 2013; Wroblewski et al., 
2013). This has resulted in the development of several promising small molecule 
inhibitors of Bcl-2, such as ABT-199 (venetoclax), that have progressed to clinical trials 
(Roberts et al., 2016; Stilgenbauer et al., 2016). 
 
Over the last 20 years, our laboratory has developed a range of novel anti-cancer 
agents (Baker et al., 1992; Becker et al., 2003; Darnell and Richardson, 1999; 
Richardson et al., 1995; Richardson and Milnes, 1997). Extensive structure-activity 
relationship studies led to the development of the DpT series, designed by incorporating 
the di-2-pyridylketone moiety into a structural backbone derived from aroylhydrazones 
(Becker et al., 2003; Bernhardt et al., 2003; Richardson et al., 2006; Yuan et al., 2004). 
The DpT analogues exhibit potent anti-tumour activity and anti-metastatic activity both 
in vitro and in vivo (Chen et al., 2012; Liu et al., 2012; Lovejoy et al., 2012; Richardson 
et al., 2006; Whitnall et al., 2006; Yuan et al., 2004). The best-characterised member of 
the DpT analogues, Dp44mT, targets the lysosome, where it redox cycles with copper 
ions (Figs. 3.6, 3.8, 3.9, 3.10, 4.17, 4.18, 4.19) (Gutierrez et al., 2014; Jansson et al., 
2015b; Lovejoy et al., 2011). The redox activity of the [Cu(Dp44mT)] complex produces 
ROS that induce LMP and apoptosis (Figs. 3.4, 3.6, 3.8, 3.9, 3.10, 4.17, 4.18, 4.19) 
(Gutierrez et al., 2014; Jansson et al., 2015b; Lovejoy et al., 2011). Dp44mT also 
affects the expression of Bcl-2 family members by increasing the ratio of pro-apoptotic 
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Bax to anti-apoptotic Bcl-2, causing the release of holocytochrome c from the 
mitochondria (Gutierrez et al., 2014; Yuan et al., 2004). Dp44mT is notable for the 
multiple ways in which it is able to “hijack” mechanisms of cellular resistance, namely, 
the Pgp drug efflux transporter and the autophagy pathway, to target lysosomes and 
induce apoptosis (Gutierrez et al., 2014; Jansson et al., 2015b; Seebacher et al., 2016a; 
Whitnall et al., 2006). 
 
Unfortunately, high, non-optimal doses of Dp44mT induced cardiac fibrosis (Whitnall et 
al., 2006), which led to the design and synthesis of the second generation of DpT 
analogues, in which the terminal H at N4 was replaced with an alkyl group. This group 
showed particular promise, and of these ligands, DpC was identified as the lead agent 
(Kovacevic et al., 2011; Lovejoy and Richardson, 2002; Lovejoy et al., 2012). 
Favourable properties such as greater anti-tumour activity in vivo (Kovacevic et al., 
2011; Lovejoy et al., 2012), and markedly improved tolerability (Lovejoy et al., 2012; 
Quach et al., 2012; Yu et al., 2012) compared to Dp44mT, resulted in DpC being 
commercialised. DpC has entered clinical trials in 2016 (ClinicalTrials.gov Identifier 
NCT02688101) for the treatment of advanced and resistant cancers (Jansson et al., 
2015a). 
 
Herein, we examined for the first time the effects of Dp44mT and DpC in cells over-
expressing Bcl-2. Interestingly, we demonstrated that DpC decreased Bcl-2 expression, 
while Dp44mT did not. Moreover, silencing of Bcl-2 only affected the cytotoxicity of 
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Dp44mT, but not DpC. Furthermore, we showed that the mechanism by which DpC and 
Dp44mT exerted their cytotoxicity in melanoma cells did not involve copper ion binding 
or ROS generation, which are characteristics that thiosemicarbazones must possess in 
order to cause LMP.  
 
This latter effect was starkly different in melanoma cells compared to other neoplastic 
cell types (Gutierrez et al., 2014; Jansson et al., 2010b; Jansson et al., 2015b; Lovejoy 
et al., 2011; Seebacher et al., 2016a), indicating a remarkably different mechanism. In 
fact, DpC induced autophagosome formation and increased the accumulation of acidic 
vesicles (e.g., autolysosomes), regardless of Bcl-2 expression. Dp44mT, on the other 
hand, did not increase the formation of autophagosomes in Bcl-2 expressing cells, and 
only increased the number of acidic vesicles in the absence of Bcl-2 expression. We 
propose the mechanism by which DpC is able to overcome Bcl-2-mediated resistance 
involves decreasing the expression of Bcl-2, which increases autophagosome formation 
and the accumulation of autolysosome-like acidic vesicles.  
 
 
5.3 Results and Discussion 
5.3.1 DpC, but Not Dp44mT, Overcomes Bcl-2-mediated MDR 
Targeting Bcl-2 expression is of interest as over-expression of Bcl-2 confers MDR by 
allowing cells to ignore cytotoxic stimuli and evade apoptosis (Amundson et al., 2000; 
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Dole et al., 1994; Miyashita and Reed, 1993; Schmitt et al., 2000; Shibata et al., 1999; 
Strasser et al., 1993; Thomas et al., 1996; Vaux et al., 1988; Wang et al., 2013). This is 
significant in a wide range of cancers, including melanoma (Grover and Wilson, 1996), 
where Bcl-2 is commonly up-regulated (Bincoletto et al., 1999; Gazzaniga et al., 1996; 
Hermine et al., 1996; Jiang et al., 1995; Joensuu et al., 1994; McDonnell et al., 1992; 
Sinicrope et al., 1995; Tothova et al., 2002; Weller et al., 1995). High Bcl-2 expression 
enables cancer cells to survive exposure to chemotherapy, thus contributing to MDR 
(Skommer et al., 2006; Wang et al., 2013; Wu et al., 2015). It has been demonstrated 
that Dp44mT causes an increase in the Bax:Bcl-2 ratio, suggesting that Dp44mT may 
act, at least in part, by regulating the ratio of pro- and anti-apoptotic Bcl-2 family 
members (Gutierrez et al., 2014; Yuan et al., 2004). Furthermore, Dp44mT induces the 
release of holocytochrome c from mitochondria and activates caspases, due to the 
increase in the Bax:Bcl-2 ratio (Yuan et al., 2004). However, the effect of Bcl-2 
expression on the cytotoxicity of Dp44mT or DpC has not previously been examined.  
 
Notably, Dp44mT and DpC are able to overcome Pgp-mediated MDR (Jansson et al., 
2015a; Seebacher et al., 2016a) (Figs. 3.4, 3.6, 3.8). Therefore, it is of interest to 
examine whether Dp44mT or DpC are also able to overcome Bcl-2-mediated MDR. We 
investigated this using the M14 melanoma cell line (Chambers, 2009; Rae et al., 2007), 
as melanoma is known to be prone to Bcl-2-mediated MDR, and there is a pressing 
need for new therapies (Grover and Wilson, 1996; Soengas and Lowe, 2003). 
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M14 Bcl-2 (Bcl-2 over-expressing) and M14 PC (control) cells were incubated with 
Dp44mT or DpC for 24 h/37°C. Dp44mT was 1.5-fold less (p < 0.001) cytotoxic in M14 
Bcl-2 cells than in M14 PC cells, demonstrating a 20 mM difference in IC50 values 
between the cell lines (Fig. 5.1). In contrast, there was no significant difference (p > 
0.05) in cytotoxicity mediated by DpC between the M14 Bcl-2 and M14 PC cell lines 
(Fig. 5.1).  
 
The results from Figure 5.1 suggested that DpC, but not Dp44mT, was capable of 
overcoming Bcl-2-mediated MDR. That is, Bcl-2 provided a survival advantage against 
Dp44mT-mediated cell killing, but not DpC-mediated cell killing. Regardless of whether 
cells expressed Bcl-2, the IC50 value of DpC did not change. However, in cells that 
expressed Bcl-2 (M14 Bcl-2), Dp44mT was significantly less cytotoxic than in cells that 
did not express Bcl-2 (M14 PC). This is an interesting result, as targeting Bcl-2 has long 
been investigated as a method of improving the efficacy of cancer treatments (Czabotar 
et al., 2014; Lessene et al., 2008; Thomas et al., 1996). Unlike overcoming Pgp-
mediated MDR, in which DpC and Dp44mT act in a similar manner, these agents differ 
in their mechanism to overcoming Bcl-2 MDR, at least in M14 melanoma cells (Figs. 
3.4, 3.6, 3.8). These results warranted further investigation in order to determine the 
mechanism by which DpC overcame Bcl-2-mediated MDR.  
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 Figure 5.1 DpC, but not Dp44mT, overcomes Bcl-2-mediated drug resistance.  
The cytotoxicity of Dp44mT was significantly (p < 0.001) less in M14 Bcl-2 over-
expressing cells than in M14 PC (control) cells following a 24 h/37°C incubation. Bcl-2 
expression did not affect the cytotoxicity of DpC. Inset Western blot of Bcl-2 expression 
in M14 bcl-2 and M14 PC cells. Results are mean ± SD (3 experiments). *** p < 0.001 
 
 
5.3.2 DpC Decreases the Expression of Bcl-2, Relative to Dp44mT and 
Control 
Dp44mT has been reported to cause an increase in the ratio of pro-apoptotic Bax to 
anti-apoptotic Bcl-2 (Gutierrez et al., 2014; Yuan et al., 2004). This indicates that 
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Dp44mT increases the sensitivity of cells to apoptosis (Raisova et al., 2001), and 
suggests that Dp44mT may regulate Bcl-2 family members (Gutierrez et al., 2014; Yuan 
et al., 2004). Herein, we have shown that DpC, but not Dp44mT, is capable of 
overcoming Bcl-2-mediated MDR in the M14 cell lines, M14 Bcl-2 and M14 PC (Fig. 
5.1). Therefore, we assessed the effects of Dp44mT and DpC on Bcl-2 protein 
expression via Western blotting in the Bcl-2 over-expressing M14 Bcl-2 cell line. 
 
A 24 h/37°C incubation with Dp44mT (30 mM) induced a non-significant (p > 0.05) 15% 
decrease in Bcl-2 expression, relative to control (Fig. 5.2A,B). Interestingly, a similar 
incubation with DpC (30 mM) resulted in a statistically significant (p < 0.01) 57% 
decrease in Bcl-2 expression, relative to control (Fig. 5.2A,B). Furthermore, incubation 
with DpC induced a 50% (p < 0.05) decrease in Bcl-2 expression, relative to Dp44mT 
(Fig. 5.2B).  
 
The results in Figure 5.2 show that DpC, but not Dp44mT, significantly (p < 0.01) 
decreased the expression of Bcl-2 in M14 Bcl-2 cells, relative to control. The decrease 
in Bcl-2 expression following treatment with DpC could explain its ability to overcome 
Bcl-2-mediated MDR (Fig. 5.1), as cells could be expected to become more sensitive to 
the apoptotic signals generated by DpC (Raisova et al., 2001). Unlike DpC, Dp44mT did 
not cause a significant (p > 0.05) decrease in Bcl-2 expression (Fig. 5.2A,B). Hence, as 
Dp44mT did not decrease Bcl-2 expression compared to DpC, this could explain why 
Dp44mT was significantly (p < 0.001) less cytotoxic in M14 Bcl-2 cells (i.e., higher IC50) 
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than in M14 PC cells (Fig. 5.1). The effect of Dp44mT on Bcl-2 expression appears to 
be dependent on the cell line used, as Dp44mT did not affect Bcl-2 expression in the 
MCF-7 cell line (Gutierrez et al., 2014), but did decrease Bcl-2 expression in the SK-N-
MC cell line (Yuan et al., 2004). Importantly, these studies highlight the potential of DpC 
to overcome Bcl-2-mediated MDR and treating melanoma. Although some have 
focused on inhibiting Bcl-2 (Lessene et al., 2008; Thomas et al., 2013), DpC instead 
decreases the expression of Bcl-2, similar to the clinically trialled drug, oblimersen 
(Bedikian et al., 2006; Bedikian et al., 2014; O'Brien et al., 2009).  
 
5.3.3 Bcl-2 Silencing Affects the Cytotoxicity of Dp44mT, but not DpC 
Bcl-2 expression is known to cause MDR by preventing apoptosis in response to 
chemotherapy treatment in cancer cells (Amundson et al., 2000; Dole et al., 1994; 
Miyashita and Reed, 1993; Schmitt et al., 2000; Shibata et al., 1999; Strasser et al., 
1993; Thomas et al., 1996; Vaux et al., 1988). Bcl-2 silencing and inhibition has been 
investigated, with some success, as an important drug discovery target (Lessene et al., 
2008; Thomas et al., 2013). DpC induced a significant decrease in Bcl-2 expression (Fig 
5.2), which may account for its ability to overcome Bcl-2-mediated MDR (Fig. 5.1). This 
is in contrast to Dp44mT, which did not reduce Bcl-2 expression (Fig. 5.2), and did not 
overcome Bcl-2-mediated MDR (Fig. 5.1). Given the different effects of DpC and 
Dp44mT on cytotoxicity and Bcl-2 expression (Figs. 5.1, 5.2), it was of interest to 
examine the effects of silencing the BCL2 gene, using siRNA. 
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Figure 5.2 DpC significantly decreases Bcl-2 expression, relative to control or 
Dp44mT.  
(A) M14 Bcl-2 cells were treated with control medium or medium containing Dp44mT 
(30 μM) or DpC (30 μM), and incubated for 24 h/ 37°C. Western blotting was performed 
to determine Bcl-2 expression. DpC, but not Dp44mT, decreased the expression of Bcl-
2. (B) Densitometric analysis (arbitrary units) of (A). DpC significantly decreased Bcl-2 
expression, relative to control (p < 0.01) and Dp44mT (p < 0.05). Blots shown are 
representative of three experiments. Densitometric analysis is the mean of 3 ± S.D. * 
p < 0.05, ** p < 0.01. 
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M14 Bcl-2 cells were incubated with Dp44mT or DpC for 24 h/37°C, following a pre-
incubation with siRNA targeting BCL2 (Fig. 5.3). Silencing of Bcl-2 protein expression 
caused a significant (p < 0.01) decrease in the cytotoxicity of Dp44mT compared to 
control (Fig. 5.3). However, siRNA-mediated Bcl-2 silencing did not significantly (p > 
0.05) affect the cytotoxicity of DpC (Fig. 5.5).  
 
Bcl-2 silencing and inhibition using drugs such as oblimersin or ABT-199, respectively, 
has been shown to increase the clinical efficacy of commonly used chemotherapies 
(Bedikian et al., 2006; Skommer et al., 2006; Tse et al., 2008). Therefore, it is 
unsurprising that Dp44mT, which did not alter Bcl-2 expression (Fig 5.2), became more 
cytotoxic following silencing of Bcl-2 (Fig. 5.3). It could be expected that because DpC 
alone so effectively decreases Bcl-2 expression (Fig. 5.3), Bcl-2 silencing has no effect 
on its cytotoxicity (Fig. 5.3). These results demonstrate that Dp44mT-mediated 
cytotoxicity is more sensitive to Bcl-2 expression than DpC (Figs. 5.1, 5.3), which is 
likely due to the fact that DpC can decrease the expression of Bcl-2 much more 
effectively than Dp44mT (Fig. 5.2). Furthermore, these studies highlight the potential of 
DpC to overcome Bcl-2-mediated MDR, as DpC-mediated cytotoxicity was unaffected 
by Bcl-2 expression (Figs. 5.1, 5.3). 
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Figure 5.5. The cytotoxicity of Dp44mT, but not DpC, is increased by Bcl-2 
silencing.  
(A) The IC50 value of Dp44mT is significantly (p < 0.01) decreased following transfection 
of M14 Bcl-2 cells with BCL2 siRNA for 96 h/ 37°C. The cytotoxicity of DpC was not 
significantly affected by Bcl-2 silencing (p > 0.05). The negative control siRNA did not 
affect the cytotoxicity of Dp44mT or DpC. (B) M14 Bcl-2 cells were transfected with 
BCL2 siRNA or negative control scramble siRNA, and Western blotting performed to 
examine Bcl-2 expression. (C) Densitometric analysis (arbitrary units) of (B). Blots 
shown are representative of three experiments. Densitometric analysis is the mean of 3 
± S.D. ** p < 0.01, *** p < 0.001  
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5.3.4 The Cytotoxicity Mediated by Dp44mT and DpC is Not 
Dependent on Copper Ions 
The importance of Cu(II) binding in the mechanism of Dp44mT (Jansson et al., 2010b; 
Lovejoy et al., 2011) and DpC (Figs. 3.6, 3.9, 4.18-4.20) has been previously 
demonstrated. Studies have shown that the binding of copper ions by the copper ion 
chelator, TM, can markedly inhibit the cytotoxicity of [Cu(Dp44mT)] and other Cu(II)-
thiosemicarbazone complexes (Figs. 3.9, 4.19, 4.20) (Jansson et al., 2015b; Lovejoy et 
al., 2011; Stefani et al., 2015). Furthermore, elesclomol, a structurally-related 
thiosemicarbazone that has been clinically trialled in melanoma (O'Day et al., 2013), is a 
potent and redox-active Cu(II) chelator (Yadav et al., 2013). We next assessed whether 
copper ion binding was involved in the cytotoxicity mediated by Dp44mT and DpC, in 
the M14 Bcl-2 and M14 PC melanoma cell lines.  
 
After a 24 h/37°C co-incubation with control medium or the copper ion chelator, TM, no 
significant (p > 0.05) difference in the cytotoxicity of Dp44mT or DpC was observed (Fig. 
5.4).  
 
These results clearly demonstrate that the cytotoxicity mediated by Dp44mT and DpC in 
the M14 Bcl-2 and M14 PC cell lines was not related to their ability to bind Cu(II) (Fig. 
5.4). This is in contrast to previous results that have shown that Cu(II) binding is 
required to induce potent cytotoxicity (Figs. 3.9, 4.19, 4.20) (Jansson et al., 2015b; 
Lovejoy et al., 2011; Stefani et al., 2015). Furthermore, DpC appears to overcome Bcl-
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2-mediated MDR in melanoma via a novel mechanism that does not involve Cu(II) 
binding (Fig. 5.4). In contrast, Cu(II) binding is a requirement for DpC to overcome Pgp-
mediated MDR (Figs. 3.6, 3.7, 3.9).  
 
Notably, the copper-binding proteins, metallothioneins, have been shown to be highly 
expressed in melanoma, and are negative prognostic indicators (Krauter et al., 1989; 
Weinlich et al., 2006; Zelger et al., 1993). The probable lack of free, unbound, 
intracellular Cu(II) in the M14 melanoma cell lines could account for the results in Figure 
5.4, as there may have been very low levels of free copper ions present within the cell 
for Dp44mT or DpC to bind (Krauter et al., 1989; Weinlich et al., 2006; Zelger et al., 
1993). High expression of metallothionein also may account for the failure of the 
structurally-related elesclomol in clinical trials for advanced melanoma (O'Day et al., 
2013), as Cu(II) binding is involved in its mechanism (Kirshner et al., 2008; Yadav et al., 
2013). Indeed, elesclomol was shown to bind Cu(II) outside of cells and enter the 
cytoplasm as a Cu(II) complex, as opposed to binding Cu(II) intracellularly (Blackman et 
al., 2012; Nagai et al., 2012). Indeed, in order to examine the redox activity of 
elesclomol in vitro in melanoma cells, Cu(II) was added to the culture medium 
(Blackman et al., 2012; Nagai et al., 2012), which would circumvent the physiologically 
low levels of unbound copper ions in melanoma (Krauter et al., 1989; Weinlich et al., 
2006; Zelger et al., 1993). However, DpC was able to overcome Bcl-2-mediated MDR 
(Fig. 5.1) in melanoma regardless of the presence of copper ions (Fig. 5.4), 
demonstrating its potential as a novel therapy for melanoma.  
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Figure 5.3 The cytotoxicity of Dp44mT and DpC is not dependent on copper ions.  
The IC50 values of Dp44mT and DpC were not significantly different (p > 0.05) following 
a 24 h/ 37°C incubation with the copper ion chelator, TM (150 μM). Results are mean ± 
SD (3 experiments).  
 
 
 
5.3.5 Cytotoxicity Mediated by Dp44mT and DpC is Not Dependent on 
Redox Stress 
Apart from acting as a crucial regulator of apoptosis, Bcl-2 has been reported to affect 
cellular redox state (Voehringer and Meyn, 2000). Evidence suggests that Bcl-2 exerts 
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anti-oxidant effects that cause cells to be resistant to oxidative injury (Ellerby et al., 
1996; Hochman et al., 1998; Voehringer and Meyn, 2000; Zimmermann et al., 2007). 
The cytotoxicity of Dp44mT (Jansson et al., 2010b; Lovejoy et al., 2011) and DpC has 
been shown to be dependent on the ability of their metal complexes to redox cycle and 
generate ROS, leading to apoptotic cell death (Figs. 3.4, 3.7, 3.10). Indeed, redox 
cycling with Cu(II) and ROS generation was a requirement for Dp44mT and DpC to 
overcome Pgp-mediated MDR in KBV1 cervical cancer cells (Figs. 3.6-3.10). 
Interestingly, despite the reported anti-oxidant effects of Bcl-2 (Voehringer and Meyn, 
2000), Dp44mT and DpC were cytotoxic in M14 Bcl-2 cells, although Dp44mT did not 
overcome Bcl-2-mediated MDR like DpC (Fig. 5.1). DpC also caused a significant 
decrease in Bcl-2 expression (Fig. 5.2), which could alter the anti-oxidant effects of Bcl-
2. We therefore next investigated whether the observed cytotoxicity of Dp44mT and 
DpC could be related to their redox activity using the membrane-permeant anti-oxidant, 
NAC (Lovejoy et al., 2011; Stefani et al., 2015).  
 
Following a 24 h/37°C co-incubation with the anti-oxidant, NAC, no significant (p > 0.05) 
difference in cytotoxicity was observed as compared to Dp44mT and DpC alone (Fig. 
5.5). This is in contrast to previous results in other cell types, which have demonstrated 
that the redox activity of Dp44mT (Jansson et al., 2010b; Lovejoy et al., 2011) and DpC, 
is a key requirement in their anti-proliferative mechanism of action (Figs. 3.6-3.10).  
 
  196 
Indeed, despite inducing a significant decrease in the expression of Bcl-2 (Fig 2), which 
has been shown to act as an anti-oxidant by regulating levels of the anti-oxidant protein, 
GSH, and by affecting mitochondrial ROS production (Ellerby et al., 1996; Hochman et 
al., 1998; Voehringer and Meyn, 2000; Zimmermann et al., 2007), DpC does not 
demonstrate evidence of redox cycling (Figs. 5.4). This could be due to the probable 
lack of free, unbound copper ions due to high metallothionein expression in the 
melanoma cell lines (Krauter et al., 1989; Weinlich et al., 2006; Zelger et al., 1993); as 
the Cu(II) complex of DpC is more potently redox-active than the ligand alone (Figs. 3.7, 
3.10, 4.17). Intriguingly, these results suggested that DpC overcame Bcl-2-mediated 
MDR via a novel mechanism that did not involve the generation of ROS.  
 
5.3.6 DpC, but Not Dp44mT, Increases Expression of the Classical 
Marker of Autophagosome Formation, LC3-II 
Dp44mT has been shown to target the pro-survival autophagy pathway (Gutierrez et al., 
2014). The formation of the double membrane vesicle, the autophagosome, involves a 
complex interplay of proteins such as the PI3K·Beclin 1 complex, ATG5·ATG12, and 
LC3-phosphatidylethanolamine conjugation system (Kondo et al., 2005).  
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Figure 5.4 The cytotoxicity of Dp44mT and DpC were not dependent on redox 
activity.  
The IC50 values of Dp44mT and DpC were not significantly different (p > 0.05) following 
a 24 h/ 37°C co-incubation with the anti-oxidant, NAC (10 mM). Results are mean ± SD 
(3 experiments).  
 
 
The fusion of autophagosomes with lysosomes results in the degradation of the 
cytoplasmic contents of the newly-formed autolysosome, which can then be recycled to 
protect the cell against apoptotic stressors, such as nutrient deprivation and cytotoxic 
signals (Kondo et al., 2005). However, the disruption of lysosomal membranes by 
Dp44mT inhibits the development of functional autolysosomes, preventing the fusion of 
  198 
the autophagosomes with lysosomes (Gutierrez et al., 2014). Dp44mT converts the pro-
survival autophagy pathway into a mechanism of cytotoxicity, resulting in a build-up of 
cellular debris, and inducing LMP that results in apoptosis due to the release of 
degradative lysosomal cathepsins into the cytosol (Gutierrez et al., 2014). 
 
Bcl-2 is a known inhibitor of autophagy, as it suppresses the activity of the key 
autophagy protein, Beclin 1 (Chang et al., 2010; Pattingre et al., 2005). Beclin 1 forms 
an integral part of the complex that participates in the initiation of autophagosome 
formation, mediating the localisation of other autophagy proteins to the pre-
autophagosomal membrane (Kihara et al., 2001). Interestingly, silencing of Beclin 1 has 
been demonstrated to inhibit Dp44mT-induced autophagy (Gutierrez et al., 2014). 
Herein, we have demonstrated that DpC inhibited Bcl-2 (Fig. 5.2) and was capable of 
overcoming Bcl-2-mediated MDR (Fig. 5.1), whereas Dp44mT was not (Figs. 5.1, 5.2). 
We therefore investigated the effects of Dp44mT and DpC on the autophagic pathway 
in the Bcl-2 expressing M14 Bcl-2 cell line, using the classical marker of 
autophagosome formation, LC3-II (Klionsky et al., 2016; Mizushima et al., 2010).  
 
The conversion of LC3-I, the cytosolic form of the protein, to LC3-II, the autophagosome 
membrane-bound form, was examined in response to a 24 h/37°C incubation with 
Dp44mT (30 mM) or DpC (30 mM) in the M14 Bcl-2 cell line. LC3-II expression was 
quantified densitometrically, as it is a classical marker of autophagosome formation 
(Klionsky et al., 2016; Mizushima et al., 2010). Dp44mT did not induce a significant (p > 
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0.05) increase in the expression of LC3-I or LC3-II, relative to the control (Fig. 5.6). 
However, DpC markedly and significantly (p < 0.001) increased LC3-I and LC3-II 
expression, compared to the control and Dp44mT (Fig. 5.6). The expression of LC3-II 
was increased 3.4-fold (p < 0.001) in response to incubation with DpC, whereas 
Dp44mT only increased LC3-II expression 1.1-fold (p > 0.05) (Fig. 5.6) 
 
Previous studies in the MCF-7 breast cancer cell line demonstrated that Dp44mT 
increases the expression of the marker of autophagosome formation, LC3-II (Gutierrez 
et al., 2014). Herein, we found that only DpC, but not Dp44mT, induced an increase in 
LC3-II, in the Bcl-2 over-expressing cell line, M14 Bcl-2. This result may be related to 
the ability of DpC, but not Dp44mT, to decrease the expression of Bcl-2 (Fig 5.2). Bcl-2 
is a known autophagy inhibitor, as it binds to Beclin 1, a BH3-only domain protein, and 
prevents it from participating in the formation of the autophagy-initiation complex 
(Chang et al., 2010; Liang et al., 1998; Pattingre et al., 2005). As DpC decreases the 
expression of Bcl-2 (Fig. 5.2), more Beclin 1 may be free to participate in autophagy 
initiation, resulting in the induction of autophagosome formation and an increase in LC3-
II expression (Fig. 5.6). Dp44mT, on the other hand, does not decrease the expression 
of Bcl-2 (Fig. 5.2). Beclin 1 may be bound to Bcl-2 and inhibited, preventing the initiation 
of autophagy and increase in autophagosome formation, as is seen with DpC (Fig. 5.6). 
Therefore, the differing effects of Dp44mT in the MCF-7 and M14 Bcl-2 cell lines may 
be related to the over-expression of Bcl-2 in the M14 Bcl-2 cell line. 
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Figure 5.6 DpC, but not Dp44mT, induces an increase in the expression of the 
autophagy marker, LC3-II. 
(A) M14 Bcl-2 cells were treated with control medium or medium containing Dp44mT 
(30 μM) or DpC (30 μM) and incubated for 24 h/ 37°C. Western blotting was performed 
to determine LC3 expression. DpC, but not Dp44mT, increased the expression of LC3-I 
and LC3-II. (B) Densitometric analysis (arbitrary units) of LC3-II expression in (A). DpC 
significantly increased LC3-II expression, relative to control (p < 0.001) and Dp44mT (p 
< 0.001) Blots shown are representative of three experiments. Densitometric analysis is 
the mean of 3 ± S.D (3 experiments). *** p < 0.001. 
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5.3.7 Formation of Acidic Vesicles Mediated by Dp44mT and DpC  
Dp44mT has multiple mechanisms for targeting lysosomes to induce cytotoxicity 
(Gutierrez et al., 2014; Jansson et al., 2010b; Jansson et al., 2015b; Lovejoy et al., 
2011). Firstly, Dp44mT and DpC have been shown to localise to the lysosomal 
compartment, where they induce LMP by redox cycling with Cu(II) to generate ROS 
(Figs. 3.6, 3.7, 3.9, 3.10) (Gutierrez et al., 2014; Jansson et al., 2010b; Jansson et al., 
2015b; Lovejoy et al., 2011). 
 
This mechanism also enables the targeting of Pgp-mediated MDR (Figs. 3.4- 3.10) 
(Jansson et al., 2015b). Additionally, Dp44mT has been shown to target the pro-survival 
autophagy pathway by inducing the formation of autophagosomes, but prevents their 
fusion with lysosomes by inducing LMP, resulting in apoptosis (Gutierrez et al., 2014). 
Herein, we showed that in M14 melanoma cells that over-express Bcl-2, DpC, but not 
Dp44mT, can increase the expression of the classical autophagy marker, LC3-II (Fig. 
5.6). This may be related to the superior ability of DpC to decrease the expression of 
Bcl-2, which is an inhibitor of autophagy (Fig. 5.2). We next investigated the effects of 
Dp44mT and DpC on the stability of lysosomal membranes in the Bcl-2 expressing M14 
Bcl-2 cell line, compared to the control M14 PC cell line. We utilised the lysosomal 
marker, AO, which stains acidic vesicles, (i.e. lysosomes, red/orange) and other, more 
alkaline cellular compartments as green. 
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Both M14 Bcl-2 and M14 PC cells exhibited comparable amounts of the classical, 
punctate pattern of orange/red AO-stained acidic vesicles, under control conditions (Fig. 
5.7). Following a 24 h/37°C incubation with Dp44mT (30 mM), the number of acidic 
vesicles remained unchanged compared to the control in M14 Bcl-2 cells (Fig. 5.7). 
However, in M14 PC cells, incubation with Dp44mT induced a significant (p < 0.001) 
increase in the number of red, AO-stained acidic vesicles, relative to both the control 
and Dp44mT-treated M14 Bcl-2 cells (Fig. 5.7). In contrast to Dp44mT, in M14 Bcl-2 
cells, DpC induced a significant (p < 0.001) increase (Fig. 5.7) in the number of red, AO-
stained vesicles relative to both Dp44mT and the control (Fig. 5.7). Similarly, incubation 
with DpC induced a significant (p < 0.001) increase in the number of acidic vesicles in 
M14 PC cells, compared to control. The increase in the number of acidic, lysosomal-like 
vesicles induced by incubation with DpC was also significantly (p < 0.001) greater in 
M14 PC cells, compared to M14 Bcl-2 cells. 
 
The accumulation of acidic vesicles observed in the M14 cell lines is a novel effect of 
Dp44mT and DpC, as in other, diverse cell lines such as MCF-7, KBV1, KB31 and SK-
N-MC, both these agents cause high levels of LMP (Figs. 3.6, 3.7, 3.9, 3.10) (Gutierrez 
et al., 2014; Jansson et al., 2010b; Lovejoy et al., 2011). However, induction of LMP in 
other cell lines was dependent on redox cycling with Cu(II) to produce ROS that 
peroxidise, and so disrupt, the lysosomal membrane (Figs. 3.6, 3.7, 3.9, 3.10) 
(Gutierrez et al., 2014; Jansson et al., 2010b; Lovejoy et al., 2011). Herein, we have 
demonstrated that the cytotoxicity of Dp44mT and DpC in the M14 cell lines is not 
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dependent on Cu(II) binding or ROS generation, therefore, it is unsurprising that LMP 
does not occur.  
 
These results showed that DpC was more effective than Dp44mT at inducing an 
increase in the number of acidic lysosomal vesicles in cells that express Bcl-2 (Fig. 5.7). 
However, in cells that did not express Bcl-2, Dp44mT and DpC were equally effective at 
inducing an increase in the number of acidic vesicles. Bcl-2 inhibits autophagy as it is 
an inhibitor of the autophagy initiator, Beclin 1 (Chang et al., 2010; Pattingre et al., 
2005). It is possible that the increased number of acidic vesicles seen in M14 Bcl-2 cells 
following treatment with DpC (Fig. 5.7) was a result of DpC decreasing the expression 
of Bcl-2 (Fig. 5.2). Consequently, Beclin 1 activity would be de-repressed, so autophagy 
would increase. Indeed, the formation of autophagosomes, which requires Beclin 1, was 
increased by DpC (Fig. 5.6). Autophagosomes ultimately fuse with lysosomes to form 
autolysosomes, so it is possible that the acidic vesicles in Figure 5.7 were in fact 
autolysosomes that had formed as a result of increased autophagy (Kondratskyi et al., 
2014; Mizushima et al., 2010). Dp44mT, on the other hand, was not capable of 
significantly decreasing Bcl-2 (Fig. 5.2), so Beclin 1 would have been inhibited. Due to 
the inhibition of Beclin 1 by Bcl-2, the formation of autophagosomes may also have 
been inhibited, as was demonstrated (Fig. 5.6). Therefore, Dp44mT would not induce 
increase in autolysosome number in Bcl-2 expressing cells (Fig. 5.7). In the M14 PC cell 
line, which do not express Bcl-2, both Dp44mT and DpC may have induced 
autolysosome formation because, in contrast to the M14 Bcl-2 cell line, Beclin 1 would 
not have been inhibited by Bcl-2 (Fig. 5.2). 
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Figure 5.7. Increase in the number of acidic vesicles induced by Dp44mT and DpC 
is affected by Bcl-2 expression.  
(A,B) Dp44mT does not induce a significant increase in the number of red/orange-
stained acidic vesicles in M14 Bcl-2 cells. However, in M14 PC cells, Dp44mT does 
induce an increase in the number of red/orange-stained acidic vesicles. In contrast, 
DpC induces a significant increase in the number of red/orange-stained acidic vesicles 
in both the M14 Bcl-2 and M14 PC cell lines. Results in (A) are representative images 
from 3 experiments. Quantification in (B) is mean ± SD (3 experiments); *** p < 0.001 
Scale bar: 10 μm. 
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5.4 Conclusions 
Our laboratory has developed novel thiosemicarbazones as anti-cancer agents for the 
past 20 years, of which the DpT series of thiosemicarbazone analogues has been the 
most successful (Jansson et al., 2015a; Kalinowski and Richardson, 2005; Kalinowski et 
al., 2007; Merlot et al., 2013). The best characterised agents from this series, Dp44mT 
and DpC, target lysosomes to induce potent cytotoxicity (Figs. 3.4- 3.10, 4.17- 4.20) 
(Gutierrez et al., 2014; Jansson et al., 2010b; Lovejoy et al., 2011; Stefani et al., 2015). 
Furthermore, Dp44mT and DpC have a propensity for co-opting cell survival 
mechanisms and utilising them to induce marked and selective cytotoxicity. Notably, 
Dp44mT and DpC overcome Pgp-mediated MDR by “hijacking” Pgp to increase their 
lysosomal accumulation (Figs. 3.4-3.10) (Jansson et al., 2015b; Seebacher et al., 
2016a).  
 
Dp44mT has also been shown to take advantage of the pro-survival autophagy pathway 
by increase autophagy, while at the same time preventing autophagosomes fusing with 
lysosomes by destabilising lysosomal membranes (Gutierrez et al., 2014). This has the 
effect of potentiating Dp44mT-induced cytotoxicity in two ways: (1) due to the build-up 
of cellular debris that can no longer be recycled via the autophagic pathway; and (2) 
through induction of LMP, resulting in the release of degradative cathepsins into the 
cytosol (Gutierrez et al., 2014). Given the ability of Dp44mT and DpC to overcome 
various mechanisms of MDR, and that DpC has entered clinical trials for advanced solid 
tumours in 2016 (ClinicalTrials.gov Identifier NCT02688101), investigating their activity 
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against other mechanisms of resistance is crucial. As Dp44mT has been shown to alter 
the ratio of anti-apoptotic Bcl-2 and pro-apoptotic Bax expression (Gutierrez et al., 2014; 
Yuan et al., 2004), we investigated the efficacy of Dp44mT and DpC in the M14 Bcl-2 
cell line, which over-expresses Bcl-2, and the M14 PC cell line, which does not express 
Bcl-2. Importantly, these cell lines are melanoma cell lines (Chambers, 2009; Rae et al., 
2007). Metastatic melanoma is inherently MDR, making it notoriously difficult to develop 
treatments for (Grover and Wilson, 1996; Soengas and Lowe, 2003). 
 
Our studies showed that DpC, but not Dp44mT, was able to overcome Bcl-2-mediated 
MDR in melanoma (Fig. 5.1). In both M14 Bcl-2 cells, which over-express Bcl-2, and 
M14 PC cells, which express negligible amounts of Bcl-2, the IC50 value of DpC was not 
significantly (p > 0.05) different. However, Dp44mT was significantly less cytotoxic in the 
M14 Bcl-2 cell line, than in the M14 PC cell line (Fig. 5.1). Therefore, Dp44mT acted 
more like a traditional chemotherapy drug in the M14 melanoma cell line, as Bcl-2 over-
expression has been shown to decrease the sensitivity of cancer cells to chemotherapy 
agents (Amundson et al., 2000; Dole et al., 1994; Miyashita and Reed, 1993; Schmitt et 
al., 2000; Shibata et al., 1999; Strasser et al., 1993; Thomas et al., 1996; Vaux et al., 
1988; Wang et al., 2013). Interestingly, DpC and Dp44mT behaved differently in Bcl-2-
mediated MDR, which only DpC could overcome; whereas their activity is 
indistinguishable in Pgp-mediated MDR, which both could overcome (Figs. 3.4-3.10).  
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The over-expression of anti-apoptotic Bcl-2 mediates resistance to apoptosis by binding 
to pro-apoptotic family members, preventing them from initiating the intrinsic, 
mitochondrial pathway of apoptosis (Cory and Adams, 2002; Czabotar et al., 2014; 
Youle and Strasser, 2008). Inhibition of Bcl-2 has been targeted with small molecule 
inhibitors that are BH3-only protein mimetics, that bind Bcl-2 and release pro-apoptotic 
proteins so that they may induce apoptosis (Souers et al., 2013; Tse et al., 2008; van 
Delft et al., 2006; Wroblewski et al., 2013). However, we demonstrated that, rather than 
inhibiting the Bcl-2 protein, DpC instead significantly (p < 0.01) decreased Bcl-2 
expression, compared to control (Fig. 5.2). Dp44mT, on the other hand, did not 
decrease expression significantly (p > 0.05), relative to control (Fig. 5.2). The ability of 
DpC to decrease Bcl-2 expression, relative to Dp44mT, may explain why DpC 
overcame Bcl-2-mediated MDR, but Dp44mT did not. Although Dp44mT has 
consistently been shown to increase the Bax:Bcl-2 ratio, its efficacy in decreasing Bcl-2 
expression appears to depend on the cell line used (Gutierrez et al., 2014; Yuan et al., 
2004).  
 
In addition to Bcl-2 over-expression having no effect on the cytotoxicity of DpC (Fig. 
5.1), we also demonstrated that silencing of Bcl-2 has no effect on DpC-mediated 
cytotoxicity (Fig. 5.3). As DpC is already efficient at decreasing Bcl-2 expression (Fig. 
5.2), it can be suggested that further silencing of Bcl-2 has no effect (Fig. 5.3). In 
contrast, the cytotoxicity of Dp44mT was significantly (p < 0.01) increased by Bcl-2 
silencing (Fig. 5.3). Compared to DpC, Dp44mT did not affect Bcl-2 expression (Fig. 
5.2), therefore, silencing of Bcl-2 increased the cytotoxicity of Dp44mT (Fig. 5.3). 
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Moreover, silencing of Bcl-2 increased the cytotoxicity of Dp44mT, which has also been 
demonstrated for common chemotherapy agents that are ineffective against Bcl-2-
mediated MDR (Nemati et al., 2014; Raisova et al., 2001; Watanabe et al., 2013; 
Wroblewski et al., 2013). Indeed, Bcl-2 silencing using oligonucleotides (oblimersen) 
was investigated as a method of targeting Bcl-2-mediated MDR, although this approach 
failed at clinical trials (Bedikian et al., 2006; Bedikian et al., 2014). DpC may offer 
significant improvements over oblimersen, as it is more like the successful small 
molecule inhibitors in terms of structure (Lessene et al., 2008; Thomas et al., 2013), as 
opposed to an oligonucleotide. Indeed, the clinical use of antisense oligonucleotides will 
always be limited due to their susceptibility to DNAse-mediated degradation and 
undesirable side effects (Dai et al., 2005). Other advantages of DpC include its ability to 
be given orally, and that it can overcome Pgp-mediated MDR as well as its 
polypharmacological mechanism that targets and inhibits multiple key biological 
processes, e.g. cell cycle progression, DNA synthesis, metastasis, etc (Jansson et al., 
2015a). 
 
Dp44mT and DpC bind to Cu(II) and redox cycle to generate ROS that induce LMP 
(Figs. 3.6-3.10, 4.17-4.20) (Gutierrez et al., 2014; Jansson et al., 2010b; Lovejoy et al., 
2011; Stefani et al., 2015). However, we showed that in the M14 melanoma cell lines, 
prevention of Cu(II) binding using the copper ion chelator, TM, had no effect on the 
cytotoxicity of either Dp44mT or DpC (Fig. 5.4). Furthermore, prevention of ROS 
generation using the anti-oxidant, NAC, did not affect the cytotoxicity of Dp44mT or DpC 
(Fig. 5.5). Studies have shown that melanoma cells express abnormally high levels of 
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the copper ion binding proteins, metallothioneins, which reduces the level of unbound 
copper ions in cells (Krauter et al., 1989; Weinlich et al., 2006; Zelger et al., 1993). This 
could account for the lack of effect TM (Fig. 5.5) and NAC (Fig. 5.6) had on the 
cytotoxicity of Dp44mT and DpC, as the levels of free copper ions for Dp44mT and DpC 
to bind and redox cycle with may have been exceedingly small. These results 
suggested that Dp44mT and DpC were acting via an alternative mechanism to induce 
cytotoxicity in the M14 PC melanoma cell line, and in the case of DpC, the M14 Bcl-2 
cell line.  
 
The effects of Dp44mT and DpC on the formation of autophagosomes in the M14 Bcl-2 
cell line were investigated using the classical marker of autophagosome formation, LC3-
II. DpC significantly (p < 0.001) increased the expression of LC3-II compared to control 
(Fig. 5.6). Dp44mT, on the other hand, did not increase LC3-II expression (Fig. 5.6). 
This is in contrast to previous results, which have shown that Dp44mT induces LC3-II 
expression (Gutierrez et al., 2014). However, Bcl-2 is a known inhibitor of Beclin 1, a 
key protein involved in autophagy initiation (Kihara et al., 2001; Liang et al., 1998; 
Pattingre et al., 2005). In the M14 Bcl-2 cell line, which over-expresses Bcl-2, the 
inhibition of Beclin 1 may have prevented the formation of autophagosomes in response 
to Dp44mT (Fig. 5.6). In contrast, DpC induced a significant decrease in the expression 
of Bcl-2 (Fig. 5.2). Therefore, the formation of autophagosomes could have occurred in 
response to DpC treatment because Beclin 1 was not inhibited by Bcl-2 (Fig. 5.6).  
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Dp44mT and DpC mediate potent cytotoxicity by targeting lysosomes and inducing LMP 
(Figs. 3.4-3.10, 4.17-4.20) (Gutierrez et al., 2014; Jansson et al., 2010b; Lovejoy et al., 
2011). However, in the M14 melanoma cell lines used in this study, neither Dp44mT nor 
DpC induced LMP (Fig. 5.7). This may be related to their inability to bind Cu(II) and 
redox cycle in the M14 melanoma cell lines (Figs. 5.4, 5.5); characteristics which are 
required in order to induce LMP (Figs. 3.4-3.10, 4.17-4.20) (Gutierrez et al., 2014; 
Jansson et al., 2010b; Lovejoy et al., 2011; Stefani et al., 2015). In fact, Dp44mT and 
DpC increased the number of acidic vesicles in a Bcl-2 dependent manner (Fig. 5.7). 
Dp44mT increased the number of acidic vesicles in the control M14 PC cell line, but not 
the Bcl-2 expressing M14 Bcl-2 cell line (Fig. 5.7). DpC, on the other hand, increased 
the number of acidic vesicles in both the M14 Bcl-2 and M14 PC cell lines (Fig. 5.7).  
 
We suggest that the acidic vesicles are in fact autolysosomes, formed by the fusion of 
autophagosomes and lysosomes (Fig. 5.8) (Kondo et al., 2005). The inhibition of Beclin 
1 by Bcl-2 in the M14 Bcl-2 cell line would have prevented the initiation of autophagy, 
thus there would be no increase in the number of autophagosomes, as observed, 
following incubation with Dp44mT (Fig. 5.6). This could explain the decreased in the 
number of acidic vesicles, which may be autolysosomes seen in response to Dp44mT 
treatment (Figs. 5.7, 5.8) (Chang et al., 2010; Pattingre et al., 2005). Indeed, when Bcl-2 
was not expressed in the M14 PC cell line, Dp44mT did increase the number of acidic 
vesicles (Figs. 5.7, 5.8). In contrast, the ability of DpC to decrease Bcl-2 expression, 
thus decreasing Beclin 1 inhibition, could have resulted in increased autophagosome 
formation in M14 Bcl-2 cells (Fig. 5.6). In agreement with this hypothesis, DpC was able 
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to increase the number of acidic vesicles, which may be autolysosomes, in both cell 
lines (Figs. 5.7, 5.8).  
 
However, further studies, using specific vesicular markers, are needed to confirm the 
specific identity of the acidic vesicles formed in Figure 5.7, and whether there is a 
relationship between the increase in acidic vesicle formation and induction of 
cytotoxicity. However, the trends in cytotoxicity were similar to the trends in acidic 
vesicle formation. DpC was equally cytotoxic in the M14 Bcl-2 and M14 PC cell lines, 
and induced similar increases in the number of acidic vesicles. Dp44mT, on the other 
hand, was less cytotoxic in the M14 Bcl-2 cell line than in the M14 PC cell line. Dp44mT 
also did not induce an increase in acidic vesicles in the M14 Bcl-2 cell line, although did 
in the M14 PC cell line. These results suggest that there may be a causal relationship 
between acidic vesicle formation and cytotoxicity induced by Dp44mT and DpC, which 
is related to Bcl-2 expression. 
 
 
Evasion of apoptosis mediated by Bcl-2 over-expression is not only a hallmark of 
carcinogenesis; it also contributes to MDR by allowing cancer cells to ignore apoptotic 
signals generated in response to cytotoxic drugs (Lessene et al., 2008; Thomas et al., 
2013). Bcl-2 is therefore an important drug target (Lessene et al., 2008; Thomas et al., 
2013). While small molecule inhibitors of Bcl-2, such as ABT-199, have been developed 
and progressed to clinical trials (Roberts et al., 2016; Stilgenbauer et al., 2016), none 
have gained Federal Drug Administration approval to date. Based on these studies, 
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further investigation into the mechanism of Dp44mT and DpC in both Bcl-2-mediated 
MDR and inherently resistant melanoma, are warranted. Importantly, we have 
demonstrated the potent ability of DpC, has entered clinical trials in 2016 
(ClinicalTrials.gov Identifier NCT02688101), to overcome Bcl-2-mediated MDR by 
decreasing the expression of Bcl-2. Furthermore, we have shown that in melanoma 
cells, Dp44mT and DpC, act in a novel, Bcl-2-dependent, Cu(II)-independent manner to 
increase the formation of acidic vesicles, as opposed to causing LMP which has been 
demonstrated in other cancer cell types (Figs. 3.6-3.10, 4.17-4.20) (Gutierrez et al., 
2014; Jansson et al., 2010b; Lovejoy et al., 2011; Seebacher et al., 2016a). We suggest 
that the increase in the formation of acidic vesicles may be related to the ability of 
Dp44mT and DpC to increase autophagy in a Bcl-2-dependent fashion. Investigations to 
determine whether the outcome of the increase in acidic vesicles is related to induction 
of cytotoxicity should be conducted. It is important to elucidate the mechanism by which 
Dp44mT and DpC exert their cytotoxic effects in melanoma, a cancer for which novel 
treatments are desperately needed as it is resistant to standard chemotherapies 
(Grover and Wilson, 1996; Soengas and Lowe, 2003).  
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Figure 5.8 Schematic illustrating the possible mechanisms of Dp44mT and DpC in 
Bcl-2 over-expressing cells. 
A Dp44mT, which did not overcome Bcl-2-mediated MDR, did not decrease the 
expression of Bcl-2. Dp44mT also did not increase the formation of autophagosomes in 
Bcl-2 over-expressing cells. This could be due to the inhibition of the autophagy 
initiation protein, Beclin 1, by Bcl-2. The prevention of autophagy by Bcl-2 could have 
accounted for the decreased number of acidic vesicles induced by Dp44mT treatment, 
relative to control. We suspect these acidic vesicles were autolysosomes, formed by the 
fusion of autophagosomes and autolysosomes. B DpC, which did overcome Bcl-2-
mediated MDR, decreased the expression of Bcl-2 and increased the formation of 
autophagosomes. This may have been due to decreased inhibition of the autophagy 
initiation protein, Beclin 1, by Bcl-2. The fusion of the increased numbers of 
autophagosomes with lysosomes could account for the increased number of acidic 
vesicles, which may in fact be autolysosomes, in Bcl-2 over-expressing cells following 
DpC treatment.  
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Chapter 6 – Discussion 
 
 
6.1 Prelude to Discussion 
Although chemotherapy is the standard treatment for metastatic and haematological 
malignancies, drug resistance represents a major clinical obstacle to successful 
treatment (Gottesman, 2002). Drug resistance can be mediated through a number of 
mechanisms, including: efflux of chemotherapeutic substrates by ABC transporters, 
such as Pgp (Gottesman et al., 2002); failure to respond to apoptotic signals induced by 
chemotherapeutics due to over-expression of Bcl-2 family members (Lessene et al., 
2008), and lysosomal drug sequestration (Zhitomirsky and Assaraf, 2016). To date, no 
treatments targeting any of these mechanisms have successfully progressed past Stage 
III clinical trials (Fletcher et al., 2010). Therefore, the development of novel therapeutic 
strategies to target MDR is crucial.  
 
In our laboratory, thiosemicarbazones have been developed which display high 
potency, both in vitro and in vivo (Jansson et al., 2015a; Jansson et al., 2015b; 
Kalinowski and Richardson, 2005; Kovacevic et al., 2011; Lovejoy et al., 2012; Whitnall 
et al., 2006; Yuan et al., 2004). The thiosemicarbazone, Dp44mT, has the notable ability 
to “highjack” lysosomal Pgp and utilise this MDR mechanism to enhance its targeting 
and effectiveness by increasing apoptosis (Gutierrez et al., 2014; Jansson et al., 2015b; 
Seebacher et al., 2016a). Given the unique properties of Dp44mT, this thesis examined 
the anti-cancer efficacy of thiosemicarbazones, and their ability to overcome MDR. 
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Specifically, in Chapter 3, structural features required by thiosemicarbazones in order to 
overcome Pgp-mediated MDR were elucidated, and the mechanism by which certain 
thiosemicarbazones overcome Pgp-mediated MDR were demonstrated. Although 
thiosemicarbazones have traditionally been thought of as Fe(III) chelators, recent 
studies have demonstrated the anti-cancer activity of Zn(II)-thiosemicarbazone 
complexes (Cowley et al., 2005; Kovala-Demertzi et al., 2006; Kowol et al., 2010). 
Therefore, in Chapter 4, we synthesised Zn(II) complexes of several of our potently anti-
neoplastic thiosemicarbazones, and investigated their mechanism of action. 
Furthermore, Dp44mT has been shown to alter the ratio of the Bcl-2 family members, 
Bax and Bcl-2, which regulate apoptosis (Gutierrez et al., 2014; Yuan et al., 2004). In 
Chapter 5, the effect of Bcl-2 expression on the anti-cancer efficacy of Dp44mT and 
DpC was investigated in mechanistic studies.  
 
 
6.2 Targeting MDR with Thiosemicarbazones 
 
6.2.1 Overcoming Pgp-Mediated MDR with Thiosemicarbazones 
Both Dp44mT (Jansson et al., 2015b; Whitnall et al., 2006) and its Cu(II) (Gutierrez et 
al., 2014; Jansson et al., 2015b) complex induce potent and selective cytotoxicity in 
MDR cancer cells expressing Pgp, relative to their non-Pgp expressing counterparts. 
Pgp expressed in lysosomal membranes transports Dp44mT into lysosomes, where it is 
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protonated (Jansson et al., 2015a; Lovejoy et al., 2011). Upon protonation of Dp44mT, 
the agent is no longer able to diffuse out of lysosomes (Jansson et al., 2015a; Lovejoy 
et al., 2011). With the high amounts of copper available in the lysosomes (Gupte and 
Mumper, 2009), Dp44mT can form redox-active Cu(II) complexes which generate ROS 
inside lysosomes (Jansson et al., 2015a; Lovejoy et al., 2011). These ROS damage 
lysosomal membranes, resulting in LMP and apoptosis in MDR cancer cells (Jansson et 
al., 2015a; Lovejoy et al., 2011). In order to examine the requirements for overcoming 
Pgp-mediated MDR via the unique mechanism of action exhibited by Dp44mT, a group 
of structurally-related thiosemicarbazones were examined in the first 5 chapters of this 
thesis, namely: Dp44mT, DpC, Bp44mT, Ap44mT, 3-AP and Bp2mT. These 
thiosemicarbazones were chosen based on their marked and selective anti-cancer 
activity, while Bp2mT was chosen as a negative control that does not bind Fe(III) or 
Cu(II) (Kalinowski et al., 2007; Knox et al., 2007; Lovejoy et al., 2012; Richardson et al., 
2009; Traynor et al., 2010; Yu et al., 2012; Yuan et al., 2004). 
 
All of the panel of thiosemicarbazones screened in this study (Dp44mT, Bp44mT, DpC, 
Ap44mT, 3-AP and Bp2mT), and their Fe(III) and Cu(II) complexes, induced Pgp 
ATPase activity, indicating that the ligands alone and when they are bound to Fe(III) or 
Cu(II) are transported by Pgp drug transporter (Fig. 3.7). Notably, the more lipophilic 
compounds induced greater Pgp-ATPase activity (i.e., ligands < Cu(II) complexes < 
Fe(III) complexes; Fig. 3.7). This is in accordance with the observation that Pgp prefers 
lipophilic substrates for transport (Kimura et al., 2004; Schmid et al., 1999; Seelig and 
Landwojtowicz, 2000). Although all of the thiosemicarbazones were Pgp substrates, 
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only Dp44mT, DpC and Bp44mT caused potentiated, Pgp-dependent cytotoxicity and 
LMP (Figs. 3.6, 3.8, 3.10). The cytotoxicity and LMP induced by Ap44mT was not 
affected by Pgp expression or Pgp inhibition with a Pgp inhibitor (Figs. 3.6, 3.8, 3.10). 
Moreover, Bp2mT and 3-AP did not induce cytotoxicity at concentrations of ≥ 800 μM, 
nor did they induce LMP (Figs. 3.6, 3.8). The lack of efficacy 3-AP demonstrated in 
MDR cancer cells could have contributed to its failure in multiple clinical trials (Knox et 
al., 2007; Merlot et al., 2013; Traynor et al., 2010). Clearly, being a Pgp substrate was 
not the only feature a thiosemicarbazone was required to possess in order to induce 
potentiated cytotoxicity and LMP in Pgp-expressing cells (Figs. 3.6-3.8).  
 
While thiosemicarbazones are traditionally thought of as Fe(III) chelators (Kalinowski et 
al., 2007), their Cu(II) complexes also exhibit pronounced anti-proliferative effects 
(Jansson et al., 2010b; Jansson et al., 2015b; Lovejoy et al., 2011). Herein, we 
demonstrated that Pgp-mediated LMP induced by Dp44mT, Bp44mT and DpC was 
dependent on their ability to bind Cu(II) (Figs. 3.8, 3.13). Indeed, [Cu(Dp44mT)], 
[Cu(Bp44mT)] and [Cu(DpC)] were potent inducers of LMP following a 30 min/37°C 
incubation; whereas the thiosemicarbazones alone did not induce LMP at this time point 
(Fig. 3.8). However, using a longer time point (24 h), we demonstrated that Dp44mT, 
Bp44mT and DpC could also induce Pgp-dependent LMP, which was found to be Cu(II) 
dependent, as the potent copper chelator, TM, prevented LMP induced by these agents 
(Figs. 3.8, 3.13). Although the thiosemicarbazones alone did not induce LMP at the 30 
min time point (Fig. 3.8), over 24 h, there is greater opportunity for the ligand to bind 
endogenous Cu(II) to form complexes that can then induce LMP (Figs. 3.8-3.14). None 
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of the other thiosemicarbazones (Bp2mT, 3-AP and Ap44mT) induced Pgp- or Cu(II)-
dependent LMP at any of the time points examined in these studies (Figs. 3.6, 3.8, 
3.13) As a substitution of a methyl group at N2 in Bp2mT prevents Cu(II) binding (Chen 
et al., 2012; Yuan et al., 2004), this could explain the lack of efficacy of Bp2mT in 
inducing LMP. Interestingly, Ap44mT and 3-AP can bind Cu(II) (Jansson et al., 2010b) 
like Dp44mT, Bp44mT and DpC, yet do not induce LMP or potentiated cytotoxicity in 
Pgp-expressing KBV1 cells (Figs. 3.6, 3.8, 3.10-3.14). As Cu(II) only potentiated the 
cytotoxic effects of some of the thiosemicarbazones examined in these studies, this 
suggested that there were further requirements for inducing Pgp-mediated LMP and 
cytotoxicity. 
  
Further investigations revealed that the generation of ROS by the Cu(II)-
thiosemicarbazone complexes was another characteristic required for the induction of 
Pgp-dependent LMP and cytotoxicity (Figs. 3.9, 3.14). None of the thiosemicarbazones 
alone or their Fe(III) complexes generated significant ROS an in vitro plate assay (as 
measured with H2DCF fluorescence), compared to the control (Fig. 3.9). However, 
[Cu(Dp44mT)], [Cu(Bp44mT) and [Cu(DpC)] demonstrated the greatest ability to induce 
ROS formation (Fig. 3.9). Although [Cu(Ap44mT)] was significantly (p < 0.001) more 
redox-active than controls, it was also significantly (p < 0.001) less redox-active than 
[Cu(Dp44mT)], [Cu(Bp44mT) and [Cu(DpC)] (Fig. 3.9). The redox activity of Bp2mT and 
3-AP in the presence of Cu(II) did not significantly differ from the controls (Fig. 3.9). In 
the case of Bp2mT, this could be accounted to its inability to form Cu(II) complexes 
(Chen et al., 2012; Yuan et al., 2004), which resulted in lack of redox activity (Fig 3.9). 
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However, 3-AP can form Cu(II) complexes. This suggested that there were 
characteristics that made 3-AP and Ap44mT less effective at redox cycling with Cu(II), 
compared to Dp44mT, Bp44mT and DpC.  
 
The differences in the redox activity of [Cu(Dp44mT)], [Cu(Bp44mT) and [Cu(DpC)], 
compared to [Cu(Ap44mT)] and [Cu(3-AP)] can be explained by structural 
characteristics of the thiosemicarbazones. For Dp44mT, Bp44mT and DpC, the 
presence of an inductively electron-withdrawing phenyl or pyridyl moiety at the imine 
carbon results in Cu(II) complexes with higher redox potentials (Jansson et al., 2010a; 
Kalinowski et al., 2007; Richardson et al., 2009), suitable for ROS generation (Fig. 3.9) 
and inducing LMP (Figs 3.8, 3.10-3.14). In contrast, for 3-AP or Ap44mT, the presence 
of a hydrogen or an inductively electron-donating methyl group at the imine carbon, 
respectively, results in Cu(II) complexes with lower redox potentials (Jansson et al., 
2010a; Kalinowski et al., 2007; Richardson et al., 2009), thus making these agents less 
avid in generating ROS (Fig. 3.9), resulting in failure to induce LMP (Fig. 3.8, 3.10-3.14) 
and overcome MDR (Figs. 3.6, 3.10). At the same time, the decreased lipophilicity of 3-
AP or Ap44mT relative to Dp44mT, Bp44mT and DpC, results in decreased membrane 
permeability and lower Pgp substrate activity (Fig. 3.7). This is consistent with the fact 
that Pgp prefers lipophilic substrates for transport (Kimura et al., 2004; Schmid et al., 
1999; Seelig and Landwojtowicz, 2000). Hence, the lower lipophilicity of the ligand, 
Ap44mT, may have contributed to its reduced entry into the cell, its slightly lower activity 
as a Pgp substrate (Fig. 3.7) and its decreased ability to induce LMP (Figs. 3.8, 3.10-
3.14) and to overcome resistance (Figs. 3.6, 3.10). 
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In summary, the principal findings of these studies were that in order for 
thiosemicarbazones to overcome MDR, they must possess five characteristics, namely: 
(1) have inductively electron-withdrawing substituents at the imine carbon (Fig. 3.1); (2) 
have high relative lipophilicity; (3) have Pgp substrate activity (Figs. 3.4, 3.5, 3.8); (4) 
have potent Cu(II) chelation efficacy (Figs. 3.6, 3.9); and (5) induce ROS generation 
(Figs. 3.7, 3.10). 
 
6.2.1 Overcoming Bcl-2 Mediated MDR with Thiosemicarbazones  
The Bcl-2 family of proteins act as master regulators of the intrinsic pathway of 
apoptosis (Cory and Adams, 2002; Czabotar et al., 2014; Youle and Strasser, 2008). As 
impairment of apoptosis is fundamental to carcinogenesis, dysregulated expression of 
the Bcl-2 family members is an underlying cause or contributor to many different types 
of cancer (Thomas et al., 2013). Furthermore, overexpression of Bcl-2 contributes to 
MDR by allowing cancer cells to evade apoptotic signals in response to 
chemotherapeutics (Amundson et al., 2000; Dole et al., 1994; Miyashita and Reed, 
1993; Schmitt et al., 2000; Shibata et al., 1999; Strasser et al., 1993; Thomas et al., 
1996; Vaux et al., 1988; Wang et al., 2013). Previously, Dp44mT was demonstrated to 
increase the ratio of pro-apoptotic Bax to anti-apoptotic Bcl-2 (Gutierrez et al., 2014; 
Yuan et al., 2004), thereby making cells more sensitive to apoptosis (Raisova et al., 
2001). The ability of Dp44mT to regulate the expression of Bcl-2 family members and 
overcome Pgp-mediated MDR, led us to investigate the anti-cancer efficacy of Dp44mT 
and our lead agent, DpC, against cells over-expressing Bcl-2. For these studies we 
utilised M14 Bcl-2 melanoma cell line, endogenously Bcl-2 expressing M14 melanoma 
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cell line, and the control cell line, M14 PC (Chambers, 2009; Del Bufalo et al., 1997; 
Rae et al., 2007).  
 
Interestingly, DpC, but not Dp44mT, overcame Bcl-2 mediated MDR following a 24 
h/37°C incubation (Fig. 5.1). While the IC50 of DpC was the same in both cell lines, 
Dp44mT was 1.5-fold (p < 0.001) less cytotoxic in the Bcl-2 expressing, M14 Bcl-2 cell 
line, than in the control, M14 PC cell line (Fig. 5.1). Moreover, as Dp44mT has been 
shown to increase the Bax:Bcl-2 ratio (Gutierrez et al., 2014; Yuan et al., 2004), the 
effect of Dp44mT and DpC on the expression of Bcl-2 was examined. Dp44mT did not 
significantly (p > 0.05) decrease Bcl-2 expression, relative to the control (Fig. 5.2). DpC, 
on the other hand, induced a 57% decrease (p < 0.01) in Bcl-2 expression, relative to 
the control (Fig. 5.2). Moreover, incubation with DpC induced a 50% (p < 0.05) 
decrease in Bcl-2 expression, relative to Dp44mT (Fig. 5.2B). The ability of DpC to 
overcome Bcl-2 mediated MDR may have been related to the significantly greater (p < 
0.05) decrease in Bcl-2 expression that was induced by DpC, compared to Dp44mT 
(Fig. 5.2).  
 
Importantly, silencing of Bcl-2 expression affected Dp44mT-induced cytotoxicity, but not 
DpC-induced cytotoxicity (Fig. 5.3). This could be due to DpC being significantly (p < 
0.05) more effective at decreasing Bcl-2 expression compared to Dp44mT (Fig. 5.2). 
Hence, it could be expected that silencing of Bcl-2 would not affect induction of 
cytotoxicity by DpC to the same extent that it would affect Dp44mT (Fig. 5.3). As 
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observed with Dp44mT (Fig. 5.3), decreasing Bcl-2 expression has been shown to be 
effective in increasing the anti-cancer efficacy of standard chemotherapies that are 
sensitive to Bcl-2-mediated MDR (Bedikian et al., 2006; Skommer et al., 2006; Tse et 
al., 2008). Importantly, unlike standard chemotherapies or Dp44mT, the cytotoxicity of 
DpC was unaffected by Bcl-2 over-expression or silencing (Figs. 5.1, 5.3), illustrating 
the potential of DpC as a novel drug candidate.  
 
Induction of cytotoxicity by Dp44mT and DpC is dependent the formation of redox-active 
Cu(II) complexes that generate ROS (Figs. 3.9, 4.19, 4.20) (Jansson et al., 2010b; 
Lovejoy et al., 2011). Cu(II) binding is also involved in the cytotoxicity of other 
thiosemicarbazones (Stefani et al., 2015), and structurally-related drugs, such as 
elesclomol (Kirshner et al., 2008; Nagai et al., 2012; Yadav et al., 2013), which has 
been clinically trialled in melanoma (O'Day et al., 2013). However, in both the M14 Bcl-2 
and M14 PC cell lines, chelation of copper ions (Fig. 5.4) and adding the GSH 
precursor, NAC, to prevent ROS generation (Fig. 5.5) had no effect on the cytotoxicity 
of Dp44mT or DpC. These results demonstrated that DpC may overcome Bcl-2 
mediated MDR in melanoma via a novel mechanism.  
 
We investigated the interplay between Bcl-2 over-expression and induction of 
autophagy mediated by Dp44mT and DpC in the M14 Bcl-2 cell line. Bcl-2 inhibits the 
pro-survival autophagy pathway, as it is an inhibitor of the autophagy initiator protein, 
Beclin 1 (Chang et al., 2010; Kihara et al., 2001; Pattingre et al., 2005). Interestingly, 
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silencing of Beclin 1 has been found to inhibit Dp44mT-induced autophagy (Gutierrez et 
al., 2014). Herein, we found that DpC, but not Dp44mT, increased the expression of the 
classical marker of autophagosome formation, LC3-II (Fig. 5.5). We hypothesise that 
this is related to the ability of DpC, but not Dp44mT, to decrease Bcl-2 expression (Fig. 
5.2). The decrease in Bcl-2 expression induced by DpC (Fig. 5.2), may result in the de-
repression of Beclin 1. Free Beclin 1 could then participate in autophagy initiation, 
resulting in an increase in LC3-II expression (Fig. 5.6). Dp44mT, on the other hand, 
does not decrease the expression of Bcl-2 (Fig. 5.2). Beclin 1 may be bound to Bcl-2 
and inhibited (Chang et al., 2010; Pattingre et al., 2005), preventing the initiation of 
autophagy and increase in autophagosome formation, as observed (Fig. 5.6). Indeed, 
Dp44mT has been shown to induce LC3-II in cells that do not over-express Bcl-2 
(Gutierrez et al., 2014).  
 
Dp44mT, DpC and other thiosemicarbazones, have been shown to target lysosomes by 
inducing LMP due to the generation of ROS (Figs. 3.6, 3.7, 3.9, 3.10) (Gutierrez et al., 
2014; Jansson et al., 2010b; Jansson et al., 2015b; Lovejoy et al., 2011; Stefani et al., 
2015). We investigated the effects of Dp44mT and DpC on lysosomal membrane 
stability, using the acidic vesicle stain, AO. Herein, in the Bcl-2 over-expressing cell line, 
M14 Bcl-2, Dp44mT did not induce a significant (p > 0.05) increase in the number of 
acidic vesicles, compared to control, following a 24 h/37°C incubation (Fig. 5.7). 
However, in the control M14 PC cell line, Dp44mT induced a significant increase in the 
number of acidic vesicles (p < 0.001) (Fig. 5.7). 
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 In contrast, DpC induced a significant increase (p < 0.001) in the number of acidic 
vesicles in both the M14 Bcl-2 and M14 PC cell lines (Fig. 5.7). Dp44mT increased the 
number of acidic vesicles in a Bcl-2 dependent fashion, whereas DpC increased 
lysosomal number regardless of Bcl-2 expression. These results may be linked to the 
ability of DpC, but not Dp44mT, to decrease the expression of Bcl-2. We hypothesised 
that the acidic vesicles may in fact be autolysosomes, which form as a result of the 
fusion between autophagosomes and lysosomes (Kondo et al., 2005). Dp44mT did not 
decrease Bcl-2 expression (Fig. 5.2) or increase autophagosome formation (Fig. 5.6), 
possibly due to the inhibition of the autophagy initiator, Beclin 1, by Bcl-2. Therefore, 
Dp44mT would not induce increase in autolysosome number in Bcl-2 expressing cells, 
as observed (Fig. 5.7). DpC, on the other hand, decreased Bcl-2 expression (Fig. 5.2), 
and thus increased autophagosome formation (Fig. 5.6), possibly due to de-repression 
of Beclin 1. Consequently, DpC would induce an increase in the formation of 
autolysosomes (Fig. 5.7). In agreement with this hypothesis, in cells which did not 
express Bcl-2, both Dp44mT and DpC increased the formation of acidic vesicles (Fig. 
5.7). This may have occurred as, in contrast to the M14 Bcl-2 cell line, Beclin 1 would 
not have been inhibited by Bcl-2 (Fig. 5.2). 
 
The principle findings of these studies showed that DpC was superior to Dp44mT in 
overcoming Bcl-2-mediated resistance (Fig. 5.1). The mechanism by which DpC targets 
Bcl-2 cells appears to be one that involves decreasing the expression of Bcl-2 (Fig. 5.2), 
and may involve induction autophagy (Fig. 5.6) and autolysosome formation (Fig. 5.7). 
Unusually, DpC and Dp44mT did not exert their anti-cancer effects in the M14 
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melanoma cell lines via the well-established mechanism observed in other cancer cell 
lines, involving Cu(II) binding, ROS generation and induction of LMP (Figs. 3.6- 3.10) 
(Gutierrez et al., 2014; Gutierrez et al., 2016; Jansson et al., 2015b; Lovejoy et al., 
2011; Seebacher et al., 2016a). The remarkable ability of DpC to overcome Bcl-2 
mediated MDR warrants further mechanistic and structure-activity studies to further 
elucidate the mechanism and structural requirements for overcoming Bcl-2 mediated 
MDR by thiosemicarbazones, similar to what has already been carried out for Pgp-
mediated MDR. 
 
6.2.3 Comparison of the Mechanisms of Overcoming Pgp and Bcl-2 
Mediated MDR by Thiosemicarbazones 
Thiosemicarbazones that possess the five characteristics identified in this thesis were 
able to target Pgp-mediated MDR. The five characteristics identified were: (1) 
inductively electron-withdrawing substituents at the imine carbon (Fig. 3.1); (2) high 
relative lipophilicity; (3) Pgp substrate activity (Figs. 3.5, 3.6, 3.8); (4) Cu(II) chelation 
efficacy (Figs. 3.6, 3.9); and (5) induction of ROS generation (Figs. 3.7, 3.10). Dp44mT, 
DpC and Bp44mT, fulfilled these requirements, and so were able to selectively and 
potently induce cytotoxicity in Pgp-expressing cells (Fig. 3.6). The mechanism by which 
they do so involves passive diffusion across the plasma membrane followed by active 
transport into lysosomes by Pgp (Jansson et al., 2015b).  
 
  226 
Inside lysosomes, Dp44mT, Bp44mT and DpC are protonated by the acidic pH of 
lysosomal lumens, effectively trapping the thiosemicarbazones inside as they can no 
longer passively diffuse out across lysosomal membranes (Jansson et al., 2010b; 
Jansson et al., 2015b; Lovejoy et al., 2011). Dp44mT, Bp44mT and DpC are able to 
bind Cu(II), which is found at high concentrations within lysosomal lumens (Gupte and 
Mumper, 2009; Kurz et al., 2006; Yu et al., 2003). Once bound to Cu(II), Dp44mT, 
Bp44mT and DpC redox cycle and generate ROS that permeabilise lysosomal 
membranes (Figs. 3.6-3.10) (Jansson et al., 2010b; Jansson et al., 2015b; Lovejoy et 
al., 2011). LMP ultimately leads to apoptosis (Fig. 3.4) due to the release of degradative 
lysosomal caspases into the cytosol (Jansson et al., 2010b; Jansson et al., 2015b; 
Lovejoy et al., 2011; Ollinger and Brunk, 1995). Dp44mT, Bp44mT and DpC met the 
five requirements identified herein, therefore, were able to utilise Pgp so that rather than 
reducing their cytotoxicity, the presence of Pgp instead potentiates their cytotoxicity by 
promoting their lysosomal accumulation.  
 
There are numerous differences between the mechanisms Dp44mT and DpC used to 
target Pgp, and  the mechanism  they used to target Bcl-2 over-expression. Overall, 
Dp44mT and DpC acted in a similar manner to selectively target Pgp-mediated MDR 
(Figs. 3.4-3.10); however, only DpC, but not Dp44mT, could overcome Bcl-2 mediated 
MDR (Fig. 5.1). In order to overcome Bcl-2-mediated MDR (Fig. 5.1), DpC decreased 
the expression of Bcl-2 (Fig. 5.2). Dp44mT, on the other hand, did not decrease Bcl-2 
expression (Fig. 5.2), thus, did not overcome Bcl-2-mediated MDR (Fig. 5.1).  
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Dp44mT appeared to act similarly to common chemotherapeutics, which fail to induce 
apoptosis in Bcl-2-expressing cells (Amundson et al., 2000; Dole et al., 1994; Miyashita 
and Reed, 1993; Schmitt et al., 2000; Shibata et al., 1999; Strasser et al., 1993; 
Thomas et al., 1996; Vaux et al., 1988; Wang et al., 2013). Additionally, silencing of Bcl-
2 increased the cytotoxicity (i.e. decreased the IC50) of Dp44mT (Fig. 5.3), which has 
also been demonstrated to increase the efficacy of chemotherapeutics (Wang et al., 
2013). However, DpC was potently effective at decreasing Bcl-2 expression, therefore, 
silencing of Bcl-2 did not further affect its cytotoxicity (Fig. 5.3). Notably, DpC decreased 
the expression of the Bcl-2 protein. However, in Pgp-mediated MDR, Dp44mT and DpC 
utilise Pgp to increase their lysosomal sequestration, which consequently increases 
their cytotoxicity (Figs. 3.4, 3.6, 3.8-3.10).  
 
While Cu(II) binding and ROS generation were required characteristics in order for 
thiosemicarbazones to induce potentiated, Pgp-mediated cytotoxicity (Figs. 3.6, 3.8, 
3.9), neither Cu(II) binding nor ROS generation were required for DpC to overcome Bcl-
2 mediated MDR (Figs. 5.4, 5.5). Furthermore, while both Dp44mT and DpC induced 
LMP to cause cytotoxicity in Pgp-mediated MDR (Figs. 3.4, 3.6-3.10), and also induce 
LMP in a variety of other cell lines (Gutierrez et al., 2014; Jansson et al., 2010b; 
Jansson et al., 2015b; Lovejoy et al., 2011; Seebacher et al., 2016a); this was not the 
case in the M14 melanoma cell lines used to assess the effects of Bcl-2 expression on 
Dp44mT- and DpC-mediated cytotoxicity (Fig. 5.7). DpC induced an accumulation of 
acidic vesicles regardless of Bcl-2 expression, however, Dp44mT only induced a 
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significant increase in acidic vesicles in the control M14 PC cell line that did not express 
Bcl-2 (Fig. 5.6).  
 
We suggest that the accumulated acidic vesicles were autolysosomes, formed by the 
fusion of autophagosomes and lysosomes (Fig. 5.7) (Kondo et al., 2005). The 
accumulation of acidic vesicles, rather than LMP, may be due to the potentially high 
levels of the copper binding proteins, metallothioneins, which is commonly found in 
melanoma and is used as a negative prognostic indicator (Krauter et al., 1989; Weinlich 
et al., 2006; Zelger et al., 1993). High metallothionein levels in the M14 cell lines would 
prevent the binding of copper ions by Dp44mT and DpC, thus, preventing the 
generation of ROS and induction of LMP (Figs. 3.6, 3.7, 3.9, 3.10, 4.17-4.20, 5.7). The 
failure of Dp44mT and DpC to induce LMP (Fig. 5.7), in addition to the ability of DpC to 
mediate the formation of autophagosomes (Fig. 5.6), underpinned our suggestion that 
accumulated acidic vesicles were autolysosomes.  
 
There are significant differences in the mechanisms by which certain 
thiosemicarbazones overcome Pgp-mediated and Bcl-2 mediated MDR. Targeting Pgp 
required thiosemicarbazones to possess characteristics that included Cu(II) binding, 
redox cycling and induction of LMP as characteristics the thiosemicarbazones must 
possess (Figs. 3.6-3.10). However, DpC required none of these characteristics to 
overcome Bcl-2-mediated MDR (Figs. 5.4, 5.5, 5.7), and rather than induction of LMP, 
there is instead an accumulation of acidic vesicles (Fig. 5.7). Moreover, whereas 
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targeting Pgp involves “hijacking” the transporter and using it to selectively target Pgp 
expressing cells (Figs. 3.5, 3.8), DpC overcame Bcl-2 mediated MDR by decreasing the 
expression of the Bcl-2 protein (Figs. 5.1-5.3).  
 
 
6.3 Targeting Lysosomes and Cu(II) with 
Thiosemicarbazones 
A major mechanism utilised by thiosemicarbazones to induce cytotoxicity involves the 
formation of redox-active Cu(II) complexes that target lysosomes (Gutierrez et al., 2014; 
Gutierrez et al., 2016; Jansson et al., 2010b; Jansson et al., 2015b; Lovejoy et al., 2011; 
Seebacher et al., 2016a; Stefani et al., 2015). Copper is an essential metal that is 
required for cell survival as it acts as a co-factor in a diverse array of enzymes 
(Antholine et al., 1976; Gaggelli et al., 2006; Petering et al., 1967; Van Giessen et al., 
1973). However, free copper ions are also damaging to the cell, due to their ability to 
catalyse redox reactions to generate cytotoxic ROS (Gaggelli et al., 2006). Upon uptake 
into the cell, Cu(II) can be found bound to chaperones, metallothionein, or in the active 
sites of enzymes (Denoyer et al., 2015). Additionally, lysosomes contain a large 
proportion of intracellular Cu(II) as a result of the degradation of Cu(II)-containing 
metalloproteins by lysosomal cathepsins (Gupte and Mumper, 2009; Kurz et al., 2010; 
Terman and Kurz, 2013).  
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The high proliferation rate of cancer cells means that they require greater amounts of 
Cu(II) than non-neoplastic cells (Al-Eisawi et al., 2016). As such, cancer cells are more 
susceptible to the damaging consequences of Cu(II) sequestration than normal cells 
(Kalinowski et al., 2016). Some thiosemicarbazones, such as Dp44mT, are able to 
exploit the higher levels of Cu(II) found in neoplastic cells by forming redox-active Cu(II) 
complexes inside lysosomes (Gutierrez et al., 2014; Jansson et al., 2010b; Jansson et 
al., 2015b; Kalinowski et al., 2016; Lovejoy et al., 2011; Stefani et al., 2015). Generally, 
lysosomal sequestration negatively impacts on the efficacy of chemotherapeutics and 
contributes to MDR (Gong et al., 2003; Hurwitz et al., 1997; Schindler et al., 1996; 
Zhitomirsky and Assaraf, 2015a). However, Dp44mT induces apoptosis by 
accumulating in lysosomes, as the redox activity of the Cu(II)-thiosemicarbazone 
complexes generates cytotoxic ROS (Gutierrez et al., 2014; Gutierrez et al., 2016; 
Jansson et al., 2010b; Jansson et al., 2015b; Johansson et al., 2010; Lovejoy et al., 
2011; Seebacher et al., 2016a; Stefani et al., 2015; Turk and Turk, 2009). This 
destabilises the membrane and results in the leaking of degradative lysosomal enzymes 
into the cytoplasm (Gutierrez et al., 2014; Gutierrez et al., 2016; Jansson et al., 2010b; 
Jansson et al., 2015b; Johansson et al., 2010; Lovejoy et al., 2011; Seebacher et al., 
2016a; Stefani et al., 2015; Turk and Turk, 2009).  
 
Although Pgp is not always required in order for some thiosemicarbazones to target 
lysosomes (Gutierrez et al., 2014; Gutierrez et al., 2016; Lovejoy et al., 2011; Stefani et 
al., 2015), it does potentiate their ability to do so (Jansson et al., 2015b; Seebacher et 
al., 2016a). We showed that inhibition of Pgp prevented LMP and cytotoxicity induced 
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by Dp44mT, Bp44mT and DpC (Figs. 3.4, 3.8). Furthermore, LMP did not occur in the 
non-Pgp expressing, KB31 cell line at the concentration and time point used in these 
studies (Fig. 3.6). Pgp potentiates the cytotoxicity of Dp44mT by actively transporting 
Dp44mT into lysosomal lumens, where it is protonated and sequestered (Jansson et al., 
2015b; Lovejoy et al., 2011). The enhanced lysosomal sequestration of Dp44mT due to 
Pgp expression in lysosomal membranes results in selective cytotoxicity in Pgp-
expressing, MDR cells (Jansson et al., 2015b; Seebacher et al., 2016a). 
 
 Whereas lysosomal accumulation has previously been demonstrated using indirect 
techniques, such as examining the destabilisation of lysosomal membranes following 
incubation with thiosemicarbazones (Figs. 3.6, 3.8-3.10) (Gutierrez et al., 2014; 
Gutierrez et al., 2016; Jansson et al., 2010b; Jansson et al., 2015b; Lovejoy et al., 2011; 
Seebacher et al., 2016a; Stefani et al., 2015); importantly, for the first time, we were 
also able to definitively localise the Zn(II) complex of our lead thiosemicarbazone, DpC, 
to lysosomes (Figs. 4.14-4.16), and not nuclei (Figs. 4.8-4.10) or mitochondria (Figs. 
4.11-4.13). We synthesised 1:1 and 1:2 Zn(II) complexes of Dp44mT, Ap44mT and 
DpC∙HCl, which were more potently cytotoxic than the ligands alone (Fig. 4.7). The 
inherent fluorescence of Zn(II) allowed us to conduct confocal microscopy studies, and 
we demonstrated that the Zn(II) complex of our lead agent, [Zn(DpC)2](ClO4)2, 
accumulated in lysosomes in the KBV1, KB31 and SW480 cell lines (Figs. 4.14- 4.16). 
This is in contrast to the Zn(II) complex of 3-AP, which was localised to the 
nucleus/nucleoli of the cell (Kowol et al., 2010). The free ligand, 3-AP, did not cause 
LMP in our studies (Fig. 3.6), which may be related to its nuclear localisation (Kowol et 
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al., 2010). We have demonstrated the importance of LMP to the cytotoxicity generated 
by thiosemicarbazones, so this may have contributed to the failure of 3-AP in clinical 
trials (Knox et al., 2007; Merlot et al., 2013; Traynor et al., 2010).  
 
In this thesis, we identified characteristics that are required for thiosemicarbazones to 
target lysosomes, which highlighted the importance of the formation of avidly redox-
active Cu(II) complexes (Figs. 3.6-3.10). The formation of Cu(II) complexes may 
facilitate the trapping of Dp44mT, Bp44mT and DpC inside lysosomes, as the Cu(II) 
complexes are more lipophilic than the ligands alone, therefore, are better Pgp 
substrates (Fig. 3.5) (Kimura et al., 2004; Schmid et al., 1999; Seelig and 
Landwojtowicz, 2000). Indeed, the Cu(II) complexes, but not the Fe(III) complexes or 
ligands alone of Dp44mT, Bp44mT and DpC, potently induced LMP in Pgp-expressing, 
KBV1 cells (Fig. 3.6). Moreover, Bp2mT, which cannot bind copper ions due to the 
substitution of a methyl group at N2, did not induce LMP (Fig. 3.6). Cu(II) chelation also 
prevented LMP mediated by [Cu(Dp44mT)], [Cu(Bp44mT)] and [Cu(DpC)] (Fig. 3.9). 
Although [Cu(Dp44mT)], [Cu(Bp44mT)] and [Cu(DpC)] were more potent inducers of 
LMP than the thiosemicarbazones alone, longer incubations and higher concentrations 
of Dp44mT, Bp44mT and DpC did induce LMP (Figs. 3.6, 3.8-3.10). Furthermore, we 
showed that the LMP induced by Dp44mT, Bp44mT and DpC was also dependent on 
their ability to bind Cu(II) (Fig. 3.9).  
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It was not enough for thiosemicarbazones to simply bind Cu(II); the Cu(II)-
thiosemicarbazone complexes were also required to be highly redox active. This was 
illustrated by 3-AP and Ap44mT, which can form Cu(II) complexes, yet did not induce 
LMP like Dp44mT, Bp44mT and DpC (Fig. 3.6). 3-AP was not sufficiently redox-active 
to induce LMP, as the Cu(II) complex, Fe(III) complex and ligand alone of 3-AP did not 
mediate the oxidation of the well-characterised redox probe, H2DCF (Fig. 3.7). However, 
[Cu(Ap44mT)], like [Cu(Dp44mT)], [Cu(Bp44mT) and [Cu(DpC)], mediated a significant 
increase in H2DCF oxidation, relative to control (Fig. 3.7). While [Cu(Ap44mT)] mediated 
the oxidation of H2DCF, it was significantly less redox-active than [Cu(Dp44mT)], 
[Cu(Bp44mT)], or [Cu(DpC)] (Fig. 3.7) and did not induce LMP (Figs. 3.6, 3.8-11). This 
suggested that the failure of [Cu(Ap44mT)] to induce LMP was, in part, related to its 
decreased ability to generate ROS (Fig. 3.7). 
 
 The inability of [Cu(Ap44mT)] to induce LMP was due to the inductively electron-
donating effects of the imine methyl group of Ap44mT which resulted in a Cu(II) 
complex with a lower redox potential (Jansson et al., 2010a) that lies outside of the 
optimal window, preventing sufficient generation of ROS (Fig. 3.7) to mediate LMP 
(Figs. 3.6, 3.8-11). In contrast, the inductively electron-withdrawing substituents located 
at the imine position of Dp44mT, Bp44mT and DpC resulted in the formation of Cu(II) 
complexes with redox potentials that lie in an optimal window that allow for a redox 
cycling mechanism to become established (Bernhardt et al., 2009; Jansson et al., 
2010a; Lovejoy et al., 2012). The inability of any of the ligands alone and the Fe(III) 
complexes to induce H2DCF oxidation further illustrated the importance of Cu(II) 
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binding, in order to form highly redox-active complexes that generate LMP-inducing 
ROS.  
 
Moreover, additional studies highlighted the importance of the formation of avidly redox-
active Cu(II) complexes in order to target lysosomes in Pgp-expressing cells, as co-
incubation with the antioxidant NAC prevented LMP induced by Dp44mT, Bp44mT, 
DpC, and their Cu(II) complexes (Fig. 3.10). Clearly, for thiosemicarbazones to induce 
potent and selective apoptosis in Pgp-expressing cells (Fig. 3.5, 3.8), they were 
required to be sequestered in lysosomes and bind Cu(II) (Fig. 3.6, 3.8) to form highly 
redox-active complexes that generate ROS (Fig. 3.7, 3.10) and induce LMP (Fig. 3.6, 
3.8-3.10). 
 
Similarly to the Cu(II) complexes of Dp44mT, DpC and Bp44mT, the Zn(II) complexes of 
Dp44mT, Ap44mT and DpC, targeted lysosomes and induced LMP (Fig. 4.17). 
Interestingly, despite the fact that Zn(II) complexes of our thiosemicarbazones were not 
redox-active, they were able to induce LMP (Fig. 4.17) (Berg and Shi, 1996; Bernhardt 
et al., 2009). However, we had previously demonstrated that thiosemicarbazones must 
generate ROS when bound to transition metals in order to induce LMP (Fig. 3.10). This 
accounts for the potency of the Cu(II) complexes, as Cu(II) is highly redox-active and 
enables the generation of large quantities of ROS (Jansson et al., 2010b; Lovejoy et al., 
2011). In agreement with the Irving-Williams series (Irving and Williams, 1953), Dp44mT 
has a preference for binding Cu(II) over Zn(II) (Gaal et al., 2014). Furthermore, it has 
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been demonstrated that Zn(II)bis(thiosemicarbazone) complexes can transmetallate 
with copper ions (Pascu et al., 2007). Herein, we demonstrated that [Zn(Dp44mT-H)2], 
[Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2, which were not redox-active, were able to 
transmetallate in vitro with copper ions to generate redox-active Cu(II) complexes (Fig. 
4.17). This ability of [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 to 
transmetallate with copper ions (Fig. 4.17) enabled them to mediate LMP (Fig. 4.19), as 
co-incubation with the copper chelator, TM, prevented induction of LMP (Fig. 4.19). 
Moreover, co-incubation of [Zn(Dp44mT-H)2], [Zn(Ap44mT-H)2] and [Zn(DpC)2](ClO4)2 
with TM decreased the cytotoxicity of the Zn(II) complexes (Fig. 4.20), illustrating the 
importance of Cu(II) binding, redox cycling and LMP induction in the mechanism of 
these thiosemicarbazones.  
 
These studies demonstrated in order to target copper and lysosomes to induce LMP 
thiosemicarbazones a required to possess several characteristics, namely: (1) high 
lipophilicity for ease of diffusion across both plasma and lysosomal membranes; (2) 
multiple ionisable hydrogen atoms, enabling protonation at pH 5 and sequestration 
within lysosomes; (3) a preference for binding copper over other transition metals (Gaal 
et al., 2014); and (4) high redox potentials enabling the generation of significant 
quantities of cytotoxic ROS. Furthermore, thiosemicarbazones are able to induce 
potentiated cytotoxicity in Pgp-expressing, MDR cancer cells due to their (5) Pgp 
substrate activity. 
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Targeting lysosomes by inducing LMP is a mechanism of cytotoxicity that Dp44mT 
exhibits in a variety of cancer cell lines, including KBV1 (cervical cancer), SK-N-MC 
(neuroblastoma), MCF-7 (breast cancer) and SW480 (colorectal adenocarcinoma) 
(Gutierrez et al., 2014; Gutierrez et al., 2016; Jansson et al., 2010b; Jansson et al., 
2015b; Lovejoy et al., 2011; Seebacher et al., 2016a; Stefani et al., 2015). However, in 
the M14 melanoma cell line, there was no evidence of LMP following incubation with 
Dp44mT or DpC (Fig. 5.7). Thiosemicarbazones are required to bind copper and redox 
cycle to generate ROS, which peroxidise the lipid bilayer of lysosomal membranes to 
induce LMP (Fig. 3.6, 3.8-3.10, 4.17- 4.20) (Gutteridge et al., 1979; Ollinger and Brunk, 
1995). However, we demonstrated that in the M14 melanoma cell lines, chelation of 
copper ions with TM had no effect on the cytotoxicity of Dp44mT or DpC (Fig. 5.4).  
 
Moreover, no ROS were generated by Dp44mT or DpC in the M14 melanoma cell lines, 
as the antioxidant, NAC, had not effect on their cytotoxicity (Fig. 5.5). We propose that 
this was due to the high levels of metallothionein that melanoma cells express, which 
could prevent the formation of Cu(II) complexes due to a lack of unbound Cu(II) (Krauter 
et al., 1989; Weinlich et al., 2006; Zelger et al., 1993). This is in accordance with 
previous results that have demonstrated the markedly greater redox activity of the Cu(II) 
complexes of Dp44mT and DpC compared to the ligands alone (Fog. 3.7). Without the 
ability to bind Cu(II) and generate ROS, Dp44mT and DpC would not be expected to 
induce LMP.  
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In fact, we found that Dp44mT and DpC increased the number of acidic vesicles in the 
M14 cell lines in a manner that was dependent on Bcl-2 expression (Fig. 5.7), possibly 
by affecting the autophagy pathway (Fig. 5.6). DpC, but not Dp44mT, induced an 
increase in the expression of the classical marker of autophagosome formation, LC3-II, 
and in the number of acidic vesicles in Bcl-2 over-expressing M14 Bcl-2 cells (Fig. 5.6, 
5.7). We believe that the increase in LC3-II expression induced by DpC is due to the 
ability of DpC to decrease the expression of Bcl-2 (Fig. 5.2), as Bcl-2 is an inhibitor of 
the autophagy initiator, Beclin 1 (Chang et al., 2010; Kihara et al., 2001; Pattingre et al., 
2005).  
 
We propose that the acidic vesicles may be autolysosomes, formed by the fusion of 
autophagosomes with lysosomes; therefore, the increase in autophagosome formation 
induced by DpC would lead to the increase in acidic vesicle/autolysosome number, as 
observed (Fig. 5.7). While Dp44mT had been found to induce autophagy in the MCF-7 
breast cancer cell line (Gutierrez et al., 2014), in the M14 Bcl-2 melanoma cell line, 
Dp44mT does not induce an decrease in Bcl-2 expression (Fig. 5.2); therefore, Beclin 1 
would likely be inhibited (Chang et al., 2010; Liang et al., 1998; Pattingre et al., 2005). 
Autophagy would not be initiated and no induction of autophagosome formation would 
be expected following incubation with Dp44mT, as observed (Fig. 5.6). Additionally, 
Dp44mT did not induce an increase in the number of acidic vesicles formed in M14 Bcl-
2 cells, although did induce a significant increase in M14 PC cells (Fig. 5.7). The 
prevention of autophagy due to Beclin 1 inhibition by Bcl-2 would prevent an increase in 
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autolysosome formation in M14 Bcl-2 cells, evidenced herein by the lack of increase in 
the number of acidic vesicles (Fig. 5.7). 
 
 In M14 PC cells, on the other hand, Beclin 1 would not be inhibited, thus autophagy 
could be induced by Dp44mT and the number of acidic vesicles/autolysosomes would 
increase, as observed (Fig. 5.7). The relationship between the increase in acidic 
vesicles and cytotoxicity induced by Dp44mT and DpC in the M14 melanoma cell lines 
is yet to be be determined. However, the trends in cytotoxicity were similar to the trends 
in acidic vesicle formation. That is, DpC was equally cytotoxic in M14 Bcl-2 and M14 PC 
cells, and also induced similar increases in the number of acidic vesicles. Dp44mT was 
less cytotoxic in M14 Bcl-2 cells than in M14 PC cells, and did not induce an increase in 
acidic vesicles in M14 Bcl-2 cells, although did in M14 PC cells. These results suggest 
that there may be a causal relationship between acidic vesicle formation and cytotoxicity 
induced by Dp44mT and DpC, which is related to Bcl-2 expression. 
 
 Herein, we have highlighted importance of lysosomal targeting in the mechanism of 
thiosemicarbazone-induced cytotoxicity. We explored requirements that enabled 
thiosemicarbazones to potently target lysosomes in Pgp-expressing MDR cells, by 
“highjacking” lysosomal Pgp to increase their accumulation in lysosomes. In accordance 
with previously published results, these studies highlighted the importance of the ability 
to bind Cu(II) and generate ROS, in order to induce LMP and apoptosis. The 
importance of Cu(II) binding and ROS generation was also demonstrated using novel 
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Zn(II) complexes of Dp44mT, Ap44mT and DpC. Interestingly, the increased cytotoxicity 
of the Zn(II) complexes of Dp44mT, Ap44mT and DpC, relative to the free ligands, was 
due to their ability to transmetallate with Cu(II) and generate ROS to induce LMP. 
 
 Additionally, for the first time, we directly observed accumulation of the Zn(II) 
complexes of our lead drug candidate, DpC, in lysosomes. It also appears that Dp44mT 
and DpC target lysosomes in melanoma, albeit via a different mechanism to what is 
observed in other cancer cell lines. Rather than inducing LMP which results in 
apoptosis, in melanoma, Dp44mT and DpC induced an increase in the number of acidic 
vesicles, which we proposed to be autolysosomes. Regardless of the mechanism by 
which they do so, a common feature of thiosemicarbazones that possess potent anti-
cancer activity is the ability to target lysosomes.  
 
 
6.4 Future Directions 
6.4.1 Future Directions for Chapter 3  
Chapter 3 confirmed the mechanism by which thiosemicarbazones target Pgp-mediated 
MDR. Furthermore, we determined five characteristics that thiosemicarbazones were 
required to possess in order to selectively target Pgp-expressing cancer cells. 
Considering our results, further studies could involve the synthesis of novel 
thiosemicarbazones in order to develop more active agents that overcome multi-drug 
  240 
resistance via the exploitation of lysosomal Pgp. Particular emphasis should be placed 
on developing thiosemicarbazones that fulfil the five criteria identified, namely: (1) 
inductively electron-withdrawing substituents at the imine carbon; (2) high relative 
lipophilicity; (3) Pgp substrate activity; (4) Cu(II) chelation efficacy; and (5) the induction 
of ROS generation.  
 
The relative importance of these properties for overcoming resistance is unclear, and 
these agents have not been optimised to overcome MDR. This is demonstrated by the 
fact that only 16% of our lead agents e.g., Dp44mT are charged & trapped at lysosomal 
pH (Lovejoy et al., 2011). Thus, this is far from optimal. We will assess a broad library of 
our thiosemicarbazones with differing substitutions at the imine C and terminal N4 atom 
(Jansson et al., 2010b; Kalinowski et al., 2007). These studies will identify the best 
agent and its Fe(III) or Cu(II) complex for further studies later. An established series of 
analogues is initially utilised, as >10 years of research have already carefully refined the 
properties vital for anti-cancer activity e.g., tumour cell selectivity, appropriate 
pharmacokinetics, safety, etc (Kovacevic et al., 2011; Lovejoy et al., 2012). We will also 
develop a second library of agents to enhance their lysosomotropic activity and Pgp 
substrate properties to result in greater lysosomal accumulation. These new agents 
(Fig. 6.1B,C) maintain the basic active pharmacophore (Fig. 9A) with the 3 key 
molecular signatures described above (i.e., (1) being a Pgp substrate; (2) charged and 
trapped in lysosomes; and (3) binding Cu and inducing LMP) that are vital for the 
marked activity of the established library (Jansson et al., 2015b; Seebacher et al., 
2016c; Yamagishi et al., 2013). New Series 1 (Fig. 6.1B) will feature substituents with 
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electron-donating effects (i.e., 2-Me, 2,2’-Me, 4-MeO), added to the pyridine rings. This 
will be done to increase the basicity and protonation of the pyridine rings (Comba et al., 
2013) to enhance lysosomal trapping at lysosomal pH 5.  
 
New Series 2 will incorporate of molecular fragments of known lysosomotropic agents 
such as chloroquine and AO that also have the crucial property of being Pgp substrates 
(Crowe et al., 2006; Kessel et al., 1991) and are trapped in lysosomes (Abok et al., 
1984; de Duve et al., 1974; Jansson et al., 2015b) (Fig. 6.1C). Chemically combining 
the structures of Dp44mT and chloroquine enables potent trapping in lysosomes, as 
chloroquine possesses multiple positive charges even after lysosomal neutralisation (Al-
Bari, 2015). Hence, these multiple positive charges markedly prevent escape across 
lysosomal membranes and will induce effective lysosomal trapping that we know is vital 
for thiosemicarbazone anti-tumour efficacy (Jansson et al., 2015b; Lovejoy et al., 2011). 
Additionally, since chloroquine and Dp44mT are both Pgp substrates (Giles et al., 2003; 
Jansson et al., 2015b) this should enable highly effective entry into lysosomes via 
lysosomal Pgp. Furthermore, both chloroquine and AO have good tolerability in vivo (Al-
Bari, 2015). Another beneficial property of the AO or chloroquine analogues is that they 
can be directly imaged due to their fluorescence, enabling tracking of their intracellular 
location (Abok et al., 1984; Amador-Hernandez et al., 2001; Jansson et al., 2015b).  
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The studies below  will assess the 3 key molecular signatures  in our analogues (Fig. 
6.1) that are vital to overcome Pgp resistance and will identify the most effective agent 
and its metal complex (Fe(III) or Cu(II)) for in vivo studies: 
 
6.4.1.1. Role of Agent Ionisation Characteristics in Lysosomal Trapping 
Lysosomal trapping occurs if the agents become protonated at lysosomal pH (pH~5) 
(Lovejoy et al., 2011). This leads to decreased passage of the positively charged ligand 
across the lysosomal membrane (Lovejoy et al., 2011). To determine if our agents are 
charged at lysosomal pH, we will assess their ionisation and Cu(II)-binding affinity as a 
function of pH via spectrophotometric/pH titrations. Thus, these experiments will identify 
the agents/complexes with optimal lysosomotropic properties leading to lysosomal 
trapping. 
 
6.4.1.2 Thiosemicarbazone Selectivity Against Pgp-Expressing Cells  
Considering that Pgp plays a crucial role in potentiating Dp44mT cytotoxicity (Jansson 
et al., 2015b), we will elucidate if Pgp is involved in the cytotoxic mechanisms of our 
thiosemicarbazones (Fig. 6.1) and/or their metal complexes. Initial studies will assess if 
the selective Pgp inhibitors, available in our lab (Jansson et al., 2015b; Yamagishi et al., 
2013),  namely: Valspodar (Val; 5 μM) (Jachez et al., 1993) (Novartis) and Ela (0.1 μM) 
(Hyafil et al., 1993) (Sigma), or silencing of Pgp with siRNA (2 siRNAs to be tested vs. 
control-siRNA) (Jansson et al., 2015b; Yamagishi et al., 2013) will decrease cytotoxicity. 
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Fig. 6.1 Pharmacophores for Development of Optimised Novel 
Thiosemicarbazones  
Optimised Optimised thiosemicarbazone pharmacophore backbone for Cu(II) binding 
and redox activity. (B) New series 1: Substitutions (X) to increase lysosomal targeting. 
(C) New series 2: Circled moieties designed to increase lysosomal-targeting and Pgp 
substrate activity.  
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We hypothesise these Pgp inhibitors will reduce the uptake of thiosemicarbazones into 
lysosomes via lysosomal Pgp, and thus, will prevent LMP and cell death. To assess 
this, MTT assays validated by viable cell counts (Kalinowski et al., 2007; Yu et al., 2011) 
will be performed using our range of cells  with high and low Pgp levels. Cellular Pgp 
levels will be monitored by Western blot (Dixon et al., 2013; Jansson et al., 2015b; 
Lovejoy et al., 2011; Yamagishi et al., 2013). We will compare the thiosemicarbazones 
and their Cu(II) and Fe(III) complexes (Fig. 6.1B,C) to Dp44mT (Kovacevic et al., 2010). 
These studies will determine which thiosemicarbazones and their complexes are best at 
overcoming Pgp resistance.  
 
6.4.1.3 Examination of Thiosemicarbazone Drugs and their Metal Complexes in 
Terms of Transport via the Pgp Pump 
To assess if our thiosemicarbazone analogues (Fig 9B,C), and their Cu(II)- and Fe(III)-
complexes are transported by Pgp, we will initially use the cell-free, Pgp-Glo ATPase 
Assay system (Promega) (Jansson et al., 2015b) and compare our agents to known 
Pgp substrates (e.g., doxorubicin, etc.). Moreover, to confirm if 
thiosemicarbazones/complexes are Pgp substrates in a cell system, we will use our 
standard radiolabelling and efflux protocols (Lovejoy et al., 2011; Richardson and 
Milnes, 1997; Yuan et al., 2004). These studies will track 67Cu- (Oak Ridge National 
Labs, TN) or 59Fe- (Perkin-Elmer) labelled complexes in cells and the 14C-labelled 
thiosemicarbazones (i.e., 14C-Dp44mT, 14C-DpC etc. available in our lab (Merlot et al., 
2010; Merlot et al., 2013)). Retention/efflux of the labelled (67Cu or 59Fe) metal-ligand 
complexes will be assessed in Pgp- vs. non-Pgp-expressing cells above. We will also 
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assess Pgp’s role in the retention/efflux of drugs by using the potent Pgp inhibitors, Val 
(5 μM) (Jachez et al., 1993) and Ela (0.1 μM) and Pgp siRNA (Hyafil et al., 1993; 
Yamagishi et al., 2013). These studies will identify the best structural features 
necessary for effective trafficking by Pgp.  
 
6.4.1.4 Thiosemicarbazone Selectivity Against Other ABC-Expressing Cells 
Other ABC transporters that have been implicated in MDR include ABCG2 and MRP1, 
which have substantially overlapping substrate specificities with Pgp. It has been 
suggested that expression of multiple ABC transporters in a tumour cell population may 
account for the failure of strategies that have only targeted a single ABC transporter. 
Due to the overlapping substrate specificities, it is possible that the thiosemicarbazones 
may be substrates of ABCG2 and MRP1, in addition to Pgp. We will examine whether 
ABCG2 or MRP1 are involved in the cytotoxic mechanisms of the thiosemicarbazones, 
and/or their metal complexes. Initial studies will assess the effect of the specific ABCG2 
inhibitor, KO143 (Allen et al., 2002), and the specific MRP1 inhibitor, MK571 (Jones et 
al., 1989), or silencing of ABCG2 or MRP1 with siRNA, on the cytotoxicity of the 
thiosemicarbazones. Lysosomal localisation of ABCG2 and MRP1 has been reported 
(Rajagopal and Simon, 2003a), so if the thiosemicarbazones are substrates of these 
transporters, they may act in a manner similar to what has been reported for Dp44mT 
and DpC in Pgp-expressing cells. MTT assays will assess the cytotoxicity of the 
thiosemicarbazones in ABCG2 positive/ABCG2 negative and MRP1 positive/MRP1 
negative cell line counterparts, such as A549-MX100/A549 and MCF7-VP/MCF7, 
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respectively. These studies will demonstrate whether the thiosemicarbazones can 
overcome resistance mediated by ABCG2 or MRP1.  
 
6.4.1.5 Examination of the Importance of the Pgp Drug Pump in Sub-Cellular 
Distribution of Thiosemicarbazone Complexes 
Cu-Dp44mT accumulates in and damages lysosomes (Jansson et al., 2015b; Lovejoy et 
al., 2011). Furthermore, Pgp is found in lysosomal membranes (Jansson et al., 2015b; 
Yamagishi et al., 2013), leading to accumulation of Pgp substrates in this organelle 
(Yamagishi et al., 2013). However, Pgp has also been reported to co-localise with other 
organelles e.g., endosomes, Golgi, mitochondria and nuclei (Merlot et al., 2010; Molinari 
et al., 2002; Munteanu et al., 2006) Therefore, we will also assess if Pgp modulates 
targeting of thiosemicarbazones and their Cu(II) complexes to destabilise these 
organelles in Pgp- versus non-Pgp-expressing cells. Organelle integrity will be studied 
using: EEA1-CY3 (early endosome); Golgin-97-CY3 (Golgi); AO; Lysotracker 
Red/Green; Lamp-2 (lysosomes); TMRE/MitoTracker red (mitochondria); and DAPI 
staining (nuclei), using confocal microscopy and quantification by flow cytometry 
(Jansson et al., 2015b; Lovejoy et al., 2011; Yamagishi et al., 2013). If Pgp correlates 
with drug-induced damage to these organelles, then the Pgp inhibitors or Pgp siRNA (2 
siRNAs to be tested vs. control-siRNA) (Yamagishi et al., 2013) will be used to rescue 
organelle destabilisation. Also, accumulation of radioactive ligands/complexes will be 
quantified in isolated organelles by density gradient centrifugation (Graham et al., 1994) 
and assessing retention of 14C-ligands (e.g., 14C-Dp44mT (Lovejoy et al., 2011), 67Cu- 
and 59Fe-complex) (Lovejoy et al., 2011). Fraction purity & morphology will be checked 
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by marker analysis (Lovejoy et al., 2011) and electron microscopy, respectively. These 
studies will examine if Pgp affects organelle targeting/trafficking of thiosemicarbazones 
to comprehensively understand their subcellular mechanism of action 
 
6.4.1.6 Investigation of Synergism of Thiosemicarbazones with Standard 
Chemotherapies 
Many common, first-line chemotherapies are substrates of Pgp, thus are ineffective 
against Pgp-expressing, MDR cancer (Gillet and Gottesman, 2010; Gottesman et al., 
2002). Examples include doxorubicin, paclitaxel, vinblastine and etoposide (Gillet and 
Gottesman, 2010; Gottesman et al., 2002). Tumour cell populations are not 
homogenous, but rather exist as heterogeneous clonal populations of neoplastic cells 
that express varying levels of proteins, such as Pgp (Burrell and Swanton, 2014). 
Therefore, in tumours where some cells express Pgp, there will be cells which express 
little or no Pgp. This heterogeneous population will exhibit different sensitivities to 
cytotoxic drugs, inhibiting treatment efficacy (Burrell and Swanton, 2014). Indeed, 
standard treatments often kill only the drug sensitive cells, leaving behind the drug 
resistant cells to survive and re-populate the tumour. The rational for using combination 
chemotherapy in such instances is clear: different chemotherapies can target different 
clonal populations within the tumour, resulting in improved efficacy. Herein, we will 
examine whether combining our thiosemicarbazones with the common first line 
chemotherapy, doxorubicin, enhances cytotoxicity in Pgp-expressing tumour cell 
populationss. Cells derived from Pgp-expressing tumours will be treated with 
thiosemicarbazones first, in order to kill drug resistant cells. The drug sensitive cells will 
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then be targeted with doxorubicin. The results of combination therapy will be compared 
to the thiosemicarbazone alone and doxorubicin alone. Cytotoxicity will be assessed in 
MTT assays. These studies will determine whether combination therapy with our 
thiosemicarbazones can improve treatment efficacy in heterogeneous tumour cell 
populations. 
 
6.4.2 Future Directions for Chapter 4  
The ability to examine the intracellular distribution and accumulation of novel drug 
candidates is useful in order to determine their mechanism of action. Indeed, we were 
able to demonstrate the lysosomal localisation of the Zn(II) complex of our lead 
candidate, DpC (Fig. 4.14-16). This supports previous results, which indirectly showed 
lysosomal accumulation of DpC, and the structurally related thiosemicarbazone, 
Dp44mT (Gutierrez et al., 2014; Jansson et al., 2010b; Jansson et al., 2015b; Lovejoy 
et al., 2011; Seebacher et al., 2016a). Herein, we demonstrated that the mechanism of 
the Zn(II) complexes involves transmetallation with Cu(II) within lysosomes, which forms 
redox-active complexes that generate ROS and induce apoptosis (Fig. 4.17-4.19). Zn(II) 
appears to be an ideal transition metal for preparing new compounds as it increases 
lipophilicity (Richardson et al., 2006), which facilitates their passage across the cellular 
and lysosomal membranes, relative to the ligands alone, leading to enhanced uptake, 
cytotoxicity and ability to induce LMP.  
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However, the pharmacokinetic profile of the Zn(II)-thiosemicarbazone complexes must 
be assessed. A favourable pharmacokinetic profile would lead to in vivo assessment of 
anti-cancer efficacy, which must also be compared to that of the Fe(III) and Cu(II) 
complexes which have been assessed to date (Jayakumar et al., 2014; Kovacevic et al., 
2011; Yuan et al., 2004). Furthermore, the ability of the Zn(II)-thiosemicarbazone 
complexes to overcome Pgp-mediated MDR warrants further investigation, as the Zn(II) 
complexes of Dp44mT and DpC appeared to exhibit potentiated cytotoxicity against 
Pgp-expressing KBV1 cells, a property essential for overcoming Pgp-mediated drug 
resistance in tumours (Fig. 4.7). The properties of the Zn(II)-thiosemicarbazone 
complexes outlined above will be assessed in the following studies: 
 
6.4.2.1 Pharmacokinetic profiles  
To assess pharmacokinetic profiles, we will implement our well-characterised UHPLC-
MS/MS-based method that we used to assess similar thiosemicarbazones (Sestak et 
al., 2015). Groups of pre-catheterised (jugular vein) rats (6/group) will be given 2 mg/kg 
doses (i.v.) of the most effective agent, its best metal complex and the vehicle control 
(Sestak et al., 2015). During a time range of 5–1800 min, 500 μL blood will be taken and 
the plasma assayed by UHPLC-MS/MS (Sestak et al., 2015). This analysis will yield: 
max. concentration (cmax); time to achieve cmax (tmax); apparent vol. of distribution (Vz); 
total plasma clearance (CL); area under curve of concentration–time profile (AUC); 
elimination half-life (t1/2) (Sestak et al., 2015). This will provide useful pre-clinical data 
that will facilitate their clinical development.  
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6.4.2.2 Examination of the Most Effective Transition Metal-Thiosemicarbazone 
Complex in Terms of Anti-Cancer Efficacy in Cancer Xenografts In Vivo 
The anti-cancer activity of the best thiosemicarbazone and its metal complex in vivo will 
be assessed by bioluminescent tumour imaging via injecting either resistant or non-
resistant (i.e., passage matched) luciferase (luc)-labelled cells (1×105/mouse) into nude 
mice.  
 
Once the tumour reaches 100 mm3 (assessed by bioluminescent tumour imaging), 
treatment will begin (Kovacevic et al., 2011). Groups of 10 mice will be randomly 
chosen and treated with: (1) vehicle control (saline) (Dykes et al., 1995); (2) the 
reference cytotoxic; (3) vehicle control for the thiosemicarbazone or its Zn(II) Fe(III) or 
Cu(II) complex (30% propylene glycol/saline (Kovacevic et al., 2011; Lovejoy et al., 
2011); (4) the most effective thiosemicarbazone (5 days/week); and (5) its metal 
complex (Zn(II) Cu(II) or Fe(III) complex, whichever is most effective - identified in SO1). 
These 5 groups will be used for each cell line at their maximum tolerated dose (MTD). 
Animal numbers and dosing protocols are based on our in vivo studies (Kovacevic et 
al., 2011; Whitnall et al., 2006) and the power is >90% based on (Kovacevic et al., 
2011; Whitnall et al., 2006). The agents or vehicles will be injected i.v. (tail vein) 5 
days/week (Kovacevic et al., 2011; Lovejoy et al., 2011); or every 4 days for Docetaxel 
or its vehicle (Dykes et al., 1995). Our specifically developed i.v. injection method 
(Kovacevic et al., 2011) does not lead to tail necrosis. 
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We will assess MTDs in nude mice using an initial i.v. starting dose (0.4 mg/kg) 
once/day (5 days/week; Mon-Fri) (Lovejoy et al., 2011) for 4 weeks. This 
dose/administration route is based on our work with Dp44mT (Kovacevic et al., 2011; 
Lovejoy et al., 2011). If the MTD is not met, this dose will be adjusted up/down by 10% 
(generally <5 dose iterations are needed to reach MTD) (Yuan et al., 2004). In these 
studies, each group consists of 5 mice. Initial studies will use Docetaxel at its MTD (i.v. 
20 mg/kg/every 4 days (Dykes et al., 1995)) over 4 weeks. Tumour growth will be 
assessed by bioluminescent imaging using the Perkin Elmer IVIS Spectrum/CT system, 
as the 22RV1-luc cells express luciferase. When the tumours have reached 1 cm3, 
blood will be collected for comprehensive haematology, biochemistry and blood smears 
for morphologic and differential analysis (i.e., safety and tolerability assessment) 
(Kovacevic et al., 2011; Lovejoy et al., 2011; Yuan et al., 2004). Mice will be sacrificed 
and the major organs & tumour weighed & assessed by histopathology  (Kovacevic et 
al., 2011; Lovejoy et al., 2012; Whitnall et al., 2006; Yuan et al., 2004). Zn(II), Fe(III) and 
Cu(II) will be assessed by inductive coupled plasma mass spectrometry (ICP-MS) 
(Lovejoy et al., 2011) These studies will determine which of the Zn(II), Fe(III) or Cu(II) 
complexes possess the greatest anti-cancer activity, which can guide the future 
development of novel transition metal-thiosemicarbazone complexes. 
 
6.4.2.3 Examination of Zn(II) Complexes in Terms of Transport via the Pgp Pump 
To assess if our Zn(II)-thiosemicarbazone complexes of Dp44mT and DpC are 
transported by Pgp, we will initially use the cell-free, Pgp-Glo ATPase Assay system 
(Promega) (Jansson et al., 2015b) and compare our agents to known Pgp substrates 
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(e.g., doxorubicin, etc.). These studies will identify the best structural features 
necessary for effective trafficking by Pgp.  
 
6.4.2.4 Zn(II)-Thiosemicarbazone Complexes Selectivity Against Pgp-Expressing 
Cells  
Considering that Pgp plays a crucial role in potentiating Dp44mT and [Cu(Dp44mT)] 
cytotoxicity (Jansson et al., 2015b), we will elucidate if Pgp is involved in the cytotoxic 
mechanisms of our Zn(II)-thiosemicarbazones, [Zn(Dp44mT)2] and [Zn(DpC)2]. Initial 
studies will assess if the selective Pgp inhibitors, available in our lab (Jansson et al., 
2015b; Yamagishi et al., 2013),  namely: Valspodar (Val; 5 μM) (Jachez et al., 1993) 
(Novartis) and Ela (0.1 μM) (Hyafil et al., 1993) (Sigma), or silencing of Pgp with siRNA 
(2 siRNAs to be tested vs. control-siRNA) (Jansson et al., 2015b; Yamagishi et al., 
2013) will decrease cytotoxicity. We hypothesise these Pgp inhibitors will reduce the 
uptake of Zn(II)-thiosemicarbazones into lysosomes via lysosomal Pgp, and thus, will 
prevent LMP and cell death. To assess this, MTT assays validated by viable cell counts 
(Kalinowski et al., 2007; Yu et al., 2009b) will be performed using our range of cells  
with high and low Pgp levels. Cellular Pgp levels will be monitored by Western blot 
(Dixon et al., 2013; Jansson et al., 2015b; Lovejoy et al., 2011; Yamagishi et al., 2013). 
These studies will determine whether Zn(II)-thiosemicarbazones overcome Pgp-
mediated resistance.  
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6.4.2.5 Examination of the Importance of the Pgp Drug Pump in Sub-Cellular 
Distribution of Zn(II)-Thiosemicarbazone Complexes 
Cu-Dp44mT accumulates in and damages lysosomes (Jansson et al., 2015b; Lovejoy et 
al., 2011). Furthermore, Pgp is found in lysosomal membranes (Jansson et al., 2015b; 
Yamagishi et al., 2013), leading to accumulation of Pgp substrates in this organelle 
(Yamagishi et al., 2013). We found that [Zn(DpC)2] was localised to the lysosomes of 
both KBV1 (+Pgp) and KB31 (-Pgp) cells, and that [Zn(Dp44mT)2] and [Zn(DpC)2] 
cause lysosomal membrane destabilisation. However, cytotoxicity data (Fig. 4.7) 
suggested that the cytotoxicity of [Zn(Dp44mT)2] and [Zn(DpC)2] may be potentiated by 
Pgp. Therefore, we will assess if Pgp modulates targeting of Zn(II)-thiosemicarbazones 
to destabilise lysosomes in Pgp- versus non-Pgp-expressing cells. Lysosomal integrity 
will be studied using alternative methods to AO, such as LysoTracker Deep Red and 
Lamp-2, using confocal microscopy and quantification by flow cytometry (Jansson et al., 
2015b; Lovejoy et al., 2011; Yamagishi et al., 2013). If Pgp correlates with drug-induced 
damage to these organelles, then the Pgp inhibitors or Pgp siRNA (2 siRNAs to be 
tested vs. control-siRNA) (Yamagishi et al., 2013) will be used to rescue organelle 
destabilisation. These studies will examine if Pgp affects organelle targeting/trafficking 
of Zn(II)-thiosemicarbazones to comprehensively understand their subcellular 
mechanism of action 
 
6.4.3 Future Directions for Chapter 5  
In Chapter 5, we demonstrated that DpC, but not Dp44mT, overcomes Bcl-2 mediated 
MDR in melanoma cells. DpC appears to do so via a novel mechanism, which unlike the 
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mechanism for overcoming Pgp-mediated MDR, does not involve Cu(II) binding or ROS 
generation. Furthermore, neither Dp44mT nor DpC induced LMP in melanoma cells. In 
contrast, DpC induced a Bcl-2 independent increase in acidic vesicles, while Dp44mT 
only induced an increase in acidic vesicles in non-Bcl-2 expressing melanoma cells.  
  
Several hypotheses were put forward in Chapter 5 and must be examined in greater 
depth. Firstly, we suggested that Cu(II) chelation using TM had no effect on the 
cytotoxicity of Dp44mT or DpC due to high levels of metallothionein, which is commonly 
found in melanoma. Secondly, we suggested that the accumulation of acidic vesicles, 
which both Dp44mT and DpC induced in the M14 PC cell line but only DpC induced in 
the M14 Bcl-2 cell line, were autolysosomes. We also suggested that the ability of DpC, 
but not Dp44mT, to induce the accumulation of acidic vesicles was due to the ability of 
DpC to decrease the expression of Bcl-2. Finally, while there is reason to believe that 
the accumulation of acidic vesicles was implicated in the cytotoxicity of Dp44mT and 
DpC in the M14 melanoma cell lines, this was not confirmed. 
 
6.4.3.1 Comparative Measurements of Intracellular Cu(II) in Neoplastic Cell Lines 
In M14 melanoma cells, the copper ion chelator, TM, did not significantly (p > 0.05) 
affect the cytotoxicity of Dp44mT or DpC (Fig. 5.4). In contrast, in KBV1, KB31 and 
SW480 cell lines (Figs. 3.13, 4.19, 4.20), intracellular Cu(II) chelation by TM decreases 
both cytotoxicity and prevents induction of LMP. We hypothesised that the M14 
melanoma cell line has lower levels of intracellular copper than other cell lines in which 
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Dp44mT and DpC have been tested. The basal intracellular Cu(II) levels of the M14 
melanoma cell lines can be determined by inductively coupled plasma mass 
spectrometry (Kim et al., 2012). The Cu(II) levels in M14 cells will then be compared to 
other cell lines in which Dp44mT and DpC have been shown to bind intracellular Cu(II), 
such as KBV1, KB31, SW480 (Figs. 3.13, 4.19, 4.20). The expression of copper ion 
binding proteins, metallothioneins, in the M14 cell lines will be compared to KBV1, KB31 
and SW480 by Western blot. Furthermore, expression of Cu(II) uptake transporter, 
CRT1, and the copper ion efflux transporters, ATP7A and ATP7B (Denoyer et al., 2015; 
Kim et al., 2012), will also be examined by Western blot in M14, KBV1, KB31 and 
SW480 cell lines. Addiionally, the functionality of the copper transporters will be using 
our standard radiolabelling and efflux protocols (Lovejoy et al., 2011; Richardson and 
Milnes, 1997; Yuan et al., 2004). These studies will track the retention/efflux of 67Cu 
metal in the cell lines listed above. The results of these studies will determine whether 
low intracellular Cu(II) accounts for the inability of TM to decrease the cytotoxicity of 
Dp44mT or DpC in M14 melanoma cells.   
 
6.4.3.2 Identification of Acidic Vesicles 
We suggested that the identity of the acidic, AO-stained vesicles induced by DpC in 
M14 Bcl-2 cells, and by DpC and Dp44mT in M14 PC cells, might be autolysosomes 
(Fig. 5.7). To determine whether these acidic vesicles are autolysosomes, co-
localisation of the autophagosome marker, LC3-II, with the lysosomal markers, LAMP2 
and Cathepsin D, will be assessed by confocal microscopy (Jansson et al., 2015b). We 
will also track the formation autolysosomes induced by Dp44mT or DpC using flow 
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cytometry, by transfecting M14 melanoma cells with the mCherry-GFP-LC3 construct, 
which measures autolysosome formation from autophagosomes (Hundeshagen et al., 
2011; Pankiv et al., 2007). Vesicles which are acidic and express LC3 (i.e. 
autolysosomes) will exhibit red fluorescence only, while those which are neutral (i.e. 
autophagosomes) will appear green (Pankiv et al., 2007). If the acidic vesicles are 
neither autolysosomes or lysosomes, endolysosomes will also be examined by confocal 
microscopy through co-localisation of Rab7 with LAMP2 and Cathepsin D (Jager et al., 
2004); and by flow cytometry using M14 cells transfected with the GFP-Rab7 construct 
(Pankiv et al., 2007). These studies will determine the identity of the acidic, vesicular, 
organelle induced in M14 melanoma cells by DpC (M14 Bcl-2 and M14 PC) and 
Dp44mT (M14 PC only). 
 
6.4.3.4 Role of Bcl-2 in DpC-Mediated Increase in Acidic Vesicles 
DpC induced the formation of acidic vesicles in both M14 Bcl-2 cells and M14 PC cells 
(Fig. 5.7). However, Dp44mT only induced the formation of acidic vesicles in M14 PC 
cells (Fig. 5.7). We proposed that Dp44mT did not increase the formation of acidic 
vesicles, as, unlike DpC, it did not decrease the expression of Bcl-2 (Fig. 5.2). Bcl-2 is 
an inhibitor of the autophagy initiator, Beclin 1 (Chang et al., 2010; Pattingre et al., 
2005), which is required for the formation of autolysosomes, which we believe the acidic 
vesicles to be. Indeed, silencing of Beclin 1 has been shown to prevent autophagy 
initiation by Dp44mT (Gutierrez et al., 2014). The role of Bcl-2 in the formation of acidic 
vesicles in M14 Bcl-2 cells will be confirmed using Bcl-2 siRNA, and examining the 
formation of acidic vesicles. Beclin 1 siRNA will also be used to determine whether 
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inhibition of Beclin 1 by Bcl-2 (Chang et al., 2010; Pattingre et al., 2005), prevents the 
formation of acidic vesicles, i.e. autolysosomes. These studies will determine the role of 
Bcl-2 and Beclin 1 in the formation of acidic vesicles mediated by Dp44mT and DpC in 
M14 melanoma cells.  
 
6.4.3.5 Importance of Induction of Acidic Vesicle Formation to Cytotoxicity of 
Dp44mT and DpC in M14 Melanoma Cells 
DpC was equally cytotoxic in the M14 Bcl-2 and M14 PC cell lines, and induced similar 
increases in the number of acidic vesicles. Dp44mT, on the other hand, was less 
cytotoxic in the M14 Bcl-2 cell line than in the M14 PC cell line. To determine whether 
there is a relationship between the acidic vesicles induced by Dp44mT (in M14 PC 
cells) and DpC (in M14 Bcl-2 and M14 PC cells) (Fig. 5.7) and induction of cytotoxicity, 
the formation of acidic vesicles will be prevented. Depending on the identity of the acidic 
vesicles, there are several methods that could be employed prevent their accumulation, 
in order to ascertain their effect on cytotoxicity. For example, if the acidic vesicles were 
autolysosomes, autophagy could be inhibited using bafilomycin A1, and the effect on 
the prevention of the formation of autolysosomes on cytotoxicity examined in MTT 
assays (Gutierrez et al., 2014). Similarly, if the acidic vesicles were lysosomes, 
lysosomes could be inhibited using chloroquine or ammonium chloride, and the effect 
on the cytotoxicity of Dp44mT or DpC assessed in MTT assays (Seguin et al., 2014).  
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6.4.3.6 Effect of Bcl-2 Over-Expression in Other Neoplastic Cell Types 
Studies will investigate the effect of DpC in other Bcl-2-expressing cell lines that 
express endogenously high levels of Bcl-2, such as the leukaemia cell line RS11846, 
the renal cancer cell line ACHN, or the CNS cancer cell line LN-229 (Placzek et al., 
2010), compared to the M14 Bcl-2 melanoma cell line, which was transfected to over-
express Bcl-2. The ability of DpC to overcome Bcl-2 mediated MDR will be assessed in 
MTT assays, and effect of Dp44mT and DpC on lysosomal stability will be assessed 
using AO. The endogenously Bcl-2 over-expressing 501-MEL cell line (Placzek et al., 
2010), will also be included, as will other melanoma cell lines such as SK-MEL-28 and 
WM-35, to evaluate whether the novel mechanism of Dp44mT and DpC observed in 
M14 cells was melanoma-specific. These studies will assess whether the important 
ability of DpC to overcome Bcl-2 mediated MDR is ubiquitous in cancer cell lines, or 
limited to melanoma cell lines.  
 
 
6.5 Concluding Remarks 
As discussed previously in this thesis, MDR is a major contributing factor to treatment 
failure (Gottesman et al., 2002). Past strategies to target MDR have not led to 
successful therapies in the clinic (Gottesman et al., 2002). Therefore, there is a demand 
for further research in order to develop novel therapies that overcome MDR. This thesis 
has expanded current knowledge through investigations of the structure-activity 
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relationships of thiosemicarbazones in MDR models. This research is crucial to the 
development of new therapeutic strategies.  
 
Herein, we showed that thiosemicarbazones overcome Pgp-mediated MDR via a 
mechanism that involves transport into lysosomes by Pgp, lysosomal sequestration, 
Cu(II) binding, ROS generation, LMP, and apoptosis. We demonstrated the importance 
of substitutions at the imine carbon of the thiosemicarbazone backbone. Specifically, in 
order to overcome Pgp-mediated MDR, inductively electron-withdrawing 2-pyridyl or 
phenyl moieties at the imine position are required to generate adequate ROS to induce 
LMP. Importantly, we showed that in addition to Dp44mT, Bp44mT and our lead agent, 
DpC, also overcome Pgp-mediated MDR via this mechanism, expanding our arsenal of 
potential drug candidates. Based on these studies, further “fine tuning” of 
thiosemicarbazone structural features could lead to more active agents to overcome 
multi-drug resistance via the exploitation of lysosomal Pgp to induce LMP and the death 
of resistant tumour cells. 
 
This thesis also demonstrated the potential of Zn(II)-thiosemicarbazone complexes as 
anti-cancer agents. These agents have improved lipophilicity compared to the 
thiosemicarbazones alone, or their Cu(II) complexes (Richardson et al., 2006), which 
facilitates their passage across the cellular and lysosomal membranes,  leading to 
enhanced uptake, cytotoxicity and ability to induce LMP. Furthermore, we utilised the 
fluorescence of the Zn(II) complexes to definitively show that the Zn(II) complex of our 
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lead agent, DpC, is localised to lysosomes. Interestingly, we also demonstrated that the 
Zn(II) complexes of our thiosemicarbazones transmetallate with Cu(II) to induce LMP 
and apoptosis, highlighting the importance of Cu(II) in the mechanism of action of these 
thiosemicarbazones. These studies could pave the way for the development of Zn(II)-
thiosemicarbazone complexes with improved anti-cancer efficacy, that take exploit 
lysosomal drug sequestration and the higher intracellular copper levels found in 
neoplastic cells (Goodman et al., 2004; Gupte and Mumper, 2009).  
 
Finally, we also investigated the ability of Dp44mT and DpC to overcome an additional, 
important cellular resistance mechanism: Bcl-2 mediated MDR. Interestingly, we 
demonstrated that DpC, but not Dp44mT, could overcome Bcl-2 mediated MDR. Further 
mechanistic studies are required; however, DpC appears to overcome Bcl-2 mediated 
MDR by decreasing the expression of Bcl-2. This attribute of DpC is clinically important, 
as Bcl-2 mediated MDR is, like Pgp-mediated MDR, a significant obstacle to the 
successful treatment of cancer (Kroemer, 1997; Lessene et al., 2008).  
 
The results presented herein clearly demonstrated the polypharmacological activity of 
thiosemicarbazones (Jansson et al., 2015a). Importantly, we showed that our lead 
candidate, DpC, is capable of not only coming Pgp-mediated MDR, but Bcl-2 mediated 
MDR as well. The ability to target two major mechanisms of MDR is clinically significant, 
and these studies form the basis for future studies that investigate the development of 
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novel, anti-cancer agents with improved efficacy against MDR, for which treatments are 
currently desperately lacking.  
  
  262 
Appendix 
Supporting Information Available 
Crystal structure of [Cu(Bp44mT-H)Cl]. This material is available free of charge via the 
Internet at http://pubs.acs.org. 
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